<!DOCTYPE html SYSTEM "about:legacy-compat"><html lang="en" class="win-std-desktop-val"><head>
<META http-equiv="Content-Type" content="text/html">
<title>Source View: https://www.cancer.gov/types/skin/hp/merkel-cell-treatment-pdq</title><meta name="robots" content="noindex,nofollow"><meta name="SortSite-IgnoreRule-Page" content="AccHtmlLinkTextReused,AccAdvancedReadingLevel,Section508-m-3,BugHtmlColgroup,BugIeCssMinMaxWidthHeight,ErrSpellingError,SeoBingTitleLength,SeoPage150k,UseGov5.1,UseGov9.2.3,UseGov10.11,UseGov11.7,UseGov14.3,UseGov17.4,UseGunningFog,W3cTitleTooLong"><link rel="icon" href="https://www-powermapper-com.azureedge.net/favicon.ico"><link rel="stylesheet" href="../Report/report-min-20200618.css"><script type="text/javascript" src="../Report/report-min-20210409.js"></script><!--[if lte IE 8]>
            <script>
                document.createElement('header');
                document.createElement('aside');
            </script>
            <![endif]--></head><body class="source"><a class="accessible" href="#content">Skip to Content</a><header><h1>
                        HTML Document
                    </h1><table><tr><th>
                        URL:
                    </th><td><a rel="nofollow" target="_top" href="https://www.cancer.gov/types/skin/hp/merkel-cell-treatment-pdq">https://www.cancer.gov/types/skin/hp/merkel-cell-treatment-pdq</a></td></tr><tr><th>
                        HTTP Status:
                    </th><td>200 OK</td></tr><tr><th>
                        MIME Type:
                    </th><td>text/html </td></tr><tr><th>
                        Last Modified:
                    </th><td>Wed, 27 Sep 2023 18:54:18 GMT</td></tr><tr><th>
                        Download Time:
                    </th><td>
                                Less than a second
                            </td></tr><tr><th>
                        Cookies:
                    </th><td>
                                None
                            </td></tr><tr><th>
                        Size:
                    </th><td>246 KB
                        </td></tr><tr><th>
                                Depth:
                            </th><td>3 clicks from home page
                            </td></tr><tr><th>
                                Charset:
                            </th><td>utf-8</td></tr><tr><th>
                                Forms:
                            </th><td>2 forms containing 3 controls
                            </td></tr><tr><th>
                        HTTP Headers:
                    </th><td><button class="chevron toggleChevron" data-toggleid="HttpHeaders"><img width="20" height="20" alt="View Headers" id="chevHttpHeaders" src="../Report/chevron-down.svg"></button>&nbsp;<span>17&nbsp;headers</span><div class="links" id="expand-HttpHeaders">Accept-Ranges: bytes<br>Cache-Control: max-age=0, no-cache<br>Connection: keep-alive<br>Content-Language: en<br>Date: Wed, 27 Sep 2023 21:45:26 GMT<br>Pragma: no-cache<br>Server: nginx<br>Strict-Transport-Security: max-age=31536000 ; includeSubDomains ; preload<br>X-AH-Environment: 01live<br>X-Age: 0<br>X-Content-Type-Options: nosniff<br>X-Drupal-Cache: MISS<br>X-Drupal-Dynamic-Cache: MISS<br>X-Frame-Options: SAMEORIGIN<br>X-Generator: Drupal 9 (https://www.drupal.org)<br>X-Request-ID: v-4320c842-5d67-11ee-a41e-6b9ed96278de<br>X-UA-Compatible: IE=edge<br></div></td></tr><tr><th>
                        Links In:
                    </th><td><button class="chevron toggleChevron" data-toggleid="LinksIn"><img width="20" height="20" alt="View Links" id="chevLinksIn" src="../Report/chevron-down.svg"></button>&nbsp;<span>1&nbsp;pages</span><div class="links" id="expand-LinksIn"><a class="viewsource" rel="nofollow" target="_top" href="https://content.montefioreeinstein.org/cancer/types/skin/merkel-cell-carcinoma-treatment" data-pageid="392" data-line="0" data-col="0">https://content.montefioreeinstein.org/cancer/types/skin/merkel-cell-carcinoma-treatment</a><br></div></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr><tr class="middle"><th><img alt="OK" width="20" height="20" src="../Report/bench-better.svg">
                                Issues:
                            </th><td>
                                No issues found
                            </td></tr></table></header><main id="content" class="pre"><p><code>1</code><code>&lt;!DOCTYPE html&gt;</code></p><p><code>2</code><code>          </code></p><p><code>3</code><code>&lt;html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#"&gt;</code></p><p><code>4</code><code>          </code></p><p><code>5</code><code>  &lt;head&gt;</code></p><p><code>6</code><code>          </code></p><p><code>7</code><code>    &lt;meta http-equiv="X-UA-Compatible" content="IE=edge"&gt;</code></p><p><code>8</code><code>          </code></p><p><code>9</code><code>    &lt;meta charset="utf-8" /&gt;</code></p><p><code>10</code><code>&lt;script type="text/javascript"&gt;</code></p><p><code>11</code><code>(window.NREUM||(NREUM={})).init={privacy:{cookies_enabled:false},ajax:{deny_list:["gov-bam.nr-data.net"]}};(window.NREUM||(NREUM={})).loader_config={xpid:"VgIHVV9VCxADUVRRAggBXlY=",licenseKey:"bfc00e1ee3",applicationID:"355359682"};;/*! For license information please see nr-loader-full-1.242.0.min.js.LICENSE.txt */</code></p><p><code>12</code><code>(()=&gt;</code></p><p><code>13</code><code>{"use strict";var e,t,r={234:(e,t,r)=&gt;</code></p><p><code>14</code><code>{r.d(t,{P_:()=&gt;</code></p><p><code>15</code><code>g,Mt:()=&gt;</code></p><p><code>16</code><code>v,C5:()=&gt;</code></p><p><code>17</code><code>s,DL:()=&gt;</code></p><p><code>18</code><code>x,OP:()=&gt;</code></p><p><code>19</code><code>S,lF:()=&gt;</code></p><p><code>20</code><code>C,Yu:()=&gt;</code></p><p><code>21</code><code>A,Dg:()=&gt;</code></p><p><code>22</code><code>m,CX:()=&gt;</code></p><p><code>23</code><code>c,GE:()=&gt;</code></p><p><code>24</code><code>w,sU:()=&gt;</code></p><p><code>25</code><code>j});var n=r(8632),i=r(9567);const a={beacon:n.ce.beacon,errorBeacon:n.ce.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},o={};function s(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!o[e])throw new Error("Info for ".concat(e," was never set"));return o[e]}function c(e,t){if(!e)throw new Error("All info objects require an agent identifier!");o[e]=(0,i.D)(t,a),(0,n.Qy)(e,o[e],"info")}const d=e=&gt;</code></p><p><code>26</code><code>{if(!e||"string"!=typeof e)return!1;try{document.createDocumentFragment().querySelector(e)}catch{return!1}return!0};var u=r(7056),l=r(50);const f=()=&gt;</code></p><p><code>27</code><code>{const e={mask_selector:"*",block_selector:"[data-nr-block]",mask_input_options:{color:!1,date:!1,"datetime-local":!1,email:!1,month:!1,number:!1,range:!1,search:!1,tel:!1,text:!1,time:!1,url:!1,week:!1,textarea:!1,select:!1,password:!0}};return{proxy:{assets:void 0,beacon:void 0},privacy:{cookies_enabled:!0},ajax:{deny_list:void 0,block_internal:!0,enabled:!0,harvestTimeSeconds:10,autoStart:!0},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},session:{domain:void 0,expiresMs:u.oD,inactiveMs:u.Hb},ssl:void 0,obfuscate:void 0,jserrors:{enabled:!0,harvestTimeSeconds:10,autoStart:!0},metrics:{enabled:!0,autoStart:!0},page_action:{enabled:!0,harvestTimeSeconds:30,autoStart:!0},page_view_event:{enabled:!0,autoStart:!0},page_view_timing:{enabled:!0,harvestTimeSeconds:30,long_task:!1,autoStart:!0},session_trace:{enabled:!0,harvestTimeSeconds:10,autoStart:!0},harvest:{tooManyRequestsDelay:60},session_replay:{autoStart:!0,enabled:!1,harvestTimeSeconds:60,sampling_rate:50,error_sampling_rate:50,mask_all_inputs:!0,get mask_text_selector(){return e.mask_selector},set mask_text_selector(t){d(t)?e.mask_selector=t+",[data-nr-mask]":null===t?e.mask_selector=t:(0,l.Z)("An invalid session_replay.mask_selector was provided and will not be used",t)},get block_class(){return"nr-block"},get ignore_class(){return"nr-ignore"},get mask_text_class(){return"nr-mask"},get block_selector(){return e.block_selector},set block_selector(t){d(t)?e.block_selector+=",".concat(t):""!==t&amp;&amp;(0,l.Z)("An invalid session_replay.block_selector was provided and will not be used",t)},get mask_input_options(){return e.mask_input_options},set mask_input_options(t){t&amp;&amp;"object"==typeof t?e.mask_input_options={...t,password:!0}:(0,l.Z)("An invalid session_replay.mask_input_option was provided and will not be used",t)}},spa:{enabled:!0,harvestTimeSeconds:10,autoStart:!0}}},h={},p="All configuration objects require an agent identifier!";function g(e){if(!e)throw new Error(p);if(!h[e])throw new Error("Configuration for ".concat(e," was never set"));return h[e]}function m(e,t){if(!e)throw new Error(p);h[e]=(0,i.D)(t,f()),(0,n.Qy)(e,h[e],"config")}function v(e,t){if(!e)throw new Error(p);var r=g(e);if(r){for(var n=t.split("."),i=0;i&lt;n.length-1;i++)if("object"!=typeof(r=r[n[i]]))return;r=r[n[n.length-1]]}return r}const b={accountID:void 0,trustKey:void 0,agentID:void 0,licenseKey:void 0,applicationID:void 0,xpid:void 0},y={};function x(e){if(!e)throw new Error("All loader-config objects require an agent identifier!");if(!y[e])throw new Error("LoaderConfig for ".concat(e," was never set"));return y[e]}function w(e,t){if(!e)throw new Error("All loader-config objects require an agent identifier!");y[e]=(0,i.D)(t,b),(0,n.Qy)(e,y[e],"loader_config")}const A=(0,n.mF)().o;var _=r(385),E=r(6818);const T={buildEnv:E.Re,customTransaction:void 0,disabled:!1,distMethod:E.gF,isolatedBacklog:!1,loaderType:void 0,maxBytes:3e4,offset:Math.floor(_._A?.performance?.timeOrigin||_._A?.performance?.timing?.navigationStart||Date.now()),onerror:void 0,origin:""+_._A.location,ptid:void 0,releaseIds:{},session:void 0,xhrWrappable:"function"==typeof _._A.XMLHttpRequest?.prototype?.addEventListener,version:E.q4,denyList:void 0},D={};function S(e){if(!e)throw new Error("All runtime objects require an agent identifier!");if(!D[e])throw new Error("Runtime for ".concat(e," was never set"));return D[e]}function j(e,t){if(!e)throw new Error("All runtime objects require an agent identifier!");D[e]=(0,i.D)(t,T),(0,n.Qy)(e,D[e],"runtime")}function C(e){return function(e){try{const t=s(e);return!!t.licenseKey&amp;&amp;!!t.errorBeacon&amp;&amp;!!t.applicationID}catch(e){return!1}}(e)}},9567:(e,t,r)=&gt;</code></p><p><code>28</code><code>{r.d(t,{D:()=&gt;</code></p><p><code>29</code><code>i});var n=r(50);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.Z)("Setting a Configurable requires an object as input");if(!t||"object"!=typeof t)return(0,n.Z)("Setting a Configurable requires a model to set its initial properties");const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),a=0===Object.keys(r).length?e:r;for(let o in a)if(void 0!==e[o])try{"object"==typeof e[o]&amp;&amp;"object"==typeof t[o]?r[o]=i(e[o],t[o]):r[o]=e[o]}catch(e){(0,n.Z)("An error occurred while setting a property of a Configurable",e)}return r}catch(e){(0,n.Z)("An error occured while setting a Configurable",e)}}},6818:(e,t,r)=&gt;</code></p><p><code>30</code><code>{r.d(t,{Re:()=&gt;</code></p><p><code>31</code><code>i,gF:()=&gt;</code></p><p><code>32</code><code>a,q4:()=&gt;</code></p><p><code>33</code><code>n});const n="1.242.0",i="PROD",a="CDN"},385:(e,t,r)=&gt;</code></p><p><code>34</code><code>{r.d(t,{FN:()=&gt;</code></p><p><code>35</code><code>s,IF:()=&gt;</code></p><p><code>36</code><code>u,Nk:()=&gt;</code></p><p><code>37</code><code>f,Tt:()=&gt;</code></p><p><code>38</code><code>c,_A:()=&gt;</code></p><p><code>39</code><code>a,cv:()=&gt;</code></p><p><code>40</code><code>h,iS:()=&gt;</code></p><p><code>41</code><code>o,il:()=&gt;</code></p><p><code>42</code><code>n,ux:()=&gt;</code></p><p><code>43</code><code>d,v6:()=&gt;</code></p><p><code>44</code><code>i,w1:()=&gt;</code></p><p><code>45</code><code>l});const n="undefined"!=typeof window&amp;&amp;!!window.document,i="undefined"!=typeof WorkerGlobalScope&amp;&amp;("undefined"!=typeof self&amp;&amp;self instanceof WorkerGlobalScope&amp;&amp;self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&amp;&amp;globalThis instanceof WorkerGlobalScope&amp;&amp;globalThis.navigator instanceof WorkerNavigator),a=n?window:"undefined"!=typeof WorkerGlobalScope&amp;&amp;("undefined"!=typeof self&amp;&amp;self instanceof WorkerGlobalScope&amp;&amp;self||"undefined"!=typeof globalThis&amp;&amp;globalThis instanceof WorkerGlobalScope&amp;&amp;globalThis),o=Boolean("hidden"===a?.document?.visibilityState),s=""+a?.location,c=/iPad|iPhone|iPod/.test(a.navigator?.userAgent),d=c&amp;&amp;"undefined"==typeof SharedWorker,u=(()=&gt;</code></p><p><code>46</code><code>{const e=a.navigator?.userAgent?.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&amp;&amp;e.length&gt;</code></p><p><code>47</code><code>=2?+e[1]:0})(),l=Boolean(n&amp;&amp;window.document.documentMode),f=!!a.navigator?.sendBeacon,h=Math.floor(a?.performance?.timeOrigin||a?.performance?.timing?.navigationStart||Date.now())},1117:(e,t,r)=&gt;</code></p><p><code>48</code><code>{r.d(t,{w:()=&gt;</code></p><p><code>49</code><code>a});var n=r(50);const i={agentIdentifier:"",ee:void 0};class a{constructor(e){try{if("object"!=typeof e)return(0,n.Z)("shared context requires an object as input");this.sharedContext={},Object.assign(this.sharedContext,i),Object.entries(e).forEach((e=&gt;</code></p><p><code>50</code><code>{let[t,r]=e;Object.keys(i).includes(t)&amp;&amp;(this.sharedContext[t]=r)}))}catch(e){(0,n.Z)("An error occured while setting SharedContext",e)}}}},8e3:(e,t,r)=&gt;</code></p><p><code>51</code><code>{r.d(t,{L:()=&gt;</code></p><p><code>52</code><code>u,R:()=&gt;</code></p><p><code>53</code><code>c});var n=r(8325),i=r(1284),a=r(4322),o=r(3325);const s={};function c(e,t){const r={staged:!1,priority:o.p[t]||0};d(e),s[e].get(t)||s[e].set(t,r)}function d(e){e&amp;&amp;(s[e]||(s[e]=new Map))}function u(){let e=arguments.length&gt;</code></p><p><code>54</code><code>0&amp;&amp;void 0!==arguments[0]?arguments[0]:"",t=arguments.length&gt;</code></p><p><code>55</code><code>1&amp;&amp;void 0!==arguments[1]?arguments[1]:"feature";if(d(e),!e||!s[e].get(t))return o(t);s[e].get(t).staged=!0;const r=[...s[e]];function o(t){const r=e?n.ee.get(e):n.ee,o=a.X.handlers;if(r.backlog&amp;&amp;o){var s=r.backlog[t],c=o[t];if(c){for(var d=0;s&amp;&amp;d&lt;s.length;++d)l(s[d],c);(0,i.D)(c,(function(e,t){(0,i.D)(t,(function(t,r){r[0].on(e,r[1])}))}))}delete o[t],r.backlog[t]=null,r.emit("drain-"+t,[])}}r.every((e=&gt;</code></p><p><code>56</code><code>{let[t,r]=e;return r.staged}))&amp;&amp;(r.sort(((e,t)=&gt;</code></p><p><code>57</code><code>e[1].priority-t[1].priority)),r.forEach((t=&gt;</code></p><p><code>58</code><code>{let[r]=t;s[e].delete(r),o(r)})))}function l(e,t){var r=e[1];(0,i.D)(t[r],(function(t,r){var n=e[0];if(r[0]===n){var i=r[1],a=e[3],o=e[2];i.apply(a,o)}}))}},8325:(e,t,r)=&gt;</code></p><p><code>59</code><code>{r.d(t,{A:()=&gt;</code></p><p><code>60</code><code>c,ee:()=&gt;</code></p><p><code>61</code><code>d});var n=r(8632),i=r(2210),a=r(234);class o{constructor(e){this.contextId=e}}var s=r(3117);const c="nr@context:".concat(s.a),d=function e(t,r){var n={},s={},u={},f=!1;try{f=16===r.length&amp;&amp;(0,a.OP)(r).isolatedBacklog}catch(e){}var h={on:g,addEventListener:g,removeEventListener:function(e,t){var r=n[e];if(!r)return;for(var i=0;i&lt;r.length;i++)r[i]===t&amp;&amp;r.splice(i,1)},emit:function(e,r,n,i,a){!1!==a&amp;&amp;(a=!0);if(d.aborted&amp;&amp;!i)return;t&amp;&amp;a&amp;&amp;t.emit(e,r,n);for(var o=p(n),c=m(e),u=c.length,l=0;l&lt;u;l++)c[l].apply(o,r);var f=b()[s[e]];f&amp;&amp;f.push([h,e,r,o]);return o},get:v,listeners:m,context:p,buffer:function(e,t){const r=b();if(t=t||"feature",h.aborted)return;Object.entries(e||{}).forEach((e=&gt;</code></p><p><code>62</code><code>{let[n,i]=e;s[i]=t,t in r||(r[t]=[])}))},abort:l,aborted:!1,isBuffering:function(e){return!!b()[s[e]]},debugId:r,backlog:f?{}:t&amp;&amp;"object"==typeof t.backlog?t.backlog:{}};return h;function p(e){return e&amp;&amp;e instanceof o?e:e?(0,i.X)(e,c,(()=&gt;</code></p><p><code>63</code><code>new o(c))):new o(c)}function g(e,t){n[e]=m(e).concat(t)}function m(e){return n[e]||[]}function v(t){return u[t]=u[t]||e(h,t)}function b(){return h.backlog}}(void 0,"globalEE"),u=(0,n.fP)();function l(){d.aborted=!0,d.backlog={}}u.ee||(u.ee=d)},5546:(e,t,r)=&gt;</code></p><p><code>64</code><code>{r.d(t,{E:()=&gt;</code></p><p><code>65</code><code>n,p:()=&gt;</code></p><p><code>66</code><code>i});var n=r(8325).ee.get("handle");function i(e,t,r,i,a){a?(a.buffer([e],i),a.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},4322:(e,t,r)=&gt;</code></p><p><code>67</code><code>{r.d(t,{X:()=&gt;</code></p><p><code>68</code><code>a});var n=r(5546);a.on=o;var i=a.handlers={};function a(e,t,r,a){o(a||n.E,i,e,t,r)}function o(e,t,r,i,a){a||(a="feature"),e||(e=n.E);var o=t[a]=t[a]||{};(o[r]=o[r]||[]).push([e,i])}},3239:(e,t,r)=&gt;</code></p><p><code>69</code><code>{r.d(t,{bP:()=&gt;</code></p><p><code>70</code><code>s,iz:()=&gt;</code></p><p><code>71</code><code>c,m$:()=&gt;</code></p><p><code>72</code><code>o});var n=r(385);let i=!1,a=!1;try{const e={get passive(){return i=!0,!1},get signal(){return a=!0,!1}};n._A.addEventListener("test",null,e),n._A.removeEventListener("test",null,e)}catch(e){}function o(e,t){return i||a?{capture:!!e,passive:i,signal:t}:!!e}function s(e,t){let r=arguments.length&gt;</code></p><p><code>73</code><code>2&amp;&amp;void 0!==arguments[2]&amp;&amp;arguments[2],n=arguments.length&gt;</code></p><p><code>74</code><code>3?arguments[3]:void 0;window.addEventListener(e,t,o(r,n))}function c(e,t){let r=arguments.length&gt;</code></p><p><code>75</code><code>2&amp;&amp;void 0!==arguments[2]&amp;&amp;arguments[2],n=arguments.length&gt;</code></p><p><code>76</code><code>3?arguments[3]:void 0;document.addEventListener(e,t,o(r,n))}},3117:(e,t,r)=&gt;</code></p><p><code>77</code><code>{r.d(t,{a:()=&gt;</code></p><p><code>78</code><code>n});const n=(0,r(4402).Rl)()},4402:(e,t,r)=&gt;</code></p><p><code>79</code><code>{r.d(t,{Ht:()=&gt;</code></p><p><code>80</code><code>d,M:()=&gt;</code></p><p><code>81</code><code>c,Rl:()=&gt;</code></p><p><code>82</code><code>o,ky:()=&gt;</code></p><p><code>83</code><code>s});var n=r(385);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function a(e,t){return e?15&amp;e[t]:16*Math.random()|0}function o(){const e=n._A?.crypto||n._A?.msCrypto;let t,r=0;return e&amp;&amp;e.getRandomValues&amp;&amp;(t=e.getRandomValues(new Uint8Array(31))),i.split("").map((e=&gt;</code></p><p><code>84</code><code>"x"===e?a(t,++r).toString(16):"y"===e?(3&amp;a()|8).toString(16):e)).join("")}function s(e){const t=n._A?.crypto||n._A?.msCrypto;let r,i=0;t&amp;&amp;t.getRandomValues&amp;&amp;(r=t.getRandomValues(new Uint8Array(31)));const o=[];for(var s=0;s&lt;e;s++)o.push(a(r,++i).toString(16));return o.join("")}function c(){return s(16)}function d(){return s(32)}},7056:(e,t,r)=&gt;</code></p><p><code>85</code><code>{r.d(t,{Bq:()=&gt;</code></p><p><code>86</code><code>n,Hb:()=&gt;</code></p><p><code>87</code><code>a,oD:()=&gt;</code></p><p><code>88</code><code>i});const n="NRBA",i=144e5,a=18e5},7894:(e,t,r)=&gt;</code></p><p><code>89</code><code>{function n(){return Math.round(performance.now())}r.d(t,{z:()=&gt;</code></p><p><code>90</code><code>n})},7243:(e,t,r)=&gt;</code></p><p><code>91</code><code>{r.d(t,{e:()=&gt;</code></p><p><code>92</code><code>a});var n=r(385),i={};function a(e){if(e in i)return i[e];if(0===(e||"").indexOf("data:"))return{protocol:"data"};let t;var r=n._A?.location,a={};if(n.il)t=document.createElement("a"),t.href=e;else try{t=new URL(e,r.href)}catch(e){return a}a.port=t.port;var o=t.href.split("://");!a.port&amp;&amp;o[1]&amp;&amp;(a.port=o[1].split("/")[0].split("@").pop().split(":")[1]),a.port&amp;&amp;"0"!==a.port||(a.port="https"===o[0]?"443":"80"),a.hostname=t.hostname||r.hostname,a.pathname=t.pathname,a.protocol=o[0],"/"!==a.pathname.charAt(0)&amp;&amp;(a.pathname="/"+a.pathname);var s=!t.protocol||":"===t.protocol||t.protocol===r.protocol,c=t.hostname===r.hostname&amp;&amp;t.port===r.port;return a.sameOrigin=s&amp;&amp;(!t.hostname||c),"/"===a.pathname&amp;&amp;(i[e]=a),a}},50:(e,t,r)=&gt;</code></p><p><code>93</code><code>{function n(e,t){"function"==typeof console.warn&amp;&amp;(console.warn("New Relic: ".concat(e)),t&amp;&amp;console.warn(t))}r.d(t,{Z:()=&gt;</code></p><p><code>94</code><code>n})},2587:(e,t,r)=&gt;</code></p><p><code>95</code><code>{r.d(t,{N:()=&gt;</code></p><p><code>96</code><code>c,T:()=&gt;</code></p><p><code>97</code><code>d});var n=r(8325),i=r(5546),a=r(3325);const o={stn:[a.D.sessionTrace],err:[a.D.jserrors,a.D.metrics],ins:[a.D.pageAction],spa:[a.D.spa],sr:[a.D.sessionReplay,a.D.sessionTrace]},s=new Set;function c(e,t){const r=n.ee.get(t);e&amp;&amp;"object"==typeof e&amp;&amp;(s.has(t)||Object.entries(e).forEach((e=&gt;</code></p><p><code>98</code><code>{let[t,n]=e;o[t]?o[t].forEach((e=&gt;</code></p><p><code>99</code><code>{n?(0,i.p)("feat-"+t,[],void 0,e,r):(0,i.p)("block-"+t,[],void 0,e,r),(0,i.p)("rumresp-"+t,[Boolean(n)],void 0,e,r)})):n&amp;&amp;(0,i.p)("feat-"+t,[],void 0,void 0,r),d[t]=Boolean(n)})),Object.keys(o).forEach((e=&gt;</code></p><p><code>100</code><code>{void 0===d[e]&amp;&amp;(o[e]?.forEach((t=&gt;</code></p><p><code>101</code><code>(0,i.p)("rumresp-"+e,[!1],void 0,t,r))),d[e]=!1)})),s.add(t))}const d={}},2210:(e,t,r)=&gt;</code></p><p><code>102</code><code>{r.d(t,{X:()=&gt;</code></p><p><code>103</code><code>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&amp;&amp;Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},1284:(e,t,r)=&gt;</code></p><p><code>104</code><code>{r.d(t,{D:()=&gt;</code></p><p><code>105</code><code>n});const n=(e,t)=&gt;</code></p><p><code>106</code><code>Object.entries(e||{}).map((e=&gt;</code></p><p><code>107</code><code>{let[r,n]=e;return t(r,n)}))},4351:(e,t,r)=&gt;</code></p><p><code>108</code><code>{r.d(t,{P:()=&gt;</code></p><p><code>109</code><code>a});var n=r(8325);const i=()=&gt;</code></p><p><code>110</code><code>{const e=new WeakSet;return(t,r)=&gt;</code></p><p><code>111</code><code>{if("object"==typeof r&amp;&amp;null!==r){if(e.has(r))return;e.add(r)}return r}};function a(e){try{return JSON.stringify(e,i())}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}}}},3960:(e,t,r)=&gt;</code></p><p><code>112</code><code>{r.d(t,{K:()=&gt;</code></p><p><code>113</code><code>o,b:()=&gt;</code></p><p><code>114</code><code>a});var n=r(3239);function i(){return"undefined"==typeof document||"complete"===document.readyState}function a(e,t){if(i())return e();(0,n.bP)("load",e,t)}function o(e){if(i())return e();(0,n.iz)("DOMContentLoaded",e)}},8632:(e,t,r)=&gt;</code></p><p><code>115</code><code>{r.d(t,{EZ:()=&gt;</code></p><p><code>116</code><code>d,Qy:()=&gt;</code></p><p><code>117</code><code>c,ce:()=&gt;</code></p><p><code>118</code><code>a,fP:()=&gt;</code></p><p><code>119</code><code>o,gG:()=&gt;</code></p><p><code>120</code><code>u,mF:()=&gt;</code></p><p><code>121</code><code>s});var n=r(7894),i=r(385);const a={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function o(){return i._A.NREUM||(i._A.NREUM={}),void 0===i._A.newrelic&amp;&amp;(i._A.newrelic=i._A.NREUM),i._A.NREUM}function s(){let e=o();return e.o||(e.o={ST:i._A.setTimeout,SI:i._A.setImmediate,CT:i._A.clearTimeout,XHR:i._A.XMLHttpRequest,REQ:i._A.Request,EV:i._A.Event,PR:i._A.Promise,MO:i._A.MutationObserver,FETCH:i._A.fetch}),e}function c(e,t,r){let i=o();const a=i.initializedAgents||{},s=a[e]||{};return Object.keys(s).length||(s.initializedAt={ms:(0,n.z)(),date:new Date}),i.initializedAgents={...a,[e]:{...s,[r]:t}},i}function d(e,t){o()[e]=t}function u(){return function(){let e=o();const t=e.info||{};e.info={beacon:a.beacon,errorBeacon:a.errorBeacon,...t}}(),function(){let e=o();const t=e.init||{};e.init={...t}}(),s(),function(){let e=o();const t=e.loader_config||{};e.loader_config={...t}}(),o()}},7956:(e,t,r)=&gt;</code></p><p><code>122</code><code>{r.d(t,{N:()=&gt;</code></p><p><code>123</code><code>i});var n=r(3239);function i(e){let t=arguments.length&gt;</code></p><p><code>124</code><code>1&amp;&amp;void 0!==arguments[1]&amp;&amp;arguments[1],r=arguments.length&gt;</code></p><p><code>125</code><code>2?arguments[2]:void 0,i=arguments.length&gt;</code></p><p><code>126</code><code>3?arguments[3]:void 0;(0,n.iz)("visibilitychange",(function(){if(t)return void("hidden"===document.visibilityState&amp;&amp;e());e(document.visibilityState)}),r,i)}},1214:(e,t,r)=&gt;</code></p><p><code>127</code><code>{r.d(t,{em:()=&gt;</code></p><p><code>128</code><code>b,u5:()=&gt;</code></p><p><code>129</code><code>S,QU:()=&gt;</code></p><p><code>130</code><code>P,Kf:()=&gt;</code></p><p><code>131</code><code>I});var n=r(8325),i=r(3117);const a="nr@original:".concat(i.a);var o=Object.prototype.hasOwnProperty,s=!1;function c(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,a){n||(n="");const o="-"===n.charAt(0);for(let s=0;s&lt;t.length;s++){const c=t[s],d=e[c];u(d)||(e[c]=r(d,o?c+n:n,i,c,a))}},r.flag=a,r;function r(t,r,n,s,c){return u(t)?t:(r||(r=""),nrWrapper[a]=t,function(e,t,r){if(Object.defineProperty&amp;&amp;Object.keys)try{return Object.keys(e).forEach((function(r){Object.defineProperty(t,r,{get:function(){return e[r]},set:function(t){return e[r]=t,t}})})),t}catch(e){d([e],r)}for(var n in e)o.call(e,n)&amp;&amp;(t[n]=e[n])}(t,nrWrapper,e),nrWrapper);function nrWrapper(){var a,o,u,l;try{o=this,a=[...arguments],u="function"==typeof n?n(a,o):n||{}}catch(t){d([t,"",[a,o,s],u],e)}i(r+"start",[a,o,s],u,c);try{return l=t.apply(o,a)}catch(e){throw i(r+"err",[a,o,e],u,c),e}finally{i(r+"end",[a,o,l],u,c)}}}function i(r,n,i,a){if(!s||t){var o=s;s=!0;try{e.emit(r,n,i,t,a)}catch(t){d([t,r,n,i],e)}s=o}}}function d(e,t){t||(t=n.ee);try{t.emit("internal-error",e)}catch(e){}}function u(e){return!(e&amp;&amp;e instanceof Function&amp;&amp;e.apply&amp;&amp;!e[a])}var l=r(2210),f=r(385);const h={},p=f._A.XMLHttpRequest,g="addEventListener",m="removeEventListener",v="nr@wrapped:".concat(n.A);function b(e){var t=function(e){return(e||n.ee).get("events")}(e);if(h[t.debugId]++)return t;h[t.debugId]=1;var r=c(t,!0);function i(e){r.inPlace(e,[g,m],"-",a)}function a(e,t){return e[1]}return"getPrototypeOf"in Object&amp;&amp;(f.il&amp;&amp;y(document,i),y(f._A,i),y(p.prototype,i)),t.on(g+"-start",(function(e,t){var n=e[1];if(null!==n&amp;&amp;("function"==typeof n||"object"==typeof n)){var i=(0,l.X)(n,v,(function(){var e={object:function(){if("function"!=typeof n.handleEvent)return;return n.handleEvent.apply(n,arguments)},function:n}[typeof n];return e?r(e,"fn-",null,e.name||"anonymous"):n}));this.wrapped=e[1]=i}})),t.on(m+"-start",(function(e){e[1]=this.wrapped||e[1]})),t}function y(e,t){let r=e;for(;"object"==typeof r&amp;&amp;!Object.prototype.hasOwnProperty.call(r,g);)r=Object.getPrototypeOf(r);for(var n=arguments.length,i=new Array(n&gt;</code></p><p><code>132</code><code>2?n-2:0),a=2;a&lt;n;a++)i[a-2]=arguments[a];r&amp;&amp;t(r,...i)}var x="fetch-",w=x+"body-",A=["arrayBuffer","blob","json","text","formData"],_=f._A.Request,E=f._A.Response,T="prototype";const D={};function S(e){const t=function(e){return(e||n.ee).get("fetch")}(e);if(!(_&amp;&amp;E&amp;&amp;f._A.fetch))return t;if(D[t.debugId]++)return t;function r(e,r,i){var a=e[r];"function"==typeof a&amp;&amp;(e[r]=function(){var e,r=[...arguments],o={};t.emit(i+"before-start",[r],o),o[n.A]&amp;&amp;o[n.A].dt&amp;&amp;(e=o[n.A].dt);var s=a.apply(this,r);return t.emit(i+"start",[r,e],s),s.then((function(e){return t.emit(i+"end",[null,e],s),e}),(function(e){throw t.emit(i+"end",[e],s),e}))})}return D[t.debugId]=1,A.forEach((e=&gt;</code></p><p><code>133</code><code>{r(_[T],e,w),r(E[T],e,w)})),r(f._A,"fetch",x),t.on(x+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&amp;&amp;(n.rxSize=i),t.emit(x+"done",[null,r],n)}else t.emit(x+"done",[e],n)})),t}const j={},C=["pushState","replaceState"];function P(e){const t=function(e){return(e||n.ee).get("history")}(e);return!f.il||j[t.debugId]++||(j[t.debugId]=1,c(t).inPlace(window.history,C,"-")),t}var O=r(3239);var R=r(50);const k={},N=["open","send"];function I(e){var t=e||n.ee;const r=function(e){return(e||n.ee).get("xhr")}(t);if(k[r.debugId]++)return r;k[r.debugId]=1,b(t);var i=c(r),a=f._A.XMLHttpRequest,o=f._A.MutationObserver,s=f._A.Promise,d=f._A.setInterval,u="readystatechange",l=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],h=[],p=f._A.XMLHttpRequest=function(e){const t=new a(e),n=r.context(t);try{r.emit("new-xhr",[t],n),t.addEventListener(u,(o=n,function(){var e=this;e.readyState&gt;</code></p><p><code>134</code><code>3&amp;&amp;!o.resolved&amp;&amp;(o.resolved=!0,r.emit("xhr-resolved",[],e)),i.inPlace(e,l,"fn-",w)}),(0,O.m$)(!1))}catch(e){(0,R.Z)("An error occurred while intercepting XHR",e);try{r.emit("internal-error",[e])}catch(e){}}var o;return t};function g(e,t){i.inPlace(t,["onreadystatechange"],"fn-",w)}if(function(e,t){for(var r in e)t[r]=e[r]}(a,p),p.prototype=a.prototype,i.inPlace(p.prototype,N,"-xhr-",w),r.on("send-xhr-start",(function(e,t){g(e,t),function(e){h.push(e),o&amp;&amp;(m?m.then(x):d?d(x):(v=-v,y.data=v))}(t)})),r.on("open-xhr-start",g),o){var m=s&amp;&amp;s.resolve();if(!d&amp;&amp;!s){var v=1,y=document.createTextNode(v);new o(x).observe(y,{characterData:!0})}}else t.on("fn-end",(function(e){e[0]&amp;&amp;e[0].type===u||x()}));function x(){for(var e=0;e&lt;h.length;e++)g(0,h[e]);h.length&amp;&amp;(h=[])}function w(e,t){return t}return r}},7825:(e,t,r)=&gt;</code></p><p><code>135</code><code>{r.d(t,{t:()=&gt;</code></p><p><code>136</code><code>n});const n=r(3325).D.ajax},6660:(e,t,r)=&gt;</code></p><p><code>137</code><code>{r.d(t,{t:()=&gt;</code></p><p><code>138</code><code>n});const n=r(3325).D.jserrors},3081:(e,t,r)=&gt;</code></p><p><code>139</code><code>{r.d(t,{gF:()=&gt;</code></p><p><code>140</code><code>a,mY:()=&gt;</code></p><p><code>141</code><code>i,t9:()=&gt;</code></p><p><code>142</code><code>n,vz:()=&gt;</code></p><p><code>143</code><code>s,xS:()=&gt;</code></p><p><code>144</code><code>o});const n=r(3325).D.metrics,i="sm",a="cm",o="storeSupportabilityMetrics",s="storeEventMetrics"},4649:(e,t,r)=&gt;</code></p><p><code>145</code><code>{r.d(t,{t:()=&gt;</code></p><p><code>146</code><code>n});const n=r(3325).D.pageAction},7633:(e,t,r)=&gt;</code></p><p><code>147</code><code>{r.d(t,{t:()=&gt;</code></p><p><code>148</code><code>n});const n=r(3325).D.pageViewEvent},9251:(e,t,r)=&gt;</code></p><p><code>149</code><code>{r.d(t,{t:()=&gt;</code></p><p><code>150</code><code>n});const n=r(3325).D.pageViewTiming},7144:(e,t,r)=&gt;</code></p><p><code>151</code><code>{r.d(t,{t:()=&gt;</code></p><p><code>152</code><code>n});const n=r(3325).D.sessionReplay},3614:(e,t,r)=&gt;</code></p><p><code>153</code><code>{r.d(t,{BST_RESOURCE:()=&gt;</code></p><p><code>154</code><code>i,END:()=&gt;</code></p><p><code>155</code><code>s,FEATURE_NAME:()=&gt;</code></p><p><code>156</code><code>n,FN_END:()=&gt;</code></p><p><code>157</code><code>d,FN_START:()=&gt;</code></p><p><code>158</code><code>c,PUSH_STATE:()=&gt;</code></p><p><code>159</code><code>u,RESOURCE:()=&gt;</code></p><p><code>160</code><code>a,START:()=&gt;</code></p><p><code>161</code><code>o});const n=r(3325).D.sessionTrace,i="bstResource",a="resource",o="-start",s="-end",c="fn"+o,d="fn"+s,u="pushState"},5938:(e,t,r)=&gt;</code></p><p><code>162</code><code>{r.d(t,{W:()=&gt;</code></p><p><code>163</code><code>a});var n=r(234),i=r(8325);class a{constructor(e,t,r){this.agentIdentifier=e,this.aggregator=t,this.ee=i.ee.get(e,(0,n.OP)(this.agentIdentifier).isolatedBacklog),this.featureName=r,this.blocked=!1}}},7530:(e,t,r)=&gt;</code></p><p><code>164</code><code>{r.d(t,{j:()=&gt;</code></p><p><code>165</code><code>b});var n=r(3325),i=r(234),a=r(5546),o=r(8325),s=r(7894),c=r(8e3),d=r(3960),u=r(385),l=r(50),f=r(3081),h=r(8632);function p(){const e=(0,h.gG)();["setErrorHandler","finished","addToTrace","inlineHit","addRelease","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId","setApplicationVersion","start"].forEach((t=&gt;</code></p><p><code>166</code><code>{e[t]=function(){for(var r=arguments.length,n=new Array(r),i=0;i&lt;r;i++)n[i]=arguments[i];return function(t){for(var r=arguments.length,n=new Array(r&gt;</code></p><p><code>167</code><code>1?r-1:0),i=1;i&lt;r;i++)n[i-1]=arguments[i];let a=[];return Object.values(e.initializedAgents).forEach((e=&gt;</code></p><p><code>168</code><code>{e.exposed&amp;&amp;e.api[t]&amp;&amp;a.push(e.api[t](...n))})),a.length&gt;</code></p><p><code>169</code><code>1?a:a[0]}(t,...n)}}))}var g=r(2587);const m=e=&gt;</code></p><p><code>170</code><code>{r.p=e};let v=!1;function b(e){let t=arguments.length&gt;</code></p><p><code>171</code><code>1&amp;&amp;void 0!==arguments[1]?arguments[1]:{},b=arguments.length&gt;</code></p><p><code>172</code><code>2?arguments[2]:void 0,y=arguments.length&gt;</code></p><p><code>173</code><code>3?arguments[3]:void 0,{init:x,info:w,loader_config:A,runtime:_={loaderType:b},exposed:E=!0}=t;const T=(0,h.gG)();w||(x=T.init,w=T.info,A=T.loader_config),(0,i.Dg)(e,x||{}),(0,i.GE)(e,A||{}),w.jsAttributes??={},u.v6&amp;&amp;(w.jsAttributes.isWorker=!0),(0,i.CX)(e,w);const D=(0,i.P_)(e),S=[w.beacon,w.errorBeacon];v||(v=!0,D.proxy.assets&amp;&amp;(m(D.proxy.assets+"/"),S.push(D.proxy.assets)),D.proxy.beacon&amp;&amp;S.push(D.proxy.beacon)),_.denyList=[...D.ajax.deny_list||[],...D.ajax.block_internal?S:[]],(0,i.sU)(e,_),p();const j=function(e,t){t||(0,c.R)(e,"api");const h={};var p=o.ee.get(e),g=p.get("tracer"),m="api-",v=m+"ixn-";function b(t,r,n,a){const o=(0,i.C5)(e);return null===r?delete o.jsAttributes[t]:(0,i.CX)(e,{...o,jsAttributes:{...o.jsAttributes,[t]:r}}),w(m,n,!0,a||null===r?"session":void 0)(t,r)}function y(){}["setErrorHandler","finished","addToTrace","inlineHit","addRelease"].forEach((e=&gt;</code></p><p><code>174</code><code>{h[e]=w(m,e,!0,"api")})),h.addPageAction=w(m,"addPageAction",!0,n.D.pageAction),h.setCurrentRouteName=w(m,"routeName",!0,n.D.spa),h.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&amp;&amp;(t="/"+t),(0,i.OP)(e).customTransaction=(r||"http://custom.transaction")+t,w(m,"setPageViewName",!0)()},h.setCustomAttribute=function(e,t){let r=arguments.length&gt;</code></p><p><code>175</code><code>2&amp;&amp;void 0!==arguments[2]&amp;&amp;arguments[2];if("string"==typeof e){if(["string","number"].includes(typeof t)||null===t)return b(e,t,"setCustomAttribute",r);(0,l.Z)("Failed to execute setCustomAttribute.\nNon-null value must be a string or number type, but a type of &lt;".concat(typeof t,"&gt;</code></p><p><code>176</code><code> was provided."))}else(0,l.Z)("Failed to execute setCustomAttribute.\nName must be a string type, but a type of &lt;".concat(typeof e,"&gt;</code></p><p><code>177</code><code> was provided."))},h.setUserId=function(e){if("string"==typeof e||null===e)return b("enduser.id",e,"setUserId",!0);(0,l.Z)("Failed to execute setUserId.\nNon-null value must be a string type, but a type of &lt;".concat(typeof e,"&gt;</code></p><p><code>178</code><code> was provided."))},h.setApplicationVersion=function(e){if("string"==typeof e||null===e)return b("application.version",e,"setApplicationVersion",!1);(0,l.Z)("Failed to execute setApplicationVersion. Expected &lt;String | null&gt;</code></p><p><code>179</code><code>, but got &lt;".concat(typeof e,"&gt;</code></p><p><code>180</code><code>."))},h.start=e=&gt;</code></p><p><code>181</code><code>{try{const t=e?"defined":"undefined";(0,a.p)(f.xS,["API/start/".concat(t,"/called")],void 0,n.D.metrics,p);const r=Object.values(n.D);if(void 0===e)e=r;else{if((e=Array.isArray(e)&amp;&amp;e.length?e:[e]).some((e=&gt;</code></p><p><code>182</code><code>!r.includes(e))))return(0,l.Z)("Invalid feature name supplied. Acceptable feature names are: ".concat(r));e.includes(n.D.pageViewEvent)||e.push(n.D.pageViewEvent)}e.forEach((e=&gt;</code></p><p><code>183</code><code>{p.emit("".concat(e,"-opt-in"))}))}catch(e){(0,l.Z)("An unexpected issue occurred",e)}},h.interaction=function(){return(new y).get()};var x=y.prototype={createTracer:function(e,t){var r={},i=this,o="function"==typeof t;return(0,a.p)(v+"tracer",[(0,s.z)(),e,r],i,n.D.spa,p),function(){if(g.emit((o?"":"no-")+"fn-start",[(0,s.z)(),i,o],r),o)try{return t.apply(this,arguments)}catch(e){throw g.emit("fn-err",[arguments,this,e],r),e}finally{g.emit("fn-end",[(0,s.z)()],r)}}}};function w(e,t,r,i){return function(){return(0,a.p)(f.xS,["API/"+t+"/called"],void 0,n.D.metrics,p),i&amp;&amp;(0,a.p)(e+t,[(0,s.z)(),...arguments],r?null:this,i,p),r?void 0:this}}function A(){r.e(63).then(r.bind(r,7438)).then((t=&gt;</code></p><p><code>184</code><code>{let{setAPI:r}=t;r(e),(0,c.L)(e,"api")})).catch((()=&gt;</code></p><p><code>185</code><code>(0,l.Z)("Downloading runtime APIs failed...")))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=&gt;</code></p><p><code>186</code><code>{x[e]=w(v,e,void 0,n.D.spa)})),h.noticeError=function(e,t){"string"==typeof e&amp;&amp;(e=new Error(e)),(0,a.p)(f.xS,["API/noticeError/called"],void 0,n.D.metrics,p),(0,a.p)("err",[e,(0,s.z)(),!1,t],void 0,n.D.jserrors,p)},u.il?(0,d.b)((()=&gt;</code></p><p><code>187</code><code>A()),!0):A(),h}(e,y);return(0,h.Qy)(e,j,"api"),(0,h.Qy)(e,E,"exposed"),(0,h.EZ)("activatedFeatures",g.T),j}},3325:(e,t,r)=&gt;</code></p><p><code>188</code><code>{r.d(t,{D:()=&gt;</code></p><p><code>189</code><code>n,p:()=&gt;</code></p><p><code>190</code><code>i});const n={ajax:"ajax",jserrors:"jserrors",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",spa:"spa"},i={[n.pageViewEvent]:1,[n.pageViewTiming]:2,[n.metrics]:3,[n.jserrors]:4,[n.ajax]:5,[n.sessionTrace]:6,[n.pageAction]:7,[n.spa]:8,[n.sessionReplay]:9}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var a=n[e]={exports:{}};return r[e](a,a.exports,i),a.exports}i.m=r,i.d=(e,t)=&gt;</code></p><p><code>191</code><code>{for(var r in t)i.o(t,r)&amp;&amp;!i.o(e,r)&amp;&amp;Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=&gt;</code></p><p><code>192</code><code>Promise.all(Object.keys(i.f).reduce(((t,r)=&gt;</code></p><p><code>193</code><code>(i.f[r](e,t),t)),[])),i.u=e=&gt;</code></p><p><code>194</code><code>({63:"nr-full",110:"nr-full-compressor",379:"nr-full-recorder"}[e]+"-1.242.0.min.js"),i.o=(e,t)=&gt;</code></p><p><code>195</code><code>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA-1.242.0.PROD:",i.l=(r,n,a,o)=&gt;</code></p><p><code>196</code><code>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==a)for(var d=document.getElementsByTagName("script"),u=0;u&lt;d.length;u++){var l=d[u];if(l.getAttribute("src")==r||l.getAttribute("data-webpack")==t+a){s=l;break}}s||(c=!0,(s=document.createElement("script")).charset="utf-8",s.timeout=120,i.nc&amp;&amp;s.setAttribute("nonce",i.nc),s.setAttribute("data-webpack",t+a),s.src=r),e[r]=[n];var f=(t,n)=&gt;</code></p><p><code>197</code><code>{s.onerror=s.onload=null,clearTimeout(h);var i=e[r];if(delete e[r],s.parentNode&amp;&amp;s.parentNode.removeChild(s),i&amp;&amp;i.forEach((e=&gt;</code></p><p><code>198</code><code>e(n))),t)return t(n)},h=setTimeout(f.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=f.bind(null,s.onerror),s.onload=f.bind(null,s.onload),c&amp;&amp;document.head.appendChild(s)}},i.r=e=&gt;</code></p><p><code>199</code><code>{"undefined"!=typeof Symbol&amp;&amp;Symbol.toStringTag&amp;&amp;Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.p="https://js-agent.newrelic.com/",(()=&gt;</code></p><p><code>200</code><code>{var e={29:0,789:0};i.f.j=(t,r)=&gt;</code></p><p><code>201</code><code>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var a=new Promise(((r,i)=&gt;</code></p><p><code>202</code><code>n=e[t]=[r,i]));r.push(n[2]=a);var o=i.p+i.u(t),s=new Error;i.l(o,(r=&gt;</code></p><p><code>203</code><code>{if(i.o(e,t)&amp;&amp;(0!==(n=e[t])&amp;&amp;(e[t]=void 0),n)){var a=r&amp;&amp;("load"===r.type?"missing":r.type),o=r&amp;&amp;r.target&amp;&amp;r.target.src;s.message="Loading chunk "+t+" failed.\n("+a+": "+o+")",s.name="ChunkLoadError",s.type=a,s.request=o,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=&gt;</code></p><p><code>204</code><code>{var n,a,[o,s,c]=r,d=0;if(o.some((t=&gt;</code></p><p><code>205</code><code>0!==e[t]))){for(n in s)i.o(s,n)&amp;&amp;(i.m[n]=s[n]);if(c)c(i)}for(t&amp;&amp;t(r);d&lt;o.length;d++)a=o[d],i.o(e,a)&amp;&amp;e[a]&amp;&amp;e[a][0](),e[a]=0},r=self["webpackChunk:NRBA-1.242.0.PROD"]=self["webpackChunk:NRBA-1.242.0.PROD"]||[];r.forEach(t.bind(null,0)),r.push=t.bind(null,r.push.bind(r))})(),(()=&gt;</code></p><p><code>206</code><code>{var e=i(50);class t{addPageAction(t,r){(0,e.Z)("Call to agent api addPageAction failed. The session trace feature is not currently initialized.")}setPageViewName(t,r){(0,e.Z)("Call to agent api setPageViewName failed. The page view feature is not currently initialized.")}setCustomAttribute(t,r,n){(0,e.Z)("Call to agent api setCustomAttribute failed. The js errors feature is not currently initialized.")}noticeError(t,r){(0,e.Z)("Call to agent api noticeError failed. The js errors feature is not currently initialized.")}setUserId(t){(0,e.Z)("Call to agent api setUserId failed. The js errors feature is not currently initialized.")}setApplicationVersion(t){(0,e.Z)("Call to agent api setApplicationVersion failed. The agent is not currently initialized.")}setErrorHandler(t){(0,e.Z)("Call to agent api setErrorHandler failed. The js errors feature is not currently initialized.")}finished(t){(0,e.Z)("Call to agent api finished failed. The page action feature is not currently initialized.")}addRelease(t,r){(0,e.Z)("Call to agent api addRelease failed. The agent is not currently initialized.")}start(t){(0,e.Z)("Call to agent api addRelease failed. The agent is not currently initialized.")}}var r=i(3325),n=i(234);const a=Object.values(r.D);function o(e){const t={};return a.forEach((r=&gt;</code></p><p><code>207</code><code>{t[r]=function(e,t){return!1!==(0,n.Mt)(t,"".concat(e,".enabled"))}(r,e)})),t}var s=i(7530);var c=i(8e3),d=i(5938),u=i(3960),l=i(385);class f extends d.W{constructor(e,t,r){let i=!(arguments.length&gt;</code></p><p><code>208</code><code>3&amp;&amp;void 0!==arguments[3])||arguments[3];super(e,t,r),this.auto=i,this.abortHandler=void 0,this.featAggregate=void 0,this.onAggregateImported=void 0,!1===(0,n.Mt)(this.agentIdentifier,"".concat(this.featureName,".autoStart"))&amp;&amp;(this.auto=!1),this.auto&amp;&amp;(0,c.R)(e,r)}importAggregator(){let t=arguments.length&gt;</code></p><p><code>209</code><code>0&amp;&amp;void 0!==arguments[0]?arguments[0]:{};if(this.featAggregate)return;if(!this.auto)return void this.ee.on("".concat(this.featureName,"-opt-in"),(()=&gt;</code></p><p><code>210</code><code>{(0,c.R)(this.agentIdentifier,this.featureName),this.auto=!0,this.importAggregator()}));const r=l.il&amp;&amp;!0===(0,n.Mt)(this.agentIdentifier,"privacy.cookies_enabled");let a;this.onAggregateImported=new Promise((e=&gt;</code></p><p><code>211</code><code>{a=e}));const o=async()=&gt;</code></p><p><code>212</code><code>{let n;try{if(r){const{setupAgentSession:e}=await i.e(63).then(i.bind(i,3228));n=e(this.agentIdentifier)}}catch(t){(0,e.Z)("A problem occurred when starting up session manager. This page will not start or extend any session.",t)}try{if(!this.shouldImportAgg(this.featureName,n))return(0,c.L)(this.agentIdentifier,this.featureName),void a(!1);const{lazyFeatureLoader:e}=await i.e(63).then(i.bind(i,8582)),{Aggregate:r}=await e(this.featureName,"aggregate");this.featAggregate=new r(this.agentIdentifier,this.aggregator,t),a(!0)}catch(t){(0,e.Z)("Downloading and initializing ".concat(this.featureName," failed..."),t),this.abortHandler?.(),(0,c.L)(this.agentIdentifier,this.featureName),a(!1)}};l.il?(0,u.b)((()=&gt;</code></p><p><code>213</code><code>o()),!0):o()}shouldImportAgg(e,t){return e!==r.D.sessionReplay||!!n.Yu.MO&amp;&amp;(!1!==(0,n.Mt)(this.agentIdentifier,"session_trace.enabled")&amp;&amp;(!!t?.isNew||!!t?.state.sessionReplay))}}var h=i(7633);class p extends f{static featureName=h.t;constructor(e,t){let r=!(arguments.length&gt;</code></p><p><code>214</code><code>2&amp;&amp;void 0!==arguments[2])||arguments[2];super(e,t,h.t,r),this.importAggregator()}}var g=i(1117),m=i(1284);class v extends g.w{constructor(e){super(e),this.aggregatedData={}}store(e,t,r,n,i){var a=this.getBucket(e,t,r,i);return a.metrics=function(e,t){t||(t={count:0});return t.count+=1,(0,m.D)(e,(function(e,r){t[e]=b(r,t[e])})),t}(n,a.metrics),a}merge(e,t,r,n,i){var a=this.getBucket(e,t,n,i);if(a.metrics){var o=a.metrics;o.count+=r.count,(0,m.D)(r,(function(e,t){if("count"!==e){var n=o[e],i=r[e];i&amp;&amp;!i.c?o[e]=b(i.t,n):o[e]=function(e,t){if(!t)return e;t.c||(t=y(t.t));return t.min=Math.min(e.min,t.min),t.max=Math.max(e.max,t.max),t.t+=e.t,t.sos+=e.sos,t.c+=e.c,t}(i,o[e])}}))}else a.metrics=r}storeMetric(e,t,r,n){var i=this.getBucket(e,t,r);return i.stats=b(n,i.stats),i}getBucket(e,t,r,n){this.aggregatedData[e]||(this.aggregatedData[e]={});var i=this.aggregatedData[e][t];return i||(i=this.aggregatedData[e][t]={params:r||{}},n&amp;&amp;(i.custom=n)),i}get(e,t){return t?this.aggregatedData[e]&amp;&amp;this.aggregatedData[e][t]:this.aggregatedData[e]}take(e){for(var t={},r="",n=!1,i=0;i&lt;e.length;i++)t[r=e[i]]=x(this.aggregatedData[r]),t[r].length&amp;&amp;(n=!0),delete this.aggregatedData[r];return n?t:null}}function b(e,t){return null==e?function(e){e?e.c++:e={c:1};return e}(t):t?(t.c||(t=y(t.t)),t.c+=1,t.t+=e,t.sos+=e*e,e&gt;</code></p><p><code>215</code><code>t.max&amp;&amp;(t.max=e),e&lt;t.min&amp;&amp;(t.min=e),t):{t:e}}function y(e){return{t:e,min:e,max:e,sos:e*e,c:1}}function x(e){return"object"!=typeof e?[]:(0,m.D)(e,w)}function w(e,t){return t}var A=i(8632),_=i(4402),E=i(4351);var T=i(5546),D=i(7956),S=i(3239),j=i(7894),C=i(9251);class P extends f{static featureName=C.t;constructor(e,t){let r=!(arguments.length&gt;</code></p><p><code>216</code><code>2&amp;&amp;void 0!==arguments[2])||arguments[2];super(e,t,C.t,r),l.il&amp;&amp;((0,D.N)((()=&gt;</code></p><p><code>217</code><code>(0,T.p)("docHidden",[(0,j.z)()],void 0,C.t,this.ee)),!0),(0,S.bP)("pagehide",(()=&gt;</code></p><p><code>218</code><code>(0,T.p)("winPagehide",[(0,j.z)()],void 0,C.t,this.ee))),this.importAggregator())}}var O=i(3081);class R extends f{static featureName=O.t9;constructor(e,t){let r=!(arguments.length&gt;</code></p><p><code>219</code><code>2&amp;&amp;void 0!==arguments[2])||arguments[2];super(e,t,O.t9,r),this.importAggregator()}}var k=i(6660);class N{constructor(e,t,r,n){this.name="UncaughtError",this.message=e,this.sourceURL=t,this.line=r,this.column=n}}class I extends f{static featureName=k.t;#e=new Set;constructor(e,t){let n=!(arguments.length&gt;</code></p><p><code>220</code><code>2&amp;&amp;void 0!==arguments[2])||arguments[2];super(e,t,k.t,n);try{this.removeOnAbort=new AbortController}catch(e){}this.ee.on("fn-err",((e,t,n)=&gt;</code></p><p><code>221</code><code>{this.abortHandler&amp;&amp;!this.#e.has(n)&amp;&amp;(this.#e.add(n),(0,T.p)("err",[this.#t(n),(0,j.z)()],void 0,r.D.jserrors,this.ee))})),this.ee.on("internal-error",(e=&gt;</code></p><p><code>222</code><code>{this.abortHandler&amp;&amp;(0,T.p)("ierr",[this.#t(e),(0,j.z)(),!0],void 0,r.D.jserrors,this.ee)})),l._A.addEventListener("unhandledrejection",(e=&gt;</code></p><p><code>223</code><code>{this.abortHandler&amp;&amp;(0,T.p)("err",[this.#r(e),(0,j.z)(),!1,{unhandledPromiseRejection:1}],void 0,r.D.jserrors,this.ee)}),(0,S.m$)(!1,this.removeOnAbort?.signal)),l._A.addEventListener("error",(e=&gt;</code></p><p><code>224</code><code>{this.abortHandler&amp;&amp;(this.#e.has(e.error)?this.#e.delete(e.error):(0,T.p)("err",[this.#n(e),(0,j.z)()],void 0,r.D.jserrors,this.ee))}),(0,S.m$)(!1,this.removeOnAbort?.signal)),this.abortHandler=this.#i,this.importAggregator()}#i(){this.removeOnAbort?.abort(),this.#e.clear(),this.abortHandler=void 0}#t(e){return e instanceof Error?e:void 0!==e?.message?new N(e.message,e.filename||e.sourceURL,e.lineno||e.line,e.colno||e.col):new N("string"==typeof e?e:(0,E.P)(e))}#r(e){let t="Unhandled Promise Rejection: ";if(e?.reason instanceof Error)try{return e.reason.message=t+e.reason.message,e.reason}catch(t){return e.reason}if(void 0===e.reason)return new N(t);const r=this.#t(e.reason);return r.message=t+r.message,r}#n(e){return e.error instanceof Error?e.error:new N(e.message,e.filename,e.lineno,e.colno)}}var z=i(2210);let H=1;const L="nr@id";function M(e){const t=typeof e;return!e||"object"!==t&amp;&amp;"function"!==t?-1:e===l._A?0:(0,z.X)(e,L,(function(){return H++}))}function Z(e){if("string"==typeof e&amp;&amp;e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&amp;&amp;e instanceof ArrayBuffer&amp;&amp;e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&amp;&amp;e instanceof Blob&amp;&amp;e.size)return e.size;if(!("undefined"!=typeof FormData&amp;&amp;e instanceof FormData))try{return(0,E.P)(e).length}catch(e){return}}}var B=i(1214),F=i(7243);class U{constructor(e){this.agentIdentifier=e}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var t=(0,n.DL)(this.agentIdentifier);if(!t)return null;var r=(t.accountID||"").toString()||null,i=(t.agentID||"").toString()||null,a=(t.trustKey||"").toString()||null;if(!r||!i)return null;var o=(0,_.M)(),s=(0,_.Ht)(),c=Date.now(),d={spanId:o,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&amp;&amp;this.useTraceContextHeadersForCors())&amp;&amp;(d.traceContextParentHeader=this.generateTraceContextParentHeader(o,s),d.traceContextStateHeader=this.generateTraceContextStateHeader(o,c,r,i,a)),(e.sameOrigin&amp;&amp;!this.excludeNewrelicHeader()||!e.sameOrigin&amp;&amp;this.isAllowedOrigin(e)&amp;&amp;this.useNewrelicHeaderForCors())&amp;&amp;(d.newrelicHeader=this.generateTraceHeader(o,s,c,r,i,a)),d}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,a){if(!("function"==typeof l._A?.btoa))return null;var o={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return a&amp;&amp;n!==a&amp;&amp;(o.d.tk=a),btoa((0,E.P)(o))}shouldGenerateTrace(e){return this.isDtEnabled()&amp;&amp;this.isAllowedOrigin(e)}isAllowedOrigin(e){var t=!1,r={};if((0,n.Mt)(this.agentIdentifier,"distributed_tracing")&amp;&amp;(r=(0,n.P_)(this.agentIdentifier).distributed_tracing),e.sameOrigin)t=!0;else if(r.allowed_origins instanceof Array)for(var i=0;i&lt;r.allowed_origins.length;i++){var a=(0,F.e)(r.allowed_origins[i]);if(e.hostname===a.hostname&amp;&amp;e.protocol===a.protocol&amp;&amp;e.port===a.port){t=!0;break}}return t}isDtEnabled(){var e=(0,n.Mt)(this.agentIdentifier,"distributed_tracing");return!!e&amp;&amp;!!e.enabled}excludeNewrelicHeader(){var e=(0,n.Mt)(this.agentIdentifier,"distributed_tracing");return!!e&amp;&amp;!!e.exclude_newrelic_header}useNewrelicHeaderForCors(){var e=(0,n.Mt)(this.agentIdentifier,"distributed_tracing");return!!e&amp;&amp;!1!==e.cors_use_newrelic_header}useTraceContextHeadersForCors(){var e=(0,n.Mt)(this.agentIdentifier,"distributed_tracing");return!!e&amp;&amp;!!e.cors_use_tracecontext_headers}}var q=i(7825),V=["load","error","abort","timeout"],G=V.length,W=n.Yu.REQ,X=n.Yu.XHR;class Q extends f{static featureName=q.t;constructor(e,t){let i=!(arguments.length&gt;</code></p><p><code>225</code><code>2&amp;&amp;void 0!==arguments[2])||arguments[2];if(super(e,t,q.t,i),(0,n.OP)(e).xhrWrappable){this.dt=new U(e),this.handler=(e,t,r,n)=&gt;</code></p><p><code>226</code><code>(0,T.p)(e,t,r,n,this.ee);try{const e={xmlhttprequest:"xhr",fetch:"fetch",beacon:"beacon"};l._A?.performance?.getEntriesByType("resource").forEach((t=&gt;</code></p><p><code>227</code><code>{if(t.initiatorType in e&amp;&amp;0!==t.responseStatus){const n={status:t.responseStatus},i={rxSize:t.transferSize,duration:Math.floor(t.duration),cbTime:0};K(n,t.name),this.handler("xhr",[n,i,t.startTime,t.responseEnd,e[t.initiatorType]],void 0,r.D.ajax)}}))}catch(e){}(0,B.u5)(this.ee),(0,B.Kf)(this.ee),function(e,t,i,a){function o(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=A,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){_(t,e)}),(0,S.m$)(!1)),l.IF||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,S.m$)(!1))}function s(e){this.params={method:e[0]},K(this,e[1]),this.metrics={}}function c(t,r){var i=(0,n.DL)(e);i.xpid&amp;&amp;this.sameOrigin&amp;&amp;r.setRequestHeader("X-NewRelic-ID",i.xpid);var o=a.generateTracePayload(this.parsedOrigin);if(o){var s=!1;o.newrelicHeader&amp;&amp;(r.setRequestHeader("newrelic",o.newrelicHeader),s=!0),o.traceContextParentHeader&amp;&amp;(r.setRequestHeader("traceparent",o.traceContextParentHeader),o.traceContextStateHeader&amp;&amp;r.setRequestHeader("tracestate",o.traceContextStateHeader),s=!0),s&amp;&amp;(this.dt=o)}}function d(e,r){var n=this.metrics,i=e[0],a=this;if(n&amp;&amp;i){var o=Z(i);o&amp;&amp;(n.txSize=o)}this.startTime=(0,j.z)(),this.listener=function(e){try{"abort"!==e.type||a.loadCaptureCalled||(a.params.aborted=!0),("load"!==e.type||a.called===a.totalCbs&amp;&amp;(a.onloadCalled||"function"!=typeof r.onload)&amp;&amp;"function"==typeof a.end)&amp;&amp;a.end(r)}catch(e){try{t.emit("internal-error",[e])}catch(e){}}};for(var s=0;s&lt;G;s++)r.addEventListener(V[s],this.listener,(0,S.m$)(!1))}function u(e,t,r){this.cbTime+=e,t?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&amp;&amp;"function"==typeof r.onload||"function"!=typeof this.end||this.end(r)}function f(e,t){var r=""+M(e)+!!t;this.xhrGuids&amp;&amp;!this.xhrGuids[r]&amp;&amp;(this.xhrGuids[r]=!0,this.totalCbs+=1)}function h(e,t){var r=""+M(e)+!!t;this.xhrGuids&amp;&amp;this.xhrGuids[r]&amp;&amp;(delete this.xhrGuids[r],this.totalCbs-=1)}function p(){this.endTime=(0,j.z)()}function g(e,r){r instanceof X&amp;&amp;"load"===e[0]&amp;&amp;t.emit("xhr-load-added",[e[1],e[2]],r)}function m(e,r){r instanceof X&amp;&amp;"load"===e[0]&amp;&amp;t.emit("xhr-load-removed",[e[1],e[2]],r)}function v(e,t,r){t instanceof X&amp;&amp;("onload"===r&amp;&amp;(this.onload=!0),("load"===(e[0]&amp;&amp;e[0].type)||this.onload)&amp;&amp;(this.xhrCbStart=(0,j.z)()))}function b(e,r){this.xhrCbStart&amp;&amp;t.emit("xhr-cb-time",[(0,j.z)()-this.xhrCbStart,this.onload,r],r)}function y(e){var t,r=e[1]||{};if("string"==typeof e[0]?0===(t=e[0]).length&amp;&amp;l.il&amp;&amp;(t=""+l._A.location.href):e[0]&amp;&amp;e[0].url?t=e[0].url:l._A?.URL&amp;&amp;e[0]&amp;&amp;e[0]instanceof URL?t=e[0].href:"function"==typeof e[0].toString&amp;&amp;(t=e[0].toString()),"string"==typeof t&amp;&amp;0!==t.length){t&amp;&amp;(this.parsedOrigin=(0,F.e)(t),this.sameOrigin=this.parsedOrigin.sameOrigin);var n=a.generateTracePayload(this.parsedOrigin);if(n&amp;&amp;(n.newrelicHeader||n.traceContextParentHeader))if(e[0]&amp;&amp;e[0].headers)s(e[0].headers,n)&amp;&amp;(this.dt=n);else{var i={};for(var o in r)i[o]=r[o];i.headers=new Headers(r.headers||{}),s(i.headers,n)&amp;&amp;(this.dt=n),e.length&gt;</code></p><p><code>228</code><code>1?e[1]=i:e.push(i)}}function s(e,t){var r=!1;return t.newrelicHeader&amp;&amp;(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&amp;&amp;(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&amp;&amp;e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,j.z)(),this.dt=t,e.length&gt;</code></p><p><code>229</code><code>=1&amp;&amp;(this.target=e[0]),e.length&gt;</code></p><p><code>230</code><code>=2&amp;&amp;(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&amp;&amp;i instanceof W?r=i.url:l._A?.URL&amp;&amp;"object"==typeof i&amp;&amp;i instanceof URL&amp;&amp;(r=i.href),K(this,r);var a=(""+(i&amp;&amp;i instanceof W&amp;&amp;i.method||n.method||"GET")).toUpperCase();this.params.method=a,this.txSize=Z(n.body)||0}function w(e,t){var n;this.endTime=(0,j.z)(),this.params||(this.params={}),this.params.status=t?t.status:0,"string"==typeof this.rxSize&amp;&amp;this.rxSize.length&gt;</code></p><p><code>231</code><code>0&amp;&amp;(n=+this.rxSize);var a={txSize:this.txSize,rxSize:n,duration:(0,j.z)()-this.startTime};i("xhr",[this.params,a,this.startTime,this.endTime,"fetch"],this,r.D.ajax)}function A(e){var t=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var a=0;a&lt;G;a++)e.removeEventListener(V[a],this.listener,!1);t.aborted||(n.duration=(0,j.z)()-this.startTime,this.loadCaptureCalled||4!==e.readyState?null==t.status&amp;&amp;(t.status=0):_(this,e),n.cbTime=this.cbTime,i("xhr",[t,n,this.startTime,this.endTime,"xhr"],this,r.D.ajax))}}function _(e,t){e.params.status=t.status;var r=function(e,t){var r=e.responseType;return"json"===r&amp;&amp;null!==t?t:"arraybuffer"===r||"blob"===r||"json"===r?Z(e.response):"text"===r||""===r||void 0===r?Z(e.responseText):void 0}(t,e.lastSize);if(r&amp;&amp;(e.metrics.rxSize=r),e.sameOrigin){var n=t.getResponseHeader("X-NewRelic-App-Data");n&amp;&amp;(e.params.cat=n.split(", ").pop())}e.loadCaptureCalled=!0}t.on("new-xhr",o),t.on("open-xhr-start",s),t.on("open-xhr-end",c),t.on("send-xhr-start",d),t.on("xhr-cb-time",u),t.on("xhr-load-added",f),t.on("xhr-load-removed",h),t.on("xhr-resolved",p),t.on("addEventListener-end",g),t.on("removeEventListener-end",m),t.on("fn-end",b),t.on("fetch-before-start",y),t.on("fetch-start",x),t.on("fn-start",v),t.on("fetch-done",w)}(e,this.ee,this.handler,this.dt),this.importAggregator()}}}function K(e,t){var r=(0,F.e)(t),n=e.params||e;n.hostname=r.hostname,n.port=r.port,n.protocol=r.protocol,n.host=r.hostname+":"+r.port,n.pathname=r.pathname,e.parsedOrigin=r,e.sameOrigin=r.sameOrigin}var Y=i(3614);const{BST_RESOURCE:J,RESOURCE:ee,START:te,END:re,FEATURE_NAME:ne,FN_END:ie,FN_START:ae,PUSH_STATE:oe}=Y;var se=i(7144);class ce extends f{static featureName=se.t;constructor(e,t){let r=!(arguments.length&gt;</code></p><p><code>232</code><code>2&amp;&amp;void 0!==arguments[2])||arguments[2];super(e,t,se.t,r),this.importAggregator()}}var de=i(4649);class ue extends f{static featureName=de.t;constructor(e,t){let r=!(arguments.length&gt;</code></p><p><code>233</code><code>2&amp;&amp;void 0!==arguments[2])||arguments[2];super(e,t,de.t,r),this.importAggregator()}}new class extends t{constructor(t){let r=arguments.length&gt;</code></p><p><code>234</code><code>1&amp;&amp;void 0!==arguments[1]?arguments[1]:(0,_.ky)(16);super(),l._A?(this.agentIdentifier=r,this.sharedAggregator=new v({agentIdentifier:this.agentIdentifier}),this.features={},this.desiredFeatures=new Set(t.features||[]),this.desiredFeatures.add(p),Object.assign(this,(0,s.j)(this.agentIdentifier,t,t.loaderType||"agent")),this.run()):(0,e.Z)("Failed to initial the agent. Could not determine the runtime environment.")}get config(){return{info:(0,n.C5)(this.agentIdentifier),init:(0,n.P_)(this.agentIdentifier),loader_config:(0,n.DL)(this.agentIdentifier),runtime:(0,n.OP)(this.agentIdentifier)}}run(){const t="features";try{const n=o(this.agentIdentifier),i=[...this.desiredFeatures];i.sort(((e,t)=&gt;</code></p><p><code>235</code><code>r.p[e.featureName]-r.p[t.featureName])),i.forEach((t=&gt;</code></p><p><code>236</code><code>{if(n[t.featureName]||t.featureName===r.D.pageViewEvent){const i=function(e){switch(e){case r.D.ajax:return[r.D.jserrors];case r.D.sessionTrace:return[r.D.ajax,r.D.pageViewEvent];case r.D.sessionReplay:return[r.D.sessionTrace];case r.D.pageViewTiming:return[r.D.pageViewEvent];default:return[]}}(t.featureName);i.every((e=&gt;</code></p><p><code>237</code><code>n[e]))||(0,e.Z)("".concat(t.featureName," is enabled but one or more dependent features has been disabled (").concat((0,E.P)(i),"). This may cause unintended consequences or missing data...")),this.features[t.featureName]=new t(this.agentIdentifier,this.sharedAggregator)}})),(0,A.Qy)(this.agentIdentifier,this.features,t)}catch(r){(0,e.Z)("Failed to initialize all enabled instrument classes (agent aborted) -",r);for(const e in this.features)this.features[e].abortHandler?.();const n=(0,A.fP)();return delete n.initializedAgents[this.agentIdentifier]?.api,delete n.initializedAgents[this.agentIdentifier]?.[t],delete this.sharedAggregator,n.ee?.abort(),delete n.ee?.get(this.agentIdentifier),!1}}addToTrace(t){(0,e.Z)("Call to agent api addToTrace failed. The page action feature is not currently initialized.")}setCurrentRouteName(t){(0,e.Z)("Call to agent api setCurrentRouteName failed. The spa feature is not currently initialized.")}interaction(){(0,e.Z)("Call to agent api interaction failed. The spa feature is not currently initialized.")}}({features:[p,P,class extends f{static featureName=ne;constructor(e,t){if(super(e,t,ne,!(arguments.length&gt;</code></p><p><code>238</code><code>2&amp;&amp;void 0!==arguments[2])||arguments[2]),!l.il)return;const n=this.ee;let i;(0,B.QU)(n),this.eventsEE=(0,B.em)(n),this.eventsEE.on(ae,(function(e,t){this.bstStart=(0,j.z)()})),this.eventsEE.on(ie,(function(e,t){(0,T.p)("bst",[e[0],t,this.bstStart,(0,j.z)()],void 0,r.D.sessionTrace,n)})),n.on(oe+te,(function(e){this.time=(0,j.z)(),this.startPath=location.pathname+location.hash})),n.on(oe+re,(function(e){(0,T.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,r.D.sessionTrace,n)}));try{i=new PerformanceObserver((e=&gt;</code></p><p><code>239</code><code>{const t=e.getEntries();(0,T.p)(J,[t],void 0,r.D.sessionTrace,n)})),i.observe({type:ee,buffered:!0})}catch(e){}this.importAggregator({resourceObserver:i})}},ce,Q,R,ue,I],loaderType:"pro"})})()})();&lt;/script&gt;</code></p><p><code>240</code><code>          </code></p><p><code>241</code><code>&lt;script&gt;</code></p><p><code>242</code><code>window.CDEConfig = {</code></p><p><code>243</code><code>  "exitDisclaimerHref":{</code></p><p><code>244</code><code>    "en":"\/policies\/linking",</code></p><p><code>245</code><code>    "es":"\/espanol\/politicas\/enlaces"</code></p><p><code>246</code><code>  },</code></p><p><code>247</code><code>  "showFloatingDelighters":true,</code></p><p><code>248</code><code>  "environmentConfig":{</code></p><p><code>249</code><code>    </code></p><p><code>250</code><code>  },</code></p><p><code>251</code><code>  "glossaryConfig":{</code></p><p><code>252</code><code>    "apiServer":"https:\/\/webapis.cancer.gov\/glossary\/v1\/"</code></p><p><code>253</code><code>  },</code></p><p><code>254</code><code>  "drugDictionaryConfig":{</code></p><p><code>255</code><code>    "apiServer":"https:\/\/webapis.cancer.gov\/drugdictionary\/v1\/"</code></p><p><code>256</code><code>  },</code></p><p><code>257</code><code>  "ctsConfig":{</code></p><p><code>258</code><code>    "apiServer":"https:\/\/clinicaltrialsapi.cancer.gov\/api\/v2",</code></p><p><code>259</code><code>    "printApiBase":"https:\/\/www.cancer.gov\/CTS.Print",</code></p><p><code>260</code><code>    "zipConversionEndpoint":"\/cts_api\/zip_code_lookup"</code></p><p><code>261</code><code>  },</code></p><p><code>262</code><code>  "r4rConfig":{</code></p><p><code>263</code><code>    "apiServer":"https:\/\/webapis.cancer.gov\/r4r\/v1"</code></p><p><code>264</code><code>  },</code></p><p><code>265</code><code>  "general":{</code></p><p><code>266</code><code>    "apiServer":"https:\/\/webapis.cancer.gov",</code></p><p><code>267</code><code>    "mediaServer":"https:\/\/nci-media.cancer.gov"</code></p><p><code>268</code><code>  },</code></p><p><code>269</code><code>  "sitewideSearchConfig":{</code></p><p><code>270</code><code>    "bestBetsApiServer":"https:\/\/webapis.cancer.gov\/bestbets\/v1\/",</code></p><p><code>271</code><code>    "searchApiServer":"https:\/\/webapis.cancer.gov\/sitewidesearch\/v1\/"</code></p><p><code>272</code><code>  },</code></p><p><code>273</code><code>  "chartData": {</code></p><p><code>274</code><code>    "factBook": {</code></p><p><code>275</code><code>      "baseUrl": "\/about-nci\/budget\/fact-book",</code></p><p><code>276</code><code>      "dataType": "json"</code></p><p><code>277</code><code>    }</code></p><p><code>278</code><code>  }</code></p><p><code>279</code><code>};&lt;/script&gt;</code></p><p><code>280</code><code>          </code></p><p><code>281</code><code>&lt;script id="ncids-nav-info"&gt;</code></p><p><code>282</code><code>window.ncidsNavInfo = { nav: { id: "11958", menu_type: "section-nav"}, item_id: 940946};&lt;/script&gt;</code></p><p><code>283</code><code>          </code></p><p><code>284</code><code>&lt;meta name="description" content="Merkel cell carcinoma treatment options include surgery, radiation therapy, and chemotherapy. Get detailed information about the diagnosis and treatment of newly diagnosed and recurrent Merkel cell carcinoma in this summary for clinicians." /&gt;</code></p><p><code>285</code><code>          </code></p><p><code>286</code><code>&lt;link rel="canonical" href="https://www.cancer.gov/types/skin/hp/merkel-cell-treatment-pdq" /&gt;</code></p><p><code>287</code><code>          </code></p><p><code>288</code><code>&lt;meta http-equiv="content-language" content="en" /&gt;</code></p><p><code>289</code><code>          </code></p><p><code>290</code><code>&lt;meta property="og:site_name" content="National Cancer Institute" /&gt;</code></p><p><code>291</code><code>          </code></p><p><code>292</code><code>&lt;meta property="og:type" content="Website" /&gt;</code></p><p><code>293</code><code>          </code></p><p><code>294</code><code>&lt;meta property="og:url" content="https://www.cancer.gov/types/skin/hp/merkel-cell-treatment-pdq" /&gt;</code></p><p><code>295</code><code>          </code></p><p><code>296</code><code>&lt;meta property="og:title" content="Merkel Cell Carcinoma Treatment (PDQ®)" /&gt;</code></p><p><code>297</code><code>          </code></p><p><code>298</code><code>&lt;meta property="og:description" content="Merkel cell carcinoma treatment options include surgery, radiation therapy, and chemotherapy. Get detailed information about the diagnosis and treatment of newly diagnosed and recurrent Merkel cell carcinoma in this summary for clinicians." /&gt;</code></p><p><code>299</code><code>          </code></p><p><code>300</code><code>&lt;meta name="dcterms.subject" content="Cancer Types" /&gt;</code></p><p><code>301</code><code>          </code></p><p><code>302</code><code>&lt;meta name="dcterms.type" content="pdqCancerInfoSummary" /&gt;</code></p><p><code>303</code><code>          </code></p><p><code>304</code><code>&lt;meta name="dcterms.coverage" content="nciglobal,ncienterprise" /&gt;</code></p><p><code>305</code><code>          </code></p><p><code>306</code><code>&lt;meta name="dcterms.audience" content="Health Professionals" /&gt;</code></p><p><code>307</code><code>          </code></p><p><code>308</code><code>&lt;meta name="dcterms.isPartOf" content="Cancer Types Landing Page" /&gt;</code></p><p><code>309</code><code>          </code></p><p><code>310</code><code>&lt;meta name="dcterms.isReferencedBy" content="event1" /&gt;</code></p><p><code>311</code><code>          </code></p><p><code>312</code><code>&lt;meta name="dcterms.issued" content="06/07/2023 - 08:00" /&gt;</code></p><p><code>313</code><code>          </code></p><p><code>314</code><code>&lt;meta name="twitter:card" content="summary" /&gt;</code></p><p><code>315</code><code>          </code></p><p><code>316</code><code>&lt;meta name="Generator" content="Drupal 9 (https://www.drupal.org)" /&gt;</code></p><p><code>317</code><code>          </code></p><p><code>318</code><code>&lt;meta name="MobileOptimized" content="width" /&gt;</code></p><p><code>319</code><code>          </code></p><p><code>320</code><code>&lt;meta name="HandheldFriendly" content="true" /&gt;</code></p><p><code>321</code><code>          </code></p><p><code>322</code><code>&lt;meta name="viewport" content="width=device-width, user-scalable=yes, initial-scale=1, minimum-scale=1" /&gt;</code></p><p><code>323</code><code>          </code></p><p><code>324</code><code>&lt;script id="cgov-adobe-url" type="text/javascript" src="//assets.adobedtm.com/6a4249cd0a2c/949e98979342/launch-5f2a5357bf66.min.js"&gt;</code></p><p><code>325</code><code>&lt;/script&gt;</code></p><p><code>326</code><code>          </code></p><p><code>327</code><code>&lt;link rel="icon" href="/core/misc/favicon.ico" type="image/vnd.microsoft.icon" /&gt;</code></p><p><code>328</code><code>          </code></p><p><code>329</code><code>&lt;link rel="alternate" hreflang="en" href="https://www.cancer.gov/types/skin/hp/merkel-cell-treatment-pdq" /&gt;</code></p><p><code>330</code><code>          </code></p><p><code>331</code><code>&lt;link rel="alternate" hreflang="es" href="https://www.cancer.gov/espanol/tipos/piel/pro/tratamiento-celulas-de-merkel-pdq" /&gt;</code></p><p><code>332</code><code>          </code></p><p><code>333</code><code>          </code></p><p><code>334</code><code>    &lt;title&gt;</code></p><p><code>335</code><code>Merkel Cell Carcinoma Treatment (PDQ®) - NCI&lt;/title&gt;</code></p><p><code>336</code><code>          </code></p><p><code>337</code><code>    &lt;link rel="preconnect" href="https://static.cancer.gov" /&gt;</code></p><p><code>338</code><code>          </code></p><p><code>339</code><code>        &lt;link rel="preconnect" href="https://fonts.googleapis.com"&gt;</code></p><p><code>340</code><code>          </code></p><p><code>341</code><code>    &lt;link rel="preconnect" href="https://fonts.gstatic.com" crossorigin&gt;</code></p><p><code>342</code><code>          </code></p><p><code>343</code><code>    &lt;link href="https://fonts.googleapis.com/css2?family=Open+Sans:ital,wght@0,300;0,400;0,600;0,700;1,300;1,400;1,600;1,700&amp;family=Poppins:ital,wght@0,300;0,400;0,500;0,600;1,300;1,400;1,500;1,600&amp;family=Roboto+Mono:ital,wght@0,300;0,400;0,700;1,300;1,400;1,700&amp;display=swap" rel="stylesheet"&gt;</code></p><p><code>344</code><code>          </code></p><p><code>345</code><code>    &lt;link rel="apple-touch-icon" sizes="180x180" href="/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/apple-touch-icon.png?v=1" /&gt;</code></p><p><code>346</code><code>          </code></p><p><code>347</code><code>    &lt;link rel="icon" type="image/png" href="/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/favicon-32x32.png?v=1" sizes="32x32" /&gt;</code></p><p><code>348</code><code>          </code></p><p><code>349</code><code>    &lt;link rel="icon" type="image/png" href="/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/favicon-16x16.png?v=1" sizes="16x16" /&gt;</code></p><p><code>350</code><code>          </code></p><p><code>351</code><code>    &lt;link rel="mask-icon" href="/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/safari-pinned-tab.svg?v=1" color="#c0143c" /&gt;</code></p><p><code>352</code><code>          </code></p><p><code>353</code><code>    &lt;link rel="shortcut icon" href="/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/favicon.ico?v=1" /&gt;</code></p><p><code>354</code><code>          </code></p><p><code>355</code><code>    &lt;meta name="apple-mobile-web-app-title" content="Cancer.gov" /&gt;</code></p><p><code>356</code><code>          </code></p><p><code>357</code><code>    &lt;meta name="application-name" content="Cancer.gov" /&gt;</code></p><p><code>358</code><code>          </code></p><p><code>359</code><code>    &lt;meta name="msapplication-config" content="/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/browserconfig.xml?v=1" /&gt;</code></p><p><code>360</code><code>          </code></p><p><code>361</code><code>    &lt;link rel="stylesheet" media="all" href="/sites/g/files/xnrzdm211/files/css/css_sl7QUD1H8m-3-HmAxYnsPVDgLlc-msHkQ9qf52aVYeE.css" /&gt;</code></p><p><code>362</code><code>          </code></p><p><code>363</code><code>&lt;link rel="stylesheet" media="all" href="/profiles/custom/cgov_site/themes/custom/ncids_trans/dist/css/ncids-common.css?s1d5be" /&gt;</code></p><p><code>364</code><code>          </code></p><p><code>365</code><code>&lt;link rel="stylesheet" media="all" href="/profiles/custom/cgov_site/themes/custom/ncids_trans/dist/css/pdq.css?s1d5be" /&gt;</code></p><p><code>366</code><code>          </code></p><p><code>367</code><code>          </code></p><p><code>368</code><code>    </code></p><p><code>369</code><code>  &lt;/head&gt;</code></p><p><code>370</code><code>          </code></p><p><code>371</code><code>  &lt;body class="has-translated-content"&gt;</code></p><p><code>372</code><code>          </code></p><p><code>373</code><code>        &lt;a href="#main-content" class="usa-skipnav"&gt;</code></p><p><code>374</code><code>          </code></p><p><code>375</code><code>      Skip to main content</code></p><p><code>376</code><code>    &lt;/a&gt;</code></p><p><code>377</code><code>          </code></p><p><code>378</code><code>    </code></p><p><code>379</code><code>      &lt;div class="dialog-off-canvas-main-canvas" data-off-canvas-main-canvas&gt;</code></p><p><code>380</code><code>          </code></p><p><code>381</code><code>    </code></p><p><code>382</code><code>          </code></p><p><code>383</code><code>          </code></p><p><code>384</code><code>  &lt;section id="usa-banner" class="usa-banner usa-banner--nci-banner" aria-label="Official government website"&gt;</code></p><p><code>385</code><code>          </code></p><p><code>386</code><code>  &lt;header class="usa-banner__header"&gt;</code></p><p><code>387</code><code>          </code></p><p><code>388</code><code>    &lt;div class="usa-banner__inner"&gt;</code></p><p><code>389</code><code>          </code></p><p><code>390</code><code>      &lt;div class="usa-banner__header-text"&gt;</code></p><p><code>391</code><code>          </code></p><p><code>392</code><code>        An official website of the United States government</code></p><p><code>393</code><code>      &lt;/div&gt;</code></p><p><code>394</code><code>          </code></p><p><code>395</code><code>            &lt;a href="/espanol/tipos/piel/pro/tratamiento-celulas-de-merkel-pdq" id="lang-toggle" class="usa-button usa-button--nci-small" hreflang="es"&gt;</code></p><p><code>396</code><code>Español&lt;/a&gt;</code></p><p><code>397</code><code>          </code></p><p><code>398</code><code>    &lt;/div&gt;</code></p><p><code>399</code><code>          </code></p><p><code>400</code><code>  &lt;/header&gt;</code></p><p><code>401</code><code>          </code></p><p><code>402</code><code>&lt;/section&gt;</code></p><p><code>403</code><code>          </code></p><p><code>404</code><code>          </code></p><p><code>405</code><code>          </code></p><p><code>406</code><code>          </code></p><p><code>407</code><code>  &lt;header id="nci-header" class="nci-header nci-header--extended" data-base-path="/"&gt;</code></p><p><code>408</code><code>          </code></p><p><code>409</code><code>	&lt;div class="nci-header__navbar"&gt;</code></p><p><code>410</code><code>          </code></p><p><code>411</code><code>		&lt;div class="nci-logo" id="extended-mega-logo"&gt;</code></p><p><code>412</code><code>          </code></p><p><code>413</code><code>			&lt;a href="/" aria-label="National Cancer Institute Home Page"&gt;</code></p><p><code>414</code><code>          </code></p><p><code>415</code><code>				&lt;picture&gt;</code></p><p><code>416</code><code>&lt;source media="(min-width: 1024px)" srcset="/sites/g/files/xnrzdm211/files/ncids_header/logos/Logo_NCI.svg" /&gt;</code></p><p><code>417</code><code>          </code></p><p><code>418</code><code>&lt;img src="/sites/g/files/xnrzdm211/files/ncids_header/logos/Logo_NCI_Mobile.svg" alt="" /&gt;</code></p><p><code>419</code><code>          </code></p><p><code>420</code><code>&lt;/picture&gt;</code></p><p><code>421</code><code>          </code></p><p><code>422</code><code>          </code></p><p><code>423</code><code>			&lt;/a&gt;</code></p><p><code>424</code><code>          </code></p><p><code>425</code><code>		&lt;/div&gt;</code></p><p><code>426</code><code>          </code></p><p><code>427</code><code>          </code></p><p><code>428</code><code>		&lt;div class="nci-header-nav__secondary"&gt;</code></p><p><code>429</code><code>          </code></p><p><code>430</code><code>			&lt;button class="usa-button nci-header-mobilenav__open-btn"&gt;</code></p><p><code>431</code><code>Menu&lt;/button&gt;</code></p><p><code>432</code><code>          </code></p><p><code>433</code><code>          </code></p><p><code>434</code><code>							&lt;form class="nci-header-search" method="get" action="/search/results" role="search"&gt;</code></p><p><code>435</code><code>          </code></p><p><code>436</code><code>					&lt;label class="usa-sr-only" for="nci-header-search__field"&gt;</code></p><p><code>437</code><code>          </code></p><p><code>438</code><code>						Search</code></p><p><code>439</code><code>					&lt;/label&gt;</code></p><p><code>440</code><code>          </code></p><p><code>441</code><code>          </code></p><p><code>442</code><code>																										&lt;input class="usa-input" id="nci-header-search__field" type="search" name="swKeyword"  data-autosuggest-collection="cgov"/&gt;</code></p><p><code>443</code><code>          </code></p><p><code>444</code><code>					&lt;button class="usa-button nci-header-search__search-button" type="submit" aria-label="Search"&gt;</code></p><p><code>445</code><code>          </code></p><p><code>446</code><code>						&lt;span class="nci-header-search__label" aria-hidden="true"&gt;</code></p><p><code>447</code><code>Search&lt;/span&gt;</code></p><p><code>448</code><code>          </code></p><p><code>449</code><code>						&lt;svg class="usa-icon" xmlns="http://www.w3.org/2000/svg" role="img" viewbox="0 0 24 24" aria-hidden="true"&gt;</code></p><p><code>450</code><code>          </code></p><p><code>451</code><code>							&lt;path d="M0 0h24v24H0z" fill="none"/&gt;</code></p><p><code>452</code><code>          </code></p><p><code>453</code><code>							&lt;path d="M15.5 14h-.79l-.28-.27C15.41 12.59 16 11.11 16 9.5 16 5.91 13.09 3 9.5 3S3 5.91 3 9.5 5.91 16 9.5 16c1.61 0 3.09-.59 4.23-1.57l.27.28v.79l5 4.99L20.49 19l-4.99-5zm-6 0C7.01 14 5 11.99 5 9.5S7.01 5 9.5 5 14 7.01 14 9.5 11.99 14 9.5 14z"/&gt;</code></p><p><code>454</code><code>          </code></p><p><code>455</code><code>						&lt;/svg&gt;</code></p><p><code>456</code><code>          </code></p><p><code>457</code><code>					&lt;/button&gt;</code></p><p><code>458</code><code>          </code></p><p><code>459</code><code>				&lt;/form&gt;</code></p><p><code>460</code><code>          </code></p><p><code>461</code><code>					&lt;/div&gt;</code></p><p><code>462</code><code>          </code></p><p><code>463</code><code>	&lt;/div&gt;</code></p><p><code>464</code><code>          </code></p><p><code>465</code><code>          </code></p><p><code>466</code><code>			&lt;nav aria-label="Primary navigation" class="nci-header-nav"&gt;</code></p><p><code>467</code><code>          </code></p><p><code>468</code><code>			&lt;div class="nci-header-nav__inner"&gt;</code></p><p><code>469</code><code>          </code></p><p><code>470</code><code>				&lt;ul class="nci-header-nav__primary"&gt;</code></p><p><code>471</code><code>          </code></p><p><code>472</code><code>											&lt;li class="nci-header-nav__primary-item"&gt;</code></p><p><code>473</code><code>          </code></p><p><code>474</code><code>																																											&lt;a  href="/about-cancer" class="nci-header-nav__primary-link" data-menu-id="829"&gt;</code></p><p><code>475</code><code>          </code></p><p><code>476</code><code>								&lt;span&gt;</code></p><p><code>477</code><code>About Cancer&lt;/span&gt;</code></p><p><code>478</code><code>          </code></p><p><code>479</code><code>							&lt;/a&gt;</code></p><p><code>480</code><code>          </code></p><p><code>481</code><code>						&lt;/li&gt;</code></p><p><code>482</code><code>          </code></p><p><code>483</code><code>											&lt;li class="nci-header-nav__primary-item"&gt;</code></p><p><code>484</code><code>          </code></p><p><code>485</code><code>																																																										&lt;a  href="/types" class="nci-header-nav__primary-link usa-current" data-menu-id="11868"&gt;</code></p><p><code>486</code><code>          </code></p><p><code>487</code><code>								&lt;span&gt;</code></p><p><code>488</code><code>Cancer Types&lt;/span&gt;</code></p><p><code>489</code><code>          </code></p><p><code>490</code><code>							&lt;/a&gt;</code></p><p><code>491</code><code>          </code></p><p><code>492</code><code>						&lt;/li&gt;</code></p><p><code>493</code><code>          </code></p><p><code>494</code><code>											&lt;li class="nci-header-nav__primary-item"&gt;</code></p><p><code>495</code><code>          </code></p><p><code>496</code><code>																																											&lt;a  href="/research" class="nci-header-nav__primary-link" data-menu-id="12732"&gt;</code></p><p><code>497</code><code>          </code></p><p><code>498</code><code>								&lt;span&gt;</code></p><p><code>499</code><code>Research&lt;/span&gt;</code></p><p><code>500</code><code>          </code></p><p><code>501</code><code>							&lt;/a&gt;</code></p><p><code>502</code><code>          </code></p><p><code>503</code><code>						&lt;/li&gt;</code></p><p><code>504</code><code>          </code></p><p><code>505</code><code>											&lt;li class="nci-header-nav__primary-item"&gt;</code></p><p><code>506</code><code>          </code></p><p><code>507</code><code>																																											&lt;a  href="/grants-training" class="nci-header-nav__primary-link" data-menu-id="914792"&gt;</code></p><p><code>508</code><code>          </code></p><p><code>509</code><code>								&lt;span&gt;</code></p><p><code>510</code><code>Grants &amp;amp; Training&lt;/span&gt;</code></p><p><code>511</code><code>          </code></p><p><code>512</code><code>							&lt;/a&gt;</code></p><p><code>513</code><code>          </code></p><p><code>514</code><code>						&lt;/li&gt;</code></p><p><code>515</code><code>          </code></p><p><code>516</code><code>											&lt;li class="nci-header-nav__primary-item"&gt;</code></p><p><code>517</code><code>          </code></p><p><code>518</code><code>																																											&lt;a  href="/news-events" class="nci-header-nav__primary-link" data-menu-id="12664"&gt;</code></p><p><code>519</code><code>          </code></p><p><code>520</code><code>								&lt;span&gt;</code></p><p><code>521</code><code>News &amp;amp; Events&lt;/span&gt;</code></p><p><code>522</code><code>          </code></p><p><code>523</code><code>							&lt;/a&gt;</code></p><p><code>524</code><code>          </code></p><p><code>525</code><code>						&lt;/li&gt;</code></p><p><code>526</code><code>          </code></p><p><code>527</code><code>											&lt;li class="nci-header-nav__primary-item"&gt;</code></p><p><code>528</code><code>          </code></p><p><code>529</code><code>																																											&lt;a  href="/about-nci" class="nci-header-nav__primary-link" data-menu-id="10952"&gt;</code></p><p><code>530</code><code>          </code></p><p><code>531</code><code>								&lt;span&gt;</code></p><p><code>532</code><code>About NCI&lt;/span&gt;</code></p><p><code>533</code><code>          </code></p><p><code>534</code><code>							&lt;/a&gt;</code></p><p><code>535</code><code>          </code></p><p><code>536</code><code>						&lt;/li&gt;</code></p><p><code>537</code><code>          </code></p><p><code>538</code><code>									&lt;/ul&gt;</code></p><p><code>539</code><code>          </code></p><p><code>540</code><code>			&lt;/div&gt;</code></p><p><code>541</code><code>          </code></p><p><code>542</code><code>		&lt;/nav&gt;</code></p><p><code>543</code><code>          </code></p><p><code>544</code><code>	</code></p><p><code>545</code><code>&lt;/header&gt;</code></p><p><code>546</code><code>          </code></p><p><code>547</code><code>          </code></p><p><code>548</code><code>          </code></p><p><code>549</code><code>          </code></p><p><code>550</code><code>&lt;div class="grid-container"&gt;</code></p><p><code>551</code><code>          </code></p><p><code>552</code><code>  &lt;div class="grid-row flex-no-wrap"&gt;</code></p><p><code>553</code><code>          </code></p><p><code>554</code><code>    &lt;div class="grid-col-10"&gt;</code></p><p><code>555</code><code>          </code></p><p><code>556</code><code>                &lt;nav class="usa-breadcrumb usa-breadcrumb--wrap" aria-label="Breadcrumbs"&gt;</code></p><p><code>557</code><code>          </code></p><p><code>558</code><code>    &lt;ol class="usa-breadcrumb__list"&gt;</code></p><p><code>559</code><code>          </code></p><p><code>560</code><code>              &lt;li class="usa-breadcrumb__list-item"&gt;</code></p><p><code>561</code><code>          </code></p><p><code>562</code><code>          &lt;a href="/" class="usa-breadcrumb__link"&gt;</code></p><p><code>563</code><code>          </code></p><p><code>564</code><code>            &lt;span&gt;</code></p><p><code>565</code><code>Home&lt;/span&gt;</code></p><p><code>566</code><code>          </code></p><p><code>567</code><code>          &lt;/a&gt;</code></p><p><code>568</code><code>          </code></p><p><code>569</code><code>        &lt;/li&gt;</code></p><p><code>570</code><code>          </code></p><p><code>571</code><code>              &lt;li class="usa-breadcrumb__list-item"&gt;</code></p><p><code>572</code><code>          </code></p><p><code>573</code><code>          &lt;a href="/types" class="usa-breadcrumb__link"&gt;</code></p><p><code>574</code><code>          </code></p><p><code>575</code><code>            &lt;span&gt;</code></p><p><code>576</code><code>Cancer Types&lt;/span&gt;</code></p><p><code>577</code><code>          </code></p><p><code>578</code><code>          &lt;/a&gt;</code></p><p><code>579</code><code>          </code></p><p><code>580</code><code>        &lt;/li&gt;</code></p><p><code>581</code><code>          </code></p><p><code>582</code><code>              &lt;li class="usa-breadcrumb__list-item"&gt;</code></p><p><code>583</code><code>          </code></p><p><code>584</code><code>          &lt;a href="/types/skin" class="usa-breadcrumb__link"&gt;</code></p><p><code>585</code><code>          </code></p><p><code>586</code><code>            &lt;span&gt;</code></p><p><code>587</code><code>Skin Cancer&lt;/span&gt;</code></p><p><code>588</code><code>          </code></p><p><code>589</code><code>          &lt;/a&gt;</code></p><p><code>590</code><code>          </code></p><p><code>591</code><code>        &lt;/li&gt;</code></p><p><code>592</code><code>          </code></p><p><code>593</code><code>              &lt;li class="usa-breadcrumb__list-item"&gt;</code></p><p><code>594</code><code>          </code></p><p><code>595</code><code>          &lt;a href="/types/skin/hp" class="usa-breadcrumb__link"&gt;</code></p><p><code>596</code><code>          </code></p><p><code>597</code><code>            &lt;span&gt;</code></p><p><code>598</code><code>Health Professional&lt;/span&gt;</code></p><p><code>599</code><code>          </code></p><p><code>600</code><code>          &lt;/a&gt;</code></p><p><code>601</code><code>          </code></p><p><code>602</code><code>        &lt;/li&gt;</code></p><p><code>603</code><code>          </code></p><p><code>604</code><code>                    &lt;li class="usa-breadcrumb__list-item usa-current" aria-current="page"&gt;</code></p><p><code>605</code><code>          </code></p><p><code>606</code><code>          &lt;span&gt;</code></p><p><code>607</code><code>Merkel Cell Carcinoma Treatment (PDQ®)–Health Professional Version&lt;/span&gt;</code></p><p><code>608</code><code>          </code></p><p><code>609</code><code>        &lt;/li&gt;</code></p><p><code>610</code><code>          </code></p><p><code>611</code><code>          &lt;/ol&gt;</code></p><p><code>612</code><code>          </code></p><p><code>613</code><code>  &lt;/nav&gt;</code></p><p><code>614</code><code>          </code></p><p><code>615</code><code>          </code></p><p><code>616</code><code>          </code></p><p><code>617</code><code>    &lt;/div&gt;</code></p><p><code>618</code><code>          </code></p><p><code>619</code><code>    </code></p><p><code>620</code><code>          </code></p><p><code>621</code><code>      </code></p><p><code>622</code><code>          </code></p><p><code>623</code><code>          </code></p><p><code>624</code><code>&lt;section  class="cgdp-page-options cgdp-page-options--top" aria-label="Page options top"&gt;</code></p><p><code>625</code><code>          </code></p><p><code>626</code><code>  &lt;button class="usa-button usa-button--unstyled" onclick="window.print()"&gt;</code></p><p><code>627</code><code>          </code></p><p><code>628</code><code>    &lt;svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" width="24" class="usa-icon" role="img" aria-hidden="true" focusable="false"&gt;</code></p><p><code>629</code><code>          </code></p><p><code>630</code><code>      &lt;path d="M0 0h24v24H0z" fill="none"/&gt;</code></p><p><code>631</code><code>          </code></p><p><code>632</code><code>      &lt;path d="M19 8H5c-1.66 0-3 1.34-3 3v6h4v4h12v-4h4v-6c0-1.66-1.34-3-3-3zm-3 11H8v-5h8v5zm3-7c-.55 0-1-.45-1-1s.45-1 1-1 1 .45 1 1-.45 1-1 1zm-1-9H6v4h12V3z"/&gt;</code></p><p><code>633</code><code>          </code></p><p><code>634</code><code>    &lt;/svg&gt;</code></p><p><code>635</code><code>          </code></p><p><code>636</code><code>    &lt;span class="usa-sr-only"&gt;</code></p><p><code>637</code><code>          </code></p><p><code>638</code><code>      Print    &lt;/span&gt;</code></p><p><code>639</code><code>          </code></p><p><code>640</code><code>  &lt;/button&gt;</code></p><p><code>641</code><code>          </code></p><p><code>642</code><code>  &lt;a class="usa-button usa-button--unstyled" href="mailto:?subject=Information from the National Cancer Institute Web Site &amp;body=I found this information on www.cancer.gov and I'd like to share it with you: https://www.cancer.gov/types/skin/hp/merkel-cell-treatment-pdq %0D%0A%0D%0A NCI's Web site, www.cancer.gov, provides accurate, up-to-date, comprehensive cancer information from the U.S. government's principal agency for cancer research. If you have questions or need additional information, we invite you to contact NCI's LiveHelp instant messaging service at https://livehelp.cancer.gov, or call the NCI's Contact Center 1-800-4-CANCER (1-800-422-6237) (toll-free from the United States)."&gt;</code></p><p><code>643</code><code>          </code></p><p><code>644</code><code>    &lt;svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" width="24" class="usa-icon" role="img" aria-hidden="true" focusable="false"&gt;</code></p><p><code>645</code><code>          </code></p><p><code>646</code><code>        &lt;path d="M0 0h24v24H0z" fill="none"/&gt;</code></p><p><code>647</code><code>          </code></p><p><code>648</code><code>        &lt;path d="M20 4H4c-1.1 0-1.99.9-1.99 2L2 18c0 1.1.9 2 2 2h16c1.1 0 2-.9 2-2V6c0-1.1-.9-2-2-2zm0 14H4V8l8 5 8-5v10zm-8-7L4 6h16l-8 5z"/&gt;</code></p><p><code>649</code><code>          </code></p><p><code>650</code><code>    &lt;/svg&gt;</code></p><p><code>651</code><code>          </code></p><p><code>652</code><code>    &lt;span class="usa-sr-only"&gt;</code></p><p><code>653</code><code>          </code></p><p><code>654</code><code>      Email    &lt;/span&gt;</code></p><p><code>655</code><code>          </code></p><p><code>656</code><code>  &lt;/a&gt;</code></p><p><code>657</code><code>          </code></p><p><code>658</code><code>&lt;/section&gt;</code></p><p><code>659</code><code>          </code></p><p><code>660</code><code>          </code></p><p><code>661</code><code>  &lt;/div&gt;</code></p><p><code>662</code><code>          </code></p><p><code>663</code><code>&lt;/div&gt;</code></p><p><code>664</code><code>          </code></p><p><code>665</code><code>          </code></p><p><code>666</code><code>&lt;div id="page" class="grid-container"&gt;</code></p><p><code>667</code><code>          </code></p><p><code>668</code><code>      &lt;div class="grid-row grid-gap"&gt;</code></p><p><code>669</code><code>          </code></p><p><code>670</code><code>      &lt;!-- SECTION NAVIGATION --&gt;</code></p><p><code>671</code><code>          </code></p><p><code>672</code><code>  &lt;div class="desktop:grid-col-3 nci-no-print"&gt;</code></p><p><code>673</code><code>          </code></p><p><code>674</code><code>    </code></p><p><code>675</code><code>          </code></p><p><code>676</code><code>          </code></p><p><code>677</code><code>          </code></p><p><code>678</code><code>  &lt;nav aria-label="Secondary navigation"&gt;</code></p><p><code>679</code><code>          </code></p><p><code>680</code><code>    &lt;ul class="usa-sidenav usa-sidenav--nci-sidenav"&gt;</code></p><p><code>681</code><code>          </code></p><p><code>682</code><code>             </code></p><p><code>683</code><code>        </code></p><p><code>684</code><code>  &lt;li class="usa-sidenav__item"&gt;</code></p><p><code>685</code><code>          </code></p><p><code>686</code><code>    &lt;a  href="/types/skin" data-menu-id="11958" class="usa-current usa-current--nci-ancestor"&gt;</code></p><p><code>687</code><code>Skin Cancer&lt;/a&gt;</code></p><p><code>688</code><code>          </code></p><p><code>689</code><code>          &lt;ul class="usa-sidenav__sublist"&gt;</code></p><p><code>690</code><code>          </code></p><p><code>691</code><code>                                    &lt;li class="usa-sidenav__item"&gt;</code></p><p><code>692</code><code>          </code></p><p><code>693</code><code>    &lt;a  href="/types/skin" data-menu-id="940944" class="nci-has-children"&gt;</code></p><p><code>694</code><code>Patient&lt;/a&gt;</code></p><p><code>695</code><code>          </code></p><p><code>696</code><code>  &lt;/li&gt;</code></p><p><code>697</code><code>          </code></p><p><code>698</code><code>          </code></p><p><code>699</code><code>  </code></p><p><code>700</code><code>                         </code></p><p><code>701</code><code>        </code></p><p><code>702</code><code>  &lt;li class="usa-sidenav__item"&gt;</code></p><p><code>703</code><code>          </code></p><p><code>704</code><code>    &lt;a  href="/types/skin/hp" data-menu-id="940946" class="usa-current usa-current--nci-ancestor"&gt;</code></p><p><code>705</code><code>Health Professional&lt;/a&gt;</code></p><p><code>706</code><code>          </code></p><p><code>707</code><code>          &lt;ul class="usa-sidenav__sublist"&gt;</code></p><p><code>708</code><code>          </code></p><p><code>709</code><code>                              &lt;li class="usa-sidenav__item"&gt;</code></p><p><code>710</code><code>          </code></p><p><code>711</code><code>    &lt;a  href="/types/skin/hp/child-skin-treatment-pdq" data-menu-id="1150591"&gt;</code></p><p><code>712</code><code>Childhood Basal &amp;amp; Squamous Cell Carcinoma of the Skin Treatment (PDQ®)&lt;/a&gt;</code></p><p><code>713</code><code>          </code></p><p><code>714</code><code>  &lt;/li&gt;</code></p><p><code>715</code><code>          </code></p><p><code>716</code><code>          </code></p><p><code>717</code><code>  </code></p><p><code>718</code><code>                              &lt;li class="usa-sidenav__item"&gt;</code></p><p><code>719</code><code>          </code></p><p><code>720</code><code>    &lt;a  href="/types/skin/hp/skin-treatment-pdq" data-menu-id="943655"&gt;</code></p><p><code>721</code><code>Skin Cancer Treatment&lt;/a&gt;</code></p><p><code>722</code><code>          </code></p><p><code>723</code><code>  &lt;/li&gt;</code></p><p><code>724</code><code>          </code></p><p><code>725</code><code>          </code></p><p><code>726</code><code>  </code></p><p><code>727</code><code>                              &lt;li class="usa-sidenav__item"&gt;</code></p><p><code>728</code><code>          </code></p><p><code>729</code><code>    &lt;a  href="/types/skin/hp/melanoma-treatment-pdq" data-menu-id="943780"&gt;</code></p><p><code>730</code><code>Melanoma Treatment&lt;/a&gt;</code></p><p><code>731</code><code>          </code></p><p><code>732</code><code>  &lt;/li&gt;</code></p><p><code>733</code><code>          </code></p><p><code>734</code><code>          </code></p><p><code>735</code><code>  </code></p><p><code>736</code><code>                              &lt;li class="usa-sidenav__item"&gt;</code></p><p><code>737</code><code>          </code></p><p><code>738</code><code>    &lt;a  href="/types/skin/hp/child-melanoma-treatment-pdq" data-menu-id="1150586"&gt;</code></p><p><code>739</code><code>Childhood Melanoma Treatment (PDQ®)&lt;/a&gt;</code></p><p><code>740</code><code>          </code></p><p><code>741</code><code>  &lt;/li&gt;</code></p><p><code>742</code><code>          </code></p><p><code>743</code><code>          </code></p><p><code>744</code><code>  </code></p><p><code>745</code><code>                         </code></p><p><code>746</code><code>        </code></p><p><code>747</code><code>  &lt;li class="usa-sidenav__item"&gt;</code></p><p><code>748</code><code>          </code></p><p><code>749</code><code>    &lt;a  href="/types/skin/hp/merkel-cell-treatment-pdq" data-menu-id="943396" class="usa-current" aria-current="page"&gt;</code></p><p><code>750</code><code>Merkel Cell Carcinoma Treatment&lt;/a&gt;</code></p><p><code>751</code><code>          </code></p><p><code>752</code><code>    </code></p><p><code>753</code><code>  &lt;/li&gt;</code></p><p><code>754</code><code>          </code></p><p><code>755</code><code>          </code></p><p><code>756</code><code>  </code></p><p><code>757</code><code>                              &lt;li class="usa-sidenav__item"&gt;</code></p><p><code>758</code><code>          </code></p><p><code>759</code><code>    &lt;a  href="/types/skin/hp/skin-prevention-pdq" data-menu-id="948688"&gt;</code></p><p><code>760</code><code>Skin Cancer Prevention&lt;/a&gt;</code></p><p><code>761</code><code>          </code></p><p><code>762</code><code>  &lt;/li&gt;</code></p><p><code>763</code><code>          </code></p><p><code>764</code><code>          </code></p><p><code>765</code><code>  </code></p><p><code>766</code><code>                              &lt;li class="usa-sidenav__item"&gt;</code></p><p><code>767</code><code>          </code></p><p><code>768</code><code>    &lt;a  href="/types/skin/hp/skin-genetics-pdq" data-menu-id="950054"&gt;</code></p><p><code>769</code><code>Genetics of Skin Cancer&lt;/a&gt;</code></p><p><code>770</code><code>          </code></p><p><code>771</code><code>  &lt;/li&gt;</code></p><p><code>772</code><code>          </code></p><p><code>773</code><code>          </code></p><p><code>774</code><code>  </code></p><p><code>775</code><code>                              &lt;li class="usa-sidenav__item"&gt;</code></p><p><code>776</code><code>          </code></p><p><code>777</code><code>    &lt;a  href="/types/skin/hp/skin-screening-pdq" data-menu-id="948551"&gt;</code></p><p><code>778</code><code>Skin Cancer Screening&lt;/a&gt;</code></p><p><code>779</code><code>          </code></p><p><code>780</code><code>  &lt;/li&gt;</code></p><p><code>781</code><code>          </code></p><p><code>782</code><code>          </code></p><p><code>783</code><code>  </code></p><p><code>784</code><code>              &lt;/ul&gt;</code></p><p><code>785</code><code>          </code></p><p><code>786</code><code>    </code></p><p><code>787</code><code>  &lt;/li&gt;</code></p><p><code>788</code><code>          </code></p><p><code>789</code><code>          </code></p><p><code>790</code><code>  </code></p><p><code>791</code><code>                                    &lt;li class="usa-sidenav__item"&gt;</code></p><p><code>792</code><code>          </code></p><p><code>793</code><code>    &lt;a  href="/types/skin/research" data-menu-id="930502" class="nci-has-children"&gt;</code></p><p><code>794</code><code>Research Advances&lt;/a&gt;</code></p><p><code>795</code><code>          </code></p><p><code>796</code><code>  &lt;/li&gt;</code></p><p><code>797</code><code>          </code></p><p><code>798</code><code>          </code></p><p><code>799</code><code>  </code></p><p><code>800</code><code>              &lt;/ul&gt;</code></p><p><code>801</code><code>          </code></p><p><code>802</code><code>    </code></p><p><code>803</code><code>  &lt;/li&gt;</code></p><p><code>804</code><code>          </code></p><p><code>805</code><code>          </code></p><p><code>806</code><code>  </code></p><p><code>807</code><code>    &lt;/ul&gt;</code></p><p><code>808</code><code>          </code></p><p><code>809</code><code>  &lt;/nav&gt;</code></p><p><code>810</code><code>          </code></p><p><code>811</code><code>          </code></p><p><code>812</code><code>  &lt;/div&gt;</code></p><p><code>813</code><code>          </code></p><p><code>814</code><code>          </code></p><p><code>815</code><code>    &lt;div class="cgdpl desktop:grid-col-9"&gt;</code></p><p><code>816</code><code>          </code></p><p><code>817</code><code>            &lt;div id="content" class=""&gt;</code></p><p><code>818</code><code>          </code></p><p><code>819</code><code>        &lt;main class="contentzone has-section-nav" id="main-content"&gt;</code></p><p><code>820</code><code>          </code></p><p><code>821</code><code>            &lt;div data-drupal-messages-fallback class="hidden"&gt;</code></p><p><code>822</code><code>&lt;/div&gt;</code></p><p><code>823</code><code>          </code></p><p><code>824</code><code>&lt;!-- ********************************* BEGIN Page Content ********************************** --&gt;</code></p><p><code>825</code><code>          </code></p><p><code>826</code><code>          </code></p><p><code>827</code><code>&lt;article&gt;</code></p><p><code>828</code><code>          </code></p><p><code>829</code><code>    &lt;div class="resize-content"&gt;</code></p><p><code>830</code><code>          </code></p><p><code>831</code><code>    &lt;h1&gt;</code></p><p><code>832</code><code>Merkel Cell Carcinoma Treatment (PDQ®)–Health Professional Version&lt;/h1&gt;</code></p><p><code>833</code><code>          </code></p><p><code>834</code><code>    &lt;div id="cgvBody"&gt;</code></p><p><code>835</code><code>          </code></p><p><code>836</code><code>      &lt;div class="summary-sections"&gt;</code></p><p><code>837</code><code>          </code></p><p><code>838</code><code>                &lt;nav class="on-this-page" role="navigation"&gt;</code></p><p><code>839</code><code>          </code></p><p><code>840</code><code>  &lt;h6&gt;</code></p><p><code>841</code><code>On This Page&lt;/h6&gt;</code></p><p><code>842</code><code>          </code></p><p><code>843</code><code>  &lt;ul&gt;</code></p><p><code>844</code><code>          </code></p><p><code>845</code><code>          &lt;li&gt;</code></p><p><code>846</code><code>&lt;a href="#_242"&gt;</code></p><p><code>847</code><code>General Information About Merkel Cell Carcinoma&lt;/a&gt;</code></p><p><code>848</code><code>&lt;/li&gt;</code></p><p><code>849</code><code>          </code></p><p><code>850</code><code>          &lt;li&gt;</code></p><p><code>851</code><code>&lt;a href="#_36"&gt;</code></p><p><code>852</code><code>Cellular Classification of Merkel Cell Carcinoma&lt;/a&gt;</code></p><p><code>853</code><code>&lt;/li&gt;</code></p><p><code>854</code><code>          </code></p><p><code>855</code><code>          &lt;li&gt;</code></p><p><code>856</code><code>&lt;a href="#_45"&gt;</code></p><p><code>857</code><code>Stage Information for Merkel Cell Carcinoma&lt;/a&gt;</code></p><p><code>858</code><code>&lt;/li&gt;</code></p><p><code>859</code><code>          </code></p><p><code>860</code><code>          &lt;li&gt;</code></p><p><code>861</code><code>&lt;a href="#_49"&gt;</code></p><p><code>862</code><code>Treatment Option Overview&lt;/a&gt;</code></p><p><code>863</code><code>&lt;/li&gt;</code></p><p><code>864</code><code>          </code></p><p><code>865</code><code>          &lt;li&gt;</code></p><p><code>866</code><code>&lt;a href="#_73"&gt;</code></p><p><code>867</code><code>Treatment of Stage I and II Merkel Cell Carcinoma&lt;/a&gt;</code></p><p><code>868</code><code>&lt;/li&gt;</code></p><p><code>869</code><code>          </code></p><p><code>870</code><code>          &lt;li&gt;</code></p><p><code>871</code><code>&lt;a href="#_78"&gt;</code></p><p><code>872</code><code>Treatment of Stage III Merkel Cell Carcinoma&lt;/a&gt;</code></p><p><code>873</code><code>&lt;/li&gt;</code></p><p><code>874</code><code>          </code></p><p><code>875</code><code>          &lt;li&gt;</code></p><p><code>876</code><code>&lt;a href="#_83"&gt;</code></p><p><code>877</code><code>Treatment of Stage IV Merkel Cell Carcinoma&lt;/a&gt;</code></p><p><code>878</code><code>&lt;/li&gt;</code></p><p><code>879</code><code>          </code></p><p><code>880</code><code>          &lt;li&gt;</code></p><p><code>881</code><code>&lt;a href="#_90"&gt;</code></p><p><code>882</code><code>Treatment of Recurrent Merkel Cell Carcinoma&lt;/a&gt;</code></p><p><code>883</code><code>&lt;/li&gt;</code></p><p><code>884</code><code>          </code></p><p><code>885</code><code>          &lt;li&gt;</code></p><p><code>886</code><code>&lt;a href="#_5"&gt;</code></p><p><code>887</code><code>Changes to This Summary (10/28/2022)&lt;/a&gt;</code></p><p><code>888</code><code>&lt;/li&gt;</code></p><p><code>889</code><code>          </code></p><p><code>890</code><code>          &lt;li&gt;</code></p><p><code>891</code><code>&lt;a href="#_AboutThis_1"&gt;</code></p><p><code>892</code><code>About This PDQ Summary&lt;/a&gt;</code></p><p><code>893</code><code>&lt;/li&gt;</code></p><p><code>894</code><code>          </code></p><p><code>895</code><code>      &lt;/ul&gt;</code></p><p><code>896</code><code>          </code></p><p><code>897</code><code>&lt;/nav&gt;</code></p><p><code>898</code><code>          </code></p><p><code>899</code><code>          </code></p><p><code>900</code><code>        &lt;div class="accordion"&gt;</code></p><p><code>901</code><code>          </code></p><p><code>902</code><code>          </code></p><p><code>903</code><code>          </code></p><p><code>904</code><code>    &lt;section id="_242"&gt;</code></p><p><code>905</code><code>          </code></p><p><code>906</code><code>        &lt;h2&gt;</code></p><p><code>907</code><code>General Information About Merkel Cell Carcinoma&lt;/h2&gt;</code></p><p><code>908</code><code>          </code></p><p><code>909</code><code>        &lt;div id="_section_242" class="pdq-sections"&gt;</code></p><p><code>910</code><code>&lt;nav class="in-this-section" role="navigation"&gt;</code></p><p><code>911</code><code>&lt;h6&gt;</code></p><p><code>912</code><code>In This Section&lt;/h6&gt;</code></p><p><code>913</code><code>&lt;ul&gt;</code></p><p><code>914</code><code>&lt;li&gt;</code></p><p><code>915</code><code>&lt;a href="#_345_toc"&gt;</code></p><p><code>916</code><code>Anatomy&lt;/a&gt;</code></p><p><code>917</code><code>&lt;/li&gt;</code></p><p><code>918</code><code>&lt;li&gt;</code></p><p><code>919</code><code>&lt;a href="#_246_toc"&gt;</code></p><p><code>920</code><code>Epidemiology/Etiology&lt;/a&gt;</code></p><p><code>921</code><code>&lt;/li&gt;</code></p><p><code>922</code><code>&lt;li&gt;</code></p><p><code>923</code><code>&lt;a href="#_346_toc"&gt;</code></p><p><code>924</code><code>Incidence and Mortality&lt;/a&gt;</code></p><p><code>925</code><code>&lt;/li&gt;</code></p><p><code>926</code><code>&lt;li&gt;</code></p><p><code>927</code><code>&lt;a href="#_347_toc"&gt;</code></p><p><code>928</code><code>Pathogenesis&lt;/a&gt;</code></p><p><code>929</code><code>&lt;/li&gt;</code></p><p><code>930</code><code>&lt;li&gt;</code></p><p><code>931</code><code>&lt;a href="#_256_toc"&gt;</code></p><p><code>932</code><code>Clinical Presentation&lt;/a&gt;</code></p><p><code>933</code><code>&lt;/li&gt;</code></p><p><code>934</code><code>&lt;li&gt;</code></p><p><code>935</code><code>&lt;a href="#_261_toc"&gt;</code></p><p><code>936</code><code>Initial Clinical Evaluation&lt;/a&gt;</code></p><p><code>937</code><code>&lt;/li&gt;</code></p><p><code>938</code><code>&lt;li&gt;</code></p><p><code>939</code><code>&lt;a href="#_265_toc"&gt;</code></p><p><code>940</code><code>Initial Staging Results&lt;/a&gt;</code></p><p><code>941</code><code>&lt;/li&gt;</code></p><p><code>942</code><code>&lt;li&gt;</code></p><p><code>943</code><code>&lt;a href="#_268_toc"&gt;</code></p><p><code>944</code><code>Clinical Progression&lt;/a&gt;</code></p><p><code>945</code><code>&lt;/li&gt;</code></p><p><code>946</code><code>&lt;li&gt;</code></p><p><code>947</code><code>&lt;a href="#_272_toc"&gt;</code></p><p><code>948</code><code>Potential Prognostic Factors&lt;/a&gt;</code></p><p><code>949</code><code>&lt;/li&gt;</code></p><p><code>950</code><code>&lt;li&gt;</code></p><p><code>951</code><code>&lt;a href="#_278_toc"&gt;</code></p><p><code>952</code><code>Prognosis&lt;/a&gt;</code></p><p><code>953</code><code>&lt;/li&gt;</code></p><p><code>954</code><code>&lt;/ul&gt;</code></p><p><code>955</code><code>&lt;/nav&gt;</code></p><p><code>956</code><code>&lt;div class="pdq-hp-patient-toggle"&gt;</code></p><p><code>957</code><code>&lt;a href="/types/skin/patient/merkel-cell-treatment-pdq"&gt;</code></p><p><code>958</code><code>Go to Patient Version&lt;/a&gt;</code></p><p><code>959</code><code>&lt;/div&gt;</code></p><p><code>960</code><code>&lt;p id="_244" tabindex="-1"&gt;</code></p><p><code>961</code><code>Merkel cell carcinoma (MCC) was originally described by Toker in 1972 as trabecular carcinoma of the skin.[&lt;a href="#cit/section_1.1"&gt;</code></p><p><code>962</code><code>1&lt;/a&gt;</code></p><p><code>963</code><code>] Other names include Toker tumor, primary small cell carcinoma of the skin, primary cutaneous neuroendocrine tumor, and malignant trichodiscoma.[&lt;a href="#cit/section_1.2"&gt;</code></p><p><code>964</code><code>2&lt;/a&gt;</code></p><p><code>965</code><code>]&lt;/p&gt;</code></p><p><code>966</code><code>&lt;p id="_245" tabindex="-1"&gt;</code></p><p><code>967</code><code>MCC is an aggressive neuroendocrine carcinoma arising in the dermoepidermal junction (see &lt;a href="/types/skin/hp/merkel-cell-treatment-pdq#_152"&gt;</code></p><p><code>968</code><code>Figure  1&lt;/a&gt;</code></p><p><code>969</code><code>), and it is the second most common cause of skin cancer death after melanoma.[&lt;a href="#cit/section_1.3"&gt;</code></p><p><code>970</code><code>3&lt;/a&gt;</code></p><p><code>971</code><code>,&lt;a href="#cit/section_1.4"&gt;</code></p><p><code>972</code><code>4&lt;/a&gt;</code></p><p><code>973</code><code>]  Although the exact origin and function of the Merkel cell remains under investigation, it is thought to have features of both epithelial and neuroendocrine origin and arise in cells with touch-sensitivity function (mechanoreceptors).[&lt;a href="#cit/section_1.5"&gt;</code></p><p><code>974</code><code>5&lt;/a&gt;</code></p><p><code>975</code><code>-&lt;a href="#cit/section_1.11"&gt;</code></p><p><code>976</code><code>11&lt;/a&gt;</code></p><p><code>977</code><code>]&lt;/p&gt;</code></p><p><code>978</code><code>&lt;p id="_395" tabindex="-1"&gt;</code></p><p><code>979</code><code>Therapeutic options have been historically limited for patients with advanced disease; however, new immunotherapeutic approaches are associated with durable responses.[&lt;a href="#cit/section_1.12"&gt;</code></p><p><code>980</code><code>12&lt;/a&gt;</code></p><p><code>981</code><code>]&lt;/p&gt;</code></p><p><code>982</code><code>&lt;section id="_345"&gt;</code></p><p><code>983</code><code>&lt;h3 id="_345_toc"&gt;</code></p><p><code>984</code><code>Anatomy&lt;/h3&gt;</code></p><p><code>985</code><code>&lt;p id="_350" tabindex="-1"&gt;</code></p><p><code>986</code><code>&lt;figure id="figure_152" class="image-center-medium"&gt;</code></p><p><code>987</code><code>&lt;a href="https://nci-media.cancer.gov/pdq/media/images/579043.jpg" target="_blank" class="article-image-enlarge"&gt;</code></p><p><code>988</code><code>Enlarge&lt;/a&gt;</code></p><p><code>989</code><code>&lt;img id="_152" alt="MerkelCell" title="MerkelCell" src="https://nci-media.cancer.gov/pdq/media/images/579043-750.jpg"&gt;</code></p><p><code>990</code><code>&lt;figcaption class="caption-container"&gt;</code></p><p><code>991</code><code>Figure 1.   Merkel Cell Anatomy.&lt;/figcaption&gt;</code></p><p><code>992</code><code>&lt;/figure&gt;</code></p><p><code>993</code><code>&lt;/p&gt;</code></p><p><code>994</code><code>&lt;/section&gt;</code></p><p><code>995</code><code>&lt;section id="_246"&gt;</code></p><p><code>996</code><code>&lt;h3 id="_246_toc"&gt;</code></p><p><code>997</code><code>Epidemiology/Etiology&lt;/h3&gt;</code></p><p><code>998</code><code>&lt;p id="_247" tabindex="-1"&gt;</code></p><p><code>999</code><code>In Surveillance, Epidemiology, and End Results (SEER) Program data from 1986 to 2001, the age-adjusted U.S. annual incidence of MCC tripled from 0.15 to 0.44 per 100,000, an increase of 8.08% per year. Although this rate of increase is faster than any other skin cancer including melanoma, the absolute number of U.S. cases per year is small. About 1,500 new cases of MCC were expected in the United States in 2007.[&lt;a href="#cit/section_1.13"&gt;</code></p><p><code>1000</code><code>13&lt;/a&gt;</code></p><p><code>1001</code><code>-&lt;a href="#cit/section_1.18"&gt;</code></p><p><code>1002</code><code>18&lt;/a&gt;</code></p><p><code>1003</code><code>]&lt;/p&gt;</code></p><p><code>1004</code><code>&lt;/section&gt;</code></p><p><code>1005</code><code>&lt;section id="_346"&gt;</code></p><p><code>1006</code><code>&lt;h3 id="_346_toc"&gt;</code></p><p><code>1007</code><code>Incidence and Mortality&lt;/h3&gt;</code></p><p><code>1008</code><code>&lt;p id="_248" tabindex="-1"&gt;</code></p><p><code>1009</code><code>MCC incidence increases progressively with age. There are few cases in patients younger than  50 years, and the median age at diagnosis is about 65 years (see &lt;a href="/types/skin/hp/merkel-cell-treatment-pdq#_240"&gt;</code></p><p><code>1010</code><code>Figure 2&lt;/a&gt;</code></p><p><code>1011</code><code>).[&lt;a href="#cit/section_1.14"&gt;</code></p><p><code>1012</code><code>14&lt;/a&gt;</code></p><p><code>1013</code><code>] Incidence is considerably greater in White individuals than in Black individuals and slightly greater in men than in women.[&lt;a href="#cit/section_1.13"&gt;</code></p><p><code>1014</code><code>13&lt;/a&gt;</code></p><p><code>1015</code><code>-&lt;a href="#cit/section_1.16"&gt;</code></p><p><code>1016</code><code>16&lt;/a&gt;</code></p><p><code>1017</code><code>,&lt;a href="#cit/section_1.18"&gt;</code></p><p><code>1018</code><code>18&lt;/a&gt;</code></p><p><code>1019</code><code>] &lt;figure id="figure_240" class="image-center"&gt;</code></p><p><code>1020</code><code>&lt;a href="https://nci-media.cancer.gov/pdq/media/images/658575.jpg" target="_blank" class="article-image-enlarge"&gt;</code></p><p><code>1021</code><code>Enlarge&lt;/a&gt;</code></p><p><code>1022</code><code>&lt;img id="_240" alt="MerkelCell" title="MerkelCell" src="https://nci-media.cancer.gov/pdq/media/images/658575-750.jpg"&gt;</code></p><p><code>1023</code><code>&lt;figcaption class="caption-container"&gt;</code></p><p><code>1024</code><code>Figure 2.  Frequency of MCC by age and sex of men (square) and women (circle). Reprinted from Journal of the American Academy of Dermatology, 49 (5), Agelli M and Clegg L, Epidemiology of primary Merkel cell carcinoma in the United States, pp. 832&amp;#8211;41, Copyright (2003), with permission from Elsevier. &lt;/figcaption&gt;</code></p><p><code>1025</code><code>&lt;/figure&gt;</code></p><p><code>1026</code><code>&lt;/p&gt;</code></p><p><code>1027</code><code>&lt;p id="_250" tabindex="-1"&gt;</code></p><p><code>1028</code><code>MCC occurs most frequently in sun-exposed areas of skin, particularly the head and neck, followed by the extremities, and then the trunk.[&lt;a href="#cit/section_1.5"&gt;</code></p><p><code>1029</code><code>5&lt;/a&gt;</code></p><p><code>1030</code><code>,&lt;a href="#cit/section_1.16"&gt;</code></p><p><code>1031</code><code>16&lt;/a&gt;</code></p><p><code>1032</code><code>,&lt;a href="#cit/section_1.19"&gt;</code></p><p><code>1033</code><code>19&lt;/a&gt;</code></p><p><code>1034</code><code>] Incidence has been reported to be greater in geographic regions with higher levels of ultraviolet B sunlight.[&lt;a href="#cit/section_1.16"&gt;</code></p><p><code>1035</code><code>16&lt;/a&gt;</code></p><p><code>1036</code><code>] &lt;/p&gt;</code></p><p><code>1037</code><code>&lt;p id="_396" tabindex="-1"&gt;</code></p><p><code>1038</code><code>As of 2013, MCC had an annual incidence of 0.7 per 100,000 in the United States.[&lt;a href="#cit/section_1.20"&gt;</code></p><p><code>1039</code><code>20&lt;/a&gt;</code></p><p><code>1040</code><code>] The incidence has been increasing over the past several decades, almost doubling in the United States between 2000 and 2013. This rise is potentially related to more accurate diagnostic pathology tools, improved clinical awareness of MCC, an aging population, increased sun exposure in susceptible populations,  and improved registry tools.   The incidence is also higher in immunosuppressed populations (HIV, hematologic malignancies, immunosuppressive medications, etc.).[&lt;a href="#cit/section_1.21"&gt;</code></p><p><code>1041</code><code>21&lt;/a&gt;</code></p><p><code>1042</code><code>] Approximately 25,000 cases of MCC have been recorded in the United States since 2000, including more than 2,200 incident cases reported in 2014 to the National Program of Cancer Registries/SEER combined registries, which captures more than 98% of the U.S.  population and the ten most common sites of MCC (see  &lt;a href="/types/skin/hp/merkel-cell-treatment-pdq#_215"&gt;</code></p><p><code>1043</code><code>Table 1&lt;/a&gt;</code></p><p><code>1044</code><code>).[&lt;a href="#cit/section_1.18"&gt;</code></p><p><code>1045</code><code>18&lt;/a&gt;</code></p><p><code>1046</code><code>]&lt;/p&gt;</code></p><p><code>1047</code><code>&lt;table id="_215" class="table-default expandable-container"&gt;</code></p><p><code>1048</code><code>&lt;caption&gt;</code></p><p><code>1049</code><code>Table 1.  The Ten Most Common Sites for Merkel Cell Carcinoma (SEER 1973&amp;#8211;2006)&lt;span class="sup"&gt;</code></p><p><code>1050</code><code>a&lt;/span&gt;</code></p><p><code>1051</code><code>&lt;/caption&gt;</code></p><p><code>1052</code><code>&lt;colgroup&gt;</code></p><p><code>1053</code><code>&lt;col width="50.00%"&gt;</code></p><p><code>1054</code><code>&lt;col width="50.00%"&gt;</code></p><p><code>1055</code><code>&lt;/colgroup&gt;</code></p><p><code>1056</code><code>&lt;THead&gt;</code></p><p><code>1057</code><code>&lt;tr&gt;</code></p><p><code>1058</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1059</code><code>Anatomic Site&lt;/th&gt;</code></p><p><code>1060</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1061</code><code>Cases (%)&lt;/th&gt;</code></p><p><code>1062</code><code>&lt;/tr&gt;</code></p><p><code>1063</code><code>&lt;/THead&gt;</code></p><p><code>1064</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>1065</code><code>&lt;tr&gt;</code></p><p><code>1066</code><code>&lt;td colspan="2"&gt;</code></p><p><code>1067</code><code>NOS = not otherwise specified; SEER = Surveillance, Epidemiology, and End Results Program.&lt;/td&gt;</code></p><p><code>1068</code><code>&lt;/tr&gt;</code></p><p><code>1069</code><code>&lt;tr&gt;</code></p><p><code>1070</code><code>&lt;td colspan="2"&gt;</code></p><p><code>1071</code><code>&lt;span class="sup"&gt;</code></p><p><code>1072</code><code>a&lt;/span&gt;</code></p><p><code>1073</code><code>Albores-Saavedra J et al: Merkel cell carcinoma demographics, morphology, and survival based on 3,870 cases: A population-based study. J Cutan Pathol.  Reprinted with permission &amp;#169; 2009. Published by  Wiley-Blackwell. All rights reserved.[&lt;a href="#cit/section_1.18"&gt;</code></p><p><code>1074</code><code>18&lt;/a&gt;</code></p><p><code>1075</code><code>]&lt;/td&gt;</code></p><p><code>1076</code><code>&lt;/tr&gt;</code></p><p><code>1077</code><code>&lt;/TFoot&gt;</code></p><p><code>1078</code><code>&lt;tbody&gt;</code></p><p><code>1079</code><code>&lt;tr&gt;</code></p><p><code>1080</code><code>&lt;td&gt;</code></p><p><code>1081</code><code>Skin, face&lt;/td&gt;</code></p><p><code>1082</code><code>&lt;td&gt;</code></p><p><code>1083</code><code>1,041 (26.9)&lt;/td&gt;</code></p><p><code>1084</code><code>&lt;/tr&gt;</code></p><p><code>1085</code><code>&lt;tr&gt;</code></p><p><code>1086</code><code>&lt;td&gt;</code></p><p><code>1087</code><code>Skin of upper limb and shoulder&lt;/td&gt;</code></p><p><code>1088</code><code>&lt;td&gt;</code></p><p><code>1089</code><code>853 (22.0)&lt;/td&gt;</code></p><p><code>1090</code><code>&lt;/tr&gt;</code></p><p><code>1091</code><code>&lt;tr&gt;</code></p><p><code>1092</code><code>&lt;td&gt;</code></p><p><code>1093</code><code>Skin of lower limb and hip&lt;/td&gt;</code></p><p><code>1094</code><code>&lt;td&gt;</code></p><p><code>1095</code><code>578 (14.9)&lt;/td&gt;</code></p><p><code>1096</code><code>&lt;/tr&gt;</code></p><p><code>1097</code><code>&lt;tr&gt;</code></p><p><code>1098</code><code>&lt;td&gt;</code></p><p><code>1099</code><code>Skin of trunk&lt;/td&gt;</code></p><p><code>1100</code><code>&lt;td&gt;</code></p><p><code>1101</code><code>410 (10.6)&lt;/td&gt;</code></p><p><code>1102</code><code>&lt;/tr&gt;</code></p><p><code>1103</code><code>&lt;tr&gt;</code></p><p><code>1104</code><code>&lt;td&gt;</code></p><p><code>1105</code><code>Skin of scalp and neck&lt;/td&gt;</code></p><p><code>1106</code><code>&lt;td&gt;</code></p><p><code>1107</code><code>348 (9.0)&lt;/td&gt;</code></p><p><code>1108</code><code>&lt;/tr&gt;</code></p><p><code>1109</code><code>&lt;tr&gt;</code></p><p><code>1110</code><code>&lt;td&gt;</code></p><p><code>1111</code><code>Skin, NOS&lt;/td&gt;</code></p><p><code>1112</code><code>&lt;td&gt;</code></p><p><code>1113</code><code>234 (6.0)&lt;/td&gt;</code></p><p><code>1114</code><code>&lt;/tr&gt;</code></p><p><code>1115</code><code>&lt;tr&gt;</code></p><p><code>1116</code><code>&lt;td&gt;</code></p><p><code>1117</code><code>External ear&lt;/td&gt;</code></p><p><code>1118</code><code>&lt;td&gt;</code></p><p><code>1119</code><code>120 (3.1)&lt;/td&gt;</code></p><p><code>1120</code><code>&lt;/tr&gt;</code></p><p><code>1121</code><code>&lt;tr&gt;</code></p><p><code>1122</code><code>&lt;td&gt;</code></p><p><code>1123</code><code>Eyelid&lt;/td&gt;</code></p><p><code>1124</code><code>&lt;td&gt;</code></p><p><code>1125</code><code>98 (2.5)&lt;/td&gt;</code></p><p><code>1126</code><code>&lt;/tr&gt;</code></p><p><code>1127</code><code>&lt;tr&gt;</code></p><p><code>1128</code><code>&lt;td&gt;</code></p><p><code>1129</code><code>Skin of lip&lt;/td&gt;</code></p><p><code>1130</code><code>&lt;td&gt;</code></p><p><code>1131</code><code>91 (2.4)&lt;/td&gt;</code></p><p><code>1132</code><code>&lt;/tr&gt;</code></p><p><code>1133</code><code>&lt;tr&gt;</code></p><p><code>1134</code><code>&lt;td&gt;</code></p><p><code>1135</code><code>Unknown primary site&lt;/td&gt;</code></p><p><code>1136</code><code>&lt;td&gt;</code></p><p><code>1137</code><code>31 (0.8)&lt;/td&gt;</code></p><p><code>1138</code><code>&lt;/tr&gt;</code></p><p><code>1139</code><code>&lt;tr&gt;</code></p><p><code>1140</code><code>&lt;td&gt;</code></p><p><code>1141</code><code>&lt;strong&gt;</code></p><p><code>1142</code><code>Total&lt;/strong&gt;</code></p><p><code>1143</code><code>&lt;/td&gt;</code></p><p><code>1144</code><code>&lt;td&gt;</code></p><p><code>1145</code><code>&lt;strong&gt;</code></p><p><code>1146</code><code>3,804 (98.3)&lt;/strong&gt;</code></p><p><code>1147</code><code>&lt;/td&gt;</code></p><p><code>1148</code><code>&lt;/tr&gt;</code></p><p><code>1149</code><code>&lt;/tbody&gt;</code></p><p><code>1150</code><code>&lt;/table&gt;</code></p><p><code>1151</code><code>&lt;p id="_252" tabindex="-1"&gt;</code></p><p><code>1152</code><code>In various cases series, up to 97% of MCCs arise in the skin. MCC primaries in other sites were very rare, as were MCCs from unknown primary sites.[&lt;a href="#cit/section_1.18"&gt;</code></p><p><code>1153</code><code>18&lt;/a&gt;</code></p><p><code>1154</code><code>]&lt;/p&gt;</code></p><p><code>1155</code><code>&lt;p id="_253" tabindex="-1"&gt;</code></p><p><code>1156</code><code>SEER registry data have shown excess risk of MCC as a first or second cancer in patients with several primary cancers.[&lt;a href="#cit/section_1.22"&gt;</code></p><p><code>1157</code><code>22&lt;/a&gt;</code></p><p><code>1158</code><code>] National cancer registries from three Scandinavian countries have identified a variety of second cancers diagnosed after MCC.[&lt;a href="#cit/section_1.23"&gt;</code></p><p><code>1159</code><code>23&lt;/a&gt;</code></p><p><code>1160</code><code>] &lt;/p&gt;</code></p><p><code>1161</code><code>&lt;/section&gt;</code></p><p><code>1162</code><code>&lt;section id="_347"&gt;</code></p><p><code>1163</code><code>&lt;h3 id="_347_toc"&gt;</code></p><p><code>1164</code><code>Pathogenesis&lt;/h3&gt;</code></p><p><code>1165</code><code>&lt;p id="_313" tabindex="-1"&gt;</code></p><p><code>1166</code><code>Increased incidence of MCC has also been seen in people treated heavily with methoxsalen (psoralen) and ultraviolet A (PUVA) for psoriasis (3 of 1,380 patients, 0.2%). This has also been seen in individuals with chronic immune suppression, especially from chronic lymphocytic leukemia, HIV, and previous solid organ transplant.[&lt;a href="#cit/section_1.16"&gt;</code></p><p><code>1167</code><code>16&lt;/a&gt;</code></p><p><code>1168</code><code>,&lt;a href="#cit/section_1.24"&gt;</code></p><p><code>1169</code><code>24&lt;/a&gt;</code></p><p><code>1170</code><code>]&lt;/p&gt;</code></p><p><code>1171</code><code>&lt;p id="_254" tabindex="-1"&gt;</code></p><p><code>1172</code><code>In 2008, a  novel polyomavirus (Merkel cell polyoma virus [MCPyV])  was first reported in MCC tumor specimens [&lt;a href="#cit/section_1.25"&gt;</code></p><p><code>1173</code><code>25&lt;/a&gt;</code></p><p><code>1174</code><code>], a finding subsequently confirmed in other laboratories.[&lt;a href="#cit/section_1.26"&gt;</code></p><p><code>1175</code><code>26&lt;/a&gt;</code></p><p><code>1176</code><code>-&lt;a href="#cit/section_1.28"&gt;</code></p><p><code>1177</code><code>28&lt;/a&gt;</code></p><p><code>1178</code><code>] High levels of viral DNA and clonal integration of the virus in MCC tumors have also been reported [&lt;a href="#cit/section_1.29"&gt;</code></p><p><code>1179</code><code>29&lt;/a&gt;</code></p><p><code>1180</code><code>] along with expression of certain viral antigens in MCC cells and the presence of antiviral antibodies.  Not all cases of MCC appear to be associated with  MCPyV infection.[&lt;a href="#cit/section_1.30"&gt;</code></p><p><code>1181</code><code>30&lt;/a&gt;</code></p><p><code>1182</code><code>]  &lt;/p&gt;</code></p><p><code>1183</code><code>&lt;p id="_314" tabindex="-1"&gt;</code></p><p><code>1184</code><code>MCPyV has been detected at very low levels in normal skin distant from the MCC primary, in a significant percentage of patients with non-MCC cutaneous disorders, in normal-appearing skin in healthy individuals, and in nonmelanoma skin cancers in immune-suppressed individuals.[&lt;a href="#cit/section_1.10"&gt;</code></p><p><code>1185</code><code>10&lt;/a&gt;</code></p><p><code>1186</code><code>,&lt;a href="#cit/section_1.31"&gt;</code></p><p><code>1187</code><code>31&lt;/a&gt;</code></p><p><code>1188</code><code>-&lt;a href="#cit/section_1.33"&gt;</code></p><p><code>1189</code><code>33&lt;/a&gt;</code></p><p><code>1190</code><code>] Various methods have been used to identify and quantify the presence of MCPyV in MCC tumor specimens, other non-MCC tumors, blood, urine, and other tissues.[&lt;a href="#cit/section_1.34"&gt;</code></p><p><code>1191</code><code>34&lt;/a&gt;</code></p><p><code>1192</code><code>,&lt;a href="#cit/section_1.35"&gt;</code></p><p><code>1193</code><code>35&lt;/a&gt;</code></p><p><code>1194</code><code>]&lt;/p&gt;</code></p><p><code>1195</code><code>&lt;p id="_315" tabindex="-1"&gt;</code></p><p><code>1196</code><code>The significance of the new MCPyV findings remains uncertain.  The prognostic significance of viral load, antibody titer levels, and the role of underlying immunosuppression in hosts (from disease and medications) are under investigation. &lt;/p&gt;</code></p><p><code>1197</code><code>&lt;p id="_316" tabindex="-1"&gt;</code></p><p><code>1198</code><code>Prevalence of  MCPyV appears to differ between MCC patients in the United States and Europe versus Australia. There may be two independent pathways for the development of MCC: one driven by the presence of MCPyV, and the other driven primarily by sun damage, especially as noted in patient series from Australia.[&lt;a href="#cit/section_1.26"&gt;</code></p><p><code>1199</code><code>26&lt;/a&gt;</code></p><p><code>1200</code><code>,&lt;a href="#cit/section_1.30"&gt;</code></p><p><code>1201</code><code>30&lt;/a&gt;</code></p><p><code>1202</code><code>,&lt;a href="#cit/section_1.36"&gt;</code></p><p><code>1203</code><code>36&lt;/a&gt;</code></p><p><code>1204</code><code>] &lt;/p&gt;</code></p><p><code>1205</code><code>&lt;p id="_255" tabindex="-1"&gt;</code></p><p><code>1206</code><code>Although no unique marker for MCC has been identified, a variety of molecular and cytogenetic markers of MCC have been reported.[&lt;a href="#cit/section_1.7"&gt;</code></p><p><code>1207</code><code>7&lt;/a&gt;</code></p><p><code>1208</code><code>,&lt;a href="#cit/section_1.10"&gt;</code></p><p><code>1209</code><code>10&lt;/a&gt;</code></p><p><code>1210</code><code>,&lt;a href="#cit/section_1.17"&gt;</code></p><p><code>1211</code><code>17&lt;/a&gt;</code></p><p><code>1212</code><code>]&lt;/p&gt;</code></p><p><code>1213</code><code>&lt;/section&gt;</code></p><p><code>1214</code><code>&lt;section id="_256"&gt;</code></p><p><code>1215</code><code>&lt;h3 id="_256_toc"&gt;</code></p><p><code>1216</code><code>Clinical Presentation&lt;/h3&gt;</code></p><p><code>1217</code><code>&lt;p id="_257" tabindex="-1"&gt;</code></p><p><code>1218</code><code>MCC usually presents as a painless, indurated, solitary dermal nodule with a slightly erythematous to deeply violaceous color, and rarely, an ulcer. MCC can infiltrate locally via dermal lymphatics, resulting in multiple satellite lesions. Because of its nonspecific clinical appearance, MCC is rarely suspected before a  biopsy is performed.[&lt;a href="#cit/section_1.5"&gt;</code></p><p><code>1219</code><code>5&lt;/a&gt;</code></p><p><code>1220</code><code>] Photographs of MCC skin lesions illustrate its clinical variability.[&lt;a href="#cit/section_1.37"&gt;</code></p><p><code>1221</code><code>37&lt;/a&gt;</code></p><p><code>1222</code><code>]&lt;/p&gt;</code></p><p><code>1223</code><code>&lt;p id="_258" tabindex="-1"&gt;</code></p><p><code>1224</code><code>A mnemonic [&lt;a href="#cit/section_1.19"&gt;</code></p><p><code>1225</code><code>19&lt;/a&gt;</code></p><p><code>1226</code><code>] summarizing typical clinical characteristics of MCC has been proposed:  &lt;/p&gt;</code></p><p><code>1227</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>1228</code><code>&lt;p class="pdq-list-title"&gt;</code></p><p><code>1229</code><code>AEIOU&lt;/p&gt;</code></p><p><code>1230</code><code>&lt;ul id="_259"&gt;</code></p><p><code>1231</code><code>&lt;li&gt;</code></p><p><code>1232</code><code>A = Asymptomatic.&lt;/li&gt;</code></p><p><code>1233</code><code>&lt;li&gt;</code></p><p><code>1234</code><code>E = Expanding rapidly.&lt;/li&gt;</code></p><p><code>1235</code><code>&lt;li&gt;</code></p><p><code>1236</code><code>I = Immune suppressed.&lt;/li&gt;</code></p><p><code>1237</code><code>&lt;li&gt;</code></p><p><code>1238</code><code>O = Older than 50 years.&lt;/li&gt;</code></p><p><code>1239</code><code>&lt;li&gt;</code></p><p><code>1240</code><code>U = UV-exposed skin.&lt;/li&gt;</code></p><p><code>1241</code><code>&lt;/ul&gt;</code></p><p><code>1242</code><code>&lt;/div&gt;</code></p><p><code>1243</code><code>&lt;p id="_260" tabindex="-1"&gt;</code></p><p><code>1244</code><code>Not all patients have every element in this mnemonic; however, in this study, 89% of patients met three or more criteria, 52% met four or more criteria, and 7% met all five criteria.[&lt;a href="#cit/section_1.19"&gt;</code></p><p><code>1245</code><code>19&lt;/a&gt;</code></p><p><code>1246</code><code>]&lt;/p&gt;</code></p><p><code>1247</code><code>&lt;/section&gt;</code></p><p><code>1248</code><code>&lt;section id="_261"&gt;</code></p><p><code>1249</code><code>&lt;h3 id="_261_toc"&gt;</code></p><p><code>1250</code><code>Initial Clinical Evaluation&lt;/h3&gt;</code></p><p><code>1251</code><code>&lt;p id="_262" tabindex="-1"&gt;</code></p><p><code>1252</code><code>Because local-regional spread is common, newly diagnosed MCC patients require a careful clinical examination that includes looking for satellite lesions and regional nodal involvement. &lt;/p&gt;</code></p><p><code>1253</code><code>&lt;p id="_263" tabindex="-1"&gt;</code></p><p><code>1254</code><code>Tailoring an imaging work-up  to the clinical presentation and any relevant signs and symptoms should be considered. There has been no systematic study of the optimal imaging work-up for newly diagnosed patients, and it is not clear if all newly diagnosed patients, especially those with the smallest primaries, benefit from a detailed imaging work-up. &lt;/p&gt;</code></p><p><code>1255</code><code>&lt;p id="_264" tabindex="-1"&gt;</code></p><p><code>1256</code><code>If an imaging work-up is performed, it may include a computed tomography (CT) scan of the chest and abdomen to rule out primary small cell lung cancer as well as distant and regional metastases. Imaging studies designed to evaluate suspicious signs and symptoms may also be recommended. In one series, CT scans had an 80% false-negative rate for regional metastases.[&lt;a href="#cit/section_1.38"&gt;</code></p><p><code>1257</code><code>38&lt;/a&gt;</code></p><p><code>1258</code><code>] Head and neck presentations may require additional imaging. Magnetic resonance imaging has been used to evaluate MCC but has not been studied systematically.[&lt;a href="#cit/section_1.39"&gt;</code></p><p><code>1259</code><code>39&lt;/a&gt;</code></p><p><code>1260</code><code>] Fluorine F 18-fludeoxyglucose positron emission tomography results have been reported in selected cases.[&lt;a href="#cit/section_1.40"&gt;</code></p><p><code>1261</code><code>40&lt;/a&gt;</code></p><p><code>1262</code><code>,&lt;a href="#cit/section_1.41"&gt;</code></p><p><code>1263</code><code>41&lt;/a&gt;</code></p><p><code>1264</code><code>] Baseline routine blood work has been recommended but has not been studied systematically. There are no known circulating tumor markers specifically for MCC.&lt;/p&gt;</code></p><p><code>1265</code><code>&lt;/section&gt;</code></p><p><code>1266</code><code>&lt;section id="_265"&gt;</code></p><p><code>1267</code><code>&lt;h3 id="_265_toc"&gt;</code></p><p><code>1268</code><code>Initial Staging Results&lt;/h3&gt;</code></p><p><code>1269</code><code>&lt;p id="_266" tabindex="-1"&gt;</code></p><p><code>1270</code><code>The results of initial clinical staging of MCC vary widely in the literature, based on retrospective case series reported over decades. For invasive cancers, 48.6% were localized, 31.1% were regional, and 8.2% were distant.[&lt;a href="#cit/section_1.18"&gt;</code></p><p><code>1271</code><code>18&lt;/a&gt;</code></p><p><code>1272</code><code>]&lt;/p&gt;</code></p><p><code>1273</code><code>&lt;p id="_267" tabindex="-1"&gt;</code></p><p><code>1274</code><code>MCC that presents in regional nodes without an identifiable primary lesion is found in a minority of patients, with the percent of these cases varying among the reported series. Tumors without an identifiable primary lesion have been attributed to either spontaneous regression of the primary or metastatic neuroendocrine carcinoma from a clinically occult site.[&lt;a href="#cit/section_1.8"&gt;</code></p><p><code>1275</code><code>8&lt;/a&gt;</code></p><p><code>1276</code><code>,&lt;a href="#cit/section_1.18"&gt;</code></p><p><code>1277</code><code>18&lt;/a&gt;</code></p><p><code>1278</code><code>,&lt;a href="#cit/section_1.19"&gt;</code></p><p><code>1279</code><code>19&lt;/a&gt;</code></p><p><code>1280</code><code>,&lt;a href="#cit/section_1.42"&gt;</code></p><p><code>1281</code><code>42&lt;/a&gt;</code></p><p><code>1282</code><code>,&lt;a href="#cit/section_1.43"&gt;</code></p><p><code>1283</code><code>43&lt;/a&gt;</code></p><p><code>1284</code><code>]&lt;/p&gt;</code></p><p><code>1285</code><code>&lt;/section&gt;</code></p><p><code>1286</code><code>&lt;section id="_268"&gt;</code></p><p><code>1287</code><code>&lt;h3 id="_268_toc"&gt;</code></p><p><code>1288</code><code>Clinical Progression&lt;/h3&gt;</code></p><p><code>1289</code><code>&lt;p id="_269" tabindex="-1"&gt;</code></p><p><code>1290</code><code>In a review of patients from 18 case series, 279 of 926 patients (30.1%) developed local recurrence during follow-up, excluding those presenting with distant metastatic disease. These events have been typically attributed to inadequate surgical margins and/or a lack of adjuvant radiation therapy. In addition, 545 of 982 patients (55.5%) had lymph node metastases at diagnosis or during follow-up.[&lt;a href="#cit/section_1.8"&gt;</code></p><p><code>1291</code><code>8&lt;/a&gt;</code></p><p><code>1292</code><code>]&lt;/p&gt;</code></p><p><code>1293</code><code>&lt;p id="_270" tabindex="-1"&gt;</code></p><p><code>1294</code><code>In the same review of 18 case series, the most common sites of distant metastases were distant lymph nodes (60.1%), distant skin (30.3%), lung (23.4%), central nervous system (18.4%), and bone (15.2%).[&lt;a href="#cit/section_1.8"&gt;</code></p><p><code>1295</code><code>8&lt;/a&gt;</code></p><p><code>1296</code><code>] Many other sites of disease have also been reported, and the distribution of metastatic sites varies among case series. &lt;/p&gt;</code></p><p><code>1297</code><code>&lt;p id="_271" tabindex="-1"&gt;</code></p><p><code>1298</code><code>In one series of 237 patients presenting with local or regional disease, the median time-to-recurrence was 9 months (range, 2&amp;#8211;70 months).  Ninety-one percent of recurrences occurred within 2 years of diagnosis.[&lt;a href="#cit/section_1.44"&gt;</code></p><p><code>1299</code><code>44&lt;/a&gt;</code></p><p><code>1300</code><code>]&lt;/p&gt;</code></p><p><code>1301</code><code>&lt;/section&gt;</code></p><p><code>1302</code><code>&lt;section id="_272"&gt;</code></p><p><code>1303</code><code>&lt;h3 id="_272_toc"&gt;</code></p><p><code>1304</code><code>Potential Prognostic Factors&lt;/h3&gt;</code></p><p><code>1305</code><code>&lt;p id="_273" tabindex="-1"&gt;</code></p><p><code>1306</code><code>The extent of disease at presentation may provide the most useful estimate of prognosis.[&lt;a href="#cit/section_1.7"&gt;</code></p><p><code>1307</code><code>7&lt;/a&gt;</code></p><p><code>1308</code><code>]&lt;/p&gt;</code></p><p><code>1309</code><code>&lt;p id="_274" tabindex="-1"&gt;</code></p><p><code>1310</code><code>Diagnostic procedures, such as sentinel lymph node biopsy, may help distinguish between local and regional disease at presentation.  One-third of patients who lack clinically palpable or radiologically visible nodes will have microscopically evident regional disease.[&lt;a href="#cit/section_1.38"&gt;</code></p><p><code>1311</code><code>38&lt;/a&gt;</code></p><p><code>1312</code><code>] Nodal positivity may be substantially lower among patients with small tumors (e.g., &amp;#8804;1.0 cm).[&lt;a href="#cit/section_1.45"&gt;</code></p><p><code>1313</code><code>45&lt;/a&gt;</code></p><p><code>1314</code><code>]&lt;/p&gt;</code></p><p><code>1315</code><code>&lt;p id="_275" tabindex="-1"&gt;</code></p><p><code>1316</code><code>Many retrospective studies have evaluated the relationship of a wide variety of biological and histological factors to survival and local-regional control.[&lt;a href="#cit/section_1.7"&gt;</code></p><p><code>1317</code><code>7&lt;/a&gt;</code></p><p><code>1318</code><code>,&lt;a href="#cit/section_1.8"&gt;</code></p><p><code>1319</code><code>8&lt;/a&gt;</code></p><p><code>1320</code><code>,&lt;a href="#cit/section_1.18"&gt;</code></p><p><code>1321</code><code>18&lt;/a&gt;</code></p><p><code>1322</code><code>,&lt;a href="#cit/section_1.38"&gt;</code></p><p><code>1323</code><code>38&lt;/a&gt;</code></p><p><code>1324</code><code>,&lt;a href="#cit/section_1.44"&gt;</code></p><p><code>1325</code><code>44&lt;/a&gt;</code></p><p><code>1326</code><code>,&lt;a href="#cit/section_1.46"&gt;</code></p><p><code>1327</code><code>46&lt;/a&gt;</code></p><p><code>1328</code><code>-&lt;a href="#cit/section_1.57"&gt;</code></p><p><code>1329</code><code>57&lt;/a&gt;</code></p><p><code>1330</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810037&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810037&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>1331</code><code>Level of evidence C2&lt;/a&gt;</code></p><p><code>1332</code><code>] Many of these reports are confounded by small numbers, potential selection bias, referral bias, short follow-up, no uniform clinical protocol for both staging and treatment, and are underpowered to detect modest differences.&lt;/p&gt;</code></p><p><code>1333</code><code>&lt;p id="_276" tabindex="-1"&gt;</code></p><p><code>1334</code><code>A large, single-institution, retrospective study of 156 MCC patients, with a median follow-up of 51 months (range, 2&amp;#8211;224 months), evaluated histological factors potentially associated with prognosis.[&lt;a href="#cit/section_1.55"&gt;</code></p><p><code>1335</code><code>55&lt;/a&gt;</code></p><p><code>1336</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810035&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810035&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>1337</code><code>Level of evidence C1&lt;/a&gt;</code></p><p><code>1338</code><code>]  Although this report was subject to potential selection and referral bias, both univariate and multivariate analyses demonstrated a relationship between improved cause-specific survival and circumscribed growth pattern versus infiltrative pattern, shallow-tumor depth versus deep-tumor depth, and absence of lymphovascular invasion versus presence of lymphovascular invasion. Adoption of these findings into a global prognostic algorithm awaits independent confirmation by adequately powered studies. &lt;/p&gt;</code></p><p><code>1339</code><code>&lt;p id="_277" tabindex="-1"&gt;</code></p><p><code>1340</code><code>A 2009 study investigated whether the presence of newly identified MCPyV in MCC tumor specimens influenced clinical outcome among 114 Finnish patients with MCC. In this small study, patients whose tumors were MCPyV-positive appeared to have better survival than patients whose tumors were MCPyV-negative.[&lt;a href="#cit/section_1.58"&gt;</code></p><p><code>1341</code><code>58&lt;/a&gt;</code></p><p><code>1342</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810037&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810037&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>1343</code><code>Level of evidence C2&lt;/a&gt;</code></p><p><code>1344</code><code>] Standardization of procedures to identify and quantify MCPyV and relevant antibodies is needed to improve understanding of  both prognostic and epidemiological questions.[&lt;a href="#cit/section_1.10"&gt;</code></p><p><code>1345</code><code>10&lt;/a&gt;</code></p><p><code>1346</code><code>] &lt;/p&gt;</code></p><p><code>1347</code><code>&lt;/section&gt;</code></p><p><code>1348</code><code>&lt;section id="_278"&gt;</code></p><p><code>1349</code><code>&lt;h3 id="_278_toc"&gt;</code></p><p><code>1350</code><code>Prognosis&lt;/h3&gt;</code></p><p><code>1351</code><code>&lt;p id="_397" tabindex="-1"&gt;</code></p><p><code>1352</code><code>The most significant prognostic parameters for MCC include tumor size and the presence of locoregional or distant metastases. These factors form the basis of the American Joint Committee on Cancer staging system for MCC.[&lt;a href="#cit/section_1.59"&gt;</code></p><p><code>1353</code><code>59&lt;/a&gt;</code></p><p><code>1354</code><code>,&lt;a href="#cit/section_1.60"&gt;</code></p><p><code>1355</code><code>60&lt;/a&gt;</code></p><p><code>1356</code><code>]  Although an increasing primary tumor size correlates with an  increased risk of metastatic disease, MCC tumors of any size have significant risk of occult metastasis, supporting the use of sentinel lymph node biopsy for all cases.[&lt;a href="#cit/section_1.61"&gt;</code></p><p><code>1357</code><code>61&lt;/a&gt;</code></p><p><code>1358</code><code>] Additional features of the primary tumor,  such as lymphovascular invasion and tumor growth pattern, may also have prognostic significance. Clinically  detectable nodal disease is associated with worse outcome than microscopic metastases.[&lt;a href="#cit/section_1.55"&gt;</code></p><p><code>1359</code><code>55&lt;/a&gt;</code></p><p><code>1360</code><code>,&lt;a href="#cit/section_1.59"&gt;</code></p><p><code>1361</code><code>59&lt;/a&gt;</code></p><p><code>1362</code><code>] Other findings associated with worse prognosis include sheet-like involvement in lymph node metastases  and an increasing number of metastatic lymph nodes.[&lt;a href="#cit/section_1.60"&gt;</code></p><p><code>1363</code><code>60&lt;/a&gt;</code></p><p><code>1364</code><code>,&lt;a href="#cit/section_1.62"&gt;</code></p><p><code>1365</code><code>62&lt;/a&gt;</code></p><p><code>1366</code><code>]&lt;/p&gt;</code></p><p><code>1367</code><code>&lt;p id="_279" tabindex="-1"&gt;</code></p><p><code>1368</code><code>The bulk of MCC literature is from small case series, which are subject to many confounding factors. For this reason, the relapse and survival rates reported by stage vary widely in the literature. In general, lower-stage disease is associated with better overall survival.[&lt;a href="#cit/section_1.63"&gt;</code></p><p><code>1369</code><code>63&lt;/a&gt;</code></p><p><code>1370</code><code>] For more information, see the &lt;a href="/types/skin/hp/merkel-cell-treatment-pdq#_272"&gt;</code></p><p><code>1371</code><code>Potential Prognostic Factors&lt;/a&gt;</code></p><p><code>1372</code><code> section.&lt;/p&gt;</code></p><p><code>1373</code><code>&lt;p id="_280" tabindex="-1"&gt;</code></p><p><code>1374</code><code>Outcomes from patients presenting with small volume local disease and pathologically confirmed cancer-negative lymph nodes report a cause-specific 5-year survival rate exceeding 90% in one report.[&lt;a href="#cit/section_1.44"&gt;</code></p><p><code>1375</code><code>44&lt;/a&gt;</code></p><p><code>1376</code><code>,&lt;a href="#cit/section_1.55"&gt;</code></p><p><code>1377</code><code>55&lt;/a&gt;</code></p><p><code>1378</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810037&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810037&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>1379</code><code>Level of evidence C2&lt;/a&gt;</code></p><p><code>1380</code><code>]&lt;/p&gt;</code></p><p><code>1381</code><code>&lt;p id="_281" tabindex="-1"&gt;</code></p><p><code>1382</code><code>A tabular summary of treatment results of MCC from 12 series illustrates the difficulty in comparing outcome data among series.[&lt;a href="#cit/section_1.7"&gt;</code></p><p><code>1383</code><code>7&lt;/a&gt;</code></p><p><code>1384</code><code>]&lt;/p&gt;</code></p><p><code>1385</code><code>&lt;p id="_282" tabindex="-1"&gt;</code></p><p><code>1386</code><code>Using the SEER Program registry MCC staging system adopted in 1973, MCC survival data (1973&amp;#8211;2006) by stage is summarized below:[&lt;a href="#cit/section_1.18"&gt;</code></p><p><code>1387</code><code>18&lt;/a&gt;</code></p><p><code>1388</code><code>]&lt;figure id="figure_220" class="image-center"&gt;</code></p><p><code>1389</code><code>&lt;a href="https://nci-media.cancer.gov/pdq/media/images/658578.jpg" target="_blank" class="article-image-enlarge"&gt;</code></p><p><code>1390</code><code>Enlarge&lt;/a&gt;</code></p><p><code>1391</code><code>&lt;img id="_220" alt="MerkelCell" title="MerkelCell" src="https://nci-media.cancer.gov/pdq/media/images/658578-750.jpg"&gt;</code></p><p><code>1392</code><code>&lt;figcaption class="caption-container"&gt;</code></p><p><code>1393</code><code>Figure    3.  Relative ten-year survival rates for Merkel Cell Carcinoma by stage (SEER 1973&amp;#8211;2006). Albores-Saavedra J et al: Merkel cell carcinoma demographics, morphology, and survival based on 3,870 cases: A population-based study. J Cutan Pathol.  Reprinted with permission &amp;#169; 2009. Published by  Wiley-Blackwell. All rights reserved.&lt;/figcaption&gt;</code></p><p><code>1394</code><code>&lt;/figure&gt;</code></p><p><code>1395</code><code>&lt;/p&gt;</code></p><p><code>1396</code><code>&lt;/section&gt;</code></p><p><code>1397</code><code>&lt;h6 do-not-show="toc"&gt;</code></p><p><code>1398</code><code>References&lt;/h6&gt;</code></p><p><code>1399</code><code>&lt;ol&gt;</code></p><p><code>1400</code><code>&lt;li id="section_1.1"&gt;</code></p><p><code>1401</code><code>Toker C: Trabecular carcinoma of the skin. Arch Dermatol 105 (1): 107-10, 1972.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=5009611&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=5009611&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1402</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1403</code><code>&lt;/li&gt;</code></p><p><code>1404</code><code>&lt;li id="section_1.2"&gt;</code></p><p><code>1405</code><code>Schwartz RA, Lambert WC: The Merkel cell carcinoma: a 50-year retrospect. J Surg Oncol 89 (1): 5, 2005.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=15611999&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=15611999&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1406</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1407</code><code>&lt;/li&gt;</code></p><p><code>1408</code><code>&lt;li id="section_1.3"&gt;</code></p><p><code>1409</code><code>Agelli M, Clegg LX, Becker JC, et al.: The etiology and epidemiology of merkel cell carcinoma. Curr Probl Cancer 34 (1): 14-37, 2010 Jan-Feb.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=20371072&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=20371072&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1410</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1411</code><code>&lt;/li&gt;</code></p><p><code>1412</code><code>&lt;li id="section_1.4"&gt;</code></p><p><code>1413</code><code>Harms PW: Update on Merkel Cell Carcinoma. Clin Lab Med 37 (3): 485-501, 2017.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=28802497&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=28802497&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1414</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1415</code><code>&lt;/li&gt;</code></p><p><code>1416</code><code>&lt;li id="section_1.5"&gt;</code></p><p><code>1417</code><code>Nghiem P, McKee PH, Haynes HA: Merkel cell (cutaneous neuroendocrine) carcinoma. In: Sober AJ, Haluska FG, eds.: Skin Cancer. BC Decker Inc., 2001, pp 127-141.&lt;/li&gt;</code></p><p><code>1418</code><code>&lt;li id="section_1.6"&gt;</code></p><p><code>1419</code><code>Nghiem P, James N: Merkel cell carcinoma. In: Wolff K, Goldsmith LA, Katz SI, et al., eds.: Fitzpatrick's Dermatology in General Medicine. 7th ed. McGraw-Hill , 2008, pp 1087-94.&lt;/li&gt;</code></p><p><code>1420</code><code>&lt;li id="section_1.7"&gt;</code></p><p><code>1421</code><code>Eng TY, Boersma MG, Fuller CD, et al.: A comprehensive review of the treatment of Merkel cell carcinoma. Am J Clin Oncol 30 (6): 624-36, 2007.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18091058&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18091058&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1422</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1423</code><code>&lt;/li&gt;</code></p><p><code>1424</code><code>&lt;li id="section_1.8"&gt;</code></p><p><code>1425</code><code>Medina-Franco H, Urist MM, Fiveash J, et al.: Multimodality treatment of Merkel cell carcinoma: case series and literature review of 1024 cases. Ann Surg Oncol 8 (3): 204-8, 2001.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11314935&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11314935&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1426</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1427</code><code>&lt;/li&gt;</code></p><p><code>1428</code><code>&lt;li id="section_1.9"&gt;</code></p><p><code>1429</code><code>Busse PM, Clark JR, Muse VV, et al.: Case records of the Massachusetts General Hospital. Case 19-2008. A 63-year-old HIV-positive man with cutaneous Merkel-cell carcinoma. N Engl J Med 358 (25): 2717-23, 2008.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18565865&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18565865&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1430</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1431</code><code>&lt;/li&gt;</code></p><p><code>1432</code><code>&lt;li id="section_1.10"&gt;</code></p><p><code>1433</code><code>Rockville Merkel Cell Carcinoma Group: Merkel cell carcinoma: recent progress and current priorities on etiology, pathogenesis, and clinical management. J Clin Oncol 27 (24): 4021-6, 2009.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19597021&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19597021&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1434</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1435</code><code>&lt;/li&gt;</code></p><p><code>1436</code><code>&lt;li id="section_1.11"&gt;</code></p><p><code>1437</code><code>Calder KB, Smoller BR: New insights into merkel cell carcinoma. Adv Anat Pathol 17 (3): 155-61, 2010.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=20418670&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=20418670&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1438</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1439</code><code>&lt;/li&gt;</code></p><p><code>1440</code><code>&lt;li id="section_1.12"&gt;</code></p><p><code>1441</code><code>Cassler NM, Merrill D, Bichakjian CK, et al.: Merkel Cell Carcinoma Therapeutic Update. Curr Treat Options Oncol 17 (7): 36, 2016.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=27262710&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=27262710&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1442</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1443</code><code>&lt;/li&gt;</code></p><p><code>1444</code><code>&lt;li id="section_1.13"&gt;</code></p><p><code>1445</code><code>Hodgson NC: Merkel cell carcinoma: changing incidence trends. J Surg Oncol 89 (1): 1-4, 2005.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=15611998&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=15611998&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1446</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1447</code><code>&lt;/li&gt;</code></p><p><code>1448</code><code>&lt;li id="section_1.14"&gt;</code></p><p><code>1449</code><code>Agelli M, Clegg LX: Epidemiology of primary Merkel cell carcinoma in the United States. J Am Acad Dermatol 49 (5): 832-41, 2003.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=14576661&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=14576661&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1450</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1451</code><code>&lt;/li&gt;</code></p><p><code>1452</code><code>&lt;li id="section_1.15"&gt;</code></p><p><code>1453</code><code>Young JL, Ward KC, Ries LAG: Cancer of rare sites. In: Ries LAG, Young JL, Keel GE, et al., eds.: SEER Survival Monograph: Cancer Survival Among Adults: U. S. SEER Program, 1988-2001, Patient and Tumor Characteristics. National Cancer Institute, 2007. NIH Pub. No. 07-6215, pp 251-61.&lt;/li&gt;</code></p><p><code>1454</code><code>&lt;li id="section_1.16"&gt;</code></p><p><code>1455</code><code>Miller RW, Rabkin CS: Merkel cell carcinoma and melanoma: etiological similarities and differences. Cancer Epidemiol Biomarkers Prev 8 (2): 153-8, 1999.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10067813&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10067813&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1456</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1457</code><code>&lt;/li&gt;</code></p><p><code>1458</code><code>&lt;li id="section_1.17"&gt;</code></p><p><code>1459</code><code>Lemos B, Nghiem P: Merkel cell carcinoma: more deaths but still no pathway to blame. J Invest Dermatol 127 (9): 2100-3, 2007.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17700621&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17700621&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1460</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1461</code><code>&lt;/li&gt;</code></p><p><code>1462</code><code>&lt;li id="section_1.18"&gt;</code></p><p><code>1463</code><code>Albores-Saavedra J, Batich K, Chable-Montero F, et al.: Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study. J Cutan Pathol 37 (1): 20-7, 2010.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19638070&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19638070&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1464</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1465</code><code>&lt;/li&gt;</code></p><p><code>1466</code><code>&lt;li id="section_1.19"&gt;</code></p><p><code>1467</code><code>Heath M, Jaimes N, Lemos B, et al.: Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol 58 (3): 375-81, 2008.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18280333&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18280333&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1468</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1469</code><code>&lt;/li&gt;</code></p><p><code>1470</code><code>&lt;li id="section_1.20"&gt;</code></p><p><code>1471</code><code>Paulson KG, Park SY, Vandeven NA, et al.: Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics. J Am Acad Dermatol 78 (3): 457-463.e2, 2018.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=29102486&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=29102486&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1472</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1473</code><code>&lt;/li&gt;</code></p><p><code>1474</code><code>&lt;li id="section_1.21"&gt;</code></p><p><code>1475</code><code>Ma JE, Brewer JD: Merkel cell carcinoma in immunosuppressed patients. Cancers (Basel) 6 (3): 1328-50, 2014.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=24978436&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=24978436&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1476</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1477</code><code>&lt;/li&gt;</code></p><p><code>1478</code><code>&lt;li id="section_1.22"&gt;</code></p><p><code>1479</code><code>Howard RA, Dores GM, Curtis RE, et al.: Merkel cell carcinoma and multiple primary cancers. Cancer Epidemiol Biomarkers Prev 15 (8): 1545-9, 2006.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=16896047&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=16896047&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1480</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1481</code><code>&lt;/li&gt;</code></p><p><code>1482</code><code>&lt;li id="section_1.23"&gt;</code></p><p><code>1483</code><code>Bzhalava D, Bray F, Storm H, et al.: Risk of second cancers after the diagnosis of Merkel cell carcinoma in Scandinavia. Br J Cancer 104 (1): 178-80, 2011.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=21081931&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=21081931&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1484</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1485</code><code>&lt;/li&gt;</code></p><p><code>1486</code><code>&lt;li id="section_1.24"&gt;</code></p><p><code>1487</code><code>Lunder EJ, Stern RS: Merkel-cell carcinomas in patients treated with methoxsalen and ultraviolet A radiation. N Engl J Med 339 (17): 1247-8, 1998.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9786759&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9786759&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1488</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1489</code><code>&lt;/li&gt;</code></p><p><code>1490</code><code>&lt;li id="section_1.25"&gt;</code></p><p><code>1491</code><code>Feng H, Shuda M, Chang Y, et al.: Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319 (5866): 1096-100, 2008.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18202256&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18202256&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1492</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1493</code><code>&lt;/li&gt;</code></p><p><code>1494</code><code>&lt;li id="section_1.26"&gt;</code></p><p><code>1495</code><code>Garneski KM, Warcola AH, Feng Q, et al.: Merkel cell polyomavirus is more frequently present in North American than Australian Merkel cell carcinoma tumors. J Invest Dermatol 129 (1): 246-8, 2009.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18650846&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18650846&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1496</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1497</code><code>&lt;/li&gt;</code></p><p><code>1498</code><code>&lt;li id="section_1.27"&gt;</code></p><p><code>1499</code><code>Becker JC, Houben R, Ugurel S, et al.: MC polyomavirus is frequently present in Merkel cell carcinoma of European patients. J Invest Dermatol 129 (1): 248-50, 2009.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18633441&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18633441&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1500</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1501</code><code>&lt;/li&gt;</code></p><p><code>1502</code><code>&lt;li id="section_1.28"&gt;</code></p><p><code>1503</code><code>Kassem A, Sch&amp;#246;pflin A, Diaz C, et al.: Frequent detection of Merkel cell polyomavirus in human Merkel cell carcinomas and identification of a unique deletion in the VP1 gene. Cancer Res 68 (13): 5009-13, 2008.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18593898&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18593898&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1504</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1505</code><code>&lt;/li&gt;</code></p><p><code>1506</code><code>&lt;li id="section_1.29"&gt;</code></p><p><code>1507</code><code>Houben R, Schrama D, Becker JC: Molecular pathogenesis of Merkel cell carcinoma. Exp Dermatol 18 (3): 193-8, 2009.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19400830&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19400830&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1508</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1509</code><code>&lt;/li&gt;</code></p><p><code>1510</code><code>&lt;li id="section_1.30"&gt;</code></p><p><code>1511</code><code>Paik JY, Hall G, Clarkson A, et al.: Immunohistochemistry for Merkel cell polyomavirus is highly specific but not sensitive for the diagnosis of Merkel cell carcinoma in the Australian population. Hum Pathol 42 (10): 1385-90, 2011.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=21453956&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=21453956&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1512</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1513</code><code>&lt;/li&gt;</code></p><p><code>1514</code><code>&lt;li id="section_1.31"&gt;</code></p><p><code>1515</code><code>Andres C, Belloni B, Puchta U, et al.: Prevalence of MCPyV in Merkel cell carcinoma and non-MCC tumors. J Cutan Pathol 37 (1): 28-34, 2010.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19615033&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19615033&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1516</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1517</code><code>&lt;/li&gt;</code></p><p><code>1518</code><code>&lt;li id="section_1.32"&gt;</code></p><p><code>1519</code><code>Kassem A, Technau K, Kurz AK, et al.: Merkel cell polyomavirus sequences are frequently detected in nonmelanoma skin cancer of immunosuppressed patients. Int J Cancer 125 (2): 356-61, 2009.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19384948&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19384948&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1520</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1521</code><code>&lt;/li&gt;</code></p><p><code>1522</code><code>&lt;li id="section_1.33"&gt;</code></p><p><code>1523</code><code>Foulongne V, Dereure O, Kluger N, et al.: Merkel cell polyomavirus DNA detection in lesional and nonlesional skin from patients with Merkel cell carcinoma or other skin diseases. Br J Dermatol 162 (1): 59-63, 2010.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19678822&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19678822&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1524</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1525</code><code>&lt;/li&gt;</code></p><p><code>1526</code><code>&lt;li id="section_1.34"&gt;</code></p><p><code>1527</code><code>DeCaprio JA: Does detection of Merkel cell polyomavirus in Merkel cell carcinoma provide prognostic information? J Natl Cancer Inst 101 (13): 905-7, 2009.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19535772&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19535772&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1528</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1529</code><code>&lt;/li&gt;</code></p><p><code>1530</code><code>&lt;li id="section_1.35"&gt;</code></p><p><code>1531</code><code>Laude HC, Jonch&amp;#232;re B, Maubec E, et al.: Distinct merkel cell polyomavirus molecular features in tumour and non tumour specimens from patients with merkel cell carcinoma. PLoS Pathog 6 (8): , 2010.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=20865165&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=20865165&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1532</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1533</code><code>&lt;/li&gt;</code></p><p><code>1534</code><code>&lt;li id="section_1.36"&gt;</code></p><p><code>1535</code><code>Buck CB, Lowy DR: Immune readouts may have prognostic value for the course of merkel cell carcinoma, a virally associated disease. J Clin Oncol 29 (12): 1506-8, 2011.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=21422431&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=21422431&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1536</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1537</code><code>&lt;/li&gt;</code></p><p><code>1538</code><code>&lt;li id="section_1.37"&gt;</code></p><p><code>1539</code><code>Seattle Cancer Care Alliance: Merkel Cell Carcinoma Information for Patients and Their Physicians: Clinical Photos/Images. Seattle, Wa: Seattle Cancer Care Alliance Skin Oncology Clinic, 2009. &lt;a href="https://merkelcell.org/resources/pictures-of-merkel-cell-carcinoma/" title="https://merkelcell.org/resources/pictures-of-merkel-cell-carcinoma/"&gt;</code></p><p><code>1540</code><code>Available online.&lt;/a&gt;</code></p><p><code>1541</code><code> Last accessed September 30, 2022.&lt;/li&gt;</code></p><p><code>1542</code><code>&lt;li id="section_1.38"&gt;</code></p><p><code>1543</code><code>Gupta SG, Wang LC, Pe&amp;#241;as PF, et al.: Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma: The Dana-Farber experience and meta-analysis of the literature. Arch Dermatol 142 (6): 685-90, 2006.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=16785370&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=16785370&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1544</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1545</code><code>&lt;/li&gt;</code></p><p><code>1546</code><code>&lt;li id="section_1.39"&gt;</code></p><p><code>1547</code><code>Anderson SE, Beer KT, Banic A, et al.: MRI of merkel cell carcinoma: histologic correlation and review of the literature. AJR Am J Roentgenol 185 (6): 1441-8, 2005.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=16303995&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=16303995&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1548</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1549</code><code>&lt;/li&gt;</code></p><p><code>1550</code><code>&lt;li id="section_1.40"&gt;</code></p><p><code>1551</code><code>Iagaru A, Quon A, McDougall IR, et al.: Merkel cell carcinoma: Is there a role for 2-deoxy-2-[f-18]fluoro-D-glucose-positron emission tomography/computed tomography? Mol Imaging Biol 8 (4): 212-7, 2006 Jul-Aug.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=16724293&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=16724293&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1552</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1553</code><code>&lt;/li&gt;</code></p><p><code>1554</code><code>&lt;li id="section_1.41"&gt;</code></p><p><code>1555</code><code>Belhocine T, Pierard GE, Fr&amp;#252;hling J, et al.: Clinical added-value of 18FDG PET in neuroendocrine-merkel cell carcinoma. Oncol Rep 16 (2): 347-52, 2006.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=16820914&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=16820914&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1556</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1557</code><code>&lt;/li&gt;</code></p><p><code>1558</code><code>&lt;li id="section_1.42"&gt;</code></p><p><code>1559</code><code>Missotten GS, de Wolff-Rouendaal D, de Keizer RJ: Merkel cell carcinoma of the eyelid review of the literature and report of patients with Merkel cell carcinoma showing spontaneous regression. Ophthalmology 115 (1): 195-201, 2008.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17531320&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17531320&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1560</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1561</code><code>&lt;/li&gt;</code></p><p><code>1562</code><code>&lt;li id="section_1.43"&gt;</code></p><p><code>1563</code><code>Richetta AG, Mancini M, Torroni A, et al.: Total spontaneous regression of advanced merkel cell carcinoma after biopsy: review and a new case. Dermatol Surg 34 (6): 815-22, 2008.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18363731&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18363731&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1564</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1565</code><code>&lt;/li&gt;</code></p><p><code>1566</code><code>&lt;li id="section_1.44"&gt;</code></p><p><code>1567</code><code>Allen PJ, Bowne WB, Jaques DP, et al.: Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol 23 (10): 2300-9, 2005.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=15800320&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=15800320&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1568</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1569</code><code>&lt;/li&gt;</code></p><p><code>1570</code><code>&lt;li id="section_1.45"&gt;</code></p><p><code>1571</code><code>Stokes JB, Graw KS, Dengel LT, et al.: Patients with Merkel cell carcinoma tumors &amp;lt; or = 1.0 cm in diameter are unlikely to harbor regional lymph node metastasis. J Clin Oncol 27 (23): 3772-7, 2009.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19581538&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19581538&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1572</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1573</code><code>&lt;/li&gt;</code></p><p><code>1574</code><code>&lt;li id="section_1.46"&gt;</code></p><p><code>1575</code><code>Jabbour J, Cumming R, Scolyer RA, et al.: Merkel cell carcinoma: assessing the effect of wide local excision, lymph node dissection, and radiotherapy on recurrence and survival in early-stage disease--results from a review of 82 consecutive cases diagnosed between 1992 and 2004. Ann Surg Oncol 14 (6): 1943-52, 2007.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17356954&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17356954&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1576</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1577</code><code>&lt;/li&gt;</code></p><p><code>1578</code><code>&lt;li id="section_1.47"&gt;</code></p><p><code>1579</code><code>Henness S, Vereecken P: Management of Merkel tumours: an evidence-based review. Curr Opin Oncol 20 (3): 280-6, 2008.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18391627&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18391627&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1580</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1581</code><code>&lt;/li&gt;</code></p><p><code>1582</code><code>&lt;li id="section_1.48"&gt;</code></p><p><code>1583</code><code>Skelton HG, Smith KJ, Hitchcock CL, et al.: Merkel cell carcinoma: analysis of clinical, histologic, and immunohistologic features of 132 cases with relation to survival. J Am Acad Dermatol 37 (5 Pt 1): 734-9, 1997.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9366819&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9366819&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1584</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1585</code><code>&lt;/li&gt;</code></p><p><code>1586</code><code>&lt;li id="section_1.49"&gt;</code></p><p><code>1587</code><code>Sandel HD, Day T, Richardson MS, et al.: Merkel cell carcinoma: does tumor size or depth of invasion correlate with recurrence, metastasis, or patient survival? Laryngoscope 116 (5): 791-5, 2006.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=16652089&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=16652089&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1588</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1589</code><code>&lt;/li&gt;</code></p><p><code>1590</code><code>&lt;li id="section_1.50"&gt;</code></p><p><code>1591</code><code>Llombart B, Monteagudo C, L&amp;#243;pez-Guerrero JA, et al.: Clinicopathological and immunohistochemical analysis of 20 cases of Merkel cell carcinoma in search of prognostic markers. Histopathology 46 (6): 622-34, 2005.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=15910593&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=15910593&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1592</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1593</code><code>&lt;/li&gt;</code></p><p><code>1594</code><code>&lt;li id="section_1.51"&gt;</code></p><p><code>1595</code><code>Senchenkov A, Barnes SA, Moran SL: Predictors of survival and recurrence in the surgical treatment of merkel cell carcinoma of the extremities. J Surg Oncol 95 (3): 229-34, 2007.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17323336&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17323336&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1596</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1597</code><code>&lt;/li&gt;</code></p><p><code>1598</code><code>&lt;li id="section_1.52"&gt;</code></p><p><code>1599</code><code>Goldberg SR, Neifeld JP, Frable WJ: Prognostic value of tumor thickness in patients with Merkel cell carcinoma. J Surg Oncol 95 (8): 618-22, 2007.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17345617&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17345617&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1600</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1601</code><code>&lt;/li&gt;</code></p><p><code>1602</code><code>&lt;li id="section_1.53"&gt;</code></p><p><code>1603</code><code>Heath ML, Nghiem P: Merkel cell carcinoma: if no breslow, then what? J Surg Oncol 95 (8): 614-5, 2007.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17221860&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17221860&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1604</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1605</code><code>&lt;/li&gt;</code></p><p><code>1606</code><code>&lt;li id="section_1.54"&gt;</code></p><p><code>1607</code><code>Tai P: Merkel cell cancer: update on biology and treatment. Curr Opin Oncol 20 (2): 196-200, 2008.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18300770&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18300770&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1608</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1609</code><code>&lt;/li&gt;</code></p><p><code>1610</code><code>&lt;li id="section_1.55"&gt;</code></p><p><code>1611</code><code>Andea AA, Coit DG, Amin B, et al.: Merkel cell carcinoma: histologic features and prognosis. Cancer 113 (9): 2549-58, 2008.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18798233&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18798233&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1612</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1613</code><code>&lt;/li&gt;</code></p><p><code>1614</code><code>&lt;li id="section_1.56"&gt;</code></p><p><code>1615</code><code>Paulson KG, Iyer JG, Tegeder AR, et al.: Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol 29 (12): 1539-46, 2011.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=21422430&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=21422430&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1616</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1617</code><code>&lt;/li&gt;</code></p><p><code>1618</code><code>&lt;li id="section_1.57"&gt;</code></p><p><code>1619</code><code>Fields RC, Busam KJ, Chou JF, et al.: Recurrence and survival in patients undergoing sentinel lymph node biopsy for merkel cell carcinoma: analysis of 153 patients from a single institution. Ann Surg Oncol 18 (9): 2529-37, 2011.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=21431988&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=21431988&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1620</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1621</code><code>&lt;/li&gt;</code></p><p><code>1622</code><code>&lt;li id="section_1.58"&gt;</code></p><p><code>1623</code><code>Sihto H, Kukko H, Koljonen V, et al.: Clinical factors associated with Merkel cell polyomavirus infection in Merkel cell carcinoma. J Natl Cancer Inst 101 (13): 938-45, 2009.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19535775&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19535775&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1624</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1625</code><code>&lt;/li&gt;</code></p><p><code>1626</code><code>&lt;li id="section_1.59"&gt;</code></p><p><code>1627</code><code>Harms KL, Healy MA, Nghiem P, et al.: Analysis of Prognostic Factors from 9387 Merkel Cell Carcinoma Cases Forms the Basis for the New 8th Edition AJCC Staging System. Ann Surg Oncol 23 (11): 3564-3571, 2016.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=27198511&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=27198511&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1628</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1629</code><code>&lt;/li&gt;</code></p><p><code>1630</code><code>&lt;li id="section_1.60"&gt;</code></p><p><code>1631</code><code>Iyer JG, Storer BE, Paulson KG, et al.: Relationships among primary tumor size, number of&amp;#160;involved nodes, and survival for 8044 cases of&amp;#160;Merkel cell carcinoma. J Am Acad Dermatol 70 (4): 637-643, 2014.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=24521828&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=24521828&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1632</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1633</code><code>&lt;/li&gt;</code></p><p><code>1634</code><code>&lt;li id="section_1.61"&gt;</code></p><p><code>1635</code><code>Schwartz JL, Griffith KA, Lowe L, et al.: Features predicting sentinel lymph node positivity in Merkel cell carcinoma. J Clin Oncol 29 (8): 1036-41, 2011.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=21300936&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=21300936&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1636</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1637</code><code>&lt;/li&gt;</code></p><p><code>1638</code><code>&lt;li id="section_1.62"&gt;</code></p><p><code>1639</code><code>Ko JS, Prieto VG, Elson PJ, et al.: Histological pattern of Merkel cell carcinoma sentinel lymph node metastasis improves stratification of Stage III patients. Mod Pathol 29 (2): 122-30, 2016.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=26541273&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=26541273&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1640</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1641</code><code>&lt;/li&gt;</code></p><p><code>1642</code><code>&lt;li id="section_1.63"&gt;</code></p><p><code>1643</code><code>Eng TY, Boersma MG, Fuller CD, et al.: Treatment of merkel cell carcinoma. Am J Clin Oncol 27 (5): 510-5, 2004.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=15596922&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=15596922&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1644</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1645</code><code>&lt;/li&gt;</code></p><p><code>1646</code><code>&lt;/ol&gt;</code></p><p><code>1647</code><code>&lt;/div&gt;</code></p><p><code>1648</code><code>          </code></p><p><code>1649</code><code>    &lt;/section&gt;</code></p><p><code>1650</code><code>          </code></p><p><code>1651</code><code>          </code></p><p><code>1652</code><code>          </code></p><p><code>1653</code><code>    &lt;section id="_36"&gt;</code></p><p><code>1654</code><code>          </code></p><p><code>1655</code><code>        &lt;h2&gt;</code></p><p><code>1656</code><code>Cellular Classification of Merkel Cell Carcinoma&lt;/h2&gt;</code></p><p><code>1657</code><code>          </code></p><p><code>1658</code><code>        &lt;div id="_section_36" class="pdq-sections"&gt;</code></p><p><code>1659</code><code>&lt;p id="_37" tabindex="-1"&gt;</code></p><p><code>1660</code><code>Although the exact origin and function of the Merkel cell remains under investigation, it is thought to have features of both epithelial and neuroendocrine origin and arise in cells with touch-sensitivity function (mechanoreceptors).[&lt;a href="#cit/section_2.1"&gt;</code></p><p><code>1661</code><code>1&lt;/a&gt;</code></p><p><code>1662</code><code>-&lt;a href="#cit/section_2.4"&gt;</code></p><p><code>1663</code><code>4&lt;/a&gt;</code></p><p><code>1664</code><code>]  &lt;/p&gt;</code></p><p><code>1665</code><code>&lt;p id="_167" tabindex="-1"&gt;</code></p><p><code>1666</code><code>Characteristic histopathological features include dense core cytoplasmic neurosecretory granules on electron microscopy and cytokeratin-20 on immunohistochemistry (see &lt;a href="/types/skin/hp/merkel-cell-treatment-pdq#_241"&gt;</code></p><p><code>1667</code><code>Figure 4&lt;/a&gt;</code></p><p><code>1668</code><code>).[&lt;a href="#cit/section_2.5"&gt;</code></p><p><code>1669</code><code>5&lt;/a&gt;</code></p><p><code>1670</code><code>]  &lt;/p&gt;</code></p><p><code>1671</code><code>&lt;p id="_168" tabindex="-1"&gt;</code></p><p><code>1672</code><code>A panel of immunoreagents (see &lt;a href="/types/skin/hp/merkel-cell-treatment-pdq#_241"&gt;</code></p><p><code>1673</code><code>Figure 4&lt;/a&gt;</code></p><p><code>1674</code><code>) can distinguish between Merkel cell carcinoma (MCC) and other similar-appearing tumors including neuroendocrine carcinoma of the lung (i.e., small cell carcinoma), lymphoma, peripheral primitive neuroectodermal tumor, metastatic carcinoid tumor, and small cell melanoma.[&lt;a href="#cit/section_2.5"&gt;</code></p><p><code>1675</code><code>5&lt;/a&gt;</code></p><p><code>1676</code><code>]&lt;figure id="figure_241" class="image-center"&gt;</code></p><p><code>1677</code><code>&lt;a href="https://nci-media.cancer.gov/pdq/media/images/661439.jpg" target="_blank" class="article-image-enlarge"&gt;</code></p><p><code>1678</code><code>Enlarge&lt;/a&gt;</code></p><p><code>1679</code><code>&lt;img id="_241" alt="MerkelCell" title="MerkelCell" src="https://nci-media.cancer.gov/pdq/media/images/661439-750.jpg"&gt;</code></p><p><code>1680</code><code>&lt;figcaption class="caption-container"&gt;</code></p><p><code>1681</code><code>Figure 4.  Merkel - Immunohistochemical differential diagnosis of Merkel-Cell Carcinoma (Typical Staining Pattern).&lt;/figcaption&gt;</code></p><p><code>1682</code><code>&lt;/figure&gt;</code></p><p><code>1683</code><code>&lt;/p&gt;</code></p><p><code>1684</code><code>&lt;p id="_39" tabindex="-1"&gt;</code></p><p><code>1685</code><code>Histologically, MCC has been classified into three distinct subtypes: [&lt;a href="#cit/section_2.6"&gt;</code></p><p><code>1686</code><code>6&lt;/a&gt;</code></p><p><code>1687</code><code>-&lt;a href="#cit/section_2.9"&gt;</code></p><p><code>1688</code><code>9&lt;/a&gt;</code></p><p><code>1689</code><code>]&lt;/p&gt;</code></p><p><code>1690</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>1691</code><code>&lt;ul id="_40"&gt;</code></p><p><code>1692</code><code>&lt;li&gt;</code></p><p><code>1693</code><code>Trabecular: classic pattern, large-cell type, high density or granules on ultrasound examination.&lt;/li&gt;</code></p><p><code>1694</code><code>&lt;li&gt;</code></p><p><code>1695</code><code>	Intermediate: solid pattern (most common).&lt;/li&gt;</code></p><p><code>1696</code><code>&lt;li&gt;</code></p><p><code>1697</code><code>	Small cell: diffuse, few high-density granules on ultrasound examination (second most common).&lt;/li&gt;</code></p><p><code>1698</code><code>&lt;/ul&gt;</code></p><p><code>1699</code><code>&lt;/div&gt;</code></p><p><code>1700</code><code>&lt;p id="_41" tabindex="-1"&gt;</code></p><p><code>1701</code><code>Mixtures of variants are common.[&lt;a href="#cit/section_2.6"&gt;</code></p><p><code>1702</code><code>6&lt;/a&gt;</code></p><p><code>1703</code><code>-&lt;a href="#cit/section_2.8"&gt;</code></p><p><code>1704</code><code>8&lt;/a&gt;</code></p><p><code>1705</code><code>] Although some small retrospective case series have suggested correlations between certain histological features and outcome, the evidence remains uncertain.[&lt;a href="#cit/section_2.10"&gt;</code></p><p><code>1706</code><code>10&lt;/a&gt;</code></p><p><code>1707</code><code>-&lt;a href="#cit/section_2.12"&gt;</code></p><p><code>1708</code><code>12&lt;/a&gt;</code></p><p><code>1709</code><code>]&lt;/p&gt;</code></p><p><code>1710</code><code>&lt;p id="_42" tabindex="-1"&gt;</code></p><p><code>1711</code><code>One group has suggested a list of 12 elements that should be described in pathology reports of resected primary lesions and  nine elements to be described  in pathology reports of sentinel lymph nodes. The prognostic significance of these elements has not been validated prospectively.[&lt;a href="#cit/section_2.13"&gt;</code></p><p><code>1712</code><code>13&lt;/a&gt;</code></p><p><code>1713</code><code>]&lt;/p&gt;</code></p><p><code>1714</code><code>&lt;p id="_171" tabindex="-1"&gt;</code></p><p><code>1715</code><code>If the following data are recorded for every MCC patient, any patient can be staged with the existing or new staging system:&lt;/p&gt;</code></p><p><code>1716</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>1717</code><code>&lt;ul id="_172"&gt;</code></p><p><code>1718</code><code>&lt;li&gt;</code></p><p><code>1719</code><code>Size of primary tumor (maximum dimension pathologically or clinically in centimeters).&lt;/li&gt;</code></p><p><code>1720</code><code>&lt;li&gt;</code></p><p><code>1721</code><code>Presence/absence of primary tumor invasion into bone, muscle, fascia, or cartilage.&lt;/li&gt;</code></p><p><code>1722</code><code>&lt;li&gt;</code></p><p><code>1723</code><code>Presence/absence of nodal metastasis.&lt;/li&gt;</code></p><p><code>1724</code><code>&lt;li&gt;</code></p><p><code>1725</code><code>Method used to ascertain status of nodal involvement (clinical or pathological examination).&lt;/li&gt;</code></p><p><code>1726</code><code>&lt;li&gt;</code></p><p><code>1727</code><code>Presence/absence of distant metastasis. &lt;/li&gt;</code></p><p><code>1728</code><code>&lt;/ul&gt;</code></p><p><code>1729</code><code>&lt;/div&gt;</code></p><p><code>1730</code><code>&lt;p id="_317" tabindex="-1"&gt;</code></p><p><code>1731</code><code>The College of American Pathologists has published a protocol for the examination of specimens from patients with MCC of the skin.[&lt;a href="#cit/section_2.14"&gt;</code></p><p><code>1732</code><code>14&lt;/a&gt;</code></p><p><code>1733</code><code>]&lt;/p&gt;</code></p><p><code>1734</code><code>&lt;p id="_196" tabindex="-1"&gt;</code></p><p><code>1735</code><code>For more information, see the &lt;a href="/types/skin/hp/merkel-cell-treatment-pdq#_45"&gt;</code></p><p><code>1736</code><code>Stage Information for Merkel Cell Carcinoma &lt;/a&gt;</code></p><p><code>1737</code><code> section.&lt;/p&gt;</code></p><p><code>1738</code><code>&lt;p id="_232" tabindex="-1"&gt;</code></p><p><code>1739</code><code>The histological variants of MCC are shown in &lt;a href="/types/skin/hp/merkel-cell-treatment-pdq#_221"&gt;</code></p><p><code>1740</code><code>Figure 5.&lt;/a&gt;</code></p><p><code>1741</code><code>&amp;#160;[&lt;a href="#cit/section_2.15"&gt;</code></p><p><code>1742</code><code>15&lt;/a&gt;</code></p><p><code>1743</code><code>]&lt;figure id="figure_221" class="image-center"&gt;</code></p><p><code>1744</code><code>&lt;a href="https://nci-media.cancer.gov/pdq/media/images/658577.jpg" target="_blank" class="article-image-enlarge"&gt;</code></p><p><code>1745</code><code>Enlarge&lt;/a&gt;</code></p><p><code>1746</code><code>&lt;img id="_221" alt="MerkelCell" title="MerkelCell" src="https://nci-media.cancer.gov/pdq/media/images/658577-750.jpg"&gt;</code></p><p><code>1747</code><code>&lt;figcaption class="caption-container"&gt;</code></p><p><code>1748</code><code>Figure 5.  (A) Intermediate variant of MCC showing vesicular, basophilic nuclei with prominent nucleoli and multiple mitoses. (B) Small-cell variant, histologically indistinguishable from bronchial small-cell carcinoma. &amp;#169;) Trabecular variant is rare and normally only seen as a small component of a mixed variant. Goessling W et al: Merkel Cell Carcinoma, J Clin Oncol, 20 (2), pp. 588&amp;#8211;98. Reprinted with permission. &amp;#169; 2009 American Society of Clinical Oncology. All rights reserved.&lt;/figcaption&gt;</code></p><p><code>1749</code><code>&lt;/figure&gt;</code></p><p><code>1750</code><code>&lt;/p&gt;</code></p><p><code>1751</code><code>&lt;h6 do-not-show="toc"&gt;</code></p><p><code>1752</code><code>References&lt;/h6&gt;</code></p><p><code>1753</code><code>&lt;ol&gt;</code></p><p><code>1754</code><code>&lt;li id="section_2.1"&gt;</code></p><p><code>1755</code><code>Nghiem P, McKee PH, Haynes HA: Merkel cell (cutaneous neuroendocrine) carcinoma. In: Sober AJ, Haluska FG, eds.: Skin Cancer. BC Decker Inc., 2001, pp 127-141.&lt;/li&gt;</code></p><p><code>1756</code><code>&lt;li id="section_2.2"&gt;</code></p><p><code>1757</code><code>Bichakjian CK, Nghiem P, Johnson T, et al.: Merkel Cell Carcinoma. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. Springer; 2017, pp 549-62.&lt;/li&gt;</code></p><p><code>1758</code><code>&lt;li id="section_2.3"&gt;</code></p><p><code>1759</code><code>Eng TY, Boersma MG, Fuller CD, et al.: A comprehensive review of the treatment of Merkel cell carcinoma. Am J Clin Oncol 30 (6): 624-36, 2007.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18091058&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18091058&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1760</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1761</code><code>&lt;/li&gt;</code></p><p><code>1762</code><code>&lt;li id="section_2.4"&gt;</code></p><p><code>1763</code><code>Medina-Franco H, Urist MM, Fiveash J, et al.: Multimodality treatment of Merkel cell carcinoma: case series and literature review of 1024 cases. Ann Surg Oncol 8 (3): 204-8, 2001.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11314935&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11314935&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1764</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1765</code><code>&lt;/li&gt;</code></p><p><code>1766</code><code>&lt;li id="section_2.5"&gt;</code></p><p><code>1767</code><code>Busse PM, Clark JR, Muse VV, et al.: Case records of the Massachusetts General Hospital. Case 19-2008. A 63-year-old HIV-positive man with cutaneous Merkel-cell carcinoma. N Engl J Med 358 (25): 2717-23, 2008.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18565865&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18565865&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1768</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1769</code><code>&lt;/li&gt;</code></p><p><code>1770</code><code>&lt;li id="section_2.6"&gt;</code></p><p><code>1771</code><code>Haag ML, Glass LF, Fenske NA: Merkel cell carcinoma. Diagnosis and treatment. Dermatol Surg 21 (8): 669-83, 1995.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=7633811&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=7633811&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1772</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1773</code><code>&lt;/li&gt;</code></p><p><code>1774</code><code>&lt;li id="section_2.7"&gt;</code></p><p><code>1775</code><code>Ratner D, Nelson BR, Brown MD, et al.: Merkel cell carcinoma. J Am Acad Dermatol 29 (2 Pt 1): 143-56, 1993.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=8335732&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=8335732&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1776</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1777</code><code>&lt;/li&gt;</code></p><p><code>1778</code><code>&lt;li id="section_2.8"&gt;</code></p><p><code>1779</code><code>Gould VE, Moll R, Moll I, et al.: Neuroendocrine (Merkel) cells of the skin: hyperplasias, dysplasias, and neoplasms. Lab Invest 52 (4): 334-53, 1985.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=2580118&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=2580118&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1780</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1781</code><code>&lt;/li&gt;</code></p><p><code>1782</code><code>&lt;li id="section_2.9"&gt;</code></p><p><code>1783</code><code>Albores-Saavedra J, Batich K, Chable-Montero F, et al.: Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study. J Cutan Pathol 37 (1): 20-7, 2010.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19638070&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19638070&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1784</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1785</code><code>&lt;/li&gt;</code></p><p><code>1786</code><code>&lt;li id="section_2.10"&gt;</code></p><p><code>1787</code><code>Alam M: Management of Merkel cell carcinoma: What we know. Arch Dermatol 142 (6): 771-4, 2006.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=16785382&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=16785382&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1788</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1789</code><code>&lt;/li&gt;</code></p><p><code>1790</code><code>&lt;li id="section_2.11"&gt;</code></p><p><code>1791</code><code>Heath ML, Nghiem P: Merkel cell carcinoma: if no breslow, then what? J Surg Oncol 95 (8): 614-5, 2007.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17221860&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17221860&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1792</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1793</code><code>&lt;/li&gt;</code></p><p><code>1794</code><code>&lt;li id="section_2.12"&gt;</code></p><p><code>1795</code><code>Andea AA, Coit DG, Amin B, et al.: Merkel cell carcinoma: histologic features and prognosis. Cancer 113 (9): 2549-58, 2008.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18798233&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18798233&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1796</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1797</code><code>&lt;/li&gt;</code></p><p><code>1798</code><code>&lt;li id="section_2.13"&gt;</code></p><p><code>1799</code><code>Bichakjian CK, Lowe L, Lao CD, et al.: Merkel cell carcinoma: critical review with guidelines for multidisciplinary management. Cancer 110 (1): 1-12, 2007.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17520670&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17520670&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1800</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1801</code><code>&lt;/li&gt;</code></p><p><code>1802</code><code>&lt;li id="section_2.14"&gt;</code></p><p><code>1803</code><code>Rao P, Balzer BL, Lemos BD, et al.: Protocol for the examination of specimens from patients with merkel cell carcinoma of the skin. Arch Pathol Lab Med 134 (3): 341-4, 2010.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=20196661&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=20196661&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1804</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1805</code><code>&lt;/li&gt;</code></p><p><code>1806</code><code>&lt;li id="section_2.15"&gt;</code></p><p><code>1807</code><code>Goessling W, McKee PH, Mayer RJ: Merkel cell carcinoma. J Clin Oncol 20 (2): 588-98, 2002.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11786590&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11786590&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1808</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1809</code><code>&lt;/li&gt;</code></p><p><code>1810</code><code>&lt;/ol&gt;</code></p><p><code>1811</code><code>&lt;/div&gt;</code></p><p><code>1812</code><code>          </code></p><p><code>1813</code><code>    &lt;/section&gt;</code></p><p><code>1814</code><code>          </code></p><p><code>1815</code><code>          </code></p><p><code>1816</code><code>          </code></p><p><code>1817</code><code>    &lt;section id="_45"&gt;</code></p><p><code>1818</code><code>          </code></p><p><code>1819</code><code>        &lt;h2&gt;</code></p><p><code>1820</code><code>Stage Information for Merkel Cell Carcinoma&lt;/h2&gt;</code></p><p><code>1821</code><code>          </code></p><p><code>1822</code><code>        &lt;div id="_section_45" class="pdq-sections"&gt;</code></p><p><code>1823</code><code>&lt;nav class="in-this-section" role="navigation"&gt;</code></p><p><code>1824</code><code>&lt;h6&gt;</code></p><p><code>1825</code><code>In This Section&lt;/h6&gt;</code></p><p><code>1826</code><code>&lt;ul&gt;</code></p><p><code>1827</code><code>&lt;li&gt;</code></p><p><code>1828</code><code>&lt;a href="#_285_toc"&gt;</code></p><p><code>1829</code><code>American Joint Committee on Cancer (AJCC) Stage Groupings and TNM Definitions&lt;/a&gt;</code></p><p><code>1830</code><code>&lt;/li&gt;</code></p><p><code>1831</code><code>&lt;/ul&gt;</code></p><p><code>1832</code><code>&lt;/nav&gt;</code></p><p><code>1833</code><code>&lt;p id="_174" tabindex="-1"&gt;</code></p><p><code>1834</code><code>Previously, five competing staging systems have been used to describe Merkel cell carcinoma (MCC) in most publications.&lt;/p&gt;</code></p><p><code>1835</code><code>&lt;table id="_193" class="table-default expandable-container"&gt;</code></p><p><code>1836</code><code>&lt;caption&gt;</code></p><p><code>1837</code><code>Table 2.  Five Previously Used Competing Merkel Cell Carcinoma Staging Systems&lt;/caption&gt;</code></p><p><code>1838</code><code>&lt;colgroup&gt;</code></p><p><code>1839</code><code>&lt;col width="33.24%"&gt;</code></p><p><code>1840</code><code>&lt;col width="12.64%"&gt;</code></p><p><code>1841</code><code>&lt;col width="20.60%"&gt;</code></p><p><code>1842</code><code>&lt;col width="16.56%"&gt;</code></p><p><code>1843</code><code>&lt;col width="16.94%"&gt;</code></p><p><code>1844</code><code>&lt;/colgroup&gt;</code></p><p><code>1845</code><code>&lt;THead&gt;</code></p><p><code>1846</code><code>&lt;tr&gt;</code></p><p><code>1847</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1848</code><code>First Author&lt;/th&gt;</code></p><p><code>1849</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1850</code><code>Publication Date &lt;/th&gt;</code></p><p><code>1851</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1852</code><code>Institution(s)&lt;/th&gt;</code></p><p><code>1853</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1854</code><code>No. of Patients in Case Series&lt;/th&gt;</code></p><p><code>1855</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1856</code><code>Dates of Cases&lt;/th&gt;</code></p><p><code>1857</code><code>&lt;/tr&gt;</code></p><p><code>1858</code><code>&lt;/THead&gt;</code></p><p><code>1859</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>1860</code><code>&lt;tr&gt;</code></p><p><code>1861</code><code>&lt;td colspan="5"&gt;</code></p><p><code>1862</code><code>MSKCC = Memorial Sloan Kettering Cancer Center;  N/A = Not applicable.&lt;/td&gt;</code></p><p><code>1863</code><code>&lt;/tr&gt;</code></p><p><code>1864</code><code>&lt;tr&gt;</code></p><p><code>1865</code><code>&lt;td colspan="5"&gt;</code></p><p><code>1866</code><code>&lt;span class="sup"&gt;</code></p><p><code>1867</code><code>a&lt;/span&gt;</code></p><p><code>1868</code><code>The MSKCC system has evolved over time. MSKCC authors have published one additional case series with 256 patients.[&lt;a href="#cit/section_3.1"&gt;</code></p><p><code>1869</code><code>1&lt;/a&gt;</code></p><p><code>1870</code><code>]&lt;/td&gt;</code></p><p><code>1871</code><code>&lt;/tr&gt;</code></p><p><code>1872</code><code>&lt;/TFoot&gt;</code></p><p><code>1873</code><code>&lt;tbody&gt;</code></p><p><code>1874</code><code>&lt;tr&gt;</code></p><p><code>1875</code><code>&lt;td&gt;</code></p><p><code>1876</code><code>Yiengpruksawan[&lt;a href="#cit/section_3.2"&gt;</code></p><p><code>1877</code><code>2&lt;/a&gt;</code></p><p><code>1878</code><code>]&lt;/td&gt;</code></p><p><code>1879</code><code>&lt;td&gt;</code></p><p><code>1880</code><code>1991&lt;/td&gt;</code></p><p><code>1881</code><code>&lt;td&gt;</code></p><p><code>1882</code><code> MSKCC&lt;span class="sup"&gt;</code></p><p><code>1883</code><code>a&lt;/span&gt;</code></p><p><code>1884</code><code>&lt;/td&gt;</code></p><p><code>1885</code><code>&lt;td&gt;</code></p><p><code>1886</code><code>77&lt;/td&gt;</code></p><p><code>1887</code><code>&lt;td&gt;</code></p><p><code>1888</code><code>1969&amp;#8211;1989&lt;/td&gt;</code></p><p><code>1889</code><code>&lt;/tr&gt;</code></p><p><code>1890</code><code>&lt;tr&gt;</code></p><p><code>1891</code><code>&lt;td&gt;</code></p><p><code>1892</code><code>Allen[&lt;a href="#cit/section_3.3"&gt;</code></p><p><code>1893</code><code>3&lt;/a&gt;</code></p><p><code>1894</code><code>]&lt;/td&gt;</code></p><p><code>1895</code><code>&lt;td&gt;</code></p><p><code>1896</code><code>1999&lt;/td&gt;</code></p><p><code>1897</code><code>&lt;td&gt;</code></p><p><code>1898</code><code>MSKCC&lt;span class="sup"&gt;</code></p><p><code>1899</code><code>a&lt;/span&gt;</code></p><p><code>1900</code><code>&lt;/td&gt;</code></p><p><code>1901</code><code>&lt;td&gt;</code></p><p><code>1902</code><code>102&lt;/td&gt;</code></p><p><code>1903</code><code>&lt;td&gt;</code></p><p><code>1904</code><code>1969&amp;#8211;1996&lt;/td&gt;</code></p><p><code>1905</code><code>&lt;/tr&gt;</code></p><p><code>1906</code><code>&lt;tr&gt;</code></p><p><code>1907</code><code>&lt;td&gt;</code></p><p><code>1908</code><code>Allen[&lt;a href="#cit/section_3.4"&gt;</code></p><p><code>1909</code><code>4&lt;/a&gt;</code></p><p><code>1910</code><code>]&lt;/td&gt;</code></p><p><code>1911</code><code>&lt;td&gt;</code></p><p><code>1912</code><code>2005&lt;/td&gt;</code></p><p><code>1913</code><code>&lt;td&gt;</code></p><p><code>1914</code><code>MSKCC&lt;span class="sup"&gt;</code></p><p><code>1915</code><code>a&lt;/span&gt;</code></p><p><code>1916</code><code>&lt;/td&gt;</code></p><p><code>1917</code><code>&lt;td&gt;</code></p><p><code>1918</code><code>250&lt;/td&gt;</code></p><p><code>1919</code><code>&lt;td&gt;</code></p><p><code>1920</code><code>1970&amp;#8211;2002&lt;/td&gt;</code></p><p><code>1921</code><code>&lt;/tr&gt;</code></p><p><code>1922</code><code>&lt;tr&gt;</code></p><p><code>1923</code><code>&lt;td&gt;</code></p><p><code>1924</code><code>American Joint Committee on Cancer[&lt;a href="#cit/section_3.5"&gt;</code></p><p><code>1925</code><code>5&lt;/a&gt;</code></p><p><code>1926</code><code>]&lt;/td&gt;</code></p><p><code>1927</code><code>&lt;td&gt;</code></p><p><code>1928</code><code>2017&lt;/td&gt;</code></p><p><code>1929</code><code>&lt;td&gt;</code></p><p><code>1930</code><code>N/A&lt;/td&gt;</code></p><p><code>1931</code><code>&lt;td&gt;</code></p><p><code>1932</code><code>N/A&lt;/td&gt;</code></p><p><code>1933</code><code>&lt;td&gt;</code></p><p><code>1934</code><code>&amp;#160;&lt;/td&gt;</code></p><p><code>1935</code><code>&lt;/tr&gt;</code></p><p><code>1936</code><code>&lt;tr&gt;</code></p><p><code>1937</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1938</code><code>Clark[&lt;a href="#cit/section_3.6"&gt;</code></p><p><code>1939</code><code>6&lt;/a&gt;</code></p><p><code>1940</code><code>]&lt;/td&gt;</code></p><p><code>1941</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1942</code><code>2007&lt;/td&gt;</code></p><p><code>1943</code><code>&lt;td&gt;</code></p><p><code>1944</code><code>Westmead Hospital, Sydney, Australia&lt;/td&gt;</code></p><p><code>1945</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1946</code><code>110&lt;/td&gt;</code></p><p><code>1947</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1948</code><code>&amp;#160;&lt;/td&gt;</code></p><p><code>1949</code><code>&lt;/tr&gt;</code></p><p><code>1950</code><code>&lt;tr&gt;</code></p><p><code>1951</code><code>&lt;td&gt;</code></p><p><code>1952</code><code>Princess Margaret Hospital/University Health Network, Toronto, Canada&lt;/td&gt;</code></p><p><code>1953</code><code>&lt;/tr&gt;</code></p><p><code>1954</code><code>&lt;tr&gt;</code></p><p><code>1955</code><code>&lt;td&gt;</code></p><p><code>1956</code><code>Sydney Head and Neck Cancer Institute/Royal Prince Alfred Hospital, Sydney, Australia&lt;/td&gt;</code></p><p><code>1957</code><code>&lt;/tr&gt;</code></p><p><code>1958</code><code>&lt;/tbody&gt;</code></p><p><code>1959</code><code>&lt;/table&gt;</code></p><p><code>1960</code><code>&lt;p id="_177" tabindex="-1"&gt;</code></p><p><code>1961</code><code>These staging systems are highly inconsistent with each other.  Stage III disease can mean anything from advanced local disease to nodal disease to distant metastatic disease.  Furthermore, all MCC staging systems in use have been based on fewer than 300 patients.  &lt;/p&gt;</code></p><p><code>1962</code><code>&lt;section id="_285"&gt;</code></p><p><code>1963</code><code>&lt;h3 id="_285_toc"&gt;</code></p><p><code>1964</code><code>American Joint Committee on Cancer (AJCC) Stage Groupings and TNM Definitions&lt;/h3&gt;</code></p><p><code>1965</code><code>&lt;p id="_178" tabindex="-1"&gt;</code></p><p><code>1966</code><code>To address these concerns, a new MCC-specific consensus staging system was developed by the AJCC to define MCC.[&lt;a href="#cit/section_3.7"&gt;</code></p><p><code>1967</code><code>7&lt;/a&gt;</code></p><p><code>1968</code><code>]   Before the publication of this new system, the AJCC advocated using the nonmelanoma staging system.&lt;/p&gt;</code></p><p><code>1969</code><code>&lt;p id="_358" tabindex="-1"&gt;</code></p><p><code>1970</code><code>Cancers staged using this staging system include primary cutaneous neuroendocrine carcinoma (MCC).&lt;/p&gt;</code></p><p><code>1971</code><code>&lt;section id="_384"&gt;</code></p><p><code>1972</code><code>&lt;p id="_385" tabindex="-1"&gt;</code></p><p><code>1973</code><code>&lt;strong&gt;</code></p><p><code>1974</code><code>Clinical Stage Group (cTNM)&lt;/strong&gt;</code></p><p><code>1975</code><code>&lt;/p&gt;</code></p><p><code>1976</code><code>&lt;table id="_378" class="table-default expandable-container"&gt;</code></p><p><code>1977</code><code>&lt;caption&gt;</code></p><p><code>1978</code><code>Table 3.  Definitions of Clinical Stage Group (cTNM)  for Stage 0&lt;span class="sup"&gt;</code></p><p><code>1979</code><code>a&lt;/span&gt;</code></p><p><code>1980</code><code>&lt;/caption&gt;</code></p><p><code>1981</code><code>&lt;colgroup&gt;</code></p><p><code>1982</code><code>&lt;col width="24.39%"&gt;</code></p><p><code>1983</code><code>&lt;col width="25.60%"&gt;</code></p><p><code>1984</code><code>&lt;col width="50.00%"&gt;</code></p><p><code>1985</code><code>&lt;/colgroup&gt;</code></p><p><code>1986</code><code>&lt;THead&gt;</code></p><p><code>1987</code><code>&lt;tr&gt;</code></p><p><code>1988</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1989</code><code>Stage&lt;/th&gt;</code></p><p><code>1990</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1991</code><code>TNM&lt;/th&gt;</code></p><p><code>1992</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1993</code><code>Description&lt;/th&gt;</code></p><p><code>1994</code><code>&lt;/tr&gt;</code></p><p><code>1995</code><code>&lt;/THead&gt;</code></p><p><code>1996</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>1997</code><code>&lt;tr&gt;</code></p><p><code>1998</code><code>&lt;td colspan="3"&gt;</code></p><p><code>1999</code><code>T = primary tumor; N = regional lymph node; M = distant metastasis; c = clinical.&lt;/td&gt;</code></p><p><code>2000</code><code>&lt;/tr&gt;</code></p><p><code>2001</code><code>&lt;tr&gt;</code></p><p><code>2002</code><code>&lt;td colspan="3"&gt;</code></p><p><code>2003</code><code>&lt;span class="sup"&gt;</code></p><p><code>2004</code><code>a&lt;/span&gt;</code></p><p><code>2005</code><code>Reprinted with permission from AJCC: Merkel Cell Carcinoma. In: Amin MB, Edge SB, Greene FL, et al., eds.: &lt;em&gt;</code></p><p><code>2006</code><code>AJCC Cancer Staging Manual&lt;/em&gt;</code></p><p><code>2007</code><code>. 8th ed. New York, NY: Springer, 2017, pp. 549&amp;#8211;62.&lt;/td&gt;</code></p><p><code>2008</code><code>&lt;/tr&gt;</code></p><p><code>2009</code><code>&lt;/TFoot&gt;</code></p><p><code>2010</code><code>&lt;tbody&gt;</code></p><p><code>2011</code><code>&lt;tr&gt;</code></p><p><code>2012</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>2013</code><code>0&lt;/td&gt;</code></p><p><code>2014</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>2015</code><code>Tis, N0, M0&lt;/td&gt;</code></p><p><code>2016</code><code>&lt;td&gt;</code></p><p><code>2017</code><code>Tis = &lt;em&gt;</code></p><p><code>2018</code><code>In situ&lt;/em&gt;</code></p><p><code>2019</code><code> primary tumor.&lt;/td&gt;</code></p><p><code>2020</code><code>&lt;/tr&gt;</code></p><p><code>2021</code><code>&lt;tr&gt;</code></p><p><code>2022</code><code>&lt;td&gt;</code></p><p><code>2023</code><code>N0 = No regional lymph node metastasis detected on clinical and/or radiologic examination.&lt;/td&gt;</code></p><p><code>2024</code><code>&lt;/tr&gt;</code></p><p><code>2025</code><code>&lt;tr&gt;</code></p><p><code>2026</code><code>&lt;td&gt;</code></p><p><code>2027</code><code>M0 = No distant metastasis detected on clinical and/or radiologic examination.&lt;/td&gt;</code></p><p><code>2028</code><code>&lt;/tr&gt;</code></p><p><code>2029</code><code>&lt;/tbody&gt;</code></p><p><code>2030</code><code>&lt;/table&gt;</code></p><p><code>2031</code><code>&lt;table id="_379" class="table-default expandable-container"&gt;</code></p><p><code>2032</code><code>&lt;caption&gt;</code></p><p><code>2033</code><code>Table 4.  Definitions of Clinical Stage Group (cTNM)  for Stage I&lt;span class="sup"&gt;</code></p><p><code>2034</code><code>a&lt;/span&gt;</code></p><p><code>2035</code><code>&lt;/caption&gt;</code></p><p><code>2036</code><code>&lt;colgroup&gt;</code></p><p><code>2037</code><code>&lt;col width="24.21%"&gt;</code></p><p><code>2038</code><code>&lt;col width="27.11%"&gt;</code></p><p><code>2039</code><code>&lt;col width="48.66%"&gt;</code></p><p><code>2040</code><code>&lt;/colgroup&gt;</code></p><p><code>2041</code><code>&lt;THead&gt;</code></p><p><code>2042</code><code>&lt;tr&gt;</code></p><p><code>2043</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2044</code><code>Stage &lt;/th&gt;</code></p><p><code>2045</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2046</code><code>TNM&lt;/th&gt;</code></p><p><code>2047</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2048</code><code>Description&lt;/th&gt;</code></p><p><code>2049</code><code>&lt;/tr&gt;</code></p><p><code>2050</code><code>&lt;/THead&gt;</code></p><p><code>2051</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>2052</code><code>&lt;tr&gt;</code></p><p><code>2053</code><code>&lt;td colspan="3"&gt;</code></p><p><code>2054</code><code>T = primary tumor; N = regional lymph node; M = distant metastasis; c = clinical.&lt;/td&gt;</code></p><p><code>2055</code><code>&lt;/tr&gt;</code></p><p><code>2056</code><code>&lt;tr&gt;</code></p><p><code>2057</code><code>&lt;td colspan="3"&gt;</code></p><p><code>2058</code><code>&lt;span class="sup"&gt;</code></p><p><code>2059</code><code>a&lt;/span&gt;</code></p><p><code>2060</code><code>Reprinted with permission from AJCC: Merkel Cell Carcinoma. In: Amin MB, Edge SB, Greene FL, et al., eds.: &lt;em&gt;</code></p><p><code>2061</code><code>AJCC Cancer Staging Manual&lt;/em&gt;</code></p><p><code>2062</code><code>. 8th ed. New York, NY: Springer, 2017, pp. 549&amp;#8211;62.&lt;/td&gt;</code></p><p><code>2063</code><code>&lt;/tr&gt;</code></p><p><code>2064</code><code>&lt;/TFoot&gt;</code></p><p><code>2065</code><code>&lt;tbody&gt;</code></p><p><code>2066</code><code>&lt;tr&gt;</code></p><p><code>2067</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>2068</code><code>I&lt;/td&gt;</code></p><p><code>2069</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>2070</code><code>T1, N0, M0&lt;/td&gt;</code></p><p><code>2071</code><code>&lt;td&gt;</code></p><p><code>2072</code><code>T1 = Maximum clinical tumor diameter &amp;#8804;2 cm.&lt;/td&gt;</code></p><p><code>2073</code><code>&lt;/tr&gt;</code></p><p><code>2074</code><code>&lt;tr&gt;</code></p><p><code>2075</code><code>&lt;td&gt;</code></p><p><code>2076</code><code>N0 = No regional lymph node metastasis detected on clinical and/or radiologic examination.&lt;/td&gt;</code></p><p><code>2077</code><code>&lt;/tr&gt;</code></p><p><code>2078</code><code>&lt;tr&gt;</code></p><p><code>2079</code><code>&lt;td&gt;</code></p><p><code>2080</code><code>M0 = No distant metastasis detected on clinical and/or radiologic examination.&lt;/td&gt;</code></p><p><code>2081</code><code>&lt;/tr&gt;</code></p><p><code>2082</code><code>&lt;/tbody&gt;</code></p><p><code>2083</code><code>&lt;/table&gt;</code></p><p><code>2084</code><code>&lt;table id="_380" class="table-default expandable-container"&gt;</code></p><p><code>2085</code><code>&lt;caption&gt;</code></p><p><code>2086</code><code>Table 5.  Definitions of Clinical Stage Group (cTNM)  for Stages IIA and IIB&lt;span class="sup"&gt;</code></p><p><code>2087</code><code>a&lt;/span&gt;</code></p><p><code>2088</code><code>&lt;/caption&gt;</code></p><p><code>2089</code><code>&lt;colgroup&gt;</code></p><p><code>2090</code><code>&lt;col width="24.33%"&gt;</code></p><p><code>2091</code><code>&lt;col width="28.71%"&gt;</code></p><p><code>2092</code><code>&lt;col width="46.95%"&gt;</code></p><p><code>2093</code><code>&lt;/colgroup&gt;</code></p><p><code>2094</code><code>&lt;THead&gt;</code></p><p><code>2095</code><code>&lt;tr&gt;</code></p><p><code>2096</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2097</code><code>Stage&lt;/th&gt;</code></p><p><code>2098</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2099</code><code>TNM&lt;/th&gt;</code></p><p><code>2100</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2101</code><code>Description&lt;/th&gt;</code></p><p><code>2102</code><code>&lt;/tr&gt;</code></p><p><code>2103</code><code>&lt;/THead&gt;</code></p><p><code>2104</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>2105</code><code>&lt;tr&gt;</code></p><p><code>2106</code><code>&lt;td colspan="3"&gt;</code></p><p><code>2107</code><code>T = primary tumor; N = regional lymph node; M = distant metastasis; c = clinical.&lt;/td&gt;</code></p><p><code>2108</code><code>&lt;/tr&gt;</code></p><p><code>2109</code><code>&lt;tr&gt;</code></p><p><code>2110</code><code>&lt;td colspan="3"&gt;</code></p><p><code>2111</code><code>&lt;span class="sup"&gt;</code></p><p><code>2112</code><code>a&lt;/span&gt;</code></p><p><code>2113</code><code>Reprinted with permission from AJCC: Merkel Cell Carcinoma. In: Amin MB, Edge SB, Greene FL, et al., eds.: &lt;em&gt;</code></p><p><code>2114</code><code>AJCC Cancer Staging Manual&lt;/em&gt;</code></p><p><code>2115</code><code>. 8th ed. New York, NY: Springer, 2017, pp. 549&amp;#8211;62.&lt;/td&gt;</code></p><p><code>2116</code><code>&lt;/tr&gt;</code></p><p><code>2117</code><code>&lt;/TFoot&gt;</code></p><p><code>2118</code><code>&lt;tbody&gt;</code></p><p><code>2119</code><code>&lt;tr&gt;</code></p><p><code>2120</code><code>&lt;td rowspan="4"&gt;</code></p><p><code>2121</code><code>IIA&lt;/td&gt;</code></p><p><code>2122</code><code>&lt;td rowspan="4"&gt;</code></p><p><code>2123</code><code>T2&amp;#8211;3, N0, M0&lt;/td&gt;</code></p><p><code>2124</code><code>&lt;td&gt;</code></p><p><code>2125</code><code>T2 = Maximum clinical tumor diameter &amp;gt;2 cm but &amp;#8804;5 cm.&lt;/td&gt;</code></p><p><code>2126</code><code>&lt;/tr&gt;</code></p><p><code>2127</code><code>&lt;tr&gt;</code></p><p><code>2128</code><code>&lt;td&gt;</code></p><p><code>2129</code><code>T3 = Maximum clinical tumor diameter &amp;gt;5 cm.&lt;/td&gt;</code></p><p><code>2130</code><code>&lt;/tr&gt;</code></p><p><code>2131</code><code>&lt;tr&gt;</code></p><p><code>2132</code><code>&lt;td&gt;</code></p><p><code>2133</code><code>N0 = No regional lymph node metastasis detected on clinical and/or radiologic examination.&lt;/td&gt;</code></p><p><code>2134</code><code>&lt;/tr&gt;</code></p><p><code>2135</code><code>&lt;tr&gt;</code></p><p><code>2136</code><code>&lt;td&gt;</code></p><p><code>2137</code><code>M0 = No distant metastasis detected on clinical and/or radiologic examination.&lt;/td&gt;</code></p><p><code>2138</code><code>&lt;/tr&gt;</code></p><p><code>2139</code><code>&lt;tr&gt;</code></p><p><code>2140</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>2141</code><code>IIB&lt;/td&gt;</code></p><p><code>2142</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>2143</code><code>T4, N0, M0&lt;/td&gt;</code></p><p><code>2144</code><code>&lt;td&gt;</code></p><p><code>2145</code><code>T4 = Primary tumor invades fascia, muscle, cartilage, or bone.&lt;/td&gt;</code></p><p><code>2146</code><code>&lt;/tr&gt;</code></p><p><code>2147</code><code>&lt;tr&gt;</code></p><p><code>2148</code><code>&lt;td&gt;</code></p><p><code>2149</code><code>N0 = No regional lymph node metastasis detected on clinical and/or radiologic examination.&lt;/td&gt;</code></p><p><code>2150</code><code>&lt;/tr&gt;</code></p><p><code>2151</code><code>&lt;tr&gt;</code></p><p><code>2152</code><code>&lt;td&gt;</code></p><p><code>2153</code><code>M0 = No distant metastasis detected on clinical and/or radiologic examination.&lt;/td&gt;</code></p><p><code>2154</code><code>&lt;/tr&gt;</code></p><p><code>2155</code><code>&lt;/tbody&gt;</code></p><p><code>2156</code><code>&lt;/table&gt;</code></p><p><code>2157</code><code>&lt;table id="_382" class="table-default expandable-container"&gt;</code></p><p><code>2158</code><code>&lt;caption&gt;</code></p><p><code>2159</code><code>Table 6.  Definitions of Clinical Stage Group (cTNM)  for Stage III&lt;span class="sup"&gt;</code></p><p><code>2160</code><code>a&lt;/span&gt;</code></p><p><code>2161</code><code>&lt;/caption&gt;</code></p><p><code>2162</code><code>&lt;colgroup&gt;</code></p><p><code>2163</code><code>&lt;col width="24.09%"&gt;</code></p><p><code>2164</code><code>&lt;col width="28.91%"&gt;</code></p><p><code>2165</code><code>&lt;col width="46.98%"&gt;</code></p><p><code>2166</code><code>&lt;/colgroup&gt;</code></p><p><code>2167</code><code>&lt;THead&gt;</code></p><p><code>2168</code><code>&lt;tr&gt;</code></p><p><code>2169</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2170</code><code>Stage&lt;/th&gt;</code></p><p><code>2171</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2172</code><code>TNM&lt;/th&gt;</code></p><p><code>2173</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2174</code><code>Description&lt;/th&gt;</code></p><p><code>2175</code><code>&lt;/tr&gt;</code></p><p><code>2176</code><code>&lt;/THead&gt;</code></p><p><code>2177</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>2178</code><code>&lt;tr&gt;</code></p><p><code>2179</code><code>&lt;td colspan="3"&gt;</code></p><p><code>2180</code><code>T = primary tumor; N = regional lymph node; M = distant metastasis; c = clinical.&lt;/td&gt;</code></p><p><code>2181</code><code>&lt;/tr&gt;</code></p><p><code>2182</code><code>&lt;tr&gt;</code></p><p><code>2183</code><code>&lt;td colspan="3"&gt;</code></p><p><code>2184</code><code>&lt;span class="sup"&gt;</code></p><p><code>2185</code><code>a&lt;/span&gt;</code></p><p><code>2186</code><code>Reprinted with permission from AJCC: Merkel Cell Carcinoma. In: Amin MB, Edge SB, Greene FL, et al., eds.: &lt;em&gt;</code></p><p><code>2187</code><code>AJCC Cancer Staging Manual&lt;/em&gt;</code></p><p><code>2188</code><code>. 8th ed. New York, NY: Springer, 2017, pp. 549&amp;#8211;62.&lt;/td&gt;</code></p><p><code>2189</code><code>&lt;/tr&gt;</code></p><p><code>2190</code><code>&lt;/TFoot&gt;</code></p><p><code>2191</code><code>&lt;tbody&gt;</code></p><p><code>2192</code><code>&lt;tr&gt;</code></p><p><code>2193</code><code>&lt;td rowspan="10"&gt;</code></p><p><code>2194</code><code>III&lt;/td&gt;</code></p><p><code>2195</code><code>&lt;td rowspan="10"&gt;</code></p><p><code>2196</code><code>T0&amp;#8211;4, N1&amp;#8211;3, M0&lt;/td&gt;</code></p><p><code>2197</code><code>&lt;td&gt;</code></p><p><code>2198</code><code>T0 = No evidence of primary tumor.&lt;/td&gt;</code></p><p><code>2199</code><code>&lt;/tr&gt;</code></p><p><code>2200</code><code>&lt;tr&gt;</code></p><p><code>2201</code><code>&lt;td&gt;</code></p><p><code>2202</code><code>Tis = &lt;em&gt;</code></p><p><code>2203</code><code>In situ&lt;/em&gt;</code></p><p><code>2204</code><code> primary tumor.&lt;/td&gt;</code></p><p><code>2205</code><code>&lt;/tr&gt;</code></p><p><code>2206</code><code>&lt;tr&gt;</code></p><p><code>2207</code><code>&lt;td&gt;</code></p><p><code>2208</code><code>T1 = Maximum clinical tumor diameter &amp;#8804;2 cm.&lt;/td&gt;</code></p><p><code>2209</code><code>&lt;/tr&gt;</code></p><p><code>2210</code><code>&lt;tr&gt;</code></p><p><code>2211</code><code>&lt;td&gt;</code></p><p><code>2212</code><code>T2 = Maximum clinical tumor diameter &amp;gt;2 but &amp;#8804;5 cm.&lt;/td&gt;</code></p><p><code>2213</code><code>&lt;/tr&gt;</code></p><p><code>2214</code><code>&lt;tr&gt;</code></p><p><code>2215</code><code>&lt;td&gt;</code></p><p><code>2216</code><code>T3 = Maximum clinical tumor diameter &amp;gt;5 cm.&lt;/td&gt;</code></p><p><code>2217</code><code>&lt;/tr&gt;</code></p><p><code>2218</code><code>&lt;tr&gt;</code></p><p><code>2219</code><code>&lt;td&gt;</code></p><p><code>2220</code><code>T4 = Primary tumor invades fascia, muscle, cartilage, or bone.&lt;/td&gt;</code></p><p><code>2221</code><code>&lt;/tr&gt;</code></p><p><code>2222</code><code>&lt;tr&gt;</code></p><p><code>2223</code><code>&lt;td&gt;</code></p><p><code>2224</code><code>N1 = Metastasis in regional lymph node(s).&lt;/td&gt;</code></p><p><code>2225</code><code>&lt;/tr&gt;</code></p><p><code>2226</code><code>&lt;tr&gt;</code></p><p><code>2227</code><code>&lt;td&gt;</code></p><p><code>2228</code><code>N2 = In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) &lt;em&gt;</code></p><p><code>2229</code><code>without&lt;/em&gt;</code></p><p><code>2230</code><code> lymph node metastasis. &lt;/td&gt;</code></p><p><code>2231</code><code>&lt;/tr&gt;</code></p><p><code>2232</code><code>&lt;tr&gt;</code></p><p><code>2233</code><code>&lt;td&gt;</code></p><p><code>2234</code><code>N3 = In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) &lt;em&gt;</code></p><p><code>2235</code><code>with&lt;/em&gt;</code></p><p><code>2236</code><code> lymph node metastasis.&lt;/td&gt;</code></p><p><code>2237</code><code>&lt;/tr&gt;</code></p><p><code>2238</code><code>&lt;tr&gt;</code></p><p><code>2239</code><code>&lt;td&gt;</code></p><p><code>2240</code><code>M0 = No distant metastasis detected on clinical and/or radiologic examination.&lt;/td&gt;</code></p><p><code>2241</code><code>&lt;/tr&gt;</code></p><p><code>2242</code><code>&lt;/tbody&gt;</code></p><p><code>2243</code><code>&lt;/table&gt;</code></p><p><code>2244</code><code>&lt;table id="_383" class="table-default expandable-container"&gt;</code></p><p><code>2245</code><code>&lt;caption&gt;</code></p><p><code>2246</code><code>Table 7.  Definitions of Clinical Stage Group (cTNM)  for Stage IV&lt;span class="sup"&gt;</code></p><p><code>2247</code><code>a&lt;/span&gt;</code></p><p><code>2248</code><code>&lt;/caption&gt;</code></p><p><code>2249</code><code>&lt;colgroup&gt;</code></p><p><code>2250</code><code>&lt;col width="22.37%"&gt;</code></p><p><code>2251</code><code>&lt;col width="29.75%"&gt;</code></p><p><code>2252</code><code>&lt;col width="47.87%"&gt;</code></p><p><code>2253</code><code>&lt;/colgroup&gt;</code></p><p><code>2254</code><code>&lt;THead&gt;</code></p><p><code>2255</code><code>&lt;tr&gt;</code></p><p><code>2256</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2257</code><code>Stage&lt;/th&gt;</code></p><p><code>2258</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2259</code><code>TNM&lt;/th&gt;</code></p><p><code>2260</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2261</code><code>Description&lt;/th&gt;</code></p><p><code>2262</code><code>&lt;/tr&gt;</code></p><p><code>2263</code><code>&lt;/THead&gt;</code></p><p><code>2264</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>2265</code><code>&lt;tr&gt;</code></p><p><code>2266</code><code>&lt;td colspan="3"&gt;</code></p><p><code>2267</code><code>T = primary tumor; N = regional lymph node; M = distant metastasis; c = clinical.&lt;/td&gt;</code></p><p><code>2268</code><code>&lt;/tr&gt;</code></p><p><code>2269</code><code>&lt;tr&gt;</code></p><p><code>2270</code><code>&lt;td colspan="3"&gt;</code></p><p><code>2271</code><code>&lt;span class="sup"&gt;</code></p><p><code>2272</code><code>a&lt;/span&gt;</code></p><p><code>2273</code><code>Reprinted with permission from AJCC: Merkel Cell Carcinoma. In: Amin MB, Edge SB, Greene FL, et al., eds.: &lt;em&gt;</code></p><p><code>2274</code><code>AJCC Cancer Staging Manual&lt;/em&gt;</code></p><p><code>2275</code><code>. 8th ed. New York, NY: Springer, 2017, pp. 549&amp;#8211;62.&lt;/td&gt;</code></p><p><code>2276</code><code>&lt;/tr&gt;</code></p><p><code>2277</code><code>&lt;/TFoot&gt;</code></p><p><code>2278</code><code>&lt;tbody&gt;</code></p><p><code>2279</code><code>&lt;tr&gt;</code></p><p><code>2280</code><code>&lt;td rowspan="12"&gt;</code></p><p><code>2281</code><code>IV&lt;/td&gt;</code></p><p><code>2282</code><code>&lt;td rowspan="12"&gt;</code></p><p><code>2283</code><code>T0&amp;#8211;4, Any N, M1&lt;/td&gt;</code></p><p><code>2284</code><code>&lt;td&gt;</code></p><p><code>2285</code><code>T0 = No evidence of primary tumor.&lt;/td&gt;</code></p><p><code>2286</code><code>&lt;/tr&gt;</code></p><p><code>2287</code><code>&lt;tr&gt;</code></p><p><code>2288</code><code>&lt;td&gt;</code></p><p><code>2289</code><code>Tis = &lt;em&gt;</code></p><p><code>2290</code><code>In situ&lt;/em&gt;</code></p><p><code>2291</code><code> primary tumor.&lt;/td&gt;</code></p><p><code>2292</code><code>&lt;/tr&gt;</code></p><p><code>2293</code><code>&lt;tr&gt;</code></p><p><code>2294</code><code>&lt;td&gt;</code></p><p><code>2295</code><code>T1 = Maximum clinical tumor diameter &amp;#8804;2 cm.&lt;/td&gt;</code></p><p><code>2296</code><code>&lt;/tr&gt;</code></p><p><code>2297</code><code>&lt;tr&gt;</code></p><p><code>2298</code><code>&lt;td&gt;</code></p><p><code>2299</code><code>T2 = Maximum clinical tumor diameter &amp;gt;2 but &amp;#8804;5 cm.&lt;/td&gt;</code></p><p><code>2300</code><code>&lt;/tr&gt;</code></p><p><code>2301</code><code>&lt;tr&gt;</code></p><p><code>2302</code><code>&lt;td&gt;</code></p><p><code>2303</code><code>T3 = Maximum clinical tumor diameter &amp;gt;5 cm.&lt;/td&gt;</code></p><p><code>2304</code><code>&lt;/tr&gt;</code></p><p><code>2305</code><code>&lt;tr&gt;</code></p><p><code>2306</code><code>&lt;td&gt;</code></p><p><code>2307</code><code>T4 = Primary tumor invades fascia, muscle, cartilage, or bone.&lt;/td&gt;</code></p><p><code>2308</code><code>&lt;/tr&gt;</code></p><p><code>2309</code><code>&lt;tr&gt;</code></p><p><code>2310</code><code>&lt;td&gt;</code></p><p><code>2311</code><code>NX = Regional lymph nodes cannot be clinically assessed (e.g., previously removed for another reason, or because of body habitus).&lt;/td&gt;</code></p><p><code>2312</code><code>&lt;/tr&gt;</code></p><p><code>2313</code><code>&lt;tr&gt;</code></p><p><code>2314</code><code>&lt;td&gt;</code></p><p><code>2315</code><code>N0 = No regional lymph node metastasis detected on clinical and/or radiologic examination.&lt;/td&gt;</code></p><p><code>2316</code><code>&lt;/tr&gt;</code></p><p><code>2317</code><code>&lt;tr&gt;</code></p><p><code>2318</code><code>&lt;td&gt;</code></p><p><code>2319</code><code>N1 = Metastasis in regional lymph node(s).&lt;/td&gt;</code></p><p><code>2320</code><code>&lt;/tr&gt;</code></p><p><code>2321</code><code>&lt;tr&gt;</code></p><p><code>2322</code><code>&lt;td&gt;</code></p><p><code>2323</code><code>N2 = In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) &lt;em&gt;</code></p><p><code>2324</code><code>without&lt;/em&gt;</code></p><p><code>2325</code><code> lymph node metastasis.&lt;/td&gt;</code></p><p><code>2326</code><code>&lt;/tr&gt;</code></p><p><code>2327</code><code>&lt;tr&gt;</code></p><p><code>2328</code><code>&lt;td&gt;</code></p><p><code>2329</code><code>N3 = In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) &lt;em&gt;</code></p><p><code>2330</code><code>with&lt;/em&gt;</code></p><p><code>2331</code><code> lymph node metastasis.&lt;/td&gt;</code></p><p><code>2332</code><code>&lt;/tr&gt;</code></p><p><code>2333</code><code>&lt;tr&gt;</code></p><p><code>2334</code><code>&lt;td&gt;</code></p><p><code>2335</code><code>M1 = Distant metastasis detected on clinical and/or radiologic examination.&lt;/td&gt;</code></p><p><code>2336</code><code>&lt;/tr&gt;</code></p><p><code>2337</code><code>&lt;/tbody&gt;</code></p><p><code>2338</code><code>&lt;/table&gt;</code></p><p><code>2339</code><code>&lt;/section&gt;</code></p><p><code>2340</code><code>&lt;section id="_386"&gt;</code></p><p><code>2341</code><code>&lt;p id="_387" tabindex="-1"&gt;</code></p><p><code>2342</code><code>&lt;strong&gt;</code></p><p><code>2343</code><code>Pathological Stage Group (pTNM)&lt;/strong&gt;</code></p><p><code>2344</code><code>&lt;/p&gt;</code></p><p><code>2345</code><code>&lt;table id="_388" class="table-default expandable-container"&gt;</code></p><p><code>2346</code><code>&lt;caption&gt;</code></p><p><code>2347</code><code>Table 8.  Definitions of Pathological Stage Group (pTNM)  for Stage 0&lt;span class="sup"&gt;</code></p><p><code>2348</code><code>a&lt;/span&gt;</code></p><p><code>2349</code><code>&lt;/caption&gt;</code></p><p><code>2350</code><code>&lt;colgroup&gt;</code></p><p><code>2351</code><code>&lt;col width="22.17%"&gt;</code></p><p><code>2352</code><code>&lt;col width="29.49%"&gt;</code></p><p><code>2353</code><code>&lt;col width="48.33%"&gt;</code></p><p><code>2354</code><code>&lt;/colgroup&gt;</code></p><p><code>2355</code><code>&lt;THead&gt;</code></p><p><code>2356</code><code>&lt;tr&gt;</code></p><p><code>2357</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2358</code><code>Stage&lt;/th&gt;</code></p><p><code>2359</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2360</code><code>TNM&lt;/th&gt;</code></p><p><code>2361</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2362</code><code>Description&lt;/th&gt;</code></p><p><code>2363</code><code>&lt;/tr&gt;</code></p><p><code>2364</code><code>&lt;/THead&gt;</code></p><p><code>2365</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>2366</code><code>&lt;tr&gt;</code></p><p><code>2367</code><code>&lt;td colspan="3"&gt;</code></p><p><code>2368</code><code>T = primary tumor; N = regional lymph node; M = distant metastasis; p = pathological.&lt;/td&gt;</code></p><p><code>2369</code><code>&lt;/tr&gt;</code></p><p><code>2370</code><code>&lt;tr&gt;</code></p><p><code>2371</code><code>&lt;td colspan="3"&gt;</code></p><p><code>2372</code><code>&lt;span class="sup"&gt;</code></p><p><code>2373</code><code>a&lt;/span&gt;</code></p><p><code>2374</code><code>Reprinted with permission from AJCC: Merkel Cell Carcinoma. In: Amin MB, Edge SB, Greene FL, et al., eds.: &lt;em&gt;</code></p><p><code>2375</code><code>AJCC Cancer Staging Manual&lt;/em&gt;</code></p><p><code>2376</code><code>. 8th ed. New York, NY: Springer, 2017, pp. 549&amp;#8211;62.&lt;/td&gt;</code></p><p><code>2377</code><code>&lt;/tr&gt;</code></p><p><code>2378</code><code>&lt;/TFoot&gt;</code></p><p><code>2379</code><code>&lt;tbody&gt;</code></p><p><code>2380</code><code>&lt;tr&gt;</code></p><p><code>2381</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>2382</code><code>0&lt;/td&gt;</code></p><p><code>2383</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>2384</code><code>Tis, pN0, M0&lt;/td&gt;</code></p><p><code>2385</code><code>&lt;td&gt;</code></p><p><code>2386</code><code>Tis = &lt;em&gt;</code></p><p><code>2387</code><code>In situ&lt;/em&gt;</code></p><p><code>2388</code><code> primary tumor.&lt;/td&gt;</code></p><p><code>2389</code><code>&lt;/tr&gt;</code></p><p><code>2390</code><code>&lt;tr&gt;</code></p><p><code>2391</code><code>&lt;td&gt;</code></p><p><code>2392</code><code>pN0 = No regional lymph node metastasis detected on pathological evaluation.&lt;/td&gt;</code></p><p><code>2393</code><code>&lt;/tr&gt;</code></p><p><code>2394</code><code>&lt;tr&gt;</code></p><p><code>2395</code><code>&lt;td&gt;</code></p><p><code>2396</code><code>M0 = No distant metastasis detected on clinical and/or radiologic examination.&lt;/td&gt;</code></p><p><code>2397</code><code>&lt;/tr&gt;</code></p><p><code>2398</code><code>&lt;/tbody&gt;</code></p><p><code>2399</code><code>&lt;/table&gt;</code></p><p><code>2400</code><code>&lt;table id="_389" class="table-default expandable-container"&gt;</code></p><p><code>2401</code><code>&lt;caption&gt;</code></p><p><code>2402</code><code>Table 9.  Definitions of Pathological Stage Group (pTNM)  for Stage I&lt;span class="sup"&gt;</code></p><p><code>2403</code><code>a&lt;/span&gt;</code></p><p><code>2404</code><code>&lt;/caption&gt;</code></p><p><code>2405</code><code>&lt;colgroup&gt;</code></p><p><code>2406</code><code>&lt;col width="22.77%"&gt;</code></p><p><code>2407</code><code>&lt;col width="28.47%"&gt;</code></p><p><code>2408</code><code>&lt;col width="48.74%"&gt;</code></p><p><code>2409</code><code>&lt;/colgroup&gt;</code></p><p><code>2410</code><code>&lt;THead&gt;</code></p><p><code>2411</code><code>&lt;tr&gt;</code></p><p><code>2412</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2413</code><code>Stage&lt;/th&gt;</code></p><p><code>2414</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2415</code><code>TNM&lt;/th&gt;</code></p><p><code>2416</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2417</code><code>Description&lt;/th&gt;</code></p><p><code>2418</code><code>&lt;/tr&gt;</code></p><p><code>2419</code><code>&lt;/THead&gt;</code></p><p><code>2420</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>2421</code><code>&lt;tr&gt;</code></p><p><code>2422</code><code>&lt;td colspan="3"&gt;</code></p><p><code>2423</code><code>T = primary tumor; N = regional lymph node; M = distant metastasis; p = pathological.&lt;/td&gt;</code></p><p><code>2424</code><code>&lt;/tr&gt;</code></p><p><code>2425</code><code>&lt;tr&gt;</code></p><p><code>2426</code><code>&lt;td colspan="3"&gt;</code></p><p><code>2427</code><code>&lt;span class="sup"&gt;</code></p><p><code>2428</code><code>a&lt;/span&gt;</code></p><p><code>2429</code><code>Reprinted with permission from AJCC: Merkel Cell Carcinoma. In: Amin MB, Edge SB, Greene FL, et al., eds.: &lt;em&gt;</code></p><p><code>2430</code><code>AJCC Cancer Staging Manual&lt;/em&gt;</code></p><p><code>2431</code><code>. 8th ed. New York, NY: Springer, 2017, pp. 549&amp;#8211;62.&lt;/td&gt;</code></p><p><code>2432</code><code>&lt;/tr&gt;</code></p><p><code>2433</code><code>&lt;/TFoot&gt;</code></p><p><code>2434</code><code>&lt;tbody&gt;</code></p><p><code>2435</code><code>&lt;tr&gt;</code></p><p><code>2436</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>2437</code><code>I&lt;/td&gt;</code></p><p><code>2438</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>2439</code><code>T1, pN0, M0&lt;/td&gt;</code></p><p><code>2440</code><code>&lt;td&gt;</code></p><p><code>2441</code><code>T1 = Maximum clinical tumor diameter &amp;#8804;2 cm.&lt;/td&gt;</code></p><p><code>2442</code><code>&lt;/tr&gt;</code></p><p><code>2443</code><code>&lt;tr&gt;</code></p><p><code>2444</code><code>&lt;td&gt;</code></p><p><code>2445</code><code>pN0 = No regional lymph node metastasis detected on pathological evaluation.&lt;/td&gt;</code></p><p><code>2446</code><code>&lt;/tr&gt;</code></p><p><code>2447</code><code>&lt;tr&gt;</code></p><p><code>2448</code><code>&lt;td&gt;</code></p><p><code>2449</code><code>M0 = No distant metastasis detected on clinical and/or radiologic examination.&lt;/td&gt;</code></p><p><code>2450</code><code>&lt;/tr&gt;</code></p><p><code>2451</code><code>&lt;/tbody&gt;</code></p><p><code>2452</code><code>&lt;/table&gt;</code></p><p><code>2453</code><code>&lt;table id="_390" class="table-default expandable-container"&gt;</code></p><p><code>2454</code><code>&lt;caption&gt;</code></p><p><code>2455</code><code>Table 10.  Definitions of Pathological Stage Group (pTNM)  for Stages IIA and IIB&lt;span class="sup"&gt;</code></p><p><code>2456</code><code>a&lt;/span&gt;</code></p><p><code>2457</code><code>&lt;/caption&gt;</code></p><p><code>2458</code><code>&lt;colgroup&gt;</code></p><p><code>2459</code><code>&lt;col width="21.64%"&gt;</code></p><p><code>2460</code><code>&lt;col width="29.22%"&gt;</code></p><p><code>2461</code><code>&lt;col width="49.13%"&gt;</code></p><p><code>2462</code><code>&lt;/colgroup&gt;</code></p><p><code>2463</code><code>&lt;THead&gt;</code></p><p><code>2464</code><code>&lt;tr&gt;</code></p><p><code>2465</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2466</code><code>Stage&lt;/th&gt;</code></p><p><code>2467</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2468</code><code>TNM&lt;/th&gt;</code></p><p><code>2469</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2470</code><code>Description&lt;/th&gt;</code></p><p><code>2471</code><code>&lt;/tr&gt;</code></p><p><code>2472</code><code>&lt;/THead&gt;</code></p><p><code>2473</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>2474</code><code>&lt;tr&gt;</code></p><p><code>2475</code><code>&lt;td colspan="3"&gt;</code></p><p><code>2476</code><code>T = primary tumor; N = regional lymph node; M = distant metastasis; p = pathological.&lt;/td&gt;</code></p><p><code>2477</code><code>&lt;/tr&gt;</code></p><p><code>2478</code><code>&lt;tr&gt;</code></p><p><code>2479</code><code>&lt;td colspan="3"&gt;</code></p><p><code>2480</code><code>&lt;span class="sup"&gt;</code></p><p><code>2481</code><code>a&lt;/span&gt;</code></p><p><code>2482</code><code>Reprinted with permission from AJCC: Merkel Cell Carcinoma. In: Amin MB, Edge SB, Greene FL, et al., eds.: &lt;em&gt;</code></p><p><code>2483</code><code>AJCC Cancer Staging Manual&lt;/em&gt;</code></p><p><code>2484</code><code>. 8th ed. New York, NY: Springer, 2017, pp. 549&amp;#8211;62.&lt;/td&gt;</code></p><p><code>2485</code><code>&lt;/tr&gt;</code></p><p><code>2486</code><code>&lt;/TFoot&gt;</code></p><p><code>2487</code><code>&lt;tbody&gt;</code></p><p><code>2488</code><code>&lt;tr&gt;</code></p><p><code>2489</code><code>&lt;td rowspan="4"&gt;</code></p><p><code>2490</code><code>IIA&lt;/td&gt;</code></p><p><code>2491</code><code>&lt;td rowspan="4"&gt;</code></p><p><code>2492</code><code>T2&amp;#8211;3, pN0, M0&lt;/td&gt;</code></p><p><code>2493</code><code>&lt;td&gt;</code></p><p><code>2494</code><code>T2 = Maximum clinical tumor diameter &amp;gt;2 but &amp;#8804;5 cm.&lt;/td&gt;</code></p><p><code>2495</code><code>&lt;/tr&gt;</code></p><p><code>2496</code><code>&lt;tr&gt;</code></p><p><code>2497</code><code>&lt;td&gt;</code></p><p><code>2498</code><code>T3 = Maximum clinical tumor diameter &amp;gt;5 cm.&lt;/td&gt;</code></p><p><code>2499</code><code>&lt;/tr&gt;</code></p><p><code>2500</code><code>&lt;tr&gt;</code></p><p><code>2501</code><code>&lt;td&gt;</code></p><p><code>2502</code><code>pN0 = No regional lymph node metastasis detected on pathological evaluation.&lt;/td&gt;</code></p><p><code>2503</code><code>&lt;/tr&gt;</code></p><p><code>2504</code><code>&lt;tr&gt;</code></p><p><code>2505</code><code>&lt;td&gt;</code></p><p><code>2506</code><code>M0 = No distant metastasis detected on clinical and/or radiologic examination.&lt;/td&gt;</code></p><p><code>2507</code><code>&lt;/tr&gt;</code></p><p><code>2508</code><code>&lt;tr&gt;</code></p><p><code>2509</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>2510</code><code>IIB&lt;/td&gt;</code></p><p><code>2511</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>2512</code><code>T4, pN0, M0&lt;/td&gt;</code></p><p><code>2513</code><code>&lt;td&gt;</code></p><p><code>2514</code><code>T4 = Primary tumor invades fascia, muscle, cartilage, or bone.&lt;/td&gt;</code></p><p><code>2515</code><code>&lt;/tr&gt;</code></p><p><code>2516</code><code>&lt;tr&gt;</code></p><p><code>2517</code><code>&lt;td&gt;</code></p><p><code>2518</code><code>pN0 = No regional lymph node metastasis detected on pathological evaluation.&lt;/td&gt;</code></p><p><code>2519</code><code>&lt;/tr&gt;</code></p><p><code>2520</code><code>&lt;tr&gt;</code></p><p><code>2521</code><code>&lt;td&gt;</code></p><p><code>2522</code><code>M0 = No distant metastasis detected on clinical and/or radiologic examination.&lt;/td&gt;</code></p><p><code>2523</code><code>&lt;/tr&gt;</code></p><p><code>2524</code><code>&lt;/tbody&gt;</code></p><p><code>2525</code><code>&lt;/table&gt;</code></p><p><code>2526</code><code>&lt;table id="_392" class="table-default expandable-container"&gt;</code></p><p><code>2527</code><code>&lt;caption&gt;</code></p><p><code>2528</code><code>Table 11.  Definitions of Pathological Stage Group (pTNM)  for Stages IIIA and IIIB&lt;span class="sup"&gt;</code></p><p><code>2529</code><code>a&lt;/span&gt;</code></p><p><code>2530</code><code>&lt;/caption&gt;</code></p><p><code>2531</code><code>&lt;colgroup&gt;</code></p><p><code>2532</code><code>&lt;col width="22.37%"&gt;</code></p><p><code>2533</code><code>&lt;col width="26.62%"&gt;</code></p><p><code>2534</code><code>&lt;col width="51.00%"&gt;</code></p><p><code>2535</code><code>&lt;/colgroup&gt;</code></p><p><code>2536</code><code>&lt;THead&gt;</code></p><p><code>2537</code><code>&lt;tr&gt;</code></p><p><code>2538</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2539</code><code>Stage&lt;/th&gt;</code></p><p><code>2540</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2541</code><code>TNM&lt;/th&gt;</code></p><p><code>2542</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2543</code><code>Description&lt;/th&gt;</code></p><p><code>2544</code><code>&lt;/tr&gt;</code></p><p><code>2545</code><code>&lt;/THead&gt;</code></p><p><code>2546</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>2547</code><code>&lt;tr&gt;</code></p><p><code>2548</code><code>&lt;td colspan="3"&gt;</code></p><p><code>2549</code><code>T = primary tumor; N = regional lymph node; M = distant metastasis; p = pathological.&lt;/td&gt;</code></p><p><code>2550</code><code>&lt;/tr&gt;</code></p><p><code>2551</code><code>&lt;tr&gt;</code></p><p><code>2552</code><code>&lt;td colspan="3"&gt;</code></p><p><code>2553</code><code>&lt;span class="sup"&gt;</code></p><p><code>2554</code><code>a&lt;/span&gt;</code></p><p><code>2555</code><code>Reprinted with permission from AJCC: Merkel Cell Carcinoma. In: Amin MB, Edge SB, Greene FL, et al., eds.: &lt;em&gt;</code></p><p><code>2556</code><code>AJCC Cancer Staging Manual&lt;/em&gt;</code></p><p><code>2557</code><code>. 8th ed. New York, NY: Springer, 2017, pp. 549&amp;#8211;62.&lt;/td&gt;</code></p><p><code>2558</code><code>&lt;/tr&gt;</code></p><p><code>2559</code><code>&lt;/TFoot&gt;</code></p><p><code>2560</code><code>&lt;tbody&gt;</code></p><p><code>2561</code><code>&lt;tr&gt;</code></p><p><code>2562</code><code>&lt;td rowspan="10"&gt;</code></p><p><code>2563</code><code>IIIA&lt;/td&gt;</code></p><p><code>2564</code><code>&lt;td rowspan="7"&gt;</code></p><p><code>2565</code><code>T1&amp;#8211;4, pN1a(sn) or pN1a, M0&lt;/td&gt;</code></p><p><code>2566</code><code>&lt;td&gt;</code></p><p><code>2567</code><code>T1 = Maximum clinical tumor diameter &amp;#8804;2 cm.&lt;/td&gt;</code></p><p><code>2568</code><code>&lt;/tr&gt;</code></p><p><code>2569</code><code>&lt;tr&gt;</code></p><p><code>2570</code><code>&lt;td&gt;</code></p><p><code>2571</code><code>T2 = Maximum clinical tumor diameter &amp;gt;2 cm but &amp;#8804;5 cm.&lt;/td&gt;</code></p><p><code>2572</code><code>&lt;/tr&gt;</code></p><p><code>2573</code><code>&lt;tr&gt;</code></p><p><code>2574</code><code>&lt;td&gt;</code></p><p><code>2575</code><code>T3 = Maximum clinical tumor diameter &amp;gt;5 cm.&lt;/td&gt;</code></p><p><code>2576</code><code>&lt;/tr&gt;</code></p><p><code>2577</code><code>&lt;tr&gt;</code></p><p><code>2578</code><code>&lt;td&gt;</code></p><p><code>2579</code><code>T4 = Primary tumor invades fascia, muscle, cartilage, or bone.&lt;/td&gt;</code></p><p><code>2580</code><code>&lt;/tr&gt;</code></p><p><code>2581</code><code>&lt;tr&gt;</code></p><p><code>2582</code><code>&lt;td&gt;</code></p><p><code>2583</code><code>pN1a(sn) = Clinically occult regional lymph node metastasis identified only by sentinel lymph node biopsy.&lt;/td&gt;</code></p><p><code>2584</code><code>&lt;/tr&gt;</code></p><p><code>2585</code><code>&lt;tr&gt;</code></p><p><code>2586</code><code>&lt;td&gt;</code></p><p><code>2587</code><code>pN1a = Clinically occult regional lymph node metastasis following lymph node dissection.&lt;/td&gt;</code></p><p><code>2588</code><code>&lt;/tr&gt;</code></p><p><code>2589</code><code>&lt;tr&gt;</code></p><p><code>2590</code><code>&lt;td&gt;</code></p><p><code>2591</code><code>M0 = No distant metastasis detected on clinical and/or radiologic examination.&lt;/td&gt;</code></p><p><code>2592</code><code>&lt;/tr&gt;</code></p><p><code>2593</code><code>&lt;tr&gt;</code></p><p><code>2594</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>2595</code><code>T0, pN1b, M0&lt;/td&gt;</code></p><p><code>2596</code><code>&lt;td&gt;</code></p><p><code>2597</code><code>T0 = No evidence of primary tumor.&lt;/td&gt;</code></p><p><code>2598</code><code>&lt;/tr&gt;</code></p><p><code>2599</code><code>&lt;tr&gt;</code></p><p><code>2600</code><code>&lt;td&gt;</code></p><p><code>2601</code><code>pN1b = Clinically and/or radiologically detected regional lymph node metastasis, microscopically confirmed.&lt;/td&gt;</code></p><p><code>2602</code><code>&lt;/tr&gt;</code></p><p><code>2603</code><code>&lt;tr&gt;</code></p><p><code>2604</code><code>&lt;td&gt;</code></p><p><code>2605</code><code>M0 = No distant metastasis detected on clinical and/or radiologic examination.&lt;/td&gt;</code></p><p><code>2606</code><code>&lt;/tr&gt;</code></p><p><code>2607</code><code>&lt;tr&gt;</code></p><p><code>2608</code><code>&lt;td rowspan="8"&gt;</code></p><p><code>2609</code><code>IIIB&lt;/td&gt;</code></p><p><code>2610</code><code>&lt;td rowspan="8"&gt;</code></p><p><code>2611</code><code>T1&amp;#8211;4, pN1b&amp;#8211;3, M0&lt;/td&gt;</code></p><p><code>2612</code><code>&lt;td&gt;</code></p><p><code>2613</code><code>T1 = Maximum clinical tumor diameter &amp;#8804;2 cm.&lt;/td&gt;</code></p><p><code>2614</code><code>&lt;/tr&gt;</code></p><p><code>2615</code><code>&lt;tr&gt;</code></p><p><code>2616</code><code>&lt;td&gt;</code></p><p><code>2617</code><code>T2 = Maximum clinical tumor diameter &amp;gt;2 cm but &amp;#8804;5 cm.&lt;/td&gt;</code></p><p><code>2618</code><code>&lt;/tr&gt;</code></p><p><code>2619</code><code>&lt;tr&gt;</code></p><p><code>2620</code><code>&lt;td&gt;</code></p><p><code>2621</code><code>T3 = Maximum clinical tumor diameter &amp;gt;5 cm.&lt;/td&gt;</code></p><p><code>2622</code><code>&lt;/tr&gt;</code></p><p><code>2623</code><code>&lt;tr&gt;</code></p><p><code>2624</code><code>&lt;td&gt;</code></p><p><code>2625</code><code>T4 = Primary tumor invades fascia, muscle, cartilage, or bone.&lt;/td&gt;</code></p><p><code>2626</code><code>&lt;/tr&gt;</code></p><p><code>2627</code><code>&lt;tr&gt;</code></p><p><code>2628</code><code>&lt;td&gt;</code></p><p><code>2629</code><code>pN1b = Clinically and/or radiologically detected regional lymph node metastasis, microscopically confirmed.&lt;/td&gt;</code></p><p><code>2630</code><code>&lt;/tr&gt;</code></p><p><code>2631</code><code>&lt;tr&gt;</code></p><p><code>2632</code><code>&lt;td&gt;</code></p><p><code>2633</code><code>pN2 = In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) &lt;em&gt;</code></p><p><code>2634</code><code>without&lt;/em&gt;</code></p><p><code>2635</code><code> lymph node metastasis.&lt;/td&gt;</code></p><p><code>2636</code><code>&lt;/tr&gt;</code></p><p><code>2637</code><code>&lt;tr&gt;</code></p><p><code>2638</code><code>&lt;td&gt;</code></p><p><code>2639</code><code>pN3 = In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) &lt;em&gt;</code></p><p><code>2640</code><code>with&lt;/em&gt;</code></p><p><code>2641</code><code> lymph node metastasis. &lt;/td&gt;</code></p><p><code>2642</code><code>&lt;/tr&gt;</code></p><p><code>2643</code><code>&lt;tr&gt;</code></p><p><code>2644</code><code>&lt;td&gt;</code></p><p><code>2645</code><code>M0 = No distant metastasis detected on clinical and/or radiologic examination.&lt;/td&gt;</code></p><p><code>2646</code><code>&lt;/tr&gt;</code></p><p><code>2647</code><code>&lt;/tbody&gt;</code></p><p><code>2648</code><code>&lt;/table&gt;</code></p><p><code>2649</code><code>&lt;table id="_394" class="table-default expandable-container"&gt;</code></p><p><code>2650</code><code>&lt;caption&gt;</code></p><p><code>2651</code><code>Table 12.  Definitions of Pathological Stage Group (pTNM)  Stage IV&lt;span class="sup"&gt;</code></p><p><code>2652</code><code>a&lt;/span&gt;</code></p><p><code>2653</code><code>&lt;/caption&gt;</code></p><p><code>2654</code><code>&lt;colgroup&gt;</code></p><p><code>2655</code><code>&lt;col width="24.50%"&gt;</code></p><p><code>2656</code><code>&lt;col width="26.71%"&gt;</code></p><p><code>2657</code><code>&lt;col width="48.77%"&gt;</code></p><p><code>2658</code><code>&lt;/colgroup&gt;</code></p><p><code>2659</code><code>&lt;THead&gt;</code></p><p><code>2660</code><code>&lt;tr&gt;</code></p><p><code>2661</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2662</code><code>Stage&lt;/th&gt;</code></p><p><code>2663</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2664</code><code>TNM&lt;/th&gt;</code></p><p><code>2665</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2666</code><code>Description&lt;/th&gt;</code></p><p><code>2667</code><code>&lt;/tr&gt;</code></p><p><code>2668</code><code>&lt;/THead&gt;</code></p><p><code>2669</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>2670</code><code>&lt;tr&gt;</code></p><p><code>2671</code><code>&lt;td colspan="3"&gt;</code></p><p><code>2672</code><code>T = primary tumor; N = regional lymph node; M = distant metastasis; p = pathological.&lt;/td&gt;</code></p><p><code>2673</code><code>&lt;/tr&gt;</code></p><p><code>2674</code><code>&lt;tr&gt;</code></p><p><code>2675</code><code>&lt;td colspan="3"&gt;</code></p><p><code>2676</code><code>&lt;span class="sup"&gt;</code></p><p><code>2677</code><code>a&lt;/span&gt;</code></p><p><code>2678</code><code>Reprinted with permission from AJCC: Merkel Cell Carcinoma. In: Amin MB, Edge SB, Greene FL, et al., eds.: &lt;em&gt;</code></p><p><code>2679</code><code>AJCC Cancer Staging Manual&lt;/em&gt;</code></p><p><code>2680</code><code>. 8th ed. New York, NY: Springer, 2017, pp. 549&amp;#8211;62.&lt;/td&gt;</code></p><p><code>2681</code><code>&lt;/tr&gt;</code></p><p><code>2682</code><code>&lt;/TFoot&gt;</code></p><p><code>2683</code><code>&lt;tbody&gt;</code></p><p><code>2684</code><code>&lt;tr&gt;</code></p><p><code>2685</code><code>&lt;td rowspan="17"&gt;</code></p><p><code>2686</code><code>IV&lt;/td&gt;</code></p><p><code>2687</code><code>&lt;td rowspan="17"&gt;</code></p><p><code>2688</code><code>T0&amp;#8211;4, Any pN, pM1&lt;/td&gt;</code></p><p><code>2689</code><code>&lt;td&gt;</code></p><p><code>2690</code><code>T0 = No evidence of primary tumor.&lt;/td&gt;</code></p><p><code>2691</code><code>&lt;/tr&gt;</code></p><p><code>2692</code><code>&lt;tr&gt;</code></p><p><code>2693</code><code>&lt;td&gt;</code></p><p><code>2694</code><code>T1 = Maximum clinical tumor diameter &amp;#8804;2 cm.&lt;/td&gt;</code></p><p><code>2695</code><code>&lt;/tr&gt;</code></p><p><code>2696</code><code>&lt;tr&gt;</code></p><p><code>2697</code><code>&lt;td&gt;</code></p><p><code>2698</code><code>T2 = Maximum clinical tumor diameter &amp;gt;2 cm but &amp;#8804;5 cm.&lt;/td&gt;</code></p><p><code>2699</code><code>&lt;/tr&gt;</code></p><p><code>2700</code><code>&lt;tr&gt;</code></p><p><code>2701</code><code>&lt;td&gt;</code></p><p><code>2702</code><code>T3 = Maximum clinical tumor diameter &amp;gt;5 cm.&lt;/td&gt;</code></p><p><code>2703</code><code>&lt;/tr&gt;</code></p><p><code>2704</code><code>&lt;tr&gt;</code></p><p><code>2705</code><code>&lt;td&gt;</code></p><p><code>2706</code><code>T4 = Primary tumor invades fascia, muscle, cartilage, or bone.&lt;/td&gt;</code></p><p><code>2707</code><code>&lt;/tr&gt;</code></p><p><code>2708</code><code>&lt;tr&gt;</code></p><p><code>2709</code><code>&lt;td&gt;</code></p><p><code>2710</code><code>pNX = Regional lymph nodes cannot be assessed (e.g., previously removed for another reason or &lt;em&gt;</code></p><p><code>2711</code><code>not&lt;/em&gt;</code></p><p><code>2712</code><code> removed for pathological evaluation).&lt;/td&gt;</code></p><p><code>2713</code><code>&lt;/tr&gt;</code></p><p><code>2714</code><code>&lt;tr&gt;</code></p><p><code>2715</code><code>&lt;td&gt;</code></p><p><code>2716</code><code>pN0 = No regional lymph node metastasis detected on pathological evaluation.&lt;/td&gt;</code></p><p><code>2717</code><code>&lt;/tr&gt;</code></p><p><code>2718</code><code>&lt;tr&gt;</code></p><p><code>2719</code><code>&lt;td&gt;</code></p><p><code>2720</code><code>pN1 = Metastasis in regional lymph node(s).&lt;/td&gt;</code></p><p><code>2721</code><code>&lt;/tr&gt;</code></p><p><code>2722</code><code>&lt;tr&gt;</code></p><p><code>2723</code><code>&lt;td&gt;</code></p><p><code>2724</code><code>&amp;#8211;pN1a(sn) = Clinically occult regional lymph node metastasis identified only by sentinel lymph node biopsy. &lt;/td&gt;</code></p><p><code>2725</code><code>&lt;/tr&gt;</code></p><p><code>2726</code><code>&lt;tr&gt;</code></p><p><code>2727</code><code>&lt;td&gt;</code></p><p><code>2728</code><code>&amp;#8211;pN1a = Clinically occult regional lymph node metastasis following lymph node dissection.&lt;/td&gt;</code></p><p><code>2729</code><code>&lt;/tr&gt;</code></p><p><code>2730</code><code>&lt;tr&gt;</code></p><p><code>2731</code><code>&lt;td&gt;</code></p><p><code>2732</code><code>&amp;#8211;pN1b = Clinically and/or radiologically detected regional lymph node metastasis, microscopically confirmed.&lt;/td&gt;</code></p><p><code>2733</code><code>&lt;/tr&gt;</code></p><p><code>2734</code><code>&lt;tr&gt;</code></p><p><code>2735</code><code>&lt;td&gt;</code></p><p><code>2736</code><code>pN2 = In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) &lt;em&gt;</code></p><p><code>2737</code><code>without&lt;/em&gt;</code></p><p><code>2738</code><code> lymph node metastasis.&lt;/td&gt;</code></p><p><code>2739</code><code>&lt;/tr&gt;</code></p><p><code>2740</code><code>&lt;tr&gt;</code></p><p><code>2741</code><code>&lt;td&gt;</code></p><p><code>2742</code><code>pN3 = In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) &lt;em&gt;</code></p><p><code>2743</code><code>with&lt;/em&gt;</code></p><p><code>2744</code><code> lymph node metastasis. &lt;/td&gt;</code></p><p><code>2745</code><code>&lt;/tr&gt;</code></p><p><code>2746</code><code>&lt;tr&gt;</code></p><p><code>2747</code><code>&lt;td&gt;</code></p><p><code>2748</code><code>pM1 = Distant metastasis microscopically confirmed.&lt;/td&gt;</code></p><p><code>2749</code><code>&lt;/tr&gt;</code></p><p><code>2750</code><code>&lt;tr&gt;</code></p><p><code>2751</code><code>&lt;td&gt;</code></p><p><code>2752</code><code>&amp;#8211;pM1a = Metastasis to distant skin, distant subcutaneous tissue, or distant lymph node(s), microscopically confirmed.&lt;/td&gt;</code></p><p><code>2753</code><code>&lt;/tr&gt;</code></p><p><code>2754</code><code>&lt;tr&gt;</code></p><p><code>2755</code><code>&lt;td&gt;</code></p><p><code>2756</code><code>&amp;#8211;pM1b = Metastasis to lung, microscopically confirmed.&lt;/td&gt;</code></p><p><code>2757</code><code>&lt;/tr&gt;</code></p><p><code>2758</code><code>&lt;tr&gt;</code></p><p><code>2759</code><code>&lt;td&gt;</code></p><p><code>2760</code><code>pM1c = Metastasis to all other distant sites, microscopically confirmed.&lt;/td&gt;</code></p><p><code>2761</code><code>&lt;/tr&gt;</code></p><p><code>2762</code><code>&lt;/tbody&gt;</code></p><p><code>2763</code><code>&lt;/table&gt;</code></p><p><code>2764</code><code>&lt;/section&gt;</code></p><p><code>2765</code><code>&lt;/section&gt;</code></p><p><code>2766</code><code>&lt;p id="_179" tabindex="-1"&gt;</code></p><p><code>2767</code><code>Before the new AJCC consensus staging system was published, the most recent Memorial Sloan Kettering Cancer Center (MSKCC) four-stage system was favored because it was based on the largest number of patients and was the best validated.[&lt;a href="#cit/section_3.1"&gt;</code></p><p><code>2768</code><code>1&lt;/a&gt;</code></p><p><code>2769</code><code>] The stages in the MSKCC system included: &lt;/p&gt;</code></p><p><code>2770</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>2771</code><code>&lt;ul id="_47"&gt;</code></p><p><code>2772</code><code>&lt;li&gt;</code></p><p><code>2773</code><code>Stage I: local disease &amp;lt;2 cm. </code></p><p><code>2774</code><code>          </code></p><p><code>2775</code><code>&lt;/li&gt;</code></p><p><code>2776</code><code>&lt;li&gt;</code></p><p><code>2777</code><code>Stage II:  local disease &amp;#8805;2 cm.&lt;/li&gt;</code></p><p><code>2778</code><code>&lt;li&gt;</code></p><p><code>2779</code><code>Stage III: regional nodal disease.</code></p><p><code>2780</code><code>&lt;/li&gt;</code></p><p><code>2781</code><code>&lt;li&gt;</code></p><p><code>2782</code><code>Stage IV: distant metastatic disease.</code></p><p><code>2783</code><code>&lt;/li&gt;</code></p><p><code>2784</code><code>&lt;/ul&gt;</code></p><p><code>2785</code><code>&lt;/div&gt;</code></p><p><code>2786</code><code>&lt;p id="_195" tabindex="-1"&gt;</code></p><p><code>2787</code><code>One group has suggested a list of 12 elements that should be described in pathology reports of resected primary lesions and nine elements to be described in pathology reports of sentinel lymph nodes. The prognostic significance of these elements has not been validated prospectively.[&lt;a href="#cit/section_3.8"&gt;</code></p><p><code>2788</code><code>8&lt;/a&gt;</code></p><p><code>2789</code><code>] The 2009 AJCC staging manual also specifies a variety of factors that should be collected prospectively on pathology reports.&lt;/p&gt;</code></p><p><code>2790</code><code>&lt;h6 do-not-show="toc"&gt;</code></p><p><code>2791</code><code>References&lt;/h6&gt;</code></p><p><code>2792</code><code>&lt;ol&gt;</code></p><p><code>2793</code><code>&lt;li id="section_3.1"&gt;</code></p><p><code>2794</code><code>Andea AA, Coit DG, Amin B, et al.: Merkel cell carcinoma: histologic features and prognosis. Cancer 113 (9): 2549-58, 2008.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18798233&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18798233&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2795</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2796</code><code>&lt;/li&gt;</code></p><p><code>2797</code><code>&lt;li id="section_3.2"&gt;</code></p><p><code>2798</code><code>Yiengpruksawan A, Coit DG, Thaler HT, et al.: Merkel cell carcinoma. Prognosis and management. Arch Surg 126 (12): 1514-9, 1991.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=1842182&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=1842182&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2799</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2800</code><code>&lt;/li&gt;</code></p><p><code>2801</code><code>&lt;li id="section_3.3"&gt;</code></p><p><code>2802</code><code>Allen PJ, Zhang ZF, Coit DG: Surgical management of Merkel cell carcinoma. Ann Surg 229 (1): 97-105, 1999.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9923806&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9923806&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2803</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2804</code><code>&lt;/li&gt;</code></p><p><code>2805</code><code>&lt;li id="section_3.4"&gt;</code></p><p><code>2806</code><code>Allen PJ, Bowne WB, Jaques DP, et al.: Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol 23 (10): 2300-9, 2005.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=15800320&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=15800320&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2807</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2808</code><code>&lt;/li&gt;</code></p><p><code>2809</code><code>&lt;li id="section_3.5"&gt;</code></p><p><code>2810</code><code>Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. Springer; 2017.&lt;/li&gt;</code></p><p><code>2811</code><code>&lt;li id="section_3.6"&gt;</code></p><p><code>2812</code><code>Clark JR, Veness MJ, Gilbert R, et al.: Merkel cell carcinoma of the head and neck: is adjuvant radiotherapy necessary? Head Neck 29 (3): 249-57, 2007.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17163472&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17163472&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2813</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2814</code><code>&lt;/li&gt;</code></p><p><code>2815</code><code>&lt;li id="section_3.7"&gt;</code></p><p><code>2816</code><code>Bichakjian CK, Nghiem P, Johnson T, et al.: Merkel Cell Carcinoma. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. Springer; 2017, pp 549-62.&lt;/li&gt;</code></p><p><code>2817</code><code>&lt;li id="section_3.8"&gt;</code></p><p><code>2818</code><code>Bichakjian CK, Lowe L, Lao CD, et al.: Merkel cell carcinoma: critical review with guidelines for multidisciplinary management. Cancer 110 (1): 1-12, 2007.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17520670&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17520670&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2819</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2820</code><code>&lt;/li&gt;</code></p><p><code>2821</code><code>&lt;/ol&gt;</code></p><p><code>2822</code><code>&lt;/div&gt;</code></p><p><code>2823</code><code>          </code></p><p><code>2824</code><code>    &lt;/section&gt;</code></p><p><code>2825</code><code>          </code></p><p><code>2826</code><code>          </code></p><p><code>2827</code><code>          </code></p><p><code>2828</code><code>    &lt;section id="_49"&gt;</code></p><p><code>2829</code><code>          </code></p><p><code>2830</code><code>        &lt;h2&gt;</code></p><p><code>2831</code><code>Treatment Option Overview&lt;/h2&gt;</code></p><p><code>2832</code><code>          </code></p><p><code>2833</code><code>        &lt;div id="_section_49" class="pdq-sections"&gt;</code></p><p><code>2834</code><code>&lt;nav class="in-this-section" role="navigation"&gt;</code></p><p><code>2835</code><code>&lt;h6&gt;</code></p><p><code>2836</code><code>In This Section&lt;/h6&gt;</code></p><p><code>2837</code><code>&lt;ul&gt;</code></p><p><code>2838</code><code>&lt;li&gt;</code></p><p><code>2839</code><code>&lt;a href="#_52_toc"&gt;</code></p><p><code>2840</code><code>Surgery for the Primary Lesion&lt;/a&gt;</code></p><p><code>2841</code><code>&lt;/li&gt;</code></p><p><code>2842</code><code>&lt;li&gt;</code></p><p><code>2843</code><code>&lt;a href="#_55_toc"&gt;</code></p><p><code>2844</code><code>Regional Lymph Node Surgery&lt;/a&gt;</code></p><p><code>2845</code><code>&lt;/li&gt;</code></p><p><code>2846</code><code>&lt;li&gt;</code></p><p><code>2847</code><code>&lt;a href="#_62_toc"&gt;</code></p><p><code>2848</code><code>Radiation Therapy&lt;/a&gt;</code></p><p><code>2849</code><code>&lt;/li&gt;</code></p><p><code>2850</code><code>&lt;li&gt;</code></p><p><code>2851</code><code>&lt;a href="#_398_toc"&gt;</code></p><p><code>2852</code><code>Immunotherapy &lt;/a&gt;</code></p><p><code>2853</code><code>&lt;/li&gt;</code></p><p><code>2854</code><code>&lt;li&gt;</code></p><p><code>2855</code><code>&lt;a href="#_67_toc"&gt;</code></p><p><code>2856</code><code>Chemotherapy&lt;/a&gt;</code></p><p><code>2857</code><code>&lt;/li&gt;</code></p><p><code>2858</code><code>&lt;li&gt;</code></p><p><code>2859</code><code>&lt;a href="#_71_toc"&gt;</code></p><p><code>2860</code><code>Follow-up&lt;/a&gt;</code></p><p><code>2861</code><code>&lt;/li&gt;</code></p><p><code>2862</code><code>&lt;li&gt;</code></p><p><code>2863</code><code>&lt;a href="#_TrialSearch_49_sid_4_toc"&gt;</code></p><p><code>2864</code><code>Current Clinical Trials&lt;/a&gt;</code></p><p><code>2865</code><code>&lt;/li&gt;</code></p><p><code>2866</code><code>&lt;/ul&gt;</code></p><p><code>2867</code><code>&lt;/nav&gt;</code></p><p><code>2868</code><code>&lt;p id="_51" tabindex="-1"&gt;</code></p><p><code>2869</code><code>Merkel cell carcinoma (MCC) is an uncommon tumor. Most clinical management recommendations in the literature are based on case series that describe a relatively small number of patients who were not entered on formal clinical trials, evaluated with uniform clinical staging procedures, treated with uniform treatment protocols, or provided with regular, prescribed follow-up. These reports are also confounded by potential selection bias, referral bias, and short follow-up. They are underpowered to detect modest differences in outcome. &lt;/p&gt;</code></p><p><code>2870</code><code>&lt;p id="_206" tabindex="-1"&gt;</code></p><p><code>2871</code><code>In addition, outcomes of patients with American Joint Committee on Cancer stage I and stage II disease are often reported together. In the absence of results from clinical trials with prescribed work-up, treatments, and follow-up, most MCC patients have been treated using institutional or practitioner preferences that consider the specifics of each case as well as patient preference.&lt;/p&gt;</code></p><p><code>2872</code><code>&lt;p id="_207" tabindex="-1"&gt;</code></p><p><code>2873</code><code>There are two competing philosophies  about the most appropriate method of treating MCC.  In the first philosophy, MCC is treated like other nonmelanoma skin cancers, with an emphasis on treating local-regional disease with surgery and radiation therapy, as appropriate.  In the second philosophy, MCC is treated according to its biological features.  This approach makes it analogous to small cell lung cancer, which is assumed to be a systemic disease, and leads to a more routine recommendation of systematic adjuvant chemotherapy.[&lt;a href="#cit/section_4.1"&gt;</code></p><p><code>2874</code><code>1&lt;/a&gt;</code></p><p><code>2875</code><code>]&lt;/p&gt;</code></p><p><code>2876</code><code>&lt;section id="_52"&gt;</code></p><p><code>2877</code><code>&lt;h3 id="_52_toc"&gt;</code></p><p><code>2878</code><code>Surgery for the Primary Lesion&lt;/h3&gt;</code></p><p><code>2879</code><code>&lt;p id="_53" tabindex="-1"&gt;</code></p><p><code>2880</code><code>In a review of 18 case series, 279 of 926 patients (30.1%) developed local recurrence during follow-up, excluding those presenting with distant metastatic disease at presentation. These recurrences have been typically attributed to inadequate surgical margins or possibly a lack of adjuvant radiation therapy.[&lt;a href="#cit/section_4.2"&gt;</code></p><p><code>2881</code><code>2&lt;/a&gt;</code></p><p><code>2882</code><code>,&lt;a href="#cit/section_4.3"&gt;</code></p><p><code>2883</code><code>3&lt;/a&gt;</code></p><p><code>2884</code><code>] </code></p><p><code>2885</code><code>&lt;/p&gt;</code></p><p><code>2886</code><code>&lt;p id="_182" tabindex="-1"&gt;</code></p><p><code>2887</code><code>Given the propensity of MCC to recur locally (sometimes with satellite lesions and/or in-transit metastases), wide local excision to reduce the risk of local recurrence has been recommended for patients with clinical stage I or stage II disease. &lt;/p&gt;</code></p><p><code>2888</code><code>&lt;p id="_183" tabindex="-1"&gt;</code></p><p><code>2889</code><code>Recommendations about the optimal minimum width and depth of normal tissue margin to be excised around the primary tumor differ among the various retrospective case series, but this question has not been studied systematically.[&lt;a href="#cit/section_4.3"&gt;</code></p><p><code>2890</code><code>3&lt;/a&gt;</code></p><p><code>2891</code><code>-&lt;a href="#cit/section_4.7"&gt;</code></p><p><code>2892</code><code>7&lt;/a&gt;</code></p><p><code>2893</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810037&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810037&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2894</code><code>Level of evidence C2&lt;/a&gt;</code></p><p><code>2895</code><code>] No definitive data suggest that extremely wide margins improve overall survival (OS), although some reports suggest that wider margins appear to improve local control.[&lt;a href="#cit/section_4.3"&gt;</code></p><p><code>2896</code><code>3&lt;/a&gt;</code></p><p><code>2897</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810037&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810037&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2898</code><code>Level of evidence C2&lt;/a&gt;</code></p><p><code>2899</code><code>] Frozen-section evaluation of margins may be useful, especially when the tumor is in an anatomical site that is not amenable to wide margins. </code></p><p><code>2900</code><code>&lt;/p&gt;</code></p><p><code>2901</code><code>&lt;p id="_54" tabindex="-1"&gt;</code></p><p><code>2902</code><code>Some authors have advocated the use of &lt;a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=442898&amp;amp;version=healthprofessional&amp;amp;language=English&amp;amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000442898&amp;amp;version=healthprofessional&amp;amp;language=English&amp;amp;dictionary=Cancer.gov'); return(false);"&gt;</code></p><p><code>2903</code><code>Mohs micrographic surgery&lt;/a&gt;</code></p><p><code>2904</code><code> as a tissue-sparing technique. The relapse rate has been reported to be similar to or better than that of wide excision, but comparatively few cases have been treated in this manner and none in randomized controlled trials.[&lt;a href="#cit/section_4.7"&gt;</code></p><p><code>2905</code><code>7&lt;/a&gt;</code></p><p><code>2906</code><code>-&lt;a href="#cit/section_4.10"&gt;</code></p><p><code>2907</code><code>10&lt;/a&gt;</code></p><p><code>2908</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810037&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810037&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2909</code><code>Level of evidence C2&lt;/a&gt;</code></p><p><code>2910</code><code>]&lt;/p&gt;</code></p><p><code>2911</code><code>&lt;/section&gt;</code></p><p><code>2912</code><code>&lt;section id="_55"&gt;</code></p><p><code>2913</code><code>&lt;h3 id="_55_toc"&gt;</code></p><p><code>2914</code><code>Regional Lymph Node Surgery&lt;/h3&gt;</code></p><p><code>2915</code><code>&lt;p id="_56" tabindex="-1"&gt;</code></p><p><code>2916</code><code>In some case series, local-regional recurrence rates are high when pathological nodal staging is omitted.  Surgical nodal staging in clinically negative patients has identified positive nodes in at least 25% to 35% of patients.[&lt;a href="#cit/section_4.4"&gt;</code></p><p><code>2917</code><code>4&lt;/a&gt;</code></p><p><code>2918</code><code>,&lt;a href="#cit/section_4.11"&gt;</code></p><p><code>2919</code><code>11&lt;/a&gt;</code></p><p><code>2920</code><code>,&lt;a href="#cit/section_4.12"&gt;</code></p><p><code>2921</code><code>12&lt;/a&gt;</code></p><p><code>2922</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810037&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810037&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2923</code><code>Level of evidence C2&lt;/a&gt;</code></p><p><code>2924</code><code>] In one retrospective series of 213 patients who underwent surgical treatment of the primary tumor and evaluation of the draining nodes,  nodal positivity was found in 2 of 54 patients with small tumors (e.g., &amp;#8804;1.0 cm) and 51 of 159 patients with tumors larger than 1.0 cm.[&lt;a href="#cit/section_4.13"&gt;</code></p><p><code>2925</code><code>13&lt;/a&gt;</code></p><p><code>2926</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810037&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810037&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2927</code><code>Level of evidence C2&lt;/a&gt;</code></p><p><code>2928</code><code>]&lt;/p&gt;</code></p><p><code>2929</code><code>&lt;p id="_57" tabindex="-1"&gt;</code></p><p><code>2930</code><code>The role of elective lymph node dissection (ELND) in the absence of clinically positive lymph nodes has not been studied in formal clinical trials.  In small case series, ELND has been recommended for larger primary tumors, tumors with more than ten mitoses per high-power field, lymphatic or vascular invasion, and the small-cell histological subtypes.[&lt;a href="#cit/section_4.14"&gt;</code></p><p><code>2931</code><code>14&lt;/a&gt;</code></p><p><code>2932</code><code>-&lt;a href="#cit/section_4.16"&gt;</code></p><p><code>2933</code><code>16&lt;/a&gt;</code></p><p><code>2934</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810037&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810037&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2935</code><code>Level of evidence C2&lt;/a&gt;</code></p><p><code>2936</code><code>]&lt;/p&gt;</code></p><p><code>2937</code><code>&lt;p id="_58" tabindex="-1"&gt;</code></p><p><code>2938</code><code>Sentinel lymph node (SLN) biopsy  has been suggested as a preferred initial alternative to complete ELND for the proper staging of MCC. SLN biopsy has less morbidity than complete nodal dissection. Furthermore, for MCC sites with indeterminate lymphatic drainage, such as those on the back, SLN biopsy techniques can be used to identify the pertinent lymph node bed(s). If performed, SLN biopsy is  done at the time of the wide resection when the local lymphatic channels are still intact. &lt;/p&gt;</code></p><p><code>2939</code><code>&lt;p id="_59" tabindex="-1"&gt;</code></p><p><code>2940</code><code>Several reports have found the use of SLN biopsy techniques in MCC to be reliable and reproducible.[&lt;a href="#cit/section_4.17"&gt;</code></p><p><code>2941</code><code>17&lt;/a&gt;</code></p><p><code>2942</code><code>-&lt;a href="#cit/section_4.20"&gt;</code></p><p><code>2943</code><code>20&lt;/a&gt;</code></p><p><code>2944</code><code>] However, the significance of SLN positivity remains unclear.&lt;/p&gt;</code></p><p><code>2945</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>2946</code><code>&lt;ul id="_318"&gt;</code></p><p><code>2947</code><code>&lt;li&gt;</code></p><p><code>2948</code><code>One meta-analysis of ten case series found that SLN positivity strongly predicted a high short-term risk of recurrence and that subsequent therapeutic lymph node dissection was effective in preventing short-term regional nodal recurrence.[&lt;a href="#cit/section_4.21"&gt;</code></p><p><code>2949</code><code>21&lt;/a&gt;</code></p><p><code>2950</code><code>] &lt;/li&gt;</code></p><p><code>2951</code><code>&lt;li&gt;</code></p><p><code>2952</code><code>Another meta-analysis of 12 retrospective case series (only partially overlapping the collection of case series in the previous meta-analysis) found that:[&lt;a href="#cit/section_4.12"&gt;</code></p><p><code>2953</code><code>12&lt;/a&gt;</code></p><p><code>2954</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810037&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810037&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2955</code><code>Level of evidence C2&lt;/a&gt;</code></p><p><code>2956</code><code>]&lt;div class="pdq-content-list"&gt;</code></p><p><code>2957</code><code>&lt;ul id="_319" class="list-dash"&gt;</code></p><p><code>2958</code><code>&lt;li&gt;</code></p><p><code>2959</code><code>SLN biopsy detected MCC spread in one-third of patients whose tumors would have otherwise been clinically and radiologically understaged.&lt;/li&gt;</code></p><p><code>2960</code><code>&lt;li&gt;</code></p><p><code>2961</code><code>The recurrence rate was three times higher in patients with a positive SLN biopsy  than in those with a  negative SLN biopsy (&lt;em&gt;</code></p><p><code>2962</code><code>P&lt;/em&gt;</code></p><p><code>2963</code><code> = .03).&lt;/li&gt;</code></p><p><code>2964</code><code>&lt;/ul&gt;</code></p><p><code>2965</code><code>&lt;/div&gt;</code></p><p><code>2966</code><code>&lt;/li&gt;</code></p><p><code>2967</code><code>&lt;li&gt;</code></p><p><code>2968</code><code>Between 2006 and 2010, a large, retrospective, single-institutional series of 95 patients (with a total of 97 primary tumors) identified a SLN in 93 instances, and nodal tumor was seen in 42 patients. Immunohistochemical techniques were used to assess node positivity. Various models of tumor and patient characteristics were studied to predict node positivity. There was no subgroup of patients predicted to have lower than 15% to 20% likelihood of SLN positivity, suggesting that SLN biopsy may be considered for all curative patients with clinically negative lymph nodes and no distant metastases.[&lt;a href="#cit/section_4.22"&gt;</code></p><p><code>2969</code><code>22&lt;/a&gt;</code></p><p><code>2970</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810037&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810037&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2971</code><code>Level of evidence C2&lt;/a&gt;</code></p><p><code>2972</code><code>]&lt;/li&gt;</code></p><p><code>2973</code><code>&lt;li&gt;</code></p><p><code>2974</code><code>From 1996 to 2010, another retrospective, single-institutional study of 153 patients with localized MCC who underwent SLN biopsy analyzed factors associated with SLN positivity. The best predictors of SLN biopsy positivity were tumor size and lymphovascular invasion.[&lt;a href="#cit/section_4.22"&gt;</code></p><p><code>2975</code><code>22&lt;/a&gt;</code></p><p><code>2976</code><code>,&lt;a href="#cit/section_4.23"&gt;</code></p><p><code>2977</code><code>23&lt;/a&gt;</code></p><p><code>2978</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810037&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810037&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2979</code><code>Level of evidence C2&lt;/a&gt;</code></p><p><code>2980</code><code>]&lt;/li&gt;</code></p><p><code>2981</code><code>&lt;/ul&gt;</code></p><p><code>2982</code><code>&lt;/div&gt;</code></p><p><code>2983</code><code>&lt;p id="_60" tabindex="-1"&gt;</code></p><p><code>2984</code><code>In the absence of adequately powered, prospective, randomized clinical trials, the following questions remain:[&lt;a href="#cit/section_4.4"&gt;</code></p><p><code>2985</code><code>4&lt;/a&gt;</code></p><p><code>2986</code><code>,&lt;a href="#cit/section_4.12"&gt;</code></p><p><code>2987</code><code>12&lt;/a&gt;</code></p><p><code>2988</code><code>,&lt;a href="#cit/section_4.21"&gt;</code></p><p><code>2989</code><code>21&lt;/a&gt;</code></p><p><code>2990</code><code>,&lt;a href="#cit/section_4.24"&gt;</code></p><p><code>2991</code><code>24&lt;/a&gt;</code></p><p><code>2992</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810037&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810037&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2993</code><code>Level of evidence C2&lt;/a&gt;</code></p><p><code>2994</code><code>]&lt;/p&gt;</code></p><p><code>2995</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>2996</code><code>&lt;ul id="_99"&gt;</code></p><p><code>2997</code><code>&lt;li&gt;</code></p><p><code>2998</code><code> Should every positive SLN biopsy be followed routinely by completion nodal surgery and/or radiation therapy? &lt;/li&gt;</code></p><p><code>2999</code><code>&lt;li&gt;</code></p><p><code>3000</code><code>Are outcomes demonstrably improved by routinely adding radiation if lymph node surgery reveals tumor in multiple nodes and/or extracapsular extension and/or lymphovascular invasion? &lt;/li&gt;</code></p><p><code>3001</code><code>&lt;li&gt;</code></p><p><code>3002</code><code> Should patients with MCCs smaller than 1 cm routinely undergo sentinel lymph node dissection (SLND)? &lt;/li&gt;</code></p><p><code>3003</code><code>&lt;li&gt;</code></p><p><code>3004</code><code> Should patients with negative or omitted nodal work-up routinely undergo local or local-regional radiation therapy?&lt;/li&gt;</code></p><p><code>3005</code><code>&lt;li&gt;</code></p><p><code>3006</code><code>Should immunohistochemical staining techniques be used to identify micrometastases in lymph nodes, and is micrometastatic disease in nodes clinically relevant?&lt;/li&gt;</code></p><p><code>3007</code><code>&lt;/ul&gt;</code></p><p><code>3008</code><code>&lt;/div&gt;</code></p><p><code>3009</code><code>&lt;p id="_189" tabindex="-1"&gt;</code></p><p><code>3010</code><code>Lymph node surgery is primarily used for staging and guiding additional treatment.&lt;/p&gt;</code></p><p><code>3011</code><code>&lt;p id="_61" tabindex="-1"&gt;</code></p><p><code>3012</code><code> Based on a small number of retrospective studies, therapeutic dissection of the regional lymph nodes after a positive SLND appears to minimize, but not totally eliminate, the risk of subsequent regional lymph node recurrence and in-transit metastases.[&lt;a href="#cit/section_4.4"&gt;</code></p><p><code>3013</code><code>4&lt;/a&gt;</code></p><p><code>3014</code><code>,&lt;a href="#cit/section_4.21"&gt;</code></p><p><code>3015</code><code>21&lt;/a&gt;</code></p><p><code>3016</code><code>,&lt;a href="#cit/section_4.24"&gt;</code></p><p><code>3017</code><code>24&lt;/a&gt;</code></p><p><code>3018</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810037&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810037&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3019</code><code>Level of evidence C2&lt;/a&gt;</code></p><p><code>3020</code><code>] There are no data from prospective randomized trials demonstrating that definitive regional nodal treatment with surgery improves survival.&lt;/p&gt;</code></p><p><code>3021</code><code>&lt;/section&gt;</code></p><p><code>3022</code><code>&lt;section id="_62"&gt;</code></p><p><code>3023</code><code>&lt;h3 id="_62_toc"&gt;</code></p><p><code>3024</code><code>Radiation Therapy&lt;/h3&gt;</code></p><p><code>3025</code><code>&lt;p id="_63" tabindex="-1"&gt;</code></p><p><code>3026</code><code>Because of the aggressive nature of MCC, its apparent radiosensitivity, and the high incidence of local and regional recurrences (including in-transit metastases after surgery alone to the primary tumor bed), some clinicians have recommended adjuvant radiation therapy to the primary site and nodal basin. Nodal basin radiation in contiguity with radiation to the primary site has been considered, especially for patients with larger tumors, locally unresectable tumors, close or positive excision margins that cannot be improved by additional surgery, and those with positive regional lymph  nodes, especially after SLND (stage II).[&lt;a href="#cit/section_4.10"&gt;</code></p><p><code>3027</code><code>10&lt;/a&gt;</code></p><p><code>3028</code><code>,&lt;a href="#cit/section_4.11"&gt;</code></p><p><code>3029</code><code>11&lt;/a&gt;</code></p><p><code>3030</code><code>,&lt;a href="#cit/section_4.14"&gt;</code></p><p><code>3031</code><code>14&lt;/a&gt;</code></p><p><code>3032</code><code>,&lt;a href="#cit/section_4.15"&gt;</code></p><p><code>3033</code><code>15&lt;/a&gt;</code></p><p><code>3034</code><code>,&lt;a href="#cit/section_4.25"&gt;</code></p><p><code>3035</code><code>25&lt;/a&gt;</code></p><p><code>3036</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810037&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810037&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3037</code><code>Level of evidence C2&lt;/a&gt;</code></p><p><code>3038</code><code>] Several small retrospective series  have shown that radiation therapy plus adequate surgery improves local-regional control compared with surgery alone, [&lt;a href="#cit/section_4.2"&gt;</code></p><p><code>3039</code><code>2&lt;/a&gt;</code></p><p><code>3040</code><code>,&lt;a href="#cit/section_4.5"&gt;</code></p><p><code>3041</code><code>5&lt;/a&gt;</code></p><p><code>3042</code><code>,&lt;a href="#cit/section_4.26"&gt;</code></p><p><code>3043</code><code>26&lt;/a&gt;</code></p><p><code>3044</code><code>-&lt;a href="#cit/section_4.29"&gt;</code></p><p><code>3045</code><code>29&lt;/a&gt;</code></p><p><code>3046</code><code>] whereas other series did not show the same results.[&lt;a href="#cit/section_4.4"&gt;</code></p><p><code>3047</code><code>4&lt;/a&gt;</code></p><p><code>3048</code><code>,&lt;a href="#cit/section_4.8"&gt;</code></p><p><code>3049</code><code>8&lt;/a&gt;</code></p><p><code>3050</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810037&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810037&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3051</code><code>Level of evidence C2&lt;/a&gt;</code></p><p><code>3052</code><code>]  &lt;/p&gt;</code></p><p><code>3053</code><code>&lt;p id="_64" tabindex="-1"&gt;</code></p><p><code>3054</code><code>In the absence of adequately powered, prospective, randomized clinical trials, the following questions remain:[&lt;a href="#cit/section_4.4"&gt;</code></p><p><code>3055</code><code>4&lt;/a&gt;</code></p><p><code>3056</code><code>,&lt;a href="#cit/section_4.8"&gt;</code></p><p><code>3057</code><code>8&lt;/a&gt;</code></p><p><code>3058</code><code>,&lt;a href="#cit/section_4.9"&gt;</code></p><p><code>3059</code><code>9&lt;/a&gt;</code></p><p><code>3060</code><code>,&lt;a href="#cit/section_4.12"&gt;</code></p><p><code>3061</code><code>12&lt;/a&gt;</code></p><p><code>3062</code><code>,&lt;a href="#cit/section_4.21"&gt;</code></p><p><code>3063</code><code>21&lt;/a&gt;</code></p><p><code>3064</code><code>,&lt;a href="#cit/section_4.24"&gt;</code></p><p><code>3065</code><code>24&lt;/a&gt;</code></p><p><code>3066</code><code>,&lt;a href="#cit/section_4.26"&gt;</code></p><p><code>3067</code><code>26&lt;/a&gt;</code></p><p><code>3068</code><code>,&lt;a href="#cit/section_4.30"&gt;</code></p><p><code>3069</code><code>30&lt;/a&gt;</code></p><p><code>3070</code><code>-&lt;a href="#cit/section_4.34"&gt;</code></p><p><code>3071</code><code>34&lt;/a&gt;</code></p><p><code>3072</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810037&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810037&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3073</code><code>Level of evidence C2&lt;/a&gt;</code></p><p><code>3074</code><code>] &lt;/p&gt;</code></p><p><code>3075</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>3076</code><code>&lt;ul id="_100"&gt;</code></p><p><code>3077</code><code>&lt;li&gt;</code></p><p><code>3078</code><code>Should every positive SLN biopsy be followed routinely by completion nodal surgery and/or radiation therapy?&lt;/li&gt;</code></p><p><code>3079</code><code>&lt;li&gt;</code></p><p><code>3080</code><code> Are outcomes demonstrably improved by routinely adding radiation only if nodal surgery reveals tumor in multiple lymph nodes and/or extracapsular extension and/or lymphovascular invasion?&lt;/li&gt;</code></p><p><code>3081</code><code>&lt;li&gt;</code></p><p><code>3082</code><code> Should all or just certain patients with negative or omitted nodal work-up receive local or local-regional radiation routinely?&lt;/li&gt;</code></p><p><code>3083</code><code>&lt;/ul&gt;</code></p><p><code>3084</code><code>&lt;/div&gt;</code></p><p><code>3085</code><code>&lt;p id="_101" tabindex="-1"&gt;</code></p><p><code>3086</code><code>Because of the small size of these nonrandomized, retrospective series, the precise benefit from radiation therapy remains unproven.&lt;/p&gt;</code></p><p><code>3087</code><code>&lt;p id="_65" tabindex="-1"&gt;</code></p><p><code>3088</code><code>When recommended, the radiation dose given has been at least 50 Gy to the surgical bed with margins and to the draining regional lymphatics, delivered in 2 Gy fractions. For patients with unresected tumors or tumors with microscopic evidence of spread beyond resected margins, higher doses of 56 Gy to 65 Gy to the primary site have been recommended.[&lt;a href="#cit/section_4.5"&gt;</code></p><p><code>3089</code><code>5&lt;/a&gt;</code></p><p><code>3090</code><code>,&lt;a href="#cit/section_4.10"&gt;</code></p><p><code>3091</code><code>10&lt;/a&gt;</code></p><p><code>3092</code><code>,&lt;a href="#cit/section_4.11"&gt;</code></p><p><code>3093</code><code>11&lt;/a&gt;</code></p><p><code>3094</code><code>,&lt;a href="#cit/section_4.14"&gt;</code></p><p><code>3095</code><code>14&lt;/a&gt;</code></p><p><code>3096</code><code>,&lt;a href="#cit/section_4.15"&gt;</code></p><p><code>3097</code><code>15&lt;/a&gt;</code></p><p><code>3098</code><code>,&lt;a href="#cit/section_4.27"&gt;</code></p><p><code>3099</code><code>27&lt;/a&gt;</code></p><p><code>3100</code><code>,&lt;a href="#cit/section_4.31"&gt;</code></p><p><code>3101</code><code>31&lt;/a&gt;</code></p><p><code>3102</code><code>,&lt;a href="#cit/section_4.35"&gt;</code></p><p><code>3103</code><code>35&lt;/a&gt;</code></p><p><code>3104</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810037&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810037&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3105</code><code>Level of evidence C2&lt;/a&gt;</code></p><p><code>3106</code><code>]  These doses have not been studied prospectively in clinical trials. &lt;/p&gt;</code></p><p><code>3107</code><code>&lt;p id="_320" tabindex="-1"&gt;</code></p><p><code>3108</code><code>Local and/or regional control of MCC with radiation therapy alone has been reported in small, highly selected, nonrandomized case series of patients with diverse clinical characteristics.[&lt;a href="#cit/section_4.29"&gt;</code></p><p><code>3109</code><code>29&lt;/a&gt;</code></p><p><code>3110</code><code>,&lt;a href="#cit/section_4.36"&gt;</code></p><p><code>3111</code><code>36&lt;/a&gt;</code></p><p><code>3112</code><code>]  Typically, these patients have had inoperable primary tumors and/or nodes or were considered medically inappropriate for surgery.[&lt;a href="#cit/section_4.29"&gt;</code></p><p><code>3113</code><code>29&lt;/a&gt;</code></p><p><code>3114</code><code>,&lt;a href="#cit/section_4.36"&gt;</code></p><p><code>3115</code><code>36&lt;/a&gt;</code></p><p><code>3116</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810037&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810037&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3117</code><code>Level of evidence C2&lt;/a&gt;</code></p><p><code>3118</code><code>]&lt;/p&gt;</code></p><p><code>3119</code><code>&lt;p id="_66" tabindex="-1"&gt;</code></p><p><code>3120</code><code>Retrospective Surveillance, Epidemiology, and End Results (SEER) Program  data suggest that adding radiation therapy to surgery adds survival value, but the conclusions are complicated by incomplete patient data, no protocol for evaluation and treatment, and potential sampling bias.[&lt;a href="#cit/section_4.32"&gt;</code></p><p><code>3121</code><code>32&lt;/a&gt;</code></p><p><code>3122</code><code>] Prospective randomized clinical trials are required to assess whether combining surgery with radiation therapy affects survival.[&lt;a href="#cit/section_4.33"&gt;</code></p><p><code>3123</code><code>33&lt;/a&gt;</code></p><p><code>3124</code><code>,&lt;a href="#cit/section_4.34"&gt;</code></p><p><code>3125</code><code>34&lt;/a&gt;</code></p><p><code>3126</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810037&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810037&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3127</code><code>Level of evidence C2&lt;/a&gt;</code></p><p><code>3128</code><code>] &lt;/p&gt;</code></p><p><code>3129</code><code>&lt;/section&gt;</code></p><p><code>3130</code><code>&lt;section id="_398"&gt;</code></p><p><code>3131</code><code>&lt;h3 id="_398_toc"&gt;</code></p><p><code>3132</code><code>Immunotherapy &lt;/h3&gt;</code></p><p><code>3133</code><code>&lt;p id="_399" tabindex="-1"&gt;</code></p><p><code>3134</code><code>Approximately 70% to 80% of MCC cases in the United States are caused by Merkel cell polyomavirus (MCPyV), and within virus-positive MCCs, the viral oncoproteins (T antigens) are constitutively expressed and growth-promoting. Furthermore, patients with stimulated immune response to MCPyV have better disease outcomes, providing a rationale for the use of immunotherapy.  &lt;/p&gt;</code></p><p><code>3135</code><code>&lt;p id="_401" tabindex="-1"&gt;</code></p><p><code>3136</code><code>In a phase II trial, 88 patients with chemotherapy-treated metastatic MCC received avelumab, a human anti&amp;#8211;programmed death ligand-1 (PD-L1) monoclonal antibody (10 mg/kg intravenously [IV] every 2 weeks). The objective rate of response was 33%, and 11% of the patients had a complete response. Median response was at 6.1 weeks and was irrespective of MCPyV or PD-L1 status. More importantly, responses were durable, with 74% lasting at least 1 year. As a result, median OS was more than twice the historical median, that is, an  OS of 4 to 6 months with second-line chemotherapy. Based on this study, the U.S. Food and Drug Administration approved avelumab in 2017 for the treatment of metastatic MCC, regardless of previous chemotherapy administration.[&lt;a href="#cit/section_4.37"&gt;</code></p><p><code>3137</code><code>37&lt;/a&gt;</code></p><p><code>3138</code><code>-&lt;a href="#cit/section_4.39"&gt;</code></p><p><code>3139</code><code>39&lt;/a&gt;</code></p><p><code>3140</code><code>]&lt;/p&gt;</code></p><p><code>3141</code><code>&lt;p id="_400" tabindex="-1"&gt;</code></p><p><code>3142</code><code>Pembrolizumab, a humanized IgG4 anti&amp;#8211;programmed cell death-1 (PD-1) monoclonal antibody, is being studied in a phase II trial (&lt;a href="/clinicaltrials/NCT02267603"&gt;</code></p><p><code>3143</code><code>NCT02267603&lt;/a&gt;</code></p><p><code>3144</code><code>) of first-line systemic treatment for patients with unresectable stage IIIB or stage IV MCC. The initial report included 26 patients; 16% had a complete response and 40% had a partial response, resulting in an objective response rate  of 56%. While the response rate was similar to historical rates with first-line chemotherapy, pembrolizumab responses were more durable, with 86% ongoing at last follow-up.[&lt;a href="#cit/section_4.40"&gt;</code></p><p><code>3145</code><code>40&lt;/a&gt;</code></p><p><code>3146</code><code>]  </code></p><p><code>3147</code><code>          </code></p><p><code>3148</code><code>&lt;/p&gt;</code></p><p><code>3149</code><code>&lt;p id="_402" tabindex="-1"&gt;</code></p><p><code>3150</code><code>Nivolumab, another anti-PD-1 antibody, is being studied (&lt;a href="/clinicaltrials/NCT02488759"&gt;</code></p><p><code>3151</code><code>NCT02488759&lt;/a&gt;</code></p><p><code>3152</code><code>) in patients with virus-associated cancers, including MCC. Patients with metastatic MCC were eligible regardless of MCPyV status or previous chemotherapy. Preliminary results reported an ongoing response rate of 87%, with responses in 13 of 15 patients at last follow-up (median follow-up, 6 months). This trial added a second cohort to investigate nivolumab plus ipilimumab (1 mg/kg) in patients with metastatic MCC.[&lt;a href="#cit/section_4.41"&gt;</code></p><p><code>3153</code><code>41&lt;/a&gt;</code></p><p><code>3154</code><code>]&lt;/p&gt;</code></p><p><code>3155</code><code>&lt;/section&gt;</code></p><p><code>3156</code><code>&lt;section id="_67"&gt;</code></p><p><code>3157</code><code>&lt;h3 id="_67_toc"&gt;</code></p><p><code>3158</code><code>Chemotherapy&lt;/h3&gt;</code></p><p><code>3159</code><code>&lt;p id="_68" tabindex="-1"&gt;</code></p><p><code>3160</code><code>A variety of chemotherapy regimens have been used for patients with MCC in the settings of adjuvant, advanced, and recurrent therapy.[&lt;a href="#cit/section_4.5"&gt;</code></p><p><code>3161</code><code>5&lt;/a&gt;</code></p><p><code>3162</code><code>,&lt;a href="#cit/section_4.34"&gt;</code></p><p><code>3163</code><code>34&lt;/a&gt;</code></p><p><code>3164</code><code>,&lt;a href="#cit/section_4.42"&gt;</code></p><p><code>3165</code><code>42&lt;/a&gt;</code></p><p><code>3166</code><code>,&lt;a href="#cit/section_4.43"&gt;</code></p><p><code>3167</code><code>43&lt;/a&gt;</code></p><p><code>3168</code><code>]  [&lt;a href="/Common/PopUps/popDefinition.aspx?id=810037&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810037&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3169</code><code>Level of evidence C2&lt;/a&gt;</code></p><p><code>3170</code><code>]  Even though no phase III clinical trials have been conducted to demonstrate that adjuvant chemotherapy produces improvements in OS, some clinicians recommend its use in most cases because of the following:&lt;/p&gt;</code></p><p><code>3171</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>3172</code><code>&lt;ul id="_208"&gt;</code></p><p><code>3173</code><code>&lt;li&gt;</code></p><p><code>3174</code><code>A biologic analogy is made between MCC and the histologically similar small cell carcinoma of the lung, which is considered a systemic disease.&lt;/li&gt;</code></p><p><code>3175</code><code>&lt;li&gt;</code></p><p><code>3176</code><code>The risk of metastases and progression with MCC is high.&lt;/li&gt;</code></p><p><code>3177</code><code>&lt;li&gt;</code></p><p><code>3178</code><code>Good initial clinical response rates have been noted with some chemotherapy regimens.&lt;/li&gt;</code></p><p><code>3179</code><code>&lt;/ul&gt;</code></p><p><code>3180</code><code>&lt;/div&gt;</code></p><p><code>3181</code><code>&lt;p id="_209" tabindex="-1"&gt;</code></p><p><code>3182</code><code> When possible, patients  can be encouraged  to participate in clinical trials.&lt;/p&gt;</code></p><p><code>3183</code><code>&lt;p id="_69" tabindex="-1"&gt;</code></p><p><code>3184</code><code>From 1997 to 2001, the Trans-Tasman Radiation Oncology Group performed a phase II evaluation of 53 MCC patients with high-risk, local-regional disease. High risk was defined as recurrence after initial therapy, involved lymph nodes, primary tumor larger than 1 cm, gross residual disease after surgery, or occult primary with positive lymph nodes. Therapy included local-regional radiation therapy (50 Gy in 25 fractions),  synchronous carboplatin (area under the curve [AUC] 4.5), and IV etoposide (89 mg/m&lt;span class="sup"&gt;</code></p><p><code>3185</code><code>2&lt;/span&gt;</code></p><p><code>3186</code><code> on  days 1&amp;#8211;3 in weeks 1, 4, 7, and 10). Surgery was not standardized for either the primary tumor or the lymph nodes, and 12 patients had close margins, positive margins, or gross residual disease. Twenty-eight patients had undissected nodal beds, and the remainder had a variety of nodal surgeries. With a median follow-up of 48 months, the 3-year OS rate was 76%, the rate of local-regional control was 75%, and the rate of distant control was 76%. Radiation reactions in the skin and febrile neutropenia were significant clinical acute toxicities. Because of the heterogeneity of the population and the nonstandardized surgery, it is difficult to infer a clear treatment benefit from the chemotherapy.[&lt;a href="#cit/section_4.44"&gt;</code></p><p><code>3187</code><code>44&lt;/a&gt;</code></p><p><code>3188</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810035&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810035&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3189</code><code>Level of evidence C1&lt;/a&gt;</code></p><p><code>3190</code><code>] &lt;/p&gt;</code></p><p><code>3191</code><code>&lt;p id="_102" tabindex="-1"&gt;</code></p><p><code>3192</code><code> In a subsequent report, the same investigators evaluated a subset of these protocol patients (n = 40, after excluding patients with unknown primaries) and compared them with 61 historical controls who received no chemotherapy, were treated at the same institutions, were diagnosed before 1997, and had no routine imaging staging studies.  Radiation therapy was given to 50 patients. There was no significant survival benefit seen for chemotherapy patients.[&lt;a href="#cit/section_4.45"&gt;</code></p><p><code>3193</code><code>45&lt;/a&gt;</code></p><p><code>3194</code><code>] &lt;/p&gt;</code></p><p><code>3195</code><code>&lt;p id="_185" tabindex="-1"&gt;</code></p><p><code>3196</code><code>In a subsequent pilot clinical trial of 18 patients from 2004 to 2006, the same investigators attempted to reduce the skin and hematological toxicity seen in Study 96-07. Carboplatin (AUC = 2) was administered weekly during radiation therapy beginning on day 1 for a maximum of five doses, followed by three cycles of carboplatin (AUC 4.5, and IV etoposide 80 mg/m&lt;span class="sup"&gt;</code></p><p><code>3197</code><code>2&lt;/span&gt;</code></p><p><code>3198</code><code> on days 1&amp;#8211;3 beginning 3 weeks after radiation and repeated every 3 weeks for three cycles). The radiation therapy was similar to that in the earlier trial.[&lt;a href="#cit/section_4.44"&gt;</code></p><p><code>3199</code><code>44&lt;/a&gt;</code></p><p><code>3200</code><code>] Results suggested a decrease in hematological and skin toxicity.[&lt;a href="#cit/section_4.46"&gt;</code></p><p><code>3201</code><code>46&lt;/a&gt;</code></p><p><code>3202</code><code>]&lt;/p&gt;</code></p><p><code>3203</code><code>&lt;p id="_70" tabindex="-1"&gt;</code></p><p><code>3204</code><code>Use of chemotherapy has also been reported in selected patients with locally advanced and metastatic disease. In one retrospective study of 107 patients, 57% of patients with metastatic disease and 69% with locally advanced disease responded to initial chemotherapy.  Median OS was 9 months for patients with metastatic disease and 24 months for patients with locally advanced disease. At 3 years, the OS rate was projected to be 17% for those with metastatic disease and 35% for those with locally advanced disease. Toxicity was significant, however, and  without clear benefit, particularly in older patients.[&lt;a href="#cit/section_4.47"&gt;</code></p><p><code>3205</code><code>47&lt;/a&gt;</code></p><p><code>3206</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810037&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810037&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3207</code><code>Level of evidence C2&lt;/a&gt;</code></p><p><code>3208</code><code>]&lt;/p&gt;</code></p><p><code>3209</code><code>&lt;/section&gt;</code></p><p><code>3210</code><code>&lt;section id="_71"&gt;</code></p><p><code>3211</code><code>&lt;h3 id="_71_toc"&gt;</code></p><p><code>3212</code><code>Follow-up&lt;/h3&gt;</code></p><p><code>3213</code><code>&lt;p id="_72" tabindex="-1"&gt;</code></p><p><code>3214</code><code>The most appropriate follow-up techniques and frequency for patients treated for MCC have not been prospectively studied. Because of the propensity for local and regional recurrence, clinicians should perform at least a thorough physical examination of the site of initial disease and the regional lymph nodes. Imaging studies may be ordered to evaluate signs and symptoms of concern,  or they may be performed to identify distant metastases early; but, there are no data suggesting that early detection and treatment of new distant metastases results in improved survival.  &lt;/p&gt;</code></p><p><code>3215</code><code>&lt;p id="_194" tabindex="-1"&gt;</code></p><p><code>3216</code><code>In one series of 237 patients presenting with local or regional disease, the median time-to-recurrence was 9 months (range, 2&amp;#8211;70 months).  Ninety-one percent of recurrences occurred within 2 years of diagnosis.[&lt;a href="#cit/section_4.4"&gt;</code></p><p><code>3217</code><code>4&lt;/a&gt;</code></p><p><code>3218</code><code>] It has been suggested that the intensity of follow-up can be gradually diminished after 2 to 3 years as the majority of recurrences are likely to have already occurred.[&lt;a href="#cit/section_4.4"&gt;</code></p><p><code>3219</code><code>4&lt;/a&gt;</code></p><p><code>3220</code><code>]&lt;/p&gt;</code></p><p><code>3221</code><code>&lt;/section&gt;</code></p><p><code>3222</code><code>&lt;section id="_TrialSearch_49_sid_4"&gt;</code></p><p><code>3223</code><code>&lt;h3 id="_TrialSearch_49_sid_4_toc"&gt;</code></p><p><code>3224</code><code>Current Clinical Trials&lt;/h3&gt;</code></p><p><code>3225</code><code>&lt;p id="_TrialSearch_49_22" tabindex="-1"&gt;</code></p><p><code>3226</code><code>Use our &lt;a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/advanced" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/advanced"&gt;</code></p><p><code>3227</code><code>advanced clinical trial search&lt;/a&gt;</code></p><p><code>3228</code><code> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. &lt;a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/"&gt;</code></p><p><code>3229</code><code>General information&lt;/a&gt;</code></p><p><code>3230</code><code> about clinical trials is also available.&lt;/p&gt;</code></p><p><code>3231</code><code>&lt;/section&gt;</code></p><p><code>3232</code><code>&lt;h6 do-not-show="toc"&gt;</code></p><p><code>3233</code><code>References&lt;/h6&gt;</code></p><p><code>3234</code><code>&lt;ol&gt;</code></p><p><code>3235</code><code>&lt;li id="section_4.1"&gt;</code></p><p><code>3236</code><code>Busse PM, Clark JR, Muse VV, et al.: Case records of the Massachusetts General Hospital. Case 19-2008. A 63-year-old HIV-positive man with cutaneous Merkel-cell carcinoma. N Engl J Med 358 (25): 2717-23, 2008.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18565865&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18565865&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3237</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3238</code><code>&lt;/li&gt;</code></p><p><code>3239</code><code>&lt;li id="section_4.2"&gt;</code></p><p><code>3240</code><code>Medina-Franco H, Urist MM, Fiveash J, et al.: Multimodality treatment of Merkel cell carcinoma: case series and literature review of 1024 cases. Ann Surg Oncol 8 (3): 204-8, 2001.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11314935&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11314935&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3241</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3242</code><code>&lt;/li&gt;</code></p><p><code>3243</code><code>&lt;li id="section_4.3"&gt;</code></p><p><code>3244</code><code>Nghiem P, James N: Merkel cell carcinoma. In: Wolff K, Goldsmith LA, Katz SI, et al., eds.: Fitzpatrick's Dermatology in General Medicine. 7th ed. McGraw-Hill , 2008, pp 1087-94.&lt;/li&gt;</code></p><p><code>3245</code><code>&lt;li id="section_4.4"&gt;</code></p><p><code>3246</code><code>Allen PJ, Bowne WB, Jaques DP, et al.: Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol 23 (10): 2300-9, 2005.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=15800320&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=15800320&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3247</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3248</code><code>&lt;/li&gt;</code></p><p><code>3249</code><code>&lt;li id="section_4.5"&gt;</code></p><p><code>3250</code><code>Goessling W, McKee PH, Mayer RJ: Merkel cell carcinoma. J Clin Oncol 20 (2): 588-98, 2002.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11786590&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11786590&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3251</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3252</code><code>&lt;/li&gt;</code></p><p><code>3253</code><code>&lt;li id="section_4.6"&gt;</code></p><p><code>3254</code><code>Senchenkov A, Barnes SA, Moran SL: Predictors of survival and recurrence in the surgical treatment of merkel cell carcinoma of the extremities. J Surg Oncol 95 (3): 229-34, 2007.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17323336&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17323336&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3255</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3256</code><code>&lt;/li&gt;</code></p><p><code>3257</code><code>&lt;li id="section_4.7"&gt;</code></p><p><code>3258</code><code>Nghiem P, McKee PH, Haynes HA: Merkel cell (cutaneous neuroendocrine) carcinoma. In: Sober AJ, Haluska FG, eds.: Skin Cancer. BC Decker Inc., 2001, pp 127-141.&lt;/li&gt;</code></p><p><code>3259</code><code>&lt;li id="section_4.8"&gt;</code></p><p><code>3260</code><code>Boyer JD, Zitelli JA, Brodland DG, et al.: Local control of primary Merkel cell carcinoma: review of 45 cases treated with Mohs micrographic surgery with and without adjuvant radiation. J Am Acad Dermatol 47 (6): 885-92, 2002.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=12451374&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=12451374&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3261</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3262</code><code>&lt;/li&gt;</code></p><p><code>3263</code><code>&lt;li id="section_4.9"&gt;</code></p><p><code>3264</code><code>Wilson LD, Gruber SB: Merkel cell carcinoma and the controversial role of adjuvant radiation therapy: clinical choices in the absence of statistical evidence. J Am Acad Dermatol 50 (3): 435-7; discussion 437-8, 2004.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=14988686&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=14988686&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3265</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3266</code><code>&lt;/li&gt;</code></p><p><code>3267</code><code>&lt;li id="section_4.10"&gt;</code></p><p><code>3268</code><code>Gollard R, Weber R, Kosty MP, et al.: Merkel cell carcinoma: review of 22 cases with surgical, pathologic, and therapeutic considerations. Cancer 88 (8): 1842-51, 2000.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10760761&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10760761&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3269</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3270</code><code>&lt;/li&gt;</code></p><p><code>3271</code><code>&lt;li id="section_4.11"&gt;</code></p><p><code>3272</code><code>Eng TY, Boersma MG, Fuller CD, et al.: A comprehensive review of the treatment of Merkel cell carcinoma. Am J Clin Oncol 30 (6): 624-36, 2007.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18091058&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18091058&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3273</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3274</code><code>&lt;/li&gt;</code></p><p><code>3275</code><code>&lt;li id="section_4.12"&gt;</code></p><p><code>3276</code><code>Gupta SG, Wang LC, Pe&amp;#241;as PF, et al.: Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma: The Dana-Farber experience and meta-analysis of the literature. Arch Dermatol 142 (6): 685-90, 2006.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=16785370&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=16785370&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3277</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3278</code><code>&lt;/li&gt;</code></p><p><code>3279</code><code>&lt;li id="section_4.13"&gt;</code></p><p><code>3280</code><code>Stokes JB, Graw KS, Dengel LT, et al.: Patients with Merkel cell carcinoma tumors &amp;lt; or = 1.0 cm in diameter are unlikely to harbor regional lymph node metastasis. J Clin Oncol 27 (23): 3772-7, 2009.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19581538&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19581538&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3281</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3282</code><code>&lt;/li&gt;</code></p><p><code>3283</code><code>&lt;li id="section_4.14"&gt;</code></p><p><code>3284</code><code>Haag ML, Glass LF, Fenske NA: Merkel cell carcinoma. Diagnosis and treatment. Dermatol Surg 21 (8): 669-83, 1995.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=7633811&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=7633811&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3285</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3286</code><code>&lt;/li&gt;</code></p><p><code>3287</code><code>&lt;li id="section_4.15"&gt;</code></p><p><code>3288</code><code>Ratner D, Nelson BR, Brown MD, et al.: Merkel cell carcinoma. J Am Acad Dermatol 29 (2 Pt 1): 143-56, 1993.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=8335732&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=8335732&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3289</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3290</code><code>&lt;/li&gt;</code></p><p><code>3291</code><code>&lt;li id="section_4.16"&gt;</code></p><p><code>3292</code><code>Yiengpruksawan A, Coit DG, Thaler HT, et al.: Merkel cell carcinoma. Prognosis and management. Arch Surg 126 (12): 1514-9, 1991.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=1842182&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=1842182&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3293</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3294</code><code>&lt;/li&gt;</code></p><p><code>3295</code><code>&lt;li id="section_4.17"&gt;</code></p><p><code>3296</code><code>Messina JL, Reintgen DS, Cruse CW, et al.: Selective lymphadenectomy in patients with Merkel cell (cutaneous neuroendocrine) carcinoma. Ann Surg Oncol 4 (5): 389-95, 1997 Jul-Aug.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9259965&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9259965&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3297</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3298</code><code>&lt;/li&gt;</code></p><p><code>3299</code><code>&lt;li id="section_4.18"&gt;</code></p><p><code>3300</code><code>Hill AD, Brady MS, Coit DG: Intraoperative lymphatic mapping and sentinel lymph node biopsy for Merkel cell carcinoma. Br J Surg 86 (4): 518-21, 1999.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10215828&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10215828&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3301</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3302</code><code>&lt;/li&gt;</code></p><p><code>3303</code><code>&lt;li id="section_4.19"&gt;</code></p><p><code>3304</code><code>Wasserberg N, Schachter J, Fenig E, et al.: Applicability of the sentinel node technique to Merkel cell carcinoma. Dermatol Surg 26 (2): 138-41, 2000.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10691943&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10691943&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3305</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3306</code><code>&lt;/li&gt;</code></p><p><code>3307</code><code>&lt;li id="section_4.20"&gt;</code></p><p><code>3308</code><code>Rodrigues LK, Leong SP, Kashani-Sabet M, et al.: Early experience with sentinel lymph node mapping for Merkel cell carcinoma. J Am Acad Dermatol 45 (2): 303-8, 2001.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11464197&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11464197&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3309</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3310</code><code>&lt;/li&gt;</code></p><p><code>3311</code><code>&lt;li id="section_4.21"&gt;</code></p><p><code>3312</code><code>Mehrany K, Otley CC, Weenig RH, et al.: A meta-analysis of the prognostic significance of sentinel lymph node status in Merkel cell carcinoma. Dermatol Surg 28 (2): 113-7; discussion 117, 2002.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11860419&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11860419&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3313</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3314</code><code>&lt;/li&gt;</code></p><p><code>3315</code><code>&lt;li id="section_4.22"&gt;</code></p><p><code>3316</code><code>Schwartz JL, Griffith KA, Lowe L, et al.: Features predicting sentinel lymph node positivity in Merkel cell carcinoma. J Clin Oncol 29 (8): 1036-41, 2011.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=21300936&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=21300936&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3317</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3318</code><code>&lt;/li&gt;</code></p><p><code>3319</code><code>&lt;li id="section_4.23"&gt;</code></p><p><code>3320</code><code>Fields RC, Busam KJ, Chou JF, et al.: Recurrence and survival in patients undergoing sentinel lymph node biopsy for merkel cell carcinoma: analysis of 153 patients from a single institution. Ann Surg Oncol 18 (9): 2529-37, 2011.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=21431988&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=21431988&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3321</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3322</code><code>&lt;/li&gt;</code></p><p><code>3323</code><code>&lt;li id="section_4.24"&gt;</code></p><p><code>3324</code><code>Maza S, Trefzer U, Hofmann M, et al.: Impact of sentinel lymph node biopsy in patients with Merkel cell carcinoma: results of a prospective study and review of the literature. Eur J Nucl Med Mol Imaging 33 (4): 433-40, 2006.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=16432719&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=16432719&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3325</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3326</code><code>&lt;/li&gt;</code></p><p><code>3327</code><code>&lt;li id="section_4.25"&gt;</code></p><p><code>3328</code><code>Goepfert H, Remmler D, Silva E, et al.: Merkel cell carcinoma (endocrine carcinoma of the skin) of the head and neck. Arch Otolaryngol 110 (11): 707-12, 1984.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=6487123&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=6487123&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3329</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3330</code><code>&lt;/li&gt;</code></p><p><code>3331</code><code>&lt;li id="section_4.26"&gt;</code></p><p><code>3332</code><code>Lewis KG, Weinstock MA, Weaver AL, et al.: Adjuvant local irradiation for Merkel cell carcinoma. Arch Dermatol 142 (6): 693-700, 2006.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=16785371&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=16785371&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3333</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3334</code><code>&lt;/li&gt;</code></p><p><code>3335</code><code>&lt;li id="section_4.27"&gt;</code></p><p><code>3336</code><code>Veness MJ, Perera L, McCourt J, et al.: Merkel cell carcinoma: improved outcome with adjuvant radiotherapy. ANZ J Surg 75 (5): 275-81, 2005.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=15932436&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=15932436&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3337</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3338</code><code>&lt;/li&gt;</code></p><p><code>3339</code><code>&lt;li id="section_4.28"&gt;</code></p><p><code>3340</code><code>Jabbour J, Cumming R, Scolyer RA, et al.: Merkel cell carcinoma: assessing the effect of wide local excision, lymph node dissection, and radiotherapy on recurrence and survival in early-stage disease--results from a review of 82 consecutive cases diagnosed between 1992 and 2004. Ann Surg Oncol 14 (6): 1943-52, 2007.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17356954&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17356954&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3341</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3342</code><code>&lt;/li&gt;</code></p><p><code>3343</code><code>&lt;li id="section_4.29"&gt;</code></p><p><code>3344</code><code>Veness M, Foote M, Gebski V, et al.: The role of radiotherapy alone in patients with merkel cell carcinoma: reporting the Australian experience of 43 patients. Int J Radiat Oncol Biol Phys 78 (3): 703-9, 2010.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19939581&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19939581&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3345</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3346</code><code>&lt;/li&gt;</code></p><p><code>3347</code><code>&lt;li id="section_4.30"&gt;</code></p><p><code>3348</code><code>Meeuwissen JA, Bourne RG, Kearsley JH: The importance of postoperative radiation therapy in the treatment of Merkel cell carcinoma. Int J Radiat Oncol Biol Phys 31 (2): 325-31, 1995.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=7836086&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=7836086&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3349</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3350</code><code>&lt;/li&gt;</code></p><p><code>3351</code><code>&lt;li id="section_4.31"&gt;</code></p><p><code>3352</code><code>Marks ME, Kim RY, Salter MM: Radiotherapy as an adjunct in the management of Merkel cell carcinoma. Cancer 65 (1): 60-4, 1990.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=2293871&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=2293871&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3353</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3354</code><code>&lt;/li&gt;</code></p><p><code>3355</code><code>&lt;li id="section_4.32"&gt;</code></p><p><code>3356</code><code>Mojica P, Smith D, Ellenhorn JD: Adjuvant radiation therapy is associated with improved survival in Merkel cell carcinoma of the skin. J Clin Oncol 25 (9): 1043-7, 2007.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17369567&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17369567&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3357</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3358</code><code>&lt;/li&gt;</code></p><p><code>3359</code><code>&lt;li id="section_4.33"&gt;</code></p><p><code>3360</code><code>Housman DM, Decker RH, Wilson LD: Regarding adjuvant radiation therapy in merkel cell carcinoma: selection bias and its affect on overall survival. J Clin Oncol 25 (28): 4503-4; author reply 4504-5, 2007.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17906216&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17906216&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3361</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3362</code><code>&lt;/li&gt;</code></p><p><code>3363</code><code>&lt;li id="section_4.34"&gt;</code></p><p><code>3364</code><code>Garneski KM, Nghiem P: Merkel cell carcinoma adjuvant therapy: current data support radiation but not chemotherapy. J Am Acad Dermatol 57 (1): 166-9, 2007.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17482714&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17482714&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3365</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3366</code><code>&lt;/li&gt;</code></p><p><code>3367</code><code>&lt;li id="section_4.35"&gt;</code></p><p><code>3368</code><code>Foote M, Harvey J, Porceddu S, et al.: Effect of radiotherapy dose and volume on relapse in Merkel cell cancer of the skin. Int J Radiat Oncol Biol Phys 77 (3): 677-84, 2010.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19906498&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19906498&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3369</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3370</code><code>&lt;/li&gt;</code></p><p><code>3371</code><code>&lt;li id="section_4.36"&gt;</code></p><p><code>3372</code><code>Fang LC, Lemos B, Douglas J, et al.: Radiation monotherapy as regional treatment for lymph node-positive Merkel cell carcinoma. Cancer 116 (7): 1783-90, 2010.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=20162707&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=20162707&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3373</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3374</code><code>&lt;/li&gt;</code></p><p><code>3375</code><code>&lt;li id="section_4.37"&gt;</code></p><p><code>3376</code><code>Becker JC, Lorenz E, Ugurel S, et al.: Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe. Oncotarget 8 (45): 79731-79741, 2017.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=29108353&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=29108353&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3377</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3378</code><code>&lt;/li&gt;</code></p><p><code>3379</code><code>&lt;li id="section_4.38"&gt;</code></p><p><code>3380</code><code>Kaufman HL, Russell JS, Hamid O, et al.: Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after &amp;#8805;1&amp;#160;year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer 6 (1): 7, 2018.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=29347993&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=29347993&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3381</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3382</code><code>&lt;/li&gt;</code></p><p><code>3383</code><code>&lt;li id="section_4.39"&gt;</code></p><p><code>3384</code><code>Cowey CL, Mahnke L, Espirito J, et al.: Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA. Future Oncol 13 (19): 1699-1710, 2017.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=28605939&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=28605939&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3385</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3386</code><code>&lt;/li&gt;</code></p><p><code>3387</code><code>&lt;li id="section_4.40"&gt;</code></p><p><code>3388</code><code>Nghiem PT, Bhatia S, Lipson EJ, et al.: PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med 374 (26): 2542-52, 2016.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=27093365&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=27093365&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3389</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3390</code><code>&lt;/li&gt;</code></p><p><code>3391</code><code>&lt;li id="section_4.41"&gt;</code></p><p><code>3392</code><code>Topalian SL, Bhatia S, Hollebecque A, et al.: Abstract CT074: Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): efficacy and safety in Merkel cell carcinoma (MCC). [Abstract] Cancer Res  77 (13 Suppl): A-CT074, 2017.&lt;/li&gt;</code></p><p><code>3393</code><code>&lt;li id="section_4.42"&gt;</code></p><p><code>3394</code><code>Tai PT, Yu E, Winquist E, et al.: Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol 18 (12): 2493-9, 2000.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10856110&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10856110&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3395</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3396</code><code>&lt;/li&gt;</code></p><p><code>3397</code><code>&lt;li id="section_4.43"&gt;</code></p><p><code>3398</code><code>Henness S, Vereecken P: Management of Merkel tumours: an evidence-based review. Curr Opin Oncol 20 (3): 280-6, 2008.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18391627&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18391627&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3399</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3400</code><code>&lt;/li&gt;</code></p><p><code>3401</code><code>&lt;li id="section_4.44"&gt;</code></p><p><code>3402</code><code>Poulsen M, Rischin D, Walpole E, et al.: High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group Study--TROG 96:07. J Clin Oncol 21 (23): 4371-6, 2003.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=14645427&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=14645427&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3403</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3404</code><code>&lt;/li&gt;</code></p><p><code>3405</code><code>&lt;li id="section_4.45"&gt;</code></p><p><code>3406</code><code>Poulsen MG, Rischin D, Porter I, et al.: Does chemotherapy improve survival in high-risk stage I and II Merkel cell carcinoma of the skin? Int J Radiat Oncol Biol Phys 64 (1): 114-9, 2006.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=16125873&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=16125873&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3407</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3408</code><code>&lt;/li&gt;</code></p><p><code>3409</code><code>&lt;li id="section_4.46"&gt;</code></p><p><code>3410</code><code>Poulsen M, Walpole E, Harvey J, et al.: Weekly carboplatin reduces toxicity during synchronous chemoradiotherapy for Merkel cell carcinoma of skin. Int J Radiat Oncol Biol Phys 72 (4): 1070-4, 2008.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18707820&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18707820&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3411</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3412</code><code>&lt;/li&gt;</code></p><p><code>3413</code><code>&lt;li id="section_4.47"&gt;</code></p><p><code>3414</code><code>Voog E, Biron P, Martin JP, et al.: Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer 85 (12): 2589-95, 1999.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10375107&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10375107&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3415</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3416</code><code>&lt;/li&gt;</code></p><p><code>3417</code><code>&lt;/ol&gt;</code></p><p><code>3418</code><code>&lt;/div&gt;</code></p><p><code>3419</code><code>          </code></p><p><code>3420</code><code>    &lt;/section&gt;</code></p><p><code>3421</code><code>          </code></p><p><code>3422</code><code>          </code></p><p><code>3423</code><code>          </code></p><p><code>3424</code><code>    &lt;section id="_73"&gt;</code></p><p><code>3425</code><code>          </code></p><p><code>3426</code><code>        &lt;h2&gt;</code></p><p><code>3427</code><code>Treatment of Stage I and II Merkel Cell Carcinoma&lt;/h2&gt;</code></p><p><code>3428</code><code>          </code></p><p><code>3429</code><code>        &lt;div id="_section_73" class="pdq-sections"&gt;</code></p><p><code>3430</code><code>&lt;nav class="in-this-section" role="navigation"&gt;</code></p><p><code>3431</code><code>&lt;h6&gt;</code></p><p><code>3432</code><code>In This Section&lt;/h6&gt;</code></p><p><code>3433</code><code>&lt;ul&gt;</code></p><p><code>3434</code><code>&lt;li&gt;</code></p><p><code>3435</code><code>&lt;a href="#_409_toc"&gt;</code></p><p><code>3436</code><code>Treatment Options for Stage I and II Merkel Cell Carcinoma&lt;/a&gt;</code></p><p><code>3437</code><code>&lt;/li&gt;</code></p><p><code>3438</code><code>&lt;li&gt;</code></p><p><code>3439</code><code>&lt;a href="#_TrialSearch_73_sid_5_toc"&gt;</code></p><p><code>3440</code><code>Current Clinical Trials&lt;/a&gt;</code></p><p><code>3441</code><code>&lt;/li&gt;</code></p><p><code>3442</code><code>&lt;/ul&gt;</code></p><p><code>3443</code><code>&lt;/nav&gt;</code></p><p><code>3444</code><code>&lt;p id="_186" tabindex="-1"&gt;</code></p><p><code>3445</code><code>Stage I and II Merkel cell carcinoma (MCC) include patients with local disease only.&lt;/p&gt;</code></p><p><code>3446</code><code>&lt;p id="_403" tabindex="-1"&gt;</code></p><p><code>3447</code><code>Excision with 1 cm to 2 cm margins and radiation therapy are the mainstays of management for primary MCC tumors. Adjuvant radiation therapy to the primary tumor site is often recommended; however, the morbidity of radiation may be avoided and low local recurrence rates maintained, as shown in a subset of patients with small low-risk lesions (i.e., tumors &amp;lt;2 cm without other adverse prognostic factors).[&lt;a href="#cit/section_5.1"&gt;</code></p><p><code>3448</code><code>1&lt;/a&gt;</code></p><p><code>3449</code><code>]&lt;/p&gt;</code></p><p><code>3450</code><code>&lt;p id="_404" tabindex="-1"&gt;</code></p><p><code>3451</code><code>Because of the risk of occult nodal disease, sentinel lymph node (SLN) biopsy is recommended for patients without clinically detectable metastatic disease.[&lt;a href="#cit/section_5.2"&gt;</code></p><p><code>3452</code><code>2&lt;/a&gt;</code></p><p><code>3453</code><code>] Any size of metastatic deposit is currently considered positive with regard to regional lymph node (N) staging; therefore, immunohistochemistry is routinely used to improve detection of micrometastases in SLN.[&lt;a href="#cit/section_5.3"&gt;</code></p><p><code>3454</code><code>3&lt;/a&gt;</code></p><p><code>3455</code><code>,&lt;a href="#cit/section_5.4"&gt;</code></p><p><code>3456</code><code>4&lt;/a&gt;</code></p><p><code>3457</code><code>] &lt;/p&gt;</code></p><p><code>3458</code><code>&lt;section id="_409"&gt;</code></p><p><code>3459</code><code>&lt;h3 id="_409_toc"&gt;</code></p><p><code>3460</code><code>Treatment Options for Stage I and II Merkel Cell Carcinoma&lt;/h3&gt;</code></p><p><code>3461</code><code>&lt;p id="_410" tabindex="-1"&gt;</code></p><p><code>3462</code><code>Treatment options for &lt;a href="/types/skin/hp/merkel-cell-treatment-pdq#_379"&gt;</code></p><p><code>3463</code><code>stage I &lt;/a&gt;</code></p><p><code>3464</code><code> and &lt;a href="/types/skin/hp/merkel-cell-treatment-pdq#_380"&gt;</code></p><p><code>3465</code><code>stage II MCC&lt;/a&gt;</code></p><p><code>3466</code><code> include the following:&lt;/p&gt;</code></p><p><code>3467</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>3468</code><code>&lt;ol id="_411"&gt;</code></p><p><code>3469</code><code>&lt;li&gt;</code></p><p><code>3470</code><code>Margin-negative local excision, attempting to maintain function. &lt;/li&gt;</code></p><p><code>3471</code><code>&lt;li&gt;</code></p><p><code>3472</code><code>Surgical nodal evaluation, typically by SLN procedure initially, may be considered for patients with significant risk of nodal disease. Completion of the nodal dissection may be considered if positive lymph nodes are found, which would upstage the patient's cancer to stage III.&lt;/li&gt;</code></p><p><code>3473</code><code>&lt;li&gt;</code></p><p><code>3474</code><code>Local radiation therapy may be considered if there is concern about the primary tumor excision margins. Regional radiation therapy may be considered if the nodal staging procedure is incomplete or omitted. For sites where the location of primary regional lymph nodes may be uncertain (e.g., mid-back), regional-node field selection is  problematic.&lt;/li&gt;</code></p><p><code>3475</code><code>&lt;li&gt;</code></p><p><code>3476</code><code> Enrollment in clinical trials is encouraged.&lt;/li&gt;</code></p><p><code>3477</code><code>&lt;/ol&gt;</code></p><p><code>3478</code><code>&lt;/div&gt;</code></p><p><code>3479</code><code>&lt;/section&gt;</code></p><p><code>3480</code><code>&lt;section id="_TrialSearch_73_sid_5"&gt;</code></p><p><code>3481</code><code>&lt;h3 id="_TrialSearch_73_sid_5_toc"&gt;</code></p><p><code>3482</code><code>Current Clinical Trials&lt;/h3&gt;</code></p><p><code>3483</code><code>&lt;p id="_TrialSearch_73_22" tabindex="-1"&gt;</code></p><p><code>3484</code><code>Use our &lt;a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/advanced" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/advanced"&gt;</code></p><p><code>3485</code><code>advanced clinical trial search&lt;/a&gt;</code></p><p><code>3486</code><code> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. &lt;a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/"&gt;</code></p><p><code>3487</code><code>General information&lt;/a&gt;</code></p><p><code>3488</code><code> about clinical trials is also available.&lt;/p&gt;</code></p><p><code>3489</code><code>&lt;/section&gt;</code></p><p><code>3490</code><code>&lt;h6 do-not-show="toc"&gt;</code></p><p><code>3491</code><code>References&lt;/h6&gt;</code></p><p><code>3492</code><code>&lt;ol&gt;</code></p><p><code>3493</code><code>&lt;li id="section_5.1"&gt;</code></p><p><code>3494</code><code>Frohm ML, Griffith KA, Harms KL, et al.: Recurrence and Survival in Patients With Merkel Cell Carcinoma Undergoing Surgery Without Adjuvant Radiation Therapy to the Primary Site. JAMA Dermatol 152 (9): 1001-7, 2016.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=27248515&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=27248515&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3495</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3496</code><code>&lt;/li&gt;</code></p><p><code>3497</code><code>&lt;li id="section_5.2"&gt;</code></p><p><code>3498</code><code>Cassler NM, Merrill D, Bichakjian CK, et al.: Merkel Cell Carcinoma Therapeutic Update. Curr Treat Options Oncol 17 (7): 36, 2016.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=27262710&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=27262710&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3499</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3500</code><code>&lt;/li&gt;</code></p><p><code>3501</code><code>&lt;li id="section_5.3"&gt;</code></p><p><code>3502</code><code>Harms PW: Update on Merkel Cell Carcinoma. Clin Lab Med 37 (3): 485-501, 2017.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=28802497&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=28802497&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3503</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3504</code><code>&lt;/li&gt;</code></p><p><code>3505</code><code>&lt;li id="section_5.4"&gt;</code></p><p><code>3506</code><code>Su LD, Lowe L, Bradford CR, et al.: Immunostaining for cytokeratin 20 improves detection of micrometastatic Merkel cell carcinoma in sentinel lymph nodes. J Am Acad Dermatol 46 (5): 661-6, 2002.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=12004304&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=12004304&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3507</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3508</code><code>&lt;/li&gt;</code></p><p><code>3509</code><code>&lt;/ol&gt;</code></p><p><code>3510</code><code>&lt;/div&gt;</code></p><p><code>3511</code><code>          </code></p><p><code>3512</code><code>    &lt;/section&gt;</code></p><p><code>3513</code><code>          </code></p><p><code>3514</code><code>          </code></p><p><code>3515</code><code>          </code></p><p><code>3516</code><code>    &lt;section id="_78"&gt;</code></p><p><code>3517</code><code>          </code></p><p><code>3518</code><code>        &lt;h2&gt;</code></p><p><code>3519</code><code>Treatment of Stage III Merkel Cell Carcinoma&lt;/h2&gt;</code></p><p><code>3520</code><code>          </code></p><p><code>3521</code><code>        &lt;div id="_section_78" class="pdq-sections"&gt;</code></p><p><code>3522</code><code>&lt;nav class="in-this-section" role="navigation"&gt;</code></p><p><code>3523</code><code>&lt;h6&gt;</code></p><p><code>3524</code><code>In This Section&lt;/h6&gt;</code></p><p><code>3525</code><code>&lt;ul&gt;</code></p><p><code>3526</code><code>&lt;li&gt;</code></p><p><code>3527</code><code>&lt;a href="#_412_toc"&gt;</code></p><p><code>3528</code><code>Treatment Options for Stage III Merkel Cell Carcinoma&lt;/a&gt;</code></p><p><code>3529</code><code>&lt;/li&gt;</code></p><p><code>3530</code><code>&lt;li&gt;</code></p><p><code>3531</code><code>&lt;a href="#_TrialSearch_78_sid_6_toc"&gt;</code></p><p><code>3532</code><code>Current Clinical Trials&lt;/a&gt;</code></p><p><code>3533</code><code>&lt;/li&gt;</code></p><p><code>3534</code><code>&lt;/ul&gt;</code></p><p><code>3535</code><code>&lt;/nav&gt;</code></p><p><code>3536</code><code>&lt;p id="_187" tabindex="-1"&gt;</code></p><p><code>3537</code><code>Stage III Merkel cell carcinoma (MCC) includes patients with nodal disease.&lt;/p&gt;</code></p><p><code>3538</code><code>&lt;section id="_412"&gt;</code></p><p><code>3539</code><code>&lt;h3 id="_412_toc"&gt;</code></p><p><code>3540</code><code>Treatment Options for Stage III Merkel Cell Carcinoma&lt;/h3&gt;</code></p><p><code>3541</code><code>&lt;p id="_413" tabindex="-1"&gt;</code></p><p><code>3542</code><code>Treatment options for &lt;a href="/types/skin/hp/merkel-cell-treatment-pdq#_382"&gt;</code></p><p><code>3543</code><code>stage III MCC&lt;/a&gt;</code></p><p><code>3544</code><code> include the following:&lt;/p&gt;</code></p><p><code>3545</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>3546</code><code>&lt;ol id="_414"&gt;</code></p><p><code>3547</code><code>&lt;li&gt;</code></p><p><code>3548</code><code>Margin-negative local excision, attempting to maintain function.&lt;/li&gt;</code></p><p><code>3549</code><code>&lt;li&gt;</code></p><p><code>3550</code><code>Sentinel lymph node procedure, possibly followed by more definitive regional node surgery if positive node(s) are found.&lt;/li&gt;</code></p><p><code>3551</code><code>&lt;li&gt;</code></p><p><code>3552</code><code>Local and regional lymph node radiation, especially if there is concern about the adequacy of the primary tumor excision margin or the risk of local-regional recurrence following the nodal surgery (e.g., multiple primary nodes, extracapsular extension, lymphovascular invasion, and evidence of in-transit metastases).&lt;/li&gt;</code></p><p><code>3553</code><code>&lt;li&gt;</code></p><p><code>3554</code><code>Systemic chemotherapy may be administered to patients with the highest risk of recurrence with the understanding that existing data have not proven a clinical survival benefit (under clinical evaluation).  &lt;/li&gt;</code></p><p><code>3555</code><code>&lt;li&gt;</code></p><p><code>3556</code><code>Enrollment in clinical trials is encouraged.&lt;/li&gt;</code></p><p><code>3557</code><code>&lt;/ol&gt;</code></p><p><code>3558</code><code>&lt;/div&gt;</code></p><p><code>3559</code><code>&lt;/section&gt;</code></p><p><code>3560</code><code>&lt;section id="_TrialSearch_78_sid_6"&gt;</code></p><p><code>3561</code><code>&lt;h3 id="_TrialSearch_78_sid_6_toc"&gt;</code></p><p><code>3562</code><code>Current Clinical Trials&lt;/h3&gt;</code></p><p><code>3563</code><code>&lt;p id="_TrialSearch_78_22" tabindex="-1"&gt;</code></p><p><code>3564</code><code>Use our &lt;a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/advanced" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/advanced"&gt;</code></p><p><code>3565</code><code>advanced clinical trial search&lt;/a&gt;</code></p><p><code>3566</code><code> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. &lt;a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/"&gt;</code></p><p><code>3567</code><code>General information&lt;/a&gt;</code></p><p><code>3568</code><code> about clinical trials is also available.&lt;/p&gt;</code></p><p><code>3569</code><code>&lt;/section&gt;</code></p><p><code>3570</code><code>&lt;/div&gt;</code></p><p><code>3571</code><code>          </code></p><p><code>3572</code><code>    &lt;/section&gt;</code></p><p><code>3573</code><code>          </code></p><p><code>3574</code><code>          </code></p><p><code>3575</code><code>          </code></p><p><code>3576</code><code>    &lt;section id="_83"&gt;</code></p><p><code>3577</code><code>          </code></p><p><code>3578</code><code>        &lt;h2&gt;</code></p><p><code>3579</code><code>Treatment of Stage IV Merkel Cell Carcinoma&lt;/h2&gt;</code></p><p><code>3580</code><code>          </code></p><p><code>3581</code><code>        &lt;div id="_section_83" class="pdq-sections"&gt;</code></p><p><code>3582</code><code>&lt;nav class="in-this-section" role="navigation"&gt;</code></p><p><code>3583</code><code>&lt;h6&gt;</code></p><p><code>3584</code><code>In This Section&lt;/h6&gt;</code></p><p><code>3585</code><code>&lt;ul&gt;</code></p><p><code>3586</code><code>&lt;li&gt;</code></p><p><code>3587</code><code>&lt;a href="#_415_toc"&gt;</code></p><p><code>3588</code><code>Treatment Options for Stage IV Merkel Cell Carcinoma&lt;/a&gt;</code></p><p><code>3589</code><code>&lt;/li&gt;</code></p><p><code>3590</code><code>&lt;li&gt;</code></p><p><code>3591</code><code>&lt;a href="#_TrialSearch_83_sid_7_toc"&gt;</code></p><p><code>3592</code><code>Current Clinical Trials&lt;/a&gt;</code></p><p><code>3593</code><code>&lt;/li&gt;</code></p><p><code>3594</code><code>&lt;/ul&gt;</code></p><p><code>3595</code><code>&lt;/nav&gt;</code></p><p><code>3596</code><code>&lt;p id="_188" tabindex="-1"&gt;</code></p><p><code>3597</code><code>Stage IV Merkel cell carcinoma (MCC) includes patients with distant metastases.&lt;/p&gt;</code></p><p><code>3598</code><code>&lt;p id="_84" tabindex="-1"&gt;</code></p><p><code>3599</code><code>Chemotherapy may be considered for patients with stage IV disease who have a good performance status. Although responses have been seen with various regimens, evidence is lacking that chemotherapy results in permanent disease control or long-term survival. &lt;/p&gt;</code></p><p><code>3600</code><code>&lt;p id="_85" tabindex="-1"&gt;</code></p><p><code>3601</code><code>In stage IV patients for whom chemotherapy is not considered an appropriate option, surgery and/or radiation therapy may be considered for local or regional palliation.&lt;/p&gt;</code></p><p><code>3602</code><code>&lt;p id="_406" tabindex="-1"&gt;</code></p><p><code>3603</code><code>Avelumab, an anti-programmed death ligand-1 antibody, has been approved by the U.S. Food and Drug Administration as therapy for metastatic MCC. Other immunotherapies for MCC are under clinical evaluation. The success of immune-based therapies represents a milestone in the management of advanced MCC. However, not all patients respond to immune-based therapies. Furthermore, patients requiring immunosuppression in the setting of solid organ transplants or those with autoimmune disease may not be optimal candidates for immune-based therapy. &lt;/p&gt;</code></p><p><code>3604</code><code>&lt;section id="_415"&gt;</code></p><p><code>3605</code><code>&lt;h3 id="_415_toc"&gt;</code></p><p><code>3606</code><code>Treatment Options for Stage IV Merkel Cell Carcinoma&lt;/h3&gt;</code></p><p><code>3607</code><code>&lt;p id="_416" tabindex="-1"&gt;</code></p><p><code>3608</code><code>Treatment options for &lt;a href="/types/skin/hp/merkel-cell-treatment-pdq#_383"&gt;</code></p><p><code>3609</code><code>stage IV MCC&lt;/a&gt;</code></p><p><code>3610</code><code> include the following:&lt;/p&gt;</code></p><p><code>3611</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>3612</code><code>&lt;ol id="_417"&gt;</code></p><p><code>3613</code><code>&lt;li&gt;</code></p><p><code>3614</code><code>Palliation with chemotherapy and/or surgery and/or radiation therapy as clinically appropriate.&lt;/li&gt;</code></p><p><code>3615</code><code>&lt;li&gt;</code></p><p><code>3616</code><code> Enrollment in clinical trials is strongly encouraged.&lt;/li&gt;</code></p><p><code>3617</code><code>&lt;/ol&gt;</code></p><p><code>3618</code><code>&lt;/div&gt;</code></p><p><code>3619</code><code>&lt;/section&gt;</code></p><p><code>3620</code><code>&lt;section id="_TrialSearch_83_sid_7"&gt;</code></p><p><code>3621</code><code>&lt;h3 id="_TrialSearch_83_sid_7_toc"&gt;</code></p><p><code>3622</code><code>Current Clinical Trials&lt;/h3&gt;</code></p><p><code>3623</code><code>&lt;p id="_TrialSearch_83_22" tabindex="-1"&gt;</code></p><p><code>3624</code><code>Use our &lt;a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/advanced" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/advanced"&gt;</code></p><p><code>3625</code><code>advanced clinical trial search&lt;/a&gt;</code></p><p><code>3626</code><code> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. &lt;a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/"&gt;</code></p><p><code>3627</code><code>General information&lt;/a&gt;</code></p><p><code>3628</code><code> about clinical trials is also available.&lt;/p&gt;</code></p><p><code>3629</code><code>&lt;/section&gt;</code></p><p><code>3630</code><code>&lt;/div&gt;</code></p><p><code>3631</code><code>          </code></p><p><code>3632</code><code>    &lt;/section&gt;</code></p><p><code>3633</code><code>          </code></p><p><code>3634</code><code>          </code></p><p><code>3635</code><code>          </code></p><p><code>3636</code><code>    &lt;section id="_90"&gt;</code></p><p><code>3637</code><code>          </code></p><p><code>3638</code><code>        &lt;h2&gt;</code></p><p><code>3639</code><code>Treatment of Recurrent Merkel Cell Carcinoma&lt;/h2&gt;</code></p><p><code>3640</code><code>          </code></p><p><code>3641</code><code>        &lt;div id="_section_90" class="pdq-sections"&gt;</code></p><p><code>3642</code><code>&lt;nav class="in-this-section" role="navigation"&gt;</code></p><p><code>3643</code><code>&lt;h6&gt;</code></p><p><code>3644</code><code>In This Section&lt;/h6&gt;</code></p><p><code>3645</code><code>&lt;ul&gt;</code></p><p><code>3646</code><code>&lt;li&gt;</code></p><p><code>3647</code><code>&lt;a href="#_418_toc"&gt;</code></p><p><code>3648</code><code>Treatment Options for Recurrent Merkel Cell Carcinoma&lt;ul&gt;</code></p><p><code>3649</code><code>&lt;li&gt;</code></p><p><code>3650</code><code>&lt;a href="#_419_toc"&gt;</code></p><p><code>3651</code><code>Local recurrence&lt;/a&gt;</code></p><p><code>3652</code><code>&lt;/li&gt;</code></p><p><code>3653</code><code>&lt;li&gt;</code></p><p><code>3654</code><code>&lt;a href="#_423_toc"&gt;</code></p><p><code>3655</code><code>Nodal recurrence&lt;/a&gt;</code></p><p><code>3656</code><code>&lt;/li&gt;</code></p><p><code>3657</code><code>&lt;li&gt;</code></p><p><code>3658</code><code>&lt;a href="#_425_toc"&gt;</code></p><p><code>3659</code><code>Distant recurrence&lt;/a&gt;</code></p><p><code>3660</code><code>&lt;/li&gt;</code></p><p><code>3661</code><code>&lt;/ul&gt;</code></p><p><code>3662</code><code>&lt;/a&gt;</code></p><p><code>3663</code><code>&lt;/li&gt;</code></p><p><code>3664</code><code>&lt;li&gt;</code></p><p><code>3665</code><code>&lt;a href="#_TrialSearch_90_sid_8_toc"&gt;</code></p><p><code>3666</code><code>Current Clinical Trials&lt;/a&gt;</code></p><p><code>3667</code><code>&lt;/li&gt;</code></p><p><code>3668</code><code>&lt;/ul&gt;</code></p><p><code>3669</code><code>&lt;/nav&gt;</code></p><p><code>3670</code><code>&lt;p id="_91" tabindex="-1"&gt;</code></p><p><code>3671</code><code>Merkel cell carcinoma is a rare tumor. There are no clinical trials reported for patients with recurrent disease exclusively. Recommendations and outcomes of various treatments for these patients are included in many large case series [&lt;a href="#cit/section_8.1"&gt;</code></p><p><code>3672</code><code>1&lt;/a&gt;</code></p><p><code>3673</code><code>-&lt;a href="#cit/section_8.3"&gt;</code></p><p><code>3674</code><code>3&lt;/a&gt;</code></p><p><code>3675</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810037&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810037&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3676</code><code>Level of evidence C2&lt;/a&gt;</code></p><p><code>3677</code><code>] and one phase II clinical trial.[&lt;a href="#cit/section_8.4"&gt;</code></p><p><code>3678</code><code>4&lt;/a&gt;</code></p><p><code>3679</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810035&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810035&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3680</code><code>Level of evidence C1&lt;/a&gt;</code></p><p><code>3681</code><code>] Treatments are usually individualized based on patient preference and the specifics of each case, and there are no standard options. Consideration should be given to enrollment in clinical trials.&lt;/p&gt;</code></p><p><code>3682</code><code>&lt;section id="_418"&gt;</code></p><p><code>3683</code><code>&lt;h3 id="_418_toc"&gt;</code></p><p><code>3684</code><code>Treatment Options for Recurrent Merkel Cell Carcinoma&lt;/h3&gt;</code></p><p><code>3685</code><code>&lt;section id="_419"&gt;</code></p><p><code>3686</code><code>&lt;h4 id="_419_toc"&gt;</code></p><p><code>3687</code><code>Local recurrence&lt;/h4&gt;</code></p><p><code>3688</code><code>&lt;p id="_420" tabindex="-1"&gt;</code></p><p><code>3689</code><code>Treatment options for patients with local recurrence include wider local surgery if possible, followed by radiation therapy, if not previously given.&lt;/p&gt;</code></p><p><code>3690</code><code>&lt;p id="_421" tabindex="-1"&gt;</code></p><p><code>3691</code><code>Regional lymph node dissection (RLND) can also be considered if regional draining nodes have not been previously removed.&lt;/p&gt;</code></p><p><code>3692</code><code>&lt;p id="_422" tabindex="-1"&gt;</code></p><p><code>3693</code><code>Because of the poor prognosis after recurrence, consideration can also be given to systemic chemotherapy, although there is no evidence that it improves survival.&lt;/p&gt;</code></p><p><code>3694</code><code>&lt;/section&gt;</code></p><p><code>3695</code><code>&lt;section id="_423"&gt;</code></p><p><code>3696</code><code>&lt;h4 id="_423_toc"&gt;</code></p><p><code>3697</code><code>Nodal recurrence&lt;/h4&gt;</code></p><p><code>3698</code><code>&lt;p id="_424" tabindex="-1"&gt;</code></p><p><code>3699</code><code>Treatment options for patients with only regional nodal recurrence include RLND and adjuvant radiation therapy if the regional draining nodes have not been previously treated. Because of the poor prognosis after recurrence, consideration can also be given to systemic chemotherapy, although there is no evidence that it improves survival.&lt;/p&gt;</code></p><p><code>3700</code><code>&lt;/section&gt;</code></p><p><code>3701</code><code>&lt;section id="_425"&gt;</code></p><p><code>3702</code><code>&lt;h4 id="_425_toc"&gt;</code></p><p><code>3703</code><code>Distant recurrence&lt;/h4&gt;</code></p><p><code>3704</code><code>&lt;p id="_426" tabindex="-1"&gt;</code></p><p><code>3705</code><code>For patients with distant recurrence only, chemotherapy is an option for patients who have good performance status.[&lt;a href="#cit/section_8.1"&gt;</code></p><p><code>3706</code><code>1&lt;/a&gt;</code></p><p><code>3707</code><code>-&lt;a href="#cit/section_8.6"&gt;</code></p><p><code>3708</code><code>6&lt;/a&gt;</code></p><p><code>3709</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810037&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810037&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3710</code><code>Level of evidence C2&lt;/a&gt;</code></p><p><code>3711</code><code>] Although responses with chemotherapy have been reported in selected patients with locally advanced and metastatic disease, toxicity has been significant and without clear benefit, particularly in older patients. When appropriate, radiation therapy and/or surgery may be offered as palliation to sites of recurrence, particularly if chemotherapy is not considered an option.&lt;/p&gt;</code></p><p><code>3712</code><code>&lt;/section&gt;</code></p><p><code>3713</code><code>&lt;/section&gt;</code></p><p><code>3714</code><code>&lt;section id="_TrialSearch_90_sid_8"&gt;</code></p><p><code>3715</code><code>&lt;h3 id="_TrialSearch_90_sid_8_toc"&gt;</code></p><p><code>3716</code><code>Current Clinical Trials&lt;/h3&gt;</code></p><p><code>3717</code><code>&lt;p id="_TrialSearch_90_22" tabindex="-1"&gt;</code></p><p><code>3718</code><code>Use our &lt;a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/advanced" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/advanced"&gt;</code></p><p><code>3719</code><code>advanced clinical trial search&lt;/a&gt;</code></p><p><code>3720</code><code> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. &lt;a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/"&gt;</code></p><p><code>3721</code><code>General information&lt;/a&gt;</code></p><p><code>3722</code><code> about clinical trials is also available.&lt;/p&gt;</code></p><p><code>3723</code><code>&lt;/section&gt;</code></p><p><code>3724</code><code>&lt;h6 do-not-show="toc"&gt;</code></p><p><code>3725</code><code>References&lt;/h6&gt;</code></p><p><code>3726</code><code>&lt;ol&gt;</code></p><p><code>3727</code><code>&lt;li id="section_8.1"&gt;</code></p><p><code>3728</code><code>Goessling W, McKee PH, Mayer RJ: Merkel cell carcinoma. J Clin Oncol 20 (2): 588-98, 2002.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11786590&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11786590&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3729</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3730</code><code>&lt;/li&gt;</code></p><p><code>3731</code><code>&lt;li id="section_8.2"&gt;</code></p><p><code>3732</code><code>Henness S, Vereecken P: Management of Merkel tumours: an evidence-based review. Curr Opin Oncol 20 (3): 280-6, 2008.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18391627&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18391627&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3733</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3734</code><code>&lt;/li&gt;</code></p><p><code>3735</code><code>&lt;li id="section_8.3"&gt;</code></p><p><code>3736</code><code>Voog E, Biron P, Martin JP, et al.: Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer 85 (12): 2589-95, 1999.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10375107&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10375107&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3737</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3738</code><code>&lt;/li&gt;</code></p><p><code>3739</code><code>&lt;li id="section_8.4"&gt;</code></p><p><code>3740</code><code>Poulsen M, Rischin D, Walpole E, et al.: High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group Study--TROG 96:07. J Clin Oncol 21 (23): 4371-6, 2003.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=14645427&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=14645427&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3741</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3742</code><code>&lt;/li&gt;</code></p><p><code>3743</code><code>&lt;li id="section_8.5"&gt;</code></p><p><code>3744</code><code>Eng TY, Boersma MG, Fuller CD, et al.: A comprehensive review of the treatment of Merkel cell carcinoma. Am J Clin Oncol 30 (6): 624-36, 2007.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18091058&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18091058&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3745</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3746</code><code>&lt;/li&gt;</code></p><p><code>3747</code><code>&lt;li id="section_8.6"&gt;</code></p><p><code>3748</code><code>Tai PT, Yu E, Winquist E, et al.: Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol 18 (12): 2493-9, 2000.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10856110&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10856110&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3749</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3750</code><code>&lt;/li&gt;</code></p><p><code>3751</code><code>&lt;/ol&gt;</code></p><p><code>3752</code><code>&lt;/div&gt;</code></p><p><code>3753</code><code>          </code></p><p><code>3754</code><code>    &lt;/section&gt;</code></p><p><code>3755</code><code>          </code></p><p><code>3756</code><code>          </code></p><p><code>3757</code><code>          </code></p><p><code>3758</code><code>    &lt;section id="_5"&gt;</code></p><p><code>3759</code><code>          </code></p><p><code>3760</code><code>        &lt;h2&gt;</code></p><p><code>3761</code><code>Changes to This Summary (10/28/2022)&lt;/h2&gt;</code></p><p><code>3762</code><code>          </code></p><p><code>3763</code><code>        &lt;div id="_section_5" class="pdq-sections"&gt;</code></p><p><code>3764</code><code>&lt;p id="_6" tabindex="-1"&gt;</code></p><p><code>3765</code><code>The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available.  This section describes the latest changes made to this summary as of the date above.&lt;/p&gt;</code></p><p><code>3766</code><code>&lt;p id="_408" tabindex="-1"&gt;</code></p><p><code>3767</code><code>Editorial changes were made to this summary.&lt;/p&gt;</code></p><p><code>3768</code><code>&lt;p id="_disclaimerHP_3" tabindex="-1"&gt;</code></p><p><code>3769</code><code>This summary is written and maintained by the &lt;a href="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment" title="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment"&gt;</code></p><p><code>3770</code><code>PDQ Adult Treatment Editorial Board&lt;/a&gt;</code></p><p><code>3771</code><code>, which is</code></p><p><code>3772</code><code>editorially independent of NCI.  The summary reflects an independent review of</code></p><p><code>3773</code><code>the literature and does not represent a policy statement of NCI or NIH.  More</code></p><p><code>3774</code><code>information about summary policies and the role of the PDQ Editorial Boards  in</code></p><p><code>3775</code><code>maintaining the PDQ summaries can be found on the &lt;a href="/types/skin/hp/merkel-cell-treatment-pdq#_AboutThis_1"&gt;</code></p><p><code>3776</code><code>About This PDQ Summary&lt;/a&gt;</code></p><p><code>3777</code><code> and &lt;a href="https://www.cancer.gov/publications/pdq" title="https://www.cancer.gov/publications/pdq"&gt;</code></p><p><code>3778</code><code>PDQ&amp;#174; Cancer Information for Health Professionals&lt;/a&gt;</code></p><p><code>3779</code><code> pages.</code></p><p><code>3780</code><code>&lt;/p&gt;</code></p><p><code>3781</code><code>&lt;/div&gt;</code></p><p><code>3782</code><code>          </code></p><p><code>3783</code><code>    &lt;/section&gt;</code></p><p><code>3784</code><code>          </code></p><p><code>3785</code><code>          </code></p><p><code>3786</code><code>          </code></p><p><code>3787</code><code>    &lt;section id="_AboutThis_1"&gt;</code></p><p><code>3788</code><code>          </code></p><p><code>3789</code><code>        &lt;h2&gt;</code></p><p><code>3790</code><code>About This PDQ Summary&lt;/h2&gt;</code></p><p><code>3791</code><code>          </code></p><p><code>3792</code><code>        &lt;div id="_section_AboutThis_1" class="pdq-sections"&gt;</code></p><p><code>3793</code><code>&lt;section id="_AboutThis_2"&gt;</code></p><p><code>3794</code><code>&lt;h3 id="_AboutThis_2_toc"&gt;</code></p><p><code>3795</code><code>Purpose of This Summary&lt;/h3&gt;</code></p><p><code>3796</code><code>&lt;p id="_AboutThis_3" tabindex="-1"&gt;</code></p><p><code>3797</code><code>This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of merkel cell carcinoma. It is intended as a resource to inform and assist clinicians in the care of their patients.  It does not provide formal guidelines or recommendations for making health care decisions.&lt;/p&gt;</code></p><p><code>3798</code><code>&lt;/section&gt;</code></p><p><code>3799</code><code>&lt;section id="_AboutThis_4"&gt;</code></p><p><code>3800</code><code>&lt;h3 id="_AboutThis_4_toc"&gt;</code></p><p><code>3801</code><code>Reviewers and Updates&lt;/h3&gt;</code></p><p><code>3802</code><code>&lt;p id="_AboutThis_5" tabindex="-1"&gt;</code></p><p><code>3803</code><code>This summary is reviewed regularly and updated as necessary by the &lt;a href="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment" title="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment"&gt;</code></p><p><code>3804</code><code>PDQ Adult Treatment Editorial Board&lt;/a&gt;</code></p><p><code>3805</code><code>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).&lt;/p&gt;</code></p><p><code>3806</code><code>&lt;p id="_AboutThis_22" tabindex="-1"&gt;</code></p><p><code>3807</code><code> Board members review recently published articles each month to determine whether an article should:&lt;/p&gt;</code></p><p><code>3808</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>3809</code><code>&lt;ul id="_AboutThis_6"&gt;</code></p><p><code>3810</code><code>&lt;li&gt;</code></p><p><code>3811</code><code>be discussed at a meeting,&lt;/li&gt;</code></p><p><code>3812</code><code>&lt;li&gt;</code></p><p><code>3813</code><code>be cited with text, or&lt;/li&gt;</code></p><p><code>3814</code><code>&lt;li&gt;</code></p><p><code>3815</code><code>replace or update an existing article that is already cited.&lt;/li&gt;</code></p><p><code>3816</code><code>&lt;/ul&gt;</code></p><p><code>3817</code><code>&lt;/div&gt;</code></p><p><code>3818</code><code>&lt;p id="_AboutThis_7" tabindex="-1"&gt;</code></p><p><code>3819</code><code>Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.&lt;/p&gt;</code></p><p><code>3820</code><code>&lt;p id="" tabindex="-1"&gt;</code></p><p><code>3821</code><code>The lead reviewer for Merkel Cell Carcinoma Treatment is:&lt;/p&gt;</code></p><p><code>3822</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>3823</code><code>&lt;ul id=""&gt;</code></p><p><code>3824</code><code>&lt;li&gt;</code></p><p><code>3825</code><code>Russell S. Berman, MD (New York University School of Medicine)&lt;/li&gt;</code></p><p><code>3826</code><code>&lt;/ul&gt;</code></p><p><code>3827</code><code>&lt;/div&gt;</code></p><p><code>3828</code><code>&lt;p id="_AboutThis_9" tabindex="-1"&gt;</code></p><p><code>3829</code><code>Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's &lt;a href="https://www.cancer.gov/contact/email-us" title="https://www.cancer.gov/contact/email-us"&gt;</code></p><p><code>3830</code><code>Email Us&lt;/a&gt;</code></p><p><code>3831</code><code>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.&lt;/p&gt;</code></p><p><code>3832</code><code>&lt;/section&gt;</code></p><p><code>3833</code><code>&lt;section id="_AboutThis_10"&gt;</code></p><p><code>3834</code><code>&lt;h3 id="_AboutThis_10_toc"&gt;</code></p><p><code>3835</code><code>Levels of Evidence&lt;/h3&gt;</code></p><p><code>3836</code><code>&lt;p id="_AboutThis_11" tabindex="-1"&gt;</code></p><p><code>3837</code><code>Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Adult Treatment Editorial Board uses a &lt;a href="/publications/pdq/levels-evidence/treatment"&gt;</code></p><p><code>3838</code><code>formal evidence ranking system&lt;/a&gt;</code></p><p><code>3839</code><code> in developing its level-of-evidence designations.&lt;/p&gt;</code></p><p><code>3840</code><code>&lt;/section&gt;</code></p><p><code>3841</code><code>&lt;section id="_AboutThis_12"&gt;</code></p><p><code>3842</code><code>&lt;h3 id="_AboutThis_12_toc"&gt;</code></p><p><code>3843</code><code>Permission to Use This Summary&lt;/h3&gt;</code></p><p><code>3844</code><code>&lt;p id="_AboutThis_13" tabindex="-1"&gt;</code></p><p><code>3845</code><code>PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as &amp;#8220;NCI&amp;#8217;s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].&amp;#8221;&lt;/p&gt;</code></p><p><code>3846</code><code>&lt;p id="_AboutThis_14" tabindex="-1"&gt;</code></p><p><code>3847</code><code>The preferred citation for this PDQ summary is:&lt;/p&gt;</code></p><p><code>3848</code><code>&lt;p id="_AboutThis_15" tabindex="-1"&gt;</code></p><p><code>3849</code><code>PDQ&amp;#174; Adult Treatment Editorial Board. PDQ Merkel Cell Carcinoma Treatment. Bethesda, MD: National Cancer Institute. Updated  &amp;lt;MM/DD/YYYY&amp;gt;. Available at: &lt;a href="https://www.cancer.gov/types/skin/hp/merkel-cell-treatment-pdq" title="https://www.cancer.gov/types/skin/hp/merkel-cell-treatment-pdq"&gt;</code></p><p><code>3850</code><code>https://www.cancer.gov/types/skin/hp/merkel-cell-treatment-pdq&lt;/a&gt;</code></p><p><code>3851</code><code>.  Accessed &amp;lt;MM/DD/YYYY&amp;gt;. [PMID:  20943647]&lt;/p&gt;</code></p><p><code>3852</code><code>&lt;p id="_AboutThis_16" tabindex="-1"&gt;</code></p><p><code>3853</code><code>Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in &lt;a href="https://visualsonline.cancer.gov/" title="https://visualsonline.cancer.gov/"&gt;</code></p><p><code>3854</code><code>Visuals Online&lt;/a&gt;</code></p><p><code>3855</code><code>, a collection of over 2,000 scientific images.</code></p><p><code>3856</code><code>          </code></p><p><code>3857</code><code>&lt;/p&gt;</code></p><p><code>3858</code><code>&lt;/section&gt;</code></p><p><code>3859</code><code>&lt;section id="_AboutThis_17"&gt;</code></p><p><code>3860</code><code>&lt;h3 id="_AboutThis_17_toc"&gt;</code></p><p><code>3861</code><code>Disclaimer&lt;/h3&gt;</code></p><p><code>3862</code><code>&lt;p id="_AboutThis_18" tabindex="-1"&gt;</code></p><p><code>3863</code><code>Based on the strength of the available evidence, treatment options may be described as either &amp;#8220;standard&amp;#8221; or &amp;#8220;under clinical evaluation.&amp;#8221; These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the &lt;a href="https://www.cancer.gov/about-cancer/managing-care" title="https://www.cancer.gov/about-cancer/managing-care"&gt;</code></p><p><code>3864</code><code>Managing Cancer Care&lt;/a&gt;</code></p><p><code>3865</code><code> page.&lt;/p&gt;</code></p><p><code>3866</code><code>&lt;/section&gt;</code></p><p><code>3867</code><code>&lt;section id="_AboutThis_20"&gt;</code></p><p><code>3868</code><code>&lt;h3 id="_AboutThis_20_toc"&gt;</code></p><p><code>3869</code><code>Contact Us&lt;/h3&gt;</code></p><p><code>3870</code><code>&lt;p id="_AboutThis_21" tabindex="-1"&gt;</code></p><p><code>3871</code><code>More information about contacting us or receiving help with the Cancer.gov website can be found on our &lt;a href="https://www.cancer.gov/contact" title="https://www.cancer.gov/contact"&gt;</code></p><p><code>3872</code><code>Contact Us for Help&lt;/a&gt;</code></p><p><code>3873</code><code> page. Questions can also be submitted to Cancer.gov through the website&amp;#8217;s &lt;a href="https://www.cancer.gov/contact/email-us" title="https://www.cancer.gov/contact/email-us"&gt;</code></p><p><code>3874</code><code>Email Us&lt;/a&gt;</code></p><p><code>3875</code><code>.&lt;/p&gt;</code></p><p><code>3876</code><code>&lt;/section&gt;</code></p><p><code>3877</code><code>&lt;/div&gt;</code></p><p><code>3878</code><code>          </code></p><p><code>3879</code><code>    &lt;/section&gt;</code></p><p><code>3880</code><code>          </code></p><p><code>3881</code><code>          </code></p><p><code>3882</code><code>        &lt;/div&gt;</code></p><p><code>3883</code><code>          </code></p><p><code>3884</code><code>      &lt;/div&gt;</code></p><p><code>3885</code><code>          </code></p><p><code>3886</code><code>    &lt;/div&gt;</code></p><p><code>3887</code><code>          </code></p><p><code>3888</code><code>  &lt;/div&gt;</code></p><p><code>3889</code><code>          </code></p><p><code>3890</code><code>          </code></p><p><code>3891</code><code>    &lt;footer class="article-footer"&gt;</code></p><p><code>3892</code><code>                    </code></p><p><code>3893</code><code>            &lt;div class="document-dates horizontal"&gt;</code></p><p><code>3894</code><code>          </code></p><p><code>3895</code><code>                &lt;ul class="clearfix"&gt;</code></p><p><code>3896</code><code>          </code></p><p><code>3897</code><code>                                                                &lt;li&gt;</code></p><p><code>3898</code><code>          </code></p><p><code>3899</code><code>                            &lt;strong&gt;</code></p><p><code>3900</code><code>Updated:&lt;/strong&gt;</code></p><p><code>3901</code><code>          </code></p><p><code>3902</code><code>                            &lt;time datetime="2022-10-28T12:00:00Z"&gt;</code></p><p><code>3903</code><code>October 28, 2022&lt;/time&gt;</code></p><p><code>3904</code><code>          </code></p><p><code>3905</code><code>          </code></p><p><code>3906</code><code>                        &lt;/li&gt;</code></p><p><code>3907</code><code>          </code></p><p><code>3908</code><code>                                                        &lt;/ul&gt;</code></p><p><code>3909</code><code>          </code></p><p><code>3910</code><code>            &lt;/div&gt;</code></p><p><code>3911</code><code>          </code></p><p><code>3912</code><code>                  &lt;div id="nvcgSlPublicUse"&gt;</code></p><p><code>3913</code><code>          </code></p><p><code>3914</code><code>  &lt;div class="slot-item only-SI"&gt;</code></p><p><code>3915</code><code>          </code></p><p><code>3916</code><code>    &lt;div class="public-use"&gt;</code></p><p><code>3917</code><code>          </code></p><p><code>3918</code><code>      &lt;div id="block-ncids-trans-public-use"&gt;</code></p><p><code>3919</code><code>          </code></p><p><code>3920</code><code>  </code></p><p><code>3921</code><code>    </code></p><p><code>3922</code><code>      &lt;p&gt;</code></p><p><code>3923</code><code>&lt;em&gt;</code></p><p><code>3924</code><code>If you would like to reproduce some or all of this content, see &lt;a href="/policies/copyright-reuse"&gt;</code></p><p><code>3925</code><code>Reuse of NCI Information&lt;/a&gt;</code></p><p><code>3926</code><code> for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Merkel Cell Carcinoma Treatment (PDQ®)–Health Professional Version was originally published by the National Cancer Institute.”&lt;/em&gt;</code></p><p><code>3927</code><code>&lt;/p&gt;</code></p><p><code>3928</code><code>          </code></p><p><code>3929</code><code>          </code></p><p><code>3930</code><code>  &lt;/div&gt;</code></p><p><code>3931</code><code>          </code></p><p><code>3932</code><code>          </code></p><p><code>3933</code><code>    &lt;/div&gt;</code></p><p><code>3934</code><code>          </code></p><p><code>3935</code><code>  &lt;/div&gt;</code></p><p><code>3936</code><code>          </code></p><p><code>3937</code><code>&lt;/div&gt;</code></p><p><code>3938</code><code>          </code></p><p><code>3939</code><code>          </code></p><p><code>3940</code><code>                &lt;div id="block-ncids-trans-syndication-message"&gt;</code></p><p><code>3941</code><code>          </code></p><p><code>3942</code><code>  </code></p><p><code>3943</code><code>    </code></p><p><code>3944</code><code>        &lt;div class="syndication"&gt;</code></p><p><code>3945</code><code>          </code></p><p><code>3946</code><code>    &lt;div&gt;</code></p><p><code>3947</code><code>          </code></p><p><code>3948</code><code>      &lt;p&gt;</code></p><p><code>3949</code><code>Want to use this content on your website or other digital platform? Our &lt;a href="/syndication"&gt;</code></p><p><code>3950</code><code>syndication services page&lt;/a&gt;</code></p><p><code>3951</code><code> shows you how.&lt;/p&gt;</code></p><p><code>3952</code><code>          </code></p><p><code>3953</code><code>    &lt;/div&gt;</code></p><p><code>3954</code><code>          </code></p><p><code>3955</code><code>  &lt;/div&gt;</code></p><p><code>3956</code><code>          </code></p><p><code>3957</code><code>          </code></p><p><code>3958</code><code>  &lt;/div&gt;</code></p><p><code>3959</code><code>          </code></p><p><code>3960</code><code>          </code></p><p><code>3961</code><code>          </code></p><p><code>3962</code><code>      &lt;/footer&gt;</code></p><p><code>3963</code><code>          </code></p><p><code>3964</code><code>&lt;/article&gt;</code></p><p><code>3965</code><code>          </code></p><p><code>3966</code><code>          </code></p><p><code>3967</code><code>          </code></p><p><code>3968</code><code>        &lt;/main&gt;</code></p><p><code>3969</code><code>          </code></p><p><code>3970</code><code>      &lt;/div&gt;</code></p><p><code>3971</code><code>          </code></p><p><code>3972</code><code>    &lt;/div&gt;</code></p><p><code>3973</code><code>          </code></p><p><code>3974</code><code>    &lt;div class="desktop:grid-col-9 desktop:grid-offset-3"&gt;</code></p><p><code>3975</code><code>          </code></p><p><code>3976</code><code>      </code></p><p><code>3977</code><code>          </code></p><p><code>3978</code><code>      </code></p><p><code>3979</code><code>          </code></p><p><code>3980</code><code>          </code></p><p><code>3981</code><code>&lt;section  class="cgdp-page-options cgdp-page-options--bottom" aria-label="Page options bottom"&gt;</code></p><p><code>3982</code><code>          </code></p><p><code>3983</code><code>  &lt;button class="usa-button usa-button--unstyled" onclick="window.print()"&gt;</code></p><p><code>3984</code><code>          </code></p><p><code>3985</code><code>    &lt;svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" width="24" class="usa-icon" role="img" aria-hidden="true" focusable="false"&gt;</code></p><p><code>3986</code><code>          </code></p><p><code>3987</code><code>      &lt;path d="M0 0h24v24H0z" fill="none"/&gt;</code></p><p><code>3988</code><code>          </code></p><p><code>3989</code><code>      &lt;path d="M19 8H5c-1.66 0-3 1.34-3 3v6h4v4h12v-4h4v-6c0-1.66-1.34-3-3-3zm-3 11H8v-5h8v5zm3-7c-.55 0-1-.45-1-1s.45-1 1-1 1 .45 1 1-.45 1-1 1zm-1-9H6v4h12V3z"/&gt;</code></p><p><code>3990</code><code>          </code></p><p><code>3991</code><code>    &lt;/svg&gt;</code></p><p><code>3992</code><code>          </code></p><p><code>3993</code><code>    &lt;span class="usa-sr-only"&gt;</code></p><p><code>3994</code><code>          </code></p><p><code>3995</code><code>      Print    &lt;/span&gt;</code></p><p><code>3996</code><code>          </code></p><p><code>3997</code><code>  &lt;/button&gt;</code></p><p><code>3998</code><code>          </code></p><p><code>3999</code><code>  &lt;a class="usa-button usa-button--unstyled" href="mailto:?subject=Information from the National Cancer Institute Web Site &amp;body=I found this information on www.cancer.gov and I'd like to share it with you: https://www.cancer.gov/types/skin/hp/merkel-cell-treatment-pdq %0D%0A%0D%0A NCI's Web site, www.cancer.gov, provides accurate, up-to-date, comprehensive cancer information from the U.S. government's principal agency for cancer research. If you have questions or need additional information, we invite you to contact NCI's LiveHelp instant messaging service at https://livehelp.cancer.gov, or call the NCI's Contact Center 1-800-4-CANCER (1-800-422-6237) (toll-free from the United States)."&gt;</code></p><p><code>4000</code><code>          </code></p><p><code>4001</code><code>    &lt;svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" width="24" class="usa-icon" role="img" aria-hidden="true" focusable="false"&gt;</code></p><p><code>4002</code><code>          </code></p><p><code>4003</code><code>        &lt;path d="M0 0h24v24H0z" fill="none"/&gt;</code></p><p><code>4004</code><code>          </code></p><p><code>4005</code><code>        &lt;path d="M20 4H4c-1.1 0-1.99.9-1.99 2L2 18c0 1.1.9 2 2 2h16c1.1 0 2-.9 2-2V6c0-1.1-.9-2-2-2zm0 14H4V8l8 5 8-5v10zm-8-7L4 6h16l-8 5z"/&gt;</code></p><p><code>4006</code><code>          </code></p><p><code>4007</code><code>    &lt;/svg&gt;</code></p><p><code>4008</code><code>          </code></p><p><code>4009</code><code>    &lt;span class="usa-sr-only"&gt;</code></p><p><code>4010</code><code>          </code></p><p><code>4011</code><code>      Email    &lt;/span&gt;</code></p><p><code>4012</code><code>          </code></p><p><code>4013</code><code>  &lt;/a&gt;</code></p><p><code>4014</code><code>          </code></p><p><code>4015</code><code>&lt;/section&gt;</code></p><p><code>4016</code><code>          </code></p><p><code>4017</code><code>          </code></p><p><code>4018</code><code>    &lt;/div&gt;</code></p><p><code>4019</code><code>          </code></p><p><code>4020</code><code>  &lt;/div&gt;</code></p><p><code>4021</code><code>          </code></p><p><code>4022</code><code>&lt;/div&gt;</code></p><p><code>4023</code><code>          </code></p><p><code>4024</code><code>          </code></p><p><code>4025</code><code>  &lt;div id="block-ncidsfooterenglish"&gt;</code></p><p><code>4026</code><code>          </code></p><p><code>4027</code><code>  </code></p><p><code>4028</code><code>    </code></p><p><code>4029</code><code>      &lt;footer</code></p><p><code>4030</code><code>  class="usa-footer usa-footer--nci-big"</code></p><p><code>4031</code><code>  id="nci-footer"</code></p><p><code>4032</code><code>  aria-label="Footer"</code></p><p><code>4033</code><code>&gt;</code></p><p><code>4034</code><code>          </code></p><p><code>4035</code><code>  &lt;div class="grid-container usa-footer__return-to-top"&gt;</code></p><p><code>4036</code><code>          </code></p><p><code>4037</code><code>    &lt;a href="#top" aria-label="Back To Top"&gt;</code></p><p><code>4038</code><code>&lt;span&gt;</code></p><p><code>4039</code><code>Back To Top&lt;/span&gt;</code></p><p><code>4040</code><code>&lt;/a&gt;</code></p><p><code>4041</code><code>          </code></p><p><code>4042</code><code>  &lt;/div&gt;</code></p><p><code>4043</code><code>          </code></p><p><code>4044</code><code>  &lt;div class="usa-footer__primary-section"&gt;</code></p><p><code>4045</code><code>          </code></p><p><code>4046</code><code>    &lt;div class="grid-container"&gt;</code></p><p><code>4047</code><code>          </code></p><p><code>4048</code><code>      &lt;div class="grid-row grid-gap"&gt;</code></p><p><code>4049</code><code>          </code></p><p><code>4050</code><code>        &lt;div class="tablet:grid-col-8"&gt;</code></p><p><code>4051</code><code>          </code></p><p><code>4052</code><code>          &lt;nav class="usa-footer__nav" aria-label="Footer navigation"&gt;</code></p><p><code>4053</code><code>          </code></p><p><code>4054</code><code>            &lt;div class="grid-row grid-gap-4"&gt;</code></p><p><code>4055</code><code>          </code></p><p><code>4056</code><code>              &lt;div class="mobile-lg:grid-col-6 desktop:grid-col-4"&gt;</code></p><p><code>4057</code><code>          </code></p><p><code>4058</code><code>                &lt;section</code></p><p><code>4059</code><code>                  class="usa-footer__primary-content usa-footer__primary-content--collapsible"</code></p><p><code>4060</code><code>                &gt;</code></p><p><code>4061</code><code>          </code></p><p><code>4062</code><code>                  &lt;div class="usa-footer__primary-link"&gt;</code></p><p><code>4063</code><code>About&lt;/div&gt;</code></p><p><code>4064</code><code>          </code></p><p><code>4065</code><code>                  &lt;ul class="usa-list usa-list--unstyled"&gt;</code></p><p><code>4066</code><code>          </code></p><p><code>4067</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4068</code><code>          </code></p><p><code>4069</code><code>                      &lt;a href="/about-website"&gt;</code></p><p><code>4070</code><code>About This Website&lt;/a&gt;</code></p><p><code>4071</code><code>          </code></p><p><code>4072</code><code>                    &lt;/li&gt;</code></p><p><code>4073</code><code>          </code></p><p><code>4074</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4075</code><code>          </code></p><p><code>4076</code><code>                      &lt;a href="/espanol"&gt;</code></p><p><code>4077</code><code>en Español&lt;/a&gt;</code></p><p><code>4078</code><code>          </code></p><p><code>4079</code><code>                    &lt;/li&gt;</code></p><p><code>4080</code><code>          </code></p><p><code>4081</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4082</code><code>          </code></p><p><code>4083</code><code>                      &lt;a href="/policies/copyright-reuse"&gt;</code></p><p><code>4084</code><code>Reuse &amp;amp; Copyright&lt;/a&gt;</code></p><p><code>4085</code><code>          </code></p><p><code>4086</code><code>                    &lt;/li&gt;</code></p><p><code>4087</code><code>          </code></p><p><code>4088</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4089</code><code>          </code></p><p><code>4090</code><code>                      &lt;a href="/social-media"&gt;</code></p><p><code>4091</code><code>Social Media&lt;/a&gt;</code></p><p><code>4092</code><code>          </code></p><p><code>4093</code><code>                    &lt;/li&gt;</code></p><p><code>4094</code><code>          </code></p><p><code>4095</code><code>                  &lt;/ul&gt;</code></p><p><code>4096</code><code>          </code></p><p><code>4097</code><code>                &lt;/section&gt;</code></p><p><code>4098</code><code>          </code></p><p><code>4099</code><code>              &lt;/div&gt;</code></p><p><code>4100</code><code>          </code></p><p><code>4101</code><code>              &lt;div class="mobile-lg:grid-col-6 desktop:grid-col-4"&gt;</code></p><p><code>4102</code><code>          </code></p><p><code>4103</code><code>                &lt;section</code></p><p><code>4104</code><code>                  class="usa-footer__primary-content usa-footer__primary-content--collapsible"</code></p><p><code>4105</code><code>                &gt;</code></p><p><code>4106</code><code>          </code></p><p><code>4107</code><code>                  &lt;div class="usa-footer__primary-link"&gt;</code></p><p><code>4108</code><code>Resources&lt;/div&gt;</code></p><p><code>4109</code><code>          </code></p><p><code>4110</code><code>                  &lt;ul class="usa-list usa-list--unstyled"&gt;</code></p><p><code>4111</code><code>          </code></p><p><code>4112</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4113</code><code>          </code></p><p><code>4114</code><code>                      &lt;a href="/contact"&gt;</code></p><p><code>4115</code><code>Contact Us&lt;/a&gt;</code></p><p><code>4116</code><code>          </code></p><p><code>4117</code><code>                    &lt;/li&gt;</code></p><p><code>4118</code><code>          </code></p><p><code>4119</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4120</code><code>          </code></p><p><code>4121</code><code>                      &lt;a href="/publications"&gt;</code></p><p><code>4122</code><code>Publications&lt;/a&gt;</code></p><p><code>4123</code><code>          </code></p><p><code>4124</code><code>                    &lt;/li&gt;</code></p><p><code>4125</code><code>          </code></p><p><code>4126</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4127</code><code>          </code></p><p><code>4128</code><code>                      &lt;a href="/publications/dictionaries/cancer-terms"</code></p><p><code>4129</code><code>                        &gt;</code></p><p><code>4130</code><code>Dictionary of Cancer Terms&lt;/a</code></p><p><code>4131</code><code>                      &gt;</code></p><p><code>4132</code><code>          </code></p><p><code>4133</code><code>                    &lt;/li&gt;</code></p><p><code>4134</code><code>          </code></p><p><code>4135</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4136</code><code>          </code></p><p><code>4137</code><code>                      &lt;a href="/research/participate/clinical-trials-search"</code></p><p><code>4138</code><code>                        &gt;</code></p><p><code>4139</code><code>Find a Clinical Trial&lt;/a</code></p><p><code>4140</code><code>                      &gt;</code></p><p><code>4141</code><code>          </code></p><p><code>4142</code><code>                    &lt;/li&gt;</code></p><p><code>4143</code><code>          </code></p><p><code>4144</code><code>                  &lt;/ul&gt;</code></p><p><code>4145</code><code>          </code></p><p><code>4146</code><code>                &lt;/section&gt;</code></p><p><code>4147</code><code>          </code></p><p><code>4148</code><code>              &lt;/div&gt;</code></p><p><code>4149</code><code>          </code></p><p><code>4150</code><code>              &lt;div class="mobile-lg:grid-col-6 desktop:grid-col-4"&gt;</code></p><p><code>4151</code><code>          </code></p><p><code>4152</code><code>                &lt;section</code></p><p><code>4153</code><code>                  class="usa-footer__primary-content usa-footer__primary-content--collapsible"</code></p><p><code>4154</code><code>                &gt;</code></p><p><code>4155</code><code>          </code></p><p><code>4156</code><code>                  &lt;div class="usa-footer__primary-link"&gt;</code></p><p><code>4157</code><code>Policies&lt;/div&gt;</code></p><p><code>4158</code><code>          </code></p><p><code>4159</code><code>                  &lt;ul class="usa-list usa-list--unstyled"&gt;</code></p><p><code>4160</code><code>          </code></p><p><code>4161</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4162</code><code>          </code></p><p><code>4163</code><code>                      &lt;a href="/policies/accessibility"&gt;</code></p><p><code>4164</code><code>Accessibility&lt;/a&gt;</code></p><p><code>4165</code><code>          </code></p><p><code>4166</code><code>                    &lt;/li&gt;</code></p><p><code>4167</code><code>          </code></p><p><code>4168</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4169</code><code>          </code></p><p><code>4170</code><code>                      &lt;a href="/policies/foia"&gt;</code></p><p><code>4171</code><code>FOIA&lt;/a&gt;</code></p><p><code>4172</code><code>          </code></p><p><code>4173</code><code>                    &lt;/li&gt;</code></p><p><code>4174</code><code>          </code></p><p><code>4175</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4176</code><code>          </code></p><p><code>4177</code><code>                      &lt;a href="/policies/privacy-security"</code></p><p><code>4178</code><code>                        &gt;</code></p><p><code>4179</code><code>Privacy &amp;amp; Security&lt;/a</code></p><p><code>4180</code><code>                      &gt;</code></p><p><code>4181</code><code>          </code></p><p><code>4182</code><code>                    &lt;/li&gt;</code></p><p><code>4183</code><code>          </code></p><p><code>4184</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4185</code><code>          </code></p><p><code>4186</code><code>                      &lt;a href="/policies/disclaimer"&gt;</code></p><p><code>4187</code><code>Disclaimers&lt;/a&gt;</code></p><p><code>4188</code><code>          </code></p><p><code>4189</code><code>                    &lt;/li&gt;</code></p><p><code>4190</code><code>          </code></p><p><code>4191</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4192</code><code>          </code></p><p><code>4193</code><code>                      &lt;a</code></p><p><code>4194</code><code>                        href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html"</code></p><p><code>4195</code><code>                        &gt;</code></p><p><code>4196</code><code>Vulnerability Disclosure&lt;/a</code></p><p><code>4197</code><code>                      &gt;</code></p><p><code>4198</code><code>          </code></p><p><code>4199</code><code>                    &lt;/li&gt;</code></p><p><code>4200</code><code>          </code></p><p><code>4201</code><code>                  &lt;/ul&gt;</code></p><p><code>4202</code><code>          </code></p><p><code>4203</code><code>                &lt;/section&gt;</code></p><p><code>4204</code><code>          </code></p><p><code>4205</code><code>              &lt;/div&gt;</code></p><p><code>4206</code><code>          </code></p><p><code>4207</code><code>            &lt;/div&gt;</code></p><p><code>4208</code><code>          </code></p><p><code>4209</code><code>          &lt;/nav&gt;</code></p><p><code>4210</code><code>          </code></p><p><code>4211</code><code>        &lt;/div&gt;</code></p><p><code>4212</code><code>          </code></p><p><code>4213</code><code>        &lt;div class="tablet:grid-col-4"&gt;</code></p><p><code>4214</code><code>          </code></p><p><code>4215</code><code>          &lt;div class="usa-sign-up"&gt;</code></p><p><code>4216</code><code>          </code></p><p><code>4217</code><code>            &lt;div class="usa-sign-up__heading"&gt;</code></p><p><code>4218</code><code>Sign up for email updates&lt;/div&gt;</code></p><p><code>4219</code><code>          </code></p><p><code>4220</code><code>            &lt;form</code></p><p><code>4221</code><code>              action="https://public.govdelivery.com/accounts/USNIHNCI/subscribers/qualify"</code></p><p><code>4222</code><code>              aria-label="Footer subscribe"</code></p><p><code>4223</code><code>              class="usa-form"</code></p><p><code>4224</code><code>              accept-charset="UTF-8"</code></p><p><code>4225</code><code>              method="post"</code></p><p><code>4226</code><code>              novalidate</code></p><p><code>4227</code><code>              target="_blank"</code></p><p><code>4228</code><code>              id="signup"</code></p><p><code>4229</code><code>            &gt;</code></p><p><code>4230</code><code>          </code></p><p><code>4231</code><code>              &lt;input</code></p><p><code>4232</code><code>                type="hidden"</code></p><p><code>4233</code><code>                name="category_id"</code></p><p><code>4234</code><code>                id="category_id"</code></p><p><code>4235</code><code>                value=""</code></p><p><code>4236</code><code>              /&gt;</code></p><p><code>4237</code><code>          </code></p><p><code>4238</code><code>              &lt;div class="usa-form-group"&gt;</code></p><p><code>4239</code><code>          </code></p><p><code>4240</code><code>                &lt;label class="usa-label" for="email"&gt;</code></p><p><code>4241</code><code>          </code></p><p><code>4242</code><code>                  Enter your email address</code></p><p><code>4243</code><code>                &lt;/label&gt;</code></p><p><code>4244</code><code>          </code></p><p><code>4245</code><code>                &lt;input</code></p><p><code>4246</code><code>                  class="usa-input width-full"</code></p><p><code>4247</code><code>                  id="email"</code></p><p><code>4248</code><code>                  name="email"</code></p><p><code>4249</code><code>                  type="email"</code></p><p><code>4250</code><code>                  value=""</code></p><p><code>4251</code><code>                /&gt;</code></p><p><code>4252</code><code>          </code></p><p><code>4253</code><code>              &lt;/div&gt;</code></p><p><code>4254</code><code>          </code></p><p><code>4255</code><code>              &lt;button class="usa-button usa-button--accent-warm" type="submit"&gt;</code></p><p><code>4256</code><code>          </code></p><p><code>4257</code><code>                Sign up</code></p><p><code>4258</code><code>              &lt;/button&gt;</code></p><p><code>4259</code><code>          </code></p><p><code>4260</code><code>            &lt;/form&gt;</code></p><p><code>4261</code><code>          </code></p><p><code>4262</code><code>          &lt;/div&gt;</code></p><p><code>4263</code><code>          </code></p><p><code>4264</code><code>        &lt;/div&gt;</code></p><p><code>4265</code><code>          </code></p><p><code>4266</code><code>      &lt;/div&gt;</code></p><p><code>4267</code><code>          </code></p><p><code>4268</code><code>    &lt;/div&gt;</code></p><p><code>4269</code><code>          </code></p><p><code>4270</code><code>  &lt;/div&gt;</code></p><p><code>4271</code><code>          </code></p><p><code>4272</code><code>  &lt;div class="usa-footer__secondary-section"&gt;</code></p><p><code>4273</code><code>          </code></p><p><code>4274</code><code>    &lt;div class="grid-container"&gt;</code></p><p><code>4275</code><code>          </code></p><p><code>4276</code><code>      &lt;div class="grid-row grid-gap"&gt;</code></p><p><code>4277</code><code>          </code></p><p><code>4278</code><code>        &lt;div class="usa-footer__logo grid-row desktop:grid-col-5"&gt;</code></p><p><code>4279</code><code>          </code></p><p><code>4280</code><code>          &lt;div class="mobile-lg:grid-col-auto desktop:margin-bottom-3"&gt;</code></p><p><code>4281</code><code>          </code></p><p><code>4282</code><code>            &lt;p class="usa-footer__logo-heading"&gt;</code></p><p><code>4283</code><code>          </code></p><p><code>4284</code><code>              &lt;span class="logo__agency-name"&gt;</code></p><p><code>4285</code><code>National Cancer Institute &lt;/span&gt;</code></p><p><code>4286</code><code>          </code></p><p><code>4287</code><code>              &lt;span class="logo__parent-organization"</code></p><p><code>4288</code><code>                &gt;</code></p><p><code>4289</code><code>at the National Institutes of Health&lt;/span</code></p><p><code>4290</code><code>              &gt;</code></p><p><code>4291</code><code>          </code></p><p><code>4292</code><code>            &lt;/p&gt;</code></p><p><code>4293</code><code>          </code></p><p><code>4294</code><code>          &lt;/div&gt;</code></p><p><code>4295</code><code>          </code></p><p><code>4296</code><code>        &lt;/div&gt;</code></p><p><code>4297</code><code>          </code></p><p><code>4298</code><code>        &lt;div class="usa-footer__contact-links mobile-lg:grid-col-7"&gt;</code></p><p><code>4299</code><code>          </code></p><p><code>4300</code><code>          &lt;div class="usa-footer__contact-heading"&gt;</code></p><p><code>4301</code><code>Contact Us&lt;/div&gt;</code></p><p><code>4302</code><code>          </code></p><p><code>4303</code><code>          &lt;div class="usa-footer__address"&gt;</code></p><p><code>4304</code><code>          </code></p><p><code>4305</code><code>            &lt;div class="usa-footer__contact-info grid-row grid-gap"&gt;</code></p><p><code>4306</code><code>          </code></p><p><code>4307</code><code>              &lt;div class="tablet:grid-col-auto"&gt;</code></p><p><code>4308</code><code>          </code></p><p><code>4309</code><code>                &lt;a href="https://livehelp.cancer.gov/"&gt;</code></p><p><code>4310</code><code>Live Chat&lt;/a&gt;</code></p><p><code>4311</code><code>          </code></p><p><code>4312</code><code>              &lt;/div&gt;</code></p><p><code>4313</code><code>          </code></p><p><code>4314</code><code>              &lt;div class="tablet:grid-col-auto"&gt;</code></p><p><code>4315</code><code>          </code></p><p><code>4316</code><code>                &lt;a href="tel:1-800-4-CANCER"&gt;</code></p><p><code>4317</code><code>1-800-4-CANCER&lt;/a&gt;</code></p><p><code>4318</code><code>          </code></p><p><code>4319</code><code>              &lt;/div&gt;</code></p><p><code>4320</code><code>          </code></p><p><code>4321</code><code>              &lt;div class="tablet:grid-col-auto"&gt;</code></p><p><code>4322</code><code>          </code></p><p><code>4323</code><code>                &lt;a href="mailto:NCIinfo@nih.gov"&gt;</code></p><p><code>4324</code><code>NCIinfo@nih.gov&lt;/a&gt;</code></p><p><code>4325</code><code>          </code></p><p><code>4326</code><code>              &lt;/div&gt;</code></p><p><code>4327</code><code>          </code></p><p><code>4328</code><code>              &lt;div class="tablet:grid-col-auto"&gt;</code></p><p><code>4329</code><code>          </code></p><p><code>4330</code><code>                &lt;a</code></p><p><code>4331</code><code>                  class="no-exit-notification"</code></p><p><code>4332</code><code>                  href="https://nci.az1.qualtrics.com/jfe/form/SV_aeLLobt6ZeGVn5I"</code></p><p><code>4333</code><code>                  target="_blank"</code></p><p><code>4334</code><code>                  &gt;</code></p><p><code>4335</code><code>Site Feedback&lt;/a</code></p><p><code>4336</code><code>                &gt;</code></p><p><code>4337</code><code>          </code></p><p><code>4338</code><code>              &lt;/div&gt;</code></p><p><code>4339</code><code>          </code></p><p><code>4340</code><code>            &lt;/div&gt;</code></p><p><code>4341</code><code>          </code></p><p><code>4342</code><code>          &lt;/div&gt;</code></p><p><code>4343</code><code>          </code></p><p><code>4344</code><code>        &lt;/div&gt;</code></p><p><code>4345</code><code>          </code></p><p><code>4346</code><code>      &lt;/div&gt;</code></p><p><code>4347</code><code>          </code></p><p><code>4348</code><code>      &lt;div class="grid-row grid-gap"&gt;</code></p><p><code>4349</code><code>          </code></p><p><code>4350</code><code>        &lt;div class="usa-footer__social-links desktop:grid-col-5"&gt;</code></p><p><code>4351</code><code>          </code></p><p><code>4352</code><code>          &lt;div class="usa-footer__social-heading"&gt;</code></p><p><code>4353</code><code>Follow us&lt;/div&gt;</code></p><p><code>4354</code><code>          </code></p><p><code>4355</code><code>          &lt;div class="grid-row grid-gap-1 nci-big__social"&gt;</code></p><p><code>4356</code><code>          </code></p><p><code>4357</code><code>            &lt;div class="grid-col-auto"&gt;</code></p><p><code>4358</code><code>          </code></p><p><code>4359</code><code>              &lt;a</code></p><p><code>4360</code><code>                class="usa-social-link usa-social-link--facebook no-exit-notification"</code></p><p><code>4361</code><code>                href="https://www.facebook.com/cancer.gov"</code></p><p><code>4362</code><code>              &gt;</code></p><p><code>4363</code><code>          </code></p><p><code>4364</code><code>                &lt;svg</code></p><p><code>4365</code><code>                  xmlns="http://www.w3.org/2000/svg"</code></p><p><code>4366</code><code>                  viewBox="0 0 24 24"</code></p><p><code>4367</code><code>                  width="24"</code></p><p><code>4368</code><code>                  class="usa-icon"</code></p><p><code>4369</code><code>                  role="img"</code></p><p><code>4370</code><code>                  aria-labelledby="facebook-title"</code></p><p><code>4371</code><code>                &gt;</code></p><p><code>4372</code><code>          </code></p><p><code>4373</code><code>                  &lt;title id="facebook-title"&gt;</code></p><p><code>4374</code><code>Facebook&lt;/title&gt;</code></p><p><code>4375</code><code>          </code></p><p><code>4376</code><code>                  &lt;rect fill="none" height="24" width="24" /&gt;</code></p><p><code>4377</code><code>          </code></p><p><code>4378</code><code>                  &lt;path</code></p><p><code>4379</code><code>                    d="M22,12c0-5.52-4.48-10-10-10S2,6.48,2,12c0,4.84,3.44,8.87,8,9.8V15H8v-3h2V9.5C10,7.57,11.57,6,13.5,6H16v3h-2 c-0.55,0-1,0.45-1,1v2h3v3h-3v6.95C18.05,21.45,22,17.19,22,12z"</code></p><p><code>4380</code><code>                  /&gt;</code></p><p><code>4381</code><code>          </code></p><p><code>4382</code><code>                &lt;/svg&gt;</code></p><p><code>4383</code><code>          </code></p><p><code>4384</code><code>              &lt;/a&gt;</code></p><p><code>4385</code><code>          </code></p><p><code>4386</code><code>            &lt;/div&gt;</code></p><p><code>4387</code><code>          </code></p><p><code>4388</code><code>            &lt;div class="grid-col-auto"&gt;</code></p><p><code>4389</code><code>          </code></p><p><code>4390</code><code>              &lt;a</code></p><p><code>4391</code><code>                class="usa-social-link usa-social-link--twitter no-exit-notification"</code></p><p><code>4392</code><code>                href="https://twitter.com/thenci"</code></p><p><code>4393</code><code>              &gt;</code></p><p><code>4394</code><code>          </code></p><p><code>4395</code><code>                &lt;svg</code></p><p><code>4396</code><code>                  xmlns="http://www.w3.org/2000/svg"</code></p><p><code>4397</code><code>                  viewBox="0 0 24 24"</code></p><p><code>4398</code><code>                  class="usa-icon"</code></p><p><code>4399</code><code>                  role="img"</code></p><p><code>4400</code><code>                  aria-labelledby="twitter-title"</code></p><p><code>4401</code><code>                &gt;</code></p><p><code>4402</code><code>          </code></p><p><code>4403</code><code>                  &lt;title id="twitter-title"&gt;</code></p><p><code>4404</code><code>Twitter&lt;/title&gt;</code></p><p><code>4405</code><code>          </code></p><p><code>4406</code><code>                  &lt;path</code></p><p><code>4407</code><code>                    id="Twitter"</code></p><p><code>4408</code><code>                    d="M12,2A10,10,0,1,0,22,12,10,10,0,0,0,12,2Zm5,8.1c0,.1,0,.21,0,.31a6.81,6.81,0,0,1-6.86,6.86,6.74,6.74,0,0,1-3.69-1.08,5.63,5.63,0,0,0,.58,0,4.79,4.79,0,0,0,3-1A2.41,2.41,0,0,1,7.8,13.51a1.75,1.75,0,0,0,.46.05,2.59,2.59,0,0,0,.63-.08A2.42,2.42,0,0,1,7,11.11v0a2.33,2.33,0,0,0,1.09.3A2.43,2.43,0,0,1,7.3,8.16a6.84,6.84,0,0,0,5,2.53,2.59,2.59,0,0,1-.07-.55,2.41,2.41,0,0,1,2.41-2.41,2.38,2.38,0,0,1,1.77.76A4.67,4.67,0,0,0,17.9,7.9a2.39,2.39,0,0,1-1.06,1.34,4.55,4.55,0,0,0,1.39-.39A5,5,0,0,1,17,10.1Z"</code></p><p><code>4409</code><code>                  /&gt;</code></p><p><code>4410</code><code>          </code></p><p><code>4411</code><code>                &lt;/svg&gt;</code></p><p><code>4412</code><code>          </code></p><p><code>4413</code><code>              &lt;/a&gt;</code></p><p><code>4414</code><code>          </code></p><p><code>4415</code><code>            &lt;/div&gt;</code></p><p><code>4416</code><code>          </code></p><p><code>4417</code><code>            &lt;div class="grid-col-auto"&gt;</code></p><p><code>4418</code><code>          </code></p><p><code>4419</code><code>              &lt;a</code></p><p><code>4420</code><code>                class="usa-social-link usa-social-link--instagram no-exit-notification"</code></p><p><code>4421</code><code>                href="https://www.instagram.com/nationalcancerinstitute/"</code></p><p><code>4422</code><code>              &gt;</code></p><p><code>4423</code><code>          </code></p><p><code>4424</code><code>                &lt;svg</code></p><p><code>4425</code><code>                  xmlns="http://www.w3.org/2000/svg"</code></p><p><code>4426</code><code>                  viewBox="0 0 24 24"</code></p><p><code>4427</code><code>                  class="usa-icon"</code></p><p><code>4428</code><code>                  role="img"</code></p><p><code>4429</code><code>                  aria-labelledby="instagram-title"</code></p><p><code>4430</code><code>                &gt;</code></p><p><code>4431</code><code>          </code></p><p><code>4432</code><code>                  &lt;title id="instagram-title"&gt;</code></p><p><code>4433</code><code>Instagram&lt;/title&gt;</code></p><p><code>4434</code><code>          </code></p><p><code>4435</code><code>                  &lt;g id="Instagram"&gt;</code></p><p><code>4436</code><code>          </code></p><p><code>4437</code><code>                    &lt;path d="M12,10a2,2,0,1,0,2,2A2,2,0,0,0,12,10Z" /&gt;</code></p><p><code>4438</code><code>          </code></p><p><code>4439</code><code>                    &lt;path</code></p><p><code>4440</code><code>                      d="M12,2A10,10,0,1,0,22,12,10,10,0,0,0,12,2Zm6,12.69A3.32,3.32,0,0,1,14.69,18H9.31A3.32,3.32,0,0,1,6,14.69V9.31A3.32,3.32,0,0,1,9.31,6h5.38A3.32,3.32,0,0,1,18,9.31Z"</code></p><p><code>4441</code><code>                    /&gt;</code></p><p><code>4442</code><code>          </code></p><p><code>4443</code><code>                    &lt;path</code></p><p><code>4444</code><code>                      d="M16.94,9.31a2.25,2.25,0,0,0-2.25-2.25H9.31A2.25,2.25,0,0,0,7.06,9.31v5.38a2.25,2.25,0,0,0,2.25,2.25h5.38a2.25,2.25,0,0,0,2.25-2.25h0ZM12,15.09A3.09,3.09,0,1,1,15.09,12,3.09,3.09,0,0,1,12,15.09Zm3.77-5.75a.79.79,0,0,1-.55.23.83.83,0,0,1-.55-.23.78.78,0,0,1,0-1.11A.82.82,0,0,1,15.22,8a.78.78,0,0,1,.55,1.33Z"</code></p><p><code>4445</code><code>                    /&gt;</code></p><p><code>4446</code><code>          </code></p><p><code>4447</code><code>                  &lt;/g&gt;</code></p><p><code>4448</code><code>          </code></p><p><code>4449</code><code>                &lt;/svg&gt;</code></p><p><code>4450</code><code>          </code></p><p><code>4451</code><code>              &lt;/a&gt;</code></p><p><code>4452</code><code>          </code></p><p><code>4453</code><code>            &lt;/div&gt;</code></p><p><code>4454</code><code>          </code></p><p><code>4455</code><code>            &lt;div class="grid-col-auto"&gt;</code></p><p><code>4456</code><code>          </code></p><p><code>4457</code><code>              &lt;a</code></p><p><code>4458</code><code>                class="usa-social-link usa-social-link--youtube no-exit-notification"</code></p><p><code>4459</code><code>                href="https://www.youtube.com/NCIgov"</code></p><p><code>4460</code><code>              &gt;</code></p><p><code>4461</code><code>          </code></p><p><code>4462</code><code>                &lt;svg</code></p><p><code>4463</code><code>                  xmlns="http://www.w3.org/2000/svg"</code></p><p><code>4464</code><code>                  viewBox="0 0 24 24"</code></p><p><code>4465</code><code>                  class="usa-icon"</code></p><p><code>4466</code><code>                  role="img"</code></p><p><code>4467</code><code>                  aria-labelledby="youtube-title"</code></p><p><code>4468</code><code>                &gt;</code></p><p><code>4469</code><code>          </code></p><p><code>4470</code><code>                  &lt;title id="youtube-title"&gt;</code></p><p><code>4471</code><code>Youtube&lt;/title&gt;</code></p><p><code>4472</code><code>          </code></p><p><code>4473</code><code>                  &lt;g id="YouTube"&gt;</code></p><p><code>4474</code><code>          </code></p><p><code>4475</code><code>                    &lt;path</code></p><p><code>4476</code><code>                      d="M12,2A10,10,0,1,0,22,12,10,10,0,0,0,12,2Zm5.75,12.91A1.49,1.49,0,0,1,16.69,16a34.65,34.65,0,0,1-4.69.26A34.65,34.65,0,0,1,7.31,16a1.49,1.49,0,0,1-1.06-1.06A15.88,15.88,0,0,1,6,12a15.88,15.88,0,0,1,.25-2.91A1.49,1.49,0,0,1,7.31,8,34.65,34.65,0,0,1,12,7.77,34.65,34.65,0,0,1,16.69,8a1.49,1.49,0,0,1,1.06,1.06A15.88,15.88,0,0,1,18,12,15.88,15.88,0,0,1,17.75,14.91Z"</code></p><p><code>4477</code><code>                    /&gt;</code></p><p><code>4478</code><code>          </code></p><p><code>4479</code><code>                    &lt;polygon</code></p><p><code>4480</code><code>                      points="10.77 13.78 13.91 12 10.77 10.22 10.77 13.78"</code></p><p><code>4481</code><code>                    /&gt;</code></p><p><code>4482</code><code>          </code></p><p><code>4483</code><code>                  &lt;/g&gt;</code></p><p><code>4484</code><code>          </code></p><p><code>4485</code><code>                &lt;/svg&gt;</code></p><p><code>4486</code><code>          </code></p><p><code>4487</code><code>              &lt;/a&gt;</code></p><p><code>4488</code><code>          </code></p><p><code>4489</code><code>            &lt;/div&gt;</code></p><p><code>4490</code><code>          </code></p><p><code>4491</code><code>            &lt;div class="grid-col-auto"&gt;</code></p><p><code>4492</code><code>          </code></p><p><code>4493</code><code>              &lt;a</code></p><p><code>4494</code><code>                class="usa-social-link usa-social-link--linkedin no-exit-notification"</code></p><p><code>4495</code><code>                href="https://www.linkedin.com/company/nationalcancerinstitute/"</code></p><p><code>4496</code><code>              &gt;</code></p><p><code>4497</code><code>          </code></p><p><code>4498</code><code>                &lt;svg</code></p><p><code>4499</code><code>                  xmlns="http://www.w3.org/2000/svg"</code></p><p><code>4500</code><code>                  viewBox="0 0 24 24"</code></p><p><code>4501</code><code>                  class="usa-icon"</code></p><p><code>4502</code><code>                  role="img"</code></p><p><code>4503</code><code>                  aria-labelledby="linkedin-title"</code></p><p><code>4504</code><code>                &gt;</code></p><p><code>4505</code><code>          </code></p><p><code>4506</code><code>                  &lt;title id="linkedin-title"&gt;</code></p><p><code>4507</code><code>Linkedin&lt;/title&gt;</code></p><p><code>4508</code><code>          </code></p><p><code>4509</code><code>                  &lt;g id="final"&gt;</code></p><p><code>4510</code><code>          </code></p><p><code>4511</code><code>                    &lt;path</code></p><p><code>4512</code><code>                      d="M12,2C6.48,2,2,6.48,2,12s4.48,10,10,10s10-4.48,10-10S17.52,2,12,2z M8.912001,17.584H6.584v-7.472h2.328001V17.584z</code></p><p><code>4513</code><code>                          M7.744,9.104C6.992,9.104,6.4,8.488,6.4,7.76c0-0.752,0.592-1.344,1.344-1.344c0.728,0,1.343999,0.592,1.343999,1.344</code></p><p><code>4514</code><code>                          C9.087999,8.488,8.472,9.104,7.744,9.104z M17.6,17.584h-2.328v-3.64c0-0.856-0.024001-1.967999-1.216001-1.967999</code></p><p><code>4515</code><code>                          s-1.392,0.927999-1.392,1.912v3.696H10.36v-7.472h2.224v1.008h0.024c0.464-0.752,1.296-1.216001,2.199999-1.192</code></p><p><code>4516</code><code>                          c2.352001,0,2.792,1.552001,2.792,3.544001C17.6,13.472,17.6,17.584,17.6,17.584z"</code></p><p><code>4517</code><code>                    /&gt;</code></p><p><code>4518</code><code>          </code></p><p><code>4519</code><code>                  &lt;/g&gt;</code></p><p><code>4520</code><code>          </code></p><p><code>4521</code><code>                &lt;/svg&gt;</code></p><p><code>4522</code><code>          </code></p><p><code>4523</code><code>              &lt;/a&gt;</code></p><p><code>4524</code><code>          </code></p><p><code>4525</code><code>            &lt;/div&gt;</code></p><p><code>4526</code><code>          </code></p><p><code>4527</code><code>          &lt;/div&gt;</code></p><p><code>4528</code><code>          </code></p><p><code>4529</code><code>        &lt;/div&gt;</code></p><p><code>4530</code><code>          </code></p><p><code>4531</code><code>        &lt;div class="usa-footer__contact-links desktop:grid-col-7"&gt;</code></p><p><code>4532</code><code>          </code></p><p><code>4533</code><code>          &lt;div class="usa-footer__address height-full"&gt;</code></p><p><code>4534</code><code>          </code></p><p><code>4535</code><code>            &lt;div class="usa-footer__contact-info grid-row grid-gap height-full"&gt;</code></p><p><code>4536</code><code>          </code></p><p><code>4537</code><code>              &lt;address&gt;</code></p><p><code>4538</code><code>          </code></p><p><code>4539</code><code>                &lt;a href="https://www.hhs.gov/"</code></p><p><code>4540</code><code>                  &gt;</code></p><p><code>4541</code><code>U.S. Department of Health and Human Services</code></p><p><code>4542</code><code>                &lt;/a&gt;</code></p><p><code>4543</code><code>          </code></p><p><code>4544</code><code>                &lt;a href="https://www.nih.gov/"</code></p><p><code>4545</code><code>                  &gt;</code></p><p><code>4546</code><code>National Institutes of Health</code></p><p><code>4547</code><code>                &lt;/a&gt;</code></p><p><code>4548</code><code>          </code></p><p><code>4549</code><code>                &lt;a href="https://www.cancer.gov/"&gt;</code></p><p><code>4550</code><code>National Cancer Institute &lt;/a&gt;</code></p><p><code>4551</code><code>          </code></p><p><code>4552</code><code>                &lt;a href="https://usa.gov/"&gt;</code></p><p><code>4553</code><code>USA.gov&lt;/a&gt;</code></p><p><code>4554</code><code>          </code></p><p><code>4555</code><code>              &lt;/address&gt;</code></p><p><code>4556</code><code>          </code></p><p><code>4557</code><code>            &lt;/div&gt;</code></p><p><code>4558</code><code>          </code></p><p><code>4559</code><code>          &lt;/div&gt;</code></p><p><code>4560</code><code>          </code></p><p><code>4561</code><code>        &lt;/div&gt;</code></p><p><code>4562</code><code>          </code></p><p><code>4563</code><code>      &lt;/div&gt;</code></p><p><code>4564</code><code>          </code></p><p><code>4565</code><code>    &lt;/div&gt;</code></p><p><code>4566</code><code>          </code></p><p><code>4567</code><code>  &lt;/div&gt;</code></p><p><code>4568</code><code>          </code></p><p><code>4569</code><code>&lt;/footer&gt;</code></p><p><code>4570</code><code>          </code></p><p><code>4571</code><code>          </code></p><p><code>4572</code><code>          </code></p><p><code>4573</code><code>  &lt;/div&gt;</code></p><p><code>4574</code><code>          </code></p><p><code>4575</code><code>          </code></p><p><code>4576</code><code>          </code></p><p><code>4577</code><code>          </code></p><p><code>4578</code><code>  &lt;/div&gt;</code></p><p><code>4579</code><code>          </code></p><p><code>4580</code><code>          </code></p><p><code>4581</code><code>    &lt;script src="/sites/g/files/xnrzdm211/files/js/js_gyckXKPoD2Pap4CjJRNIMCAxSADZa425IpIz5JlrgqE.js"&gt;</code></p><p><code>4582</code><code>&lt;/script&gt;</code></p><p><code>4583</code><code>          </code></p><p><code>4584</code><code>&lt;script src="/profiles/custom/cgov_site/themes/custom/ncids_trans/dist/js/ncids-common.js?s1d5be"&gt;</code></p><p><code>4585</code><code>&lt;/script&gt;</code></p><p><code>4586</code><code>          </code></p><p><code>4587</code><code>&lt;script src="/profiles/custom/cgov_site/themes/custom/ncids_trans/dist/js/pdq.js?s1d5be"&gt;</code></p><p><code>4588</code><code>&lt;/script&gt;</code></p><p><code>4589</code><code>          </code></p><p><code>4590</code><code>          </code></p><p><code>4591</code><code>    &lt;script id="cgov-adobe-bottom" type="text/javascript"&gt;</code></p><p><code>4592</code><code>_satellite.pageBottom();&lt;/script&gt;</code></p><p><code>4593</code><code>          </code></p><p><code>4594</code><code>          </code></p><p><code>4595</code><code>  &lt;script type="text/javascript"&gt;</code></p><p><code>4596</code><code>window.NREUM||(NREUM={});NREUM.info={"beacon":"gov-bam.nr-data.net","licenseKey":"bfc00e1ee3","applicationID":"355359682,336353556","transactionName":"NVVTbBMHDEQDBUVcDgwfcFsVDw1ZTSJDQBEDXG1WDgIHayEJX0ETDVxdXRM6LFgGA2dcBBVzXlYVFA1bDgNDGF8UWVRP","queueTime":37,"applicationTime":864,"atts":"GRJQGlsdH0o=","errorBeacon":"gov-bam.nr-data.net","agent":""}&lt;/script&gt;</code></p><p><code>4597</code><code>&lt;/body&gt;</code></p><p><code>4598</code><code>          </code></p><p><code>4599</code><code>&lt;/html&gt;</code></p><p><code>4600</code><code>          </code></p><div></div></main><iframe hidden="hidden" title="Hidden frame for spell checking" src="about:blank" id="iframeSpelling"></iframe></body></html>